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Background: A noncoding (G4C2)n hexanucleotide repeat expansion in chromosome 9 open 
reading frame 72 (C9orf72) is a major cause of both amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD), together referred to as C9-ALS/FTD. It is unknown how the 
repeat expansion causes C9-ALS/FTD, however there is evidence that C9orf72 mRNA levels 
are reduced in patients, suggesting C9orf72 loss-of-function (LOF) via haploinsufficiency 
may contribute to C9-ALS/FTD. Understanding how haploinsufficiency may lead to the 
development of C9-ALS/FTD is dependent on a better understanding of C9orf72 protein 
function. Recent work from our laboratory and others in cell lines have shown that C9orf72 
regulates autophagy, but the in vivo relevance of autophagy-deficits remains unclear.  
Objectives: To investigate if C9orf72 LOF via haploinsufficiency results in C9-ALS/FTD 
due to defective autophagy using a stable zebrafish C9orf72 LOF model.  
Methods: Genome editing techniques were used to target sequences within exon 1 and exon 
7 of the zebrafish orthologue of C9orf72 (C13H9orf72; zgc10846). To investigate the effects 
of C13H9orf72 LOF, we characterised survival, motor function and anxiety-like behaviour. 
Immunohistochemical analysis of neuromuscular junctions (NMJs) was also performed. To 
investigate the role of C9orf72 in autophagy in vivo, autophagic flux was measured. 
Additionally, we looked for symptoms of splenomegaly, due to recent evidence that full 
ablation of C9orf72 in mice resulted in immune system-related pathology.   
Results: Three independent lines of zebrafish carrying different frameshift mutations in exon 
1 (SH470) and exon 7 (SH448 and SH451) were characterised. Survival monitoring suggests 
that mutations in C13H9orf72 do not lead to loss of viability. A subtle reduction in motor 
function is observed in adult C13H9orf72 LOF zebrafish, but no corresponding NMJ 
pathology, and there is no evidence of anxiety-like behaviour in adults. Zebrafish 
C13H9orf72 was found to interact with a member of the autophagy initiation complex, but 
further work is needed to determine whether it plays a regulatory role in autophagy in 
zebrafish. Additionally, no signs of significant splenomegaly were observed in these 
zebrafish.  
Conclusions: Results obtained do not support the hypothesis that C9orf72 LOF is sufficient 
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1.1. Amyotrophic Lateral Sclerosis  
1.1.1. Background  
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, fatal neurodegenerative 
disease. It is characterised by degeneration of motor neurons (MNs) within the cerebral 
cortex (known as upper motor neurons – UMNs), brainstem and the ventral horn of the 
spinal cord (lower motor neurons – LMNs) (Rowland and Shneider 2001) (see figure 1.1). 
The result of this degeneration is muscle weakness, wasting and eventual paralysis. The 
disease is fatal, usually within 2-5 years of diagnosis, due to respiratory failure. There are 
currently two treatments available, including Riluzole, which has a modest effect on life 
span, and more recently Edaravone, which has been reported to show efficacy in a small 
subset of people with ALS (Bensimon et al. 1994, Abe et al. 2017). 
 
 
Figure 1.1 Schematic diagram of upper and lower motor neurons. Upper motor 
neurons (UMN) are motor neurons that originate in the motor region of the cerebral 
cortex. They carry motor information to lower motor neurons (LMN) located in the 
brainstem or the ventral horn of the spinal cord. The LMN innervate skeletal muscle 
fibres, acting as a link between UMN and muscles. (Rowland and Shneider 2001). 
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1.1.2. Clinical features of ALS 
The term motor neuron disease (MND) describes a group of neurodegenerative disorders 
which selectively affect MNs. There are four main types of MND; ALS, Primary Lateral 
Sclerosis (PLS), Progressive Muscular Atrophy (PMA) and Progressive Bulbar Palsy 
(PBP). Although there is both clinical and neuropathological overlap between these 
different forms, each type has distinct features. ALS is the most common form of MND 
characterised by progressive degeneration of both UMNs and LMNs. Other less common 
forms of MND are characterised by the MNs initially affected. It is reported that less than 
5% of cases are classified as PLS, which affects only the UMNs (Rowland and Shneider 
2001). Additionally, PMA comprises around 10% of MND cases, characterised by 
initially affecting LMNs (Rowland and Shneider 2001). Finally, around 25% of cases are 
classified as PBP, although a recent study reported 87% of such patients eventually 
develop ALS, suggesting these are actually bulbar-onset ALS patients (Karam, Scelsa 
and MacGowan 2010).  
The clinical hallmarks of ALS are due to a distinctive combination of signs of both LMN 
degeneration, including muscle weakness, atrophy and fasciculations, alongside features 
of UMN degeneration, such as muscular spasticity and hyperreflexia (Rowland and 
Shneider 2001). Interestingly, certain subgroups of LMNs appear to be resistant to 
degeneration throughout the disease course (Comley et al. 2016, Nijssen, Comley and 
Hedlund 2017). Oculomotor MNs, including the oculomotor (CNIII), trochlear (IV) and 
abducens (VI) nuclei appear to be spared during disease (Gizzi et al. 1992). These are 
involved in regulating eye movement; thus eye-tracking devices can be used which enable 
ALS patients to communicate when they can no longer speak (Caligari et al. 2013). 
Additionally, MNs in the Onuf’s nucleus of the sacral spinal cord, which innervate the 
pelvic floor muscles, remain relatively unaffected (Carvalho, Schwartz and Swash 1995). 
This means that ALS patients do not suffer from incontinence. However, the reasons for 
this differential vulnerability in MNs is not fully understood. 
Approximately 70% of ALS patients present with limb-onset disease, with around 25% 
suffering from bulbar-onset disease (Kiernan et al. 2011). In contrast, symptom onset 
involving the trunk or respiratory muscles is rare (Swinnen and Robberecht 2014). 
Typically, symptoms rapidly progress throughout the course of the disorder before 
culminating in a debilitating failure of the neuromuscular system. Incidence rates of ALS 
are estimated to be 2.16 per 100,000 persons-years in western populations (Logroscino et 
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al. 2010). Additionally, it has been reported that incidence rates are higher amongst males 
(3.0 per 100,000 person-years) compared to females (2.4 per 100,000 persons-years) in 
Europe (Logroscino et al. 2010). It is reported that the lifetime risk of developing ALS is 
1 in 400 (Johnston et al. 2006). The peak age of onset is 58-63 for sporadic disease and 
47-52 for familial disease (Kiernan et al. 2011); however there are also rare juvenile 
variants of ALS, such as ALS2, where onset of symptoms occurs in either the first or 
second decade of life (Yang et al. 2001).  
The disease is usually fatal within 2 to 5 years post initial diagnosis, due to respiratory 
failure (Kiernan et al. 2011). However, around 5-10% of patients can survive up to 10 
years post initial diagnosis (Chio et al. 2009). It has been observed that older age at 
symptom onset, bulbar-onset disease and onset of disease within the trunk or respiratory 
muscles are all linked to reduced survival (Swinnen and Robberecht 2014, Talbot 2009). 
Alternatively, a younger age of symptom onset and limb-onset disease are linked to 
prolonged survival (Swinnen and Robberecht 2014, Talbot 2009). There are currently two 
treatments available. Firstly, Riluzole, which has a modest effect on life span (Bensimon 
et al. 1994). Secondly, there is Edaravone, which has recently been reported to show 
efficacy in a small subset of people with ALS (Abe et al. 2017). Aside from this, standard 
treatment for ALS is palliative and involves multidisciplinary care, including nutritional 
and respiratory support.  
It has been observed that ALS patients have clinical, pathological and genetic overlap 
with other neurodegenerative diseases. Loss of cortical neurons in the frontal and/or 
temporal lobes is commonly seen, resulting in a condition called frontal temporal 
dementia (FTD). The link between ALS and FTD will be covered in greater detail in 
section 1.1.6. 
1.1.3. Neuropathological features of ALS 
Regarding neuropathology, it was discovered in 1988 that ubiquitinated inclusions (UBIs) 
are hallmarks of ALS (Leigh et al. 1988, Lowe et al. 1988). Microscopically, UBIs are 
observed as skein-like aggregates or dense, round structures. They are most commonly 
observed in neurons, but have also been reported in glial cells (Arai et al. 2003). For many 
years, the protein constituents of UBIs were unknown. It is now known that TAR DNA-
binding protein 43 (TDP-43) is the major constituent of UBIs in both ALS and FTD 
patients (Neumann et al. 2006). Although inclusions positive for TDP-43 are noted in the 
majority of ALS cases, they are not seen in fused in sarcoma (FUS)- or Cu/Zn superoxide 
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dismutase 1 (SOD1)-linked ALS. The characteristic pathology in FUS-ALS are UBIs 
positive for FUS, but negative for TDP-43, tau and α-synuclein (Kwiatkowski et al. 2009, 
Vance et al. 2009). Additionally, in SOD1-ALS, UBIs positive for SOD1, but negative 
for TDP-43 are observed (Mackenzie et al. 2007).  
In addition to UBIs, there are several other pathognomonic features of ALS. Bunina 
bodies (BBs) are small, eosinophilic inclusions observed in the remaining LMNs in 
approximately 80-100% of patients (Piao et al. 2003). BBs stain positive for cystatin C 
and transferrin (Okamoto et al. 1993, Mizuno et al. 2006b), but negative for a variety of 
proteins associated with neurodegeneration such as tau, p62, α-synuclein and amyloid 
precursor protein (Okamoto et al. 1993, Mizuno et al. 2006b, Sasaki and Iwata 2006, 
Mizuno et al. 2006a). However, the biological significance of BBs is still not fully 
understood. Additionally, large multifocal accumulations of phosphorylated and non-
phosphorylated neurofilament subunits, called hyaline conglomerate inclusions (HCIs), 
have been observed (Ince, Lowe and Shaw 1998). However, these are also noted in other 
diseases and in normal patients, questioning their specificity to ALS (Leigh et al. 1989, 
Sobue et al. 1990).  
As well as the pathognomonic neuropathology reported, it has been observed that genetic 
variants of ALS show distinct pathology in patients. For example, C9-ALS/FTD patients 
have been reported to have p62/SQSTM1 positive, TDP-43 negative UBIs in the 
cerebellum, hippocampus and neocortex (Al-Sarraj et al. 2011, Cooper-Knock et al. 
2012), aggregates of dipeptide repeat (DPRs) proteins in the cerebellum, hippocampus 
and frontotemporal neocortex (Ash et al. 2013, Mori et al. 2013c, Mori et al. 2013a, Zu 
et al. 2013), and RNA foci in the frontal cortex, motor cortex, hippocampus, cerebellum 
and spinal cord (Cooper-Knock et al. 2014b, Mizielinska et al. 2013). These will be 







1.1.4. Genetics of ALS 
Sporadic ALS cases (sALS), where a patient has no evident family history of ALS, are 
estimated to account for 90-95% of all ALS cases, with familial ALS cases (fALS), where 
a patient has a family history of ALS in a first- or second-degree relative, account for 5-
10% of ALS cases. Typically, fALS is inherited in an autosomal dominant (AD) manner; 
however, there are rare cases of both autosomal recessive (AR) and X-linked disease. 
Since the discovery that mutations in SOD1 cause around 20% of fALS cases more than 
two decades ago (Rosen et al. 1993), more than 20 ALS-causing genes have subsequently 
been identified, revealing the genetic heterogeneity of this disorder. It is reported that the 
genetic etiology for around two-thirds of fALS and 11% of sALS is now known (Renton, 
Chio and Traynor 2014). The genes identified to be associated with fALS and fALS/FTD 












Table 1.1 Causal genetic mutations in fALS and fALS/FTD. Chromosomal loci, function and inheritance of genes found to be involved in fALS. 
Gene Chromosome Pathology/Function Inheritance Phenotype Reference(s) 
SOD1 21q22 Oxidative stress, UPS and autophagy AD ALS (Rosen et al. 1993) 
ALSIN 2q33 Endosomal trafficking and cell signalling AR ALS (Yang et al. 2001) 
DCTN1 2p13 Axonal transport AD ALS (Puls et al. 2003) 
Unknown 18q21 -- AD ALS (Hand et al. 2002) 
SETX 9q34 RNA processing  AD  ALS (Chen et al. 2004) 
SPG11 15q21.1 DNA damage repair and axonal growth  AR ALS (Orlacchio et al. 2010) 
FUS 16p11.2 RNA processing AD ALS, FTD (Kwiatkowski et al. 2009, Vance et al. 2009) 
Unknown 20p13 -- AD ALS (Sapp et al. 2003) 
VAPB 20q13.32 Vesicle trafficking, UPR and ER stress AD ALS (Nishimura et al. 2004) 
ANG 14q11.2 RNA metabolism and angiogenesis  AD ALS, FTD (Greenway et al. 2006) 
TARDBP 1p36.22 RNA metabolism AD ALS, FTD (Sreedharan et al. 2008) 
FIG4 6q21 Endosomal trafficking  AD ALS (Chow et al. 2009) 
OPTN 10p13 Autophagy AD and AR ALS (Maruyama et al. 2010) 
VCP 9p13.3 Autophagy AD ALS, FTD (Johnson et al. 2010) 
UBQLN2 Xp11.21 UPS and autophagy XD ALS/FTD (Deng et al. 2011) 
SIGMAR1 9p13.3 UPR, ER stress and proteasome AD ALS/FTD (Luty et al. 2010, Al-Saif, Al-Mohanna and 
Bohlega 2011) 
CHMP2B 3p11.2 Endosomal trafficking and autophagy AD ALS, FTD (Parkinson et al. 2006) 
PFN1 17p13.2 Cytoskeleton and axonal growth AD ALS, FTD (Wu et al. 2012) 
ERBB4 2q34 Neuronal development AD ALS (Takahashi et al. 2013) 
HNRNPA1 12q13.13 RNA metabolism AD ALS (Kim et al. 2013) 
MATR3 5q31.2 RNA metabolism AD ALS (Johnson et al. 2014) 
C9orf72 9p21.2 RNA metabolism, endosomal trafficking and 
autophagy 
AD ALS/FTD (Renton et al. 2011, DeJesus-Hernandez et al. 
2011) 
CHCHD10 22q11.23 Mitochondrial maintenance AD ALS/FTD (Bannwarth et al. 2014) 
SQSTM1 5q35.2 Autophagy and protein degradation AD ALS/FTD (Fecto et al. 2011) 
TBK1 12q14.2 Autophagy and neuroinflammation AD ALS/FTD (Cirulli et al. 2015, Freischmidt et al. 2015) 
TUBA4A 2q35 Cytoskeleton AD ALS (Smith et al. 2014) 
ANXA11 10q22.3 Vesicular trafficking protein  AD ALS (Smith et al. 2017) 
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1.1.4.1. Genetic risk factors in ALS  
In addition to known ALS causal genes, several genetic risk factors have been identified 
that increase the risk of developing ALS and/or to modify the disease phenotype in 
patients, via methods such as genome-wide association studies (GWAS) or whole-exome 
sequencing. Such genetic risk factors include ATXN2 (Elden et al. 2010). Large 
expansions of repeats within the trinucleotide CAG in ATXN2 have previously been 
reported to cause spinocerebellar ataxia type 2 (Imbert et al. 1996). However, in 2010 it 
was identified that intermediate-length expansions increased the risk for ALS (Elden et 
al. 2010). These intermediate-length expansions in ATXN2 have now been reported as the 
most important risk factor for ALS-FTD, as they have been observed to coincide with 
C9orf72 repeat expansions in C9-ALS/FTD patients (Ciura et al. 2016). In addition to 
ATXN2, other genetic risk factors have been identified including UNC13A (van Es et al. 
2009), SMN1 (Corcia et al. 2006) and EPHA4 (Van Hoecke et al. 2012). Identification of 
genetic risk factors could help to explain why members of the same family, who inherit 
the same causal mutation, present with ALS at different ages and sites of onset for 
example. Further understanding these variants in the future may help in developing more 
effective therapies to treat ALS.  
1.1.4.2. The oligogenic nature of ALS 
An emerging theme in ALS is oligogenic inheritance. This refers to a situation in which 
mutations in two or more ALS-linked genes may be required to develop disease (Lattante 
et al. 2015a). Several large scale studies have revealed the oligogenic nature of ALS. For 
example, in 5/97 fALS probands, mutations in more than one ALS-associated gene were 
identified, including: FUS and TARDBP mutations in combination with ANG mutations; 
and C9orf72 repeat expansions with TARDBP, SOD1 and FUS mutations (van 
Blitterswijk et al. 2012b). Additionally an Irish population-based study examining over 
400 ALS cases reported that 1.6% of the cohort had mutations in more than one ALS 
gene (Kenna et al. 2013). Interestingly, oligogenic inheritance of C9orf72 with other 
ALS-linked genes is the most commonly reported combination, with over 10 ALS-
causing genetic variants described (Lattante et al. 2015a).  
As expansions in C9orf72 are so common, it is important to re-evaluate ALS cases where 
the causal mutation was identified before the discovery of C9orf72, as this may increase 
the number of cases with mutations in two or more ALS-linked genes. It could be that 
one of the mutations is weakly penetrant, thus both are needed to develop disease in a 
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synergistic or additive way. Alternatively, it could be one of the mutations, or the whole 
gene itself, has been falsely related to ALS. In the future, large-scale global studies will 
be needed to investigate the relevance of oligogenic inheritance to ALS. Additionally, 
cellular and animal models will be required to model oligogenic disease to functionally 
characterise how identified genes interact to cause disease.  
1.1.5. General pathogenic mechanisms   
The identification of multiple ALS-causing genes has enabled researchers to elucidate 
potential molecular mechanisms underlying the disorder. In common with other 
neurodegenerative diseases, pathogenic mechanisms are multifactorial and not yet fully 
understood. The general consensus is that a complex interplay between several 
mechanisms leads to the selective degeneration of UMNs and LMNs observed in ALS. 
Some of the cellular events believed to cause such destruction include; oxidative stress, 
excitotoxicity, mitochondrial dysfunction, protein aggregation, impaired axonal 
transport, defective RNA/DNA processing and activation of non-neuronal cells 
(Ferraiuolo et al. 2011) – all of which share commonality with other neurodegenerative 
disorders. See table 1.2 for an overview of these mechanisms.   
Understanding the potential molecular mechanisms in ALS is not only important in 
further understanding clinical features of ALS, but it is also essential in unmasking 
potential targets for neuroprotective therapies. For example, ameliorating excitotoxicity 
via the use of Riluzole has been a successful pharmacological strategy to slow down the 
progression of ALS (Lacomblez et al. 1996, Bensimon et al. 1994). Additionally, the 
newly approved Edaravone, a neuroprotective drug with properties of a free radical 
scavenger, has been shown to reduce oxidative stress and slow down the progression of 
ALS (Abe et al. 2017). There is a growing need to further understand the genetics and 
pathogenic mechanisms underlying ALS, in order to develop more effective disease 
modifying therapies.
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Table 1.2 Summary of general pathogenic mechanisms involved in ALS. 
Pathogenic mechanism      Key evidence with reference(s) 
Oxidative stress; 
Imbalance in generation and/or removal 
of reactive oxygen species (ROS), 
coinciding with inability of the system 
to remove and/or repair ROS-induced 
damage  
- Oxidative stress results in structural damage, including DNA, RNA and proteins, and disrupts redox-
sensitive signalling pathways  
- Mutations in the gene SOD1, which encodes major antioxidant protein, account for approx. 20% of 
fALS cases (Rosen et al. 1993) 
- Biosamples from ALS patients show elevated levels of free radical damage (Simpson et al. 2004) 
- Increased levels of oxidative damage to proteins, lipids and DNA found in sALS and SOD1-related 
fALS post-mortem tissue (Shaw et al. 1995) 
- Oxidative damage occurs in cellular and murine models of SOD1 related ALS (Ferraiuolo et al. 2011) 
Excitoxicity; 
Excitoxicity results in excessive 
stimulation of glutamate receptors 
resulting in increased calcium influx into 
post-synaptic neurons, which results in 
toxicity   
- Raised levels of glutamate found in CSF of ALS (Rothstein et al. 1990) 
- KO of EAAT2 in vitro and in vivo (astrocytic glutamate transporter) results in neuronal death 
(Rothstein et al. 1996) 
- Overexpression of EAAT2 in mutant SOD1 transgenic mouse delayed onset of motor deficits (Guo et 
al. 2003) 
- Reduction in spinal cord EAAT2 protein in end-stage SOD1 rodent models of ALS (Bruijn et al. 1997, 
Howland et al. 2002) 
- Only disease-modifying drug to date, Riluzole, has anti-glutamatergic activity (Doble 1996) 
Mitochondrial dysfunction; 
Mitochondria are critical to cell survival, 
acting as an energy source, buffering 
intracellular calcium and regulating 
apoptosis 
- Defective respiratory chain function found in tissue from ALS patients and mSOD1 rodent models, 
associated with oxidative damage to mitochondrial proteins and lipids (Wiedemann et al. 2002, 
Mattiazzi et al. 2002) 
- Thus dysregulated energy metabolism likely to contribute to MN dysfunction in ALS 
- Calcium buffering impaired in mitochondria purified from CNS of mSOD1 mice (Damiano et al. 2006) 
- Altered mitochondrial morphology observed in spinal MNs from ALS patients (Sasaki and Iwata 2007) 
- This is also observed in primary motor neurons and NSC-34 cells expressing mutant SOD1 (Menzies et 
al. 2002) 
Protein aggregation; 
Insoluble protein aggregates are a 
hallmark of ALS, suggesting a collapse 
in protein homeostasis (see section 1.2)  
- Inclusions found in both degenerating neurons and surrounding glia (Piao et al. 2003, Zhang et al. 
2008, Nishihira et al. 2008) 
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- Most common inclusions contain ubiquitinated proteins, indicating a problem with the ubiquitin-
proteasome system (UPS) and autophagy degradation pathways (Neumann et al. 2006, Blokhuis et al. 
2013) 
- Several ALS-linked genes play role in protein trafficking or degradation pathways, including UBQLN2, 
p62/SQSTM1, VCP, C9orf72, OPTN, TBK-1 (see table 1.1)  
- Evidence of ER stress in ALS patient CNS tissue, plus cellular and animal models (Matus et al. 2013) 
Impaired axonal transport; 
Efficient axonal transport is critical for 
axonal function  
 
- Many ALS-linked genes are involved with axonal transport and/or the cytoskeleton (see table 1.1), 
suggesting impaired axonal transport contributes to ALS pathogenesis  
- Defective axonal transport occurs early in disease in mSOD1 mice and impairs anterograde transport of 
mitochondria (De Vos et al. 2007, Kieran et al. 2005, Williamson and Cleveland 1999, Bilsland et al. 
2010) 
- Mutations in DCTN1, essential for retrograde transport, led to degeneration of MNs and premature 
death in rodents (Puls et al. 2003, Laird et al. 2008)  
Dysregulated RNA metabolism; 
Numerous RNA/DNA binding proteins 
associated with fALS, including TDP-
43, FUS, ANG, ATXN-2 and hnRNPA1 
(see table 1.1) 
 
- TDP-43 forms the characteristic neuronal inclusions in most ALS cases (Neumann et al. 2006), minus 
fALS cases linked to FUS and SOD1 mutations (Mackenzie et al. 2007, Vance et al. 2009, 
Kwiatkowski et al. 2009) 
- Sense and antisense RNA transcripts are present in intranuclear foci in C9-ALS cases (Gendron et al. 
2013), which are reported to sequester a number of RNA binding proteins and perturb their function, 
including: hnRNP A3, hnRNP A1, hnRNP-H1/F, SRSF2, ALYREF and ADARB2 (Mori et al. 2013b, 
Xu et al. 2013, Lee et al. 2013, Donnelly et al. 2013, Cooper-Knock et al. 2014b) 
Activation of non-neuronal cells; 
Widely accepted concept that ALS is a 
non-cell autonomous process (Ferraiuolo 
et al. 2011) 
 
- Survival of mice expressing SOD1G93A in MNs improved when surrounded by WT non-neuronal cells 
(Clement et al. 2003) 
- Survival of SOD1G93A transgenic mice is prolonged by eliminating mutant SOD1 gene from several 
non-neuronal cell types (Yamanaka et al. 2008, Boillee et al. 2006, Kang et al. 2013) 
- ALS-derived astrocytes have been shown to be toxic to MNs in vitro (Nagai et al. 2007) 
- Astrocytes and microglia are activated in ALS, resulting in an increase in pro-inflammatory cytokine 
activity, which is seen in CNS tissues from ALS patients (Philips and Robberecht 2011) 
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1.1.6. The ALS-FTD spectrum  
ALS patients often show a loss of cortical neurons in the frontal and/or temporal lobes. 
Such neurodegeneration is characteristic of a condition called FTD, which is the leading 
cause of dementia after Alzheimer’s disease. It presents in individuals under 65, with an 
incidence rate of 3.5-4.1 per 100 000 person-years in the 45-64 age group (Van 
Langenhove, van der Zee and Van Broeckhoven 2012). Disease duration is approximately 
6-8 years post diagnosis and there is currently no cure (Hodges et al. 2003, Vossel and 
Miller 2008). It is a heterogeneous condition and there are three clinically recognised 
subgroups of the disease, with variable symptoms and distinct locations of 
neurodegeneration (Van Langenhove et al. 2012) (see table 1.3). There is a strong genetic 
contribution to FTD and around 50% of cases are thought to be familial. Mutations in the 
microtubule associated protein tau (MAPT) (Hutton et al. 1998) and progranulin (PGRN) 
(Baker et al. 2006, Cruts et al. 2006) are believed to explain around 10-20% of these 
cases. Accumulating evidence has revealed that ALS and FTD are linked clinically, 
pathologically and genetically, with both disorders recognised as two extremes of a 
clinico-pathological continuum.   
Table 1.3 Subgroups of frontotemporal dementia (FTD). 




Prefrontal neurodegeneration  Disinhibition, apathy, lack of 
emotional concern, stereotypic 
behaviour, executive 









Atrophy of anterior temporal 
lobes 
Comprehension deficits, 
naming error with fluent 
speech  
 
Clinically, in addition to the characteristic motor dysfunction observed in ALS, it has 
been estimated that up to 50% of patients show evidence of cognitive or behavioural 
impairment (Ringholz et al. 2005). Two studies on large ALS patient cohorts revealed 
around 15-18% of such patients met the clinical criteria for FTD (see table 1.3) (Ringholz 
et al. 2005, Lomen-Hoerth et al. 2003). Additionally, it is estimated around 15% of FTD 
patients have motor dysfunction, meeting the clinical criteria of ALS (Lomen-Hoerth et 
al. 2002, Burrell et al. 2011). The cognitive changes in patients with both ALS and FTD 
usually resembles bvFTD (Lillo et al. 2010), however there are reports describing PNFA 
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or SD in association with ALS (Ostberg and Bogdanovic 2011, Catani et al. 2004). 
Interestingly, FTD-ALS patients sometimes develop hallucinations or delusions, which 
is not often seen in pure FTD (Mendez et al. 2008, Lillo et al. 2010). In the majority of 
cases, FTD symptoms precede those of ALS  (Van Langenhove et al. 2012).   
A major breakthrough in elucidating shared pathogenic mechanisms between ALS and 
FTD occurred in 2006, when evidence revealed that TDP-43 was the major ubiquitinated 
protein found within UBIs in both disorders (Neumann et al. 2006). Subsequently, it was 
identified that mutations in the gene encoding TDP-43, were causative in ALS 
(Sreedharan et al. 2008) and FTD (Borroni et al. 2009) cases. Additionally, mutations in 
the gene encoding FUS,  were discovered to account for rare ALS and FTD cases (Van 
Deerlin et al. 2008, Kwiatkowski et al. 2009, Vance et al. 2009). Interestingly, both of 
these are RNA binding proteins and play a role in RNA metabolism. Therefore, this 
suggests that aberrant RNA processing may be a central pathogenic mechanism in the 
causation of ALS, ALS/FTD and/or FTD. 
Additionally, several other genes which encode proteins involved in protein degradation 
pathways or maintaining protein homeostasis, have been identified to cause ALS, 
ALS/FTD and/or FTD. This non-exhaustive list includes: ubiquillin-2 (UBQLN-2) (Deng 
et al. 2011); valosin containing protein (VCP) (Johnson et al. 2010); optineurin (OPTN) 
(Maruyama et al. 2010); vesicle-associated membrane protein-associated protein B 
(VAPB) (Nishimura et al. 2004); charged multivesicular body protein 2B or chromatin 
modifying protein 2B (CHMP2B) (Parkinson et al. 2006); and p62/sequestosome 
(SQSTM1) (Fecto et al. 2011). Alongside the characteristic protein aggregates identified 
in both ALS and FTD, these discoveries indicate a disruption in proteostasis may also be 
a central pathogenic mechanism in both diseases, as well as aberrant RNA processing.  
In 2011 a non-coding hexanucleotide repeat expansion in chromosome 9 open reading 
frame 72 (C9orf72) was identified as the most common mutation found in ALS (40% of 
fALS and 6-20% sALS) and FTD (25% of fFTD and 6% sFTD) (DeJesus-Hernandez et 





1.2. Chromosome 9 open reading frame 72 (C9orf72) 
1.2.1. Identification of C9orf72 as an ALS- and FTD-disease gene  
In 2006, genetic linkage analysis performed by two individual groups (Vance et al. 2006, 
Morita et al. 2006) on families affected by both ALS and FTD revealed linkage of ALS-
FTD to chromosome 9p. Subsequent genetic linkage reports indicated this shared 
chromosomal region was located at 9p21.2-9p21.1 (Van Langenhove et al. 2012). 
Additionally, several genome wide association studies (GWAS) on large cohorts of 
unrelated ALS patients and controls (van Es et al. 2009, Shatunov et al. 2010, Laaksovirta 
et al. 2010) also reported linkage to chromosome 9p region, located at 9p21. This trend 
was also demonstrated in a GWAS on a large group of FTD-TDP patients (Van Deerlin 
et al. 2010). Amalgamation of these reports indicated that genetic variation within the 
identified chromosomal region affected both familial and sporadic ALS and FTD cases. 
In 2010, the identified locus which linked these families on chromosome 9p was narrowed 
to a 232 kb interval, which was shown to contain three protein encoding genes: C9orf72, 
MOBKL2B, IFNK (Laaksovirta et al. 2010). Finally, in 2011, two individual research 
teams reported that the causative mutation within this region was a (G4C2)n 
hexanucleotide repeat expansion in intron 1 of C9orf72 (DeJesus-Hernandez et al. 2011, 
Renton et al. 2011). This was later confirmed in a separate study (Gijselinck et al. 2012). 
1.2.2. (G4C2)n hexanucleotide repeat expansions in C9orf72  
As discussed, a non-coding hexanucleotide repeat expansion in C9orf72 is the most 
common mutation found in ALS (40% of fALS and 6-20% sALS) and FTD (25% of 
fFTD and 6% sFTD) (DeJesus-Hernandez et al. 2011, Renton et al. 2011). The human 
C9orf72 gene (ENST00000619707.4) has 11 exons in total, 10 of which are coding exons, 
and is reported to be alternatively spliced into three protein-coding transcript variants, 
V1-V3 (DeJesus-Hernandez et al. 2011, Renton et al. 2011) (Figure 1.2). It is predicted 
that these three transcripts lead to the expression of two alternative isoforms of the 
C9orf72 protein. Firstly, a long protein isoform (C9orf72L) of 481 amino acids (aa), 
encoded by V1 and V3. Secondly, a short protein isoform (C9orf72S) of 222aa, encoded 
for by V2. It is reported that these isoforms are widely expressed in a number of brain 
regions and peripheral tissues (DeJesus-Hernandez et al. 2011, Waite et al. 2014). 
However, such data has been hampered by the fact that reliable anti-C9orf72 antibodies 
were not commercially available. Recently, a group designed antibodies which 
specifically recognise the two C9orf72 protein isoforms (Xiao et al. 2015). It was reported 
that the two isoforms are localised to distinct parts of the cell. For example, C9orf72L is 
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localised diffusely throughout the cytoplasm in cerebellar Purkinje cells, and C9orf72S 
expression is localised to the nuclear membrane of Purkinje cells (Xiao et al. 2015) 
 
 
Figure 1.2 Schematic diagram of C9orf72. Introns are represented by lines and exons 
by boxes; white boxes are coding exons whereas red boxes are non-coding exons/UTRs. 
The (G4C2)n repeat expansion is located between the non-coding exons 1a and 1b of 
C9orf72, as indicated by the yellow box. C9orf72 is alternatively spliced into three 
protein-coding transcripts; V1-V3. Transcript variants V1 and V3 encode the long 
isoform (C9orf72-L). Transcript variant V2 encodes the short isoform (C9orf72-S). The 
transcription start site is upstream of exon 1A and the (G4C2)n repeat in V2 and V3. 
However, in V1 the (G4C2)n repeat is upstream of the transcription start site. Adapted 







Repeat-primed PCR (rpPCR) assays were often used to determine whether a sample 
carries a large pathogenic expansion. However, this technique could only reliably predict 
size up to a maximum of 30 repeats (Renton et al. 2011), thus amplification of the entire 
pathogenic C9orf72 repeat expansion was not possible by this method. Southern blotting 
is a much more reliable method to predict true repeat size. Using this technique, ‘normal’ 
repeat size in healthy individuals is estimated to be <30 units, although approximately 
90% have fewer than 10 units (Picher-Martel et al. 2016). Conversely, the number of 
repeats in ALS patients can range from several hundred to several thousand units (Beck 
et al. 2013, Buchman et al. 2013, van Blitterswijk et al. 2013).  
In many repeat expansion disorders, the size of the pathological repeat expansion 
influences the observed clinical phenotype. For example, myotonic dystrophy type I 
(DM1) is caused by a (CTG)n repeat expansion in a noncoding region of DMPK (Brook 
et al. 1992, Mahadevan et al. 1992). The number of repeats in DMPK is reported to show 
a high degree of instability, which appear to predispose the repeat toward further 
expansion (van Blitterswijk, DeJesus-Hernandez and Rademakers 2012a). Additionally, 
longer expansions have been reported to correlate with more severe symptoms and an 
earlier age of onset in successive generations (genetic anticipation) (van Blitterswijk et 
al. 2012a). Regarding C9orf72, sizing of the (G4C2)n repeat expansion via southern 
blotting has revealed somatic heterogeneity within individuals, with different expansion 
lengths observed in different tissues (Beck et al. 2013, van Blitterswijk et al. 2013, Harms 
et al. 2013, Huebers et al. 2014). Somatic heterogeneity suggests instability within the 
(G4C2)n repeat expansion and evidence of genetic anticipation in C9-ALS/FTD has been 
reported, with decreasing onset age of 7-11 years in subsequent generations (Benussi et 
al. 2014, Chio et al. 2012, Gijselinck et al. 2012, Hsiung et al. 2012, Stewart et al. 2012). 
However, genetic anticipation is not seen in all cohorts (DeJesus-Hernandez et al. 2011, 
Renton et al. 2011). It is still not clear whether the observed genetic anticipation in C9-
ALS/FTD patients is related to expansion size. Although, a recent study reported an 
increase in expansion size from parent to offspring (Gijselinck et al. 2016).  
1.2.3. Clinical features of C9-ALS/FTD  
In general, the ALS and/or FTD phenotypes associated with the (G4C2)n repeat expansion 
are representative of the whole clinical spectrum. However, some distinct phenotypes 
have been reported. There is a higher incidence of bulbar-onset disease (Cooper-Knock 
et al. 2012, Millecamps et al. 2012, Stewart et al. 2012). An earlier age of onset is often 
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observed in C9orf72-linked ALS (C9-linked) (Byrne et al. 2012, Cooper-Knock, Shaw 
and Kirby 2014a). Some cohorts report that male C9-linked ALS patients present at a 
younger age of onset than non-C9 ALS cases (Williams et al. 2013). There is also 
evidence for a shorter disease duration in patients carrying the (G4C2)n repeat expansion 
(Cooper-Knock et al. 2014a). There is a higher prevalence of cognitive and/or behavioural 
changes in C9-linked ALS patients, with co-morbid dementia observed in approximately 
50% of C9-linked ALS patients compared to only 12% in non-C9 ALS cases (Byrne et 
al. 2012). The cognitive changes in C9-linked ALS and/or FTD resembles bvFTD (Lillo 
et al. 2010). Additionally, a higher frequency of psychotic symptoms, including 
hallucinations and delusions, is often observed in C9-linked FTD compared to classical 
FTD (Mendez et al. 2008, Lillo et al. 2010). There is also a higher than expected incidence 
of parkinsonism in patients carrying the (G4C2)n repeat expansion, displaying symptoms 
such as hypokinesia/bradykinesia (Wilke et al. 2016). However, the (G4C2)n repeat 
expansion does not seem to be associated directly with Parkinson’s Disease (Cooper-
Knock et al. 2013).  
The basis for the clinical heterogeneity noted in patients carrying the (G4C2)n repeat 
expansion is not fully understood. A potential explanation is that there is a correlation 
between expansion size and clinical phenotype. There is evidence for this in C9-linked 
FTD, where repeat size in the cerebellum has been identified to correlate with disease 
(van Blitterswijk et al. 2013). However, there is no conclusive data to support this in ALS 
(Cooper-Knock et al. 2014a). Additionally, patients carrying the repeat expansion in 
C9orf72 are often observed to have mutations in other ALS-linked genes. Interestingly, 
it has been identified that C9orf72 repeat expansions coinciding with TDP-43, FUS or 
SOD1 mutations are linked to causing pure ALS (Lattante et al. 2015a). Alternatively, 
C9orf72 repeat expansions coinciding with tau or p62/SQSTM1 mutations are linked to 
causing pure FTD (Lattante et al. 2015a). This suggests that C9orf72 repeat expansions 
may be a risk factor for developing ALS, ALS/FTD and/or FTD in patients, with the 
second mutation potentially contributing to where along the spectrum the patient lies. 
However, the molecular mechanisms underlying the oligogenic hypothesis would need to 
be further investigated, using cellular and animal models. 
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1.2.4. Neuropathological features of C9-ALS/FTD 
In relation to pathology, patients with the repeat expansions exhibit typical characteristics 
noted in classical ALS. However, there are a number of neuropathological changes which 
appear to be specific to C9orf72 patients.  
Firstly, several studies have reported the presence of dotlike or star shaped p62/SQSTM1 
and/or ubiquillin-2 positive nuclear or cytoplasmic inclusions (NCIs) which are negative 
for TDP-43 (Al-Sarraj et al. 2011, Cooper-Knock et al. 2012, Stewart et al. 2012). It is 
believed that these inclusions are a specific feature of ALS caused by pathological repeat 
expansions in C9orf72 (Al-Sarraj et al. 2011, Cooper-Knock et al. 2012). These 
inclusions have been found to be located in regions such as the cerebellum, hippocampus 
and frontotemporal neocortex (Cooper-Knock et al. 2012). The presence of these 
inclusions suggest that there is a coinciding pathomechanism to TDP-43 aggregates in 
C9-linked ALS.  
Secondly, it is known that the C9orf72 repeat expansion is transcribed in both a sense and 
antisense direction. This results in the presence of both sense (G4C2)n and antisense 
(C2G4)n RNA foci in several locations in the CNS of patients, including; the frontal cortex, 
motor cortex, hippocampus, cerebellum and spinal cord (Gendron et al. 2013, Mizielinska 
et al. 2013, Lagier-Tourenne et al. 2013). Whilst the majority of RNA foci are neuronal, 
it has been reported that they are present in astrocytes, microglia and oligodendrocytes at 
a much lower frequency (Mizielinska et al. 2013). Several studies have observed that 
these RNA foci co-localise with various RNA binding proteins, which could perturb their 
function (Mori et al. 2013b, Xu et al. 2013, Lee et al. 2013, Donnelly et al. 2013, Cooper-
Knock et al. 2014b).  
Lastly, it is reported that the (G4C2)n sense and (C4G2)n antisense transcripts undergo 
repeat-associated non-ATG (RAN) translation in all reading frames, resulting in the 
synthesis of five aggregation-prone dipeptide repeat (DPR) proteins (Ash et al. 2013, 
Mori et al. 2013a, Mori et al. 2013c). All five of these DPR proteins co-aggregate in the 
characteristic p62 positive, TDP-43 negative inclusions seen in C9FTD/ALS patients 
(Mori et al. 2013b, Mori et al. 2013c, Mori et al. 2013a, Ash et al. 2013), in locations 
such as the cerebellum, hippocampus and frontotemporal neocortex. Additionally, it is 
suggested that DPR protein aggregation may precede TDP-43 pathology, with evidence 
of some DPRs within TDP-43 positive inclusions (Mori et al. 2013c).  
18 
1.2.5. C9orf72 protein function  
Currently, the function(s) of the C9orf72 protein are beginning to be elucidated, but are 
not fully understood. It is imperative to gain a better knowledge on the normal function 
of this protein in order to both understand C9-linked disease mechanisms and to identify 
novel neuroprotective targets for future therapies. Evidence for some of the potential roles 
of C9orf72 is detailed in this section.  
1.2.5.1. C9orf72: a novel DENN protein? 
There is emerging evidence that C9orf72 may play a role in protein trafficking, as a 
member of the DENN-like superfamily (Levine et al. 2013, Zhang et al. 2012). The 
tripartite DENN (meaning ‘differentially expressed in normal and neoplastic cells’) 
module, consists of; an N-terminal longin domain, a central DENN domain and a C-
terminal d-DENN domain. The DENN domain is an evolutionary conserved protein 
module, and its best characterised function is as a specific guanine nucleotide exchange 
factor (GEF) for Rab GTPases (Levivier et al. 2001). The role of these GEFs is to catalyse 
the exchange of GDP for GTP, which results in the activation of Rab GTPases. The 
human genome is thought to encode up to 66 Rab GTPases (Kloepper et al. 2012), many 
of which are master regulators of intracellular membrane trafficking (Zerial and McBride 
2001). Once activated, GTP-bound Rab interacts with various effector proteins to mediate 
numerous functions, including directing vesicles to the correct site of fusion (Hutagalung 
and Novick 2011). 
C9orf72L is a full-length homologue containing all three DENN domains, whereas the 
short isoform appears to show homology only to the N-terminal longin domain (Levine 
et al. 2013). However, the implications of these differences are not known, as the distinct 
roles of each of the DENN domains are not fully understood. Consistent with the 
prediction that C9orf72 may be a DENN-like protein, an initial report showed that 
C9orf72 co-localised and co-immunoprecipitated with Rab proteins implicated in both 
autophagy and endocytic trafficking, including Rab-1, -7 and -11 (Farg et al. 2014). 
However, clear mechanistic details were lacking. Recently, data from our lab has shown 
that C9orf72 interacts with Rab1a (Webster et al. 2016a). Interestingly, it was found that 
it preferentially binds to GTP-bound Rab1a, suggestive that C9orf72 functions as an 
effector of Rab1a rather than a GEF, as would be expected of a DENN-like protein 
(Webster et al. 2016a). Additionally, it was shown that as a Rab1a effector, C9orf72 was 
essential in mediating the Rab1a-mediated translocation of the ULK-1 complex to the 
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phagophore, essential in initiating autophagosome formation (Webster et al. 2016a, Hara 
et al. 2008). Conversely, it has also been reported recently that C9orf72 acts as a GEF for 
Rab8a and Rab39b, in complex with SMCR8, another DENN-like protein, and WDR41 
(Sellier et al. 2016). However, the interaction of C9orf72/SMCR8/WDR41 complex with 
these particular Rabs appears to be mediated by SMCR8, as GEF activity is only observed 
when SMCR8 is present in the complex (Sellier et al. 2016). It is known that Rab GTPases 
can act in Rab GEF/GAP cascades. In such cascades, the upstream Rab, and its effectors, 
recruit the GEF for the downstream Rab, whilst the downstream Rab simultaneously 
recruits the GAP for the upstream Rab (Hutagalung and Novick 2011). Thus, our lab 
suggests that C9orf72 acts in a Rab cascade (Webster et al. 2016b). Therefore, it is likely 
that C9orf72 links autophagy initiation to downstream events via a Rab GEF/GAP 
cascade, with Rab1a upstream, and Rab8a and Rab39b downstream (Webster et al. 
2016b).  
1.2.5.2. C9orf72 and autophagy  
DENN domain-containing proteins function as GDP/GTP exchange factors (GEFs) for 
Rab GTPases, which are involved in regulating a number of cellular trafficking events, 
including autophagy (Zerial and McBride 2001, Kloepper et al. 2012). Recent research 
has revealed a direct mechanistic role for C9orf72 in macroautophagy (hereafter referred 
to as autophagy). Autophagy is a conserved lysosomal degradation pathway which 
involves the degradation of cytoplasmic components, such as misfolded proteins and 
damaged organelles, within an autophagolysosome, for bulk degradation or recycling 
(Klionsky et al. 2012). This important cellular process can be divided into four sequential 
steps: translocation and initiation; elongation and recruitment; completion; lysosome 
fusion and degradation (figure 1.3) (Bento et al. 2016). Autophagy is known to be 
essential for neuronal health; for example, neuronal-specific knockout (KO) of essential 
autophagy genes - such as ATG7, ATG5 and FIP200 - results in the inhibition of 
autophagy in neurons and subsequently neurodegeneration in mouse models (Hara et al. 
2006, Komatsu et al. 2006, Liang et al. 2010). Furthermore, there are increasing reports 
that defective autophagy plays a role in the pathogenesis of ALS (Menzies et al. 2017). 
As mentioned, UBIs are a neuropathological hallmark of C9-linked ALS, as well as non-
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Figure 1.3 The autophagy pathway. Schematic diagram of the autophagy pathway. Inhibition of mTOR (in nutrient poor conditions) releases 
the ULK1 complex. ULK 1 then phosphorylates ATG13 and FIP200, activating the complex, which then translocates to the phagophore. This is 
the first step of autophagy initiation. The Class III PI3 Kinase Complex then translocates to the phagophore, which is essential for elongation of 
the membrane. Cargo is transported to the growing phagophore by autophagy receptors, such as p62/SQSTM1, which bind to both the poly-
ubiquitin chains on the cargo (via the ubiquitin binding (UBI) domain) and LC3-II on the phagophore membrane (via the LC3 interacting region 
(LIR) domain). Mature autophagosomes then fuse with the lysosome. Autophagosome-lysosome fusion results in an autophagolysosome, where 
cargo is degraded via lysosomal hydrolases. Conversely in nutrient rich conditions, mTOR suppresses the ULK1 complex via phosphorylating 
ULK 1/2 and ATG13. This suppresses autophagy initiation. 
21 
C9 linked ALS (Menzies et al. 2017). Additionally, several ALS-linked genes are known 
to encode proteins which function within the pathway, including: p62/SQSTM1, 
UBQLN2, OPTN, TBK-1 and VCP (see table 1.1). Therefore, the implication that C9orf72 
also plays a role in autophagy is consistent with the fact that autophagy is an important 
pathway in ALS.  
A characteristic neuropathology observed in C9-ALS/FTD patients is p62/SQSTM1 
positive, TDP-43 negative inclusions (Cooper-Knock et al. 2012, Al-Sarraj et al. 2011). 
The protein p62/SQSTM1 targets ubiquitinated proteins to the autophagy pathway for 
degradation (Bento et al. 2016) and accumulation of this protein has been associated with 
inhibition of autophagy (Hara et al. 2006). Thus this pathology, alongside early evidence 
for C9orf72 haploinsufficiency, suggested the possibility of defective autophagy via loss 
of C9orf72 function in C9-ALS/FTD. There is now increasing evidence in our lab and 
others, that the C9orf72 protein is a key regulator of autophagy (Amick, Roczniak-
Ferguson and Ferguson 2016, Sellier et al. 2016, Sullivan et al. 2016a, Webster et al. 
2016b, Webster et al. 2016a, Yang et al. 2016). In particular, there are a wealth of reports 
that show C9orf72 plays a role upstream, regulating initiation of the pathway. As shown 
in figure 1.3, autophagy can be activated by the ULK-1 complex, which consists of ULK-
1, FIP200, ATG13 and ATG101. This complex is kept inactive via the phosphorylation 
of ULK-1 by mTOR. Inactivation of mTOR, for example in nutrient poor conditions, 
results in the release of the ULK-1 initiation complex. ULK-1 is then able to 
phosphorylate FIP200 and ATG13, activating the complex and initiating autophagy (Jung 
et al. 2009, Ganley et al. 2009). Overexpression of C9orf72 has been shown to activate 
autophagy (Webster et al. 2016a). Furthermore, following disruption of the ULK-1 
initiation complex, via depletion of FIP200, overexpression of C9orf72 no longer 
activated the pathway, indicating that C9orf72 may also function at the level of the ULK-
1 complex (Webster et al. 2016a). Strengthening this association, it is reported that 
C9orf72 directly interacts with several members of this complex, including; ULK-1, 
FIP200 and ATG13 (Behrends et al. 2010, Webster et al. 2016a). Also, recent studies 
have published that depletion of C9orf72, in both cell lines and primary neurons, results 
in defective autophagy initiation and accumulation of p62/SQSTM1, similar to the 
pathology seen in C9-ALS/FTD patients (Farg et al. 2014, Yang et al. 2016, Sellier et al. 
2016, Sullivan et al. 2016a, Webster et al. 2016a). Adding to the story, our lab has also 
identified that the C9orf72 protein is an effector of Rab1a, facilitating trafficking of the 
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ULK-1 initiation complex to the phagophore, which is essential for autophagosome 
formation (Webster et al. 2016a). Conversely, others have demonstrated that a complex 
consisting of C9orf72/SMCR8/WDR41 acts as a GEF for Rab8a and Rab39b, which act 
further downstream the autophagy pathway, during autophagosome maturation (Sellier et 
al. 2016). However, the GEF activity of the C9orf72/SMCR8/WDR41 appears to be 
dependent on SMCR8 (Sellier et al. 2016). Adding further complexity to its function, 
C9orf72 co-localises with lysosomes in cells when starved of amino acids (Amick et al. 
2016), consistent with the lysosome being an important site of function for C9orf72. 
Overall, although different roles have been suggested, recent evidence supports the 
involvement of C9orf72 in autophagy regulation.  
1.2.6. C9orf72 specific pathogenic mechanisms  
Due to the discovery of the (G4C2)n hexanucleotide repeat expansion in C9orf72, ALS 
and FTD are now part of a growing class of ‘non-coding repeat expansion disorders’, 
including myotonic dystrophies, fragile-X associated tremor/ataxia and several 
spinocerebellar ataxias (La Spada and Taylor 2010). Research into these has elucidated 
various mechanisms by which non coding repeat expansions may cause disease. 
Regarding the C9orf72 repeat expansion, three principal mechanisms have gained 
particular attention; haploinsufficiency, RNA toxicity and repeat-associated, non-ATG 
(RAN) translation (figure 1.4). The pathogenic mechanism underlying C9orf72-linked 












Figure 1.4 Potential disease mechanisms associated with C9orf72 (G4C2)n repeat 
expansion. There are currently three potential mechanisms by which the C9orf72 
associated hexanucleotide expansion could cause neurotoxicity. Firstly, transcriptional 
silencing of C9orf72 via hypermethylation or transcription abortion may lead to reduced 
C9orf72 expression and haploinsufficiency. Secondly, the hexanucleotide repeat is 
transcribed in a sense and antisense direction. This (G4Cn)2 and/or (C4G2)n repeat 
containing RNA form foci, which may sequester RNA binding proteins, perturbing their 
function and causing toxicity. Finally, the (G4Cn)2 and/or (C4G2)n repeat containing RNA 
undergoes repeat-associated non-ATG (RAN) translation producing dipeptide repeat 




1.2.6.1. Haploinsufficiency  
The haploinsufficiency model suggests partial or complete loss of function of the repeat 
containing allele. This pathogenic mechanism has been reported to underlie other repeat 
expansion disorders such a Fragile X Syndrome (FXS) (Wen et al. 2017). A reduction in 
variant-specific or total C9orf72 messenger RNA (mRNA) in various CNS tissues, 
lymphoblast cells and iPSC-derived neurons from C9orf72 repeat expansion carriers has 
been observed by several groups (DeJesus-Hernandez et al. 2011, Gijselinck et al. 2012, 
Belzil et al. 2013, Fratta et al. 2013, Almeida et al. 2013). Additionally, it has been 
reported that C9orf72 protein levels are reduced in various regions of the CNS in C9orf72 
repeat expansion carriers (Waite et al. 2014, Xiao et al. 2015). There are several reports 
suggesting that the decrease in C9orf72 mRNA expression may be due to epigenetic 
alterations, such as varying levels of DNA and histone methylation, which are events 
known to repress gene expression. It has been reported that trimethylated histones (H3K9, 
H3K27, H3K79, H4K20) bind the pathogenic repeat expansion of C9orf72 in brain 
regions that correspond to decreased C9orf72 mRNA levels in patients (Belzil et al. 
2013). In addition, it has been shown that aberrant CpG island methylation 5’ of the 
(G4C2)n hexanucleotide repeat is significantly associated with C9-ALS/FTD and that 
levels of methylation are inversely correlated with disease onset (Xi et al. 2013). 
However, others have reported that this aberrant methylation may actually be protective 
(Liu et al. 2014). Additionally, another recent report suggests that this decrease in 
C9orf72 mRNA may be a result of stalled transcription. The formation of distinct 
polymorphic structures within the C9orf72 hexanucleotide repeat expansion, including 
G-quadruplexes and RNA•DNA hybrids (R-loops), may cause the RNA polymerase 
processivity to be impaired in the repeat region (Haeusler et al. 2014).  
In order to establish whether decreased C9orf72 expression contributes to disease 
pathogenesis, a number of C9orf72 knock down (KD) or knock out (KO) models have 
been generated, with varying results. Deletion of ALFA-1, the C.elegans orthologue of 
C9orf72, resulted in age-dependent progressive motor defects with an increased 
sensitivity to stress induced paralysis (Therrien et al. 2013). Additionally, transient KD 
of C9orf72 during embryonic development has been shown to result in locomotor and 
axonal deficits in zebrafish (Ciura et al. 2013). In mice, C9orf72 has been conditionally 
removed in neuronal and glial cells using the Nestin-Cre system or constitutively removed 
in all cell types using targeted genome editing techniques (Wen et al. 2017). Although it 
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is reported that the C9orf72 KO mouse models do not show signs of neurodegeneration 
(Koppers et al. 2015, Sudria-Lopez et al. 2016, O'Rourke et al. 2016, Atanasio et al. 
2016), two KO mouse models did show mild motor defects (Atanasio et al. 2016) and 
decreased survival (Sudria-Lopez et al. 2016). However, these phenotypes may be 
attributed to other underlying conditions rather than ALS/FTD, as these models have 
consistently reported symptoms such as enlarged spleens and lymph nodes, microglia 
activation with abnormal lysosomal activity and altered cytokine production (Atanasio et 
al. 2016, O'Rourke et al. 2016, Sudria-Lopez et al. 2016).  In addition to animal models, 
two studies of human C9-ALS/FTD have provided contradictory evidence for a LOF 
disease mechanism. Firstly, a case report on a patient homozygous for the C9orf72 repeat 
expansion argued against haploinsufficiency, as if it was the major disease mechanism it 
would be expected that this patient would have a more severe phenotype, but analysis 
revealed that the phenotype was no more severe than a patient heterozygous for the 
C9orf72 repeat expansion (Fratta et al. 2013).  Conversely, a recent study reported the 
presence of a novel LOF C9orf72 splice site mutation in a patient with ALS, supporting 
haploinsufficiency as a disease mechanism in C9-ALS/FTD (Liu et al. 2016). 
Taken together, these findings suggest that haploinsufficiency may not be the sole 
pathogenic mechanism in C9-ALS/FTD. However, normal function of C9orf72 still 
remains poorly understood, particularly in vivo. Experiments to define the biological role 
of C9orf72 are necessary to guide research into how alterations in its function may 
contribute to disease. C9orf72 is thought to function in autophagy, thus partial or 
complete loss of its function may disrupt the pathway, exacerbating RNA toxicity or 
dipeptide repeat (DPR) protein toxicity (see section 1.2.6.2 and 1.2.6.3).  
1.2.6.2. RNA toxicity  
The RNA toxicity hypothesis proposes that transcripts containing the (G4C2)n repeat 
expansion aggregate to form RNA foci and subsequently sequester RNA-binding proteins 
(RBPs). This is hypothesised to result in the perturbed physiological function of such 
RBPs. This is an attractive pathogenic mechanism as it is seen in other non-coding repeat 
expansion disorders such as myotonic dystrophy type 1 (DM1) (La Spada and Taylor 
2010). Evidence of RNA foci in ALS was first reported in 2011, when they were observed 
in the frontal cortex and spinal cord of two patients carrying the repeat expansion 
(DeJesus-Hernandez et al. 2011).  Several groups have reported that the C9orf72 repeat 
expansion is transcribed in both a sense and antisense direction, resulting in the presence 
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of both sense (G4C2)n and antisense (C2G4)n RNA foci in several locations in the CNS of 
patients, including; the frontal cortex, motor cortex, hippocampus, cerebellum and spinal 
cord (Gendron et al. 2013, Mizielinska et al. 2013, Lagier-Tourenne et al. 2013, Zu et al. 
2013). Whilst the majority of RNA foci are neuronal, it has been reported that they are 
present in astrocytes, microglia and oligodendrocytes at a much lower frequency 
(Mizielinska et al. 2013). A number of RBPs have been reported to be sequestered by the 
(G4C2)n repeat in vitro, including; hnRNP A3, hnRNP A1, hnRNP-H1/F, hnRNP-H, 
SRSF2, ALYREF, ADARB2, nucleolin, Pur-α, ASF/SF2, RanGAP1 (Mori et al. 2013b, 
Xu et al. 2013, Lee et al. 2013, Donnelly et al. 2013, Cooper-Knock et al. 2014b, Haeusler 
et al. 2014, Sareen et al. 2013, Reddy et al. 2013, Zhang et al. 2015). It is hypothesised 
that this will lead to lost or reduced function of these RBPs. Interestingly, transcriptomic 
analysis of C9-ALS/FTD patient tissue has shown dysregulation of RNA splicing, which 
may be due to sequestration of particular RBPs (Cooper-Knock et al. 2015).  
To investigate whether the RNA foci seen in patients are sufficient to cause 
neurodegeneration, a number of models have been made. Expression of 30 G4C2 repeats 
in Drosophila was found to be sufficient to cause neurodegeneration, resulting in 
decreased locomotor activity and disrupted eye morphology (Xu et al. 2013). Pur-α was 
found to interact with the repeat in this study and overexpression of this RBP rescued the 
phenotype (Xu et al. 2013). Additionally, in a zebrafish model expressing 38 or longer 
G4C2 repeats, RNA foci formed and initiated apoptotic cell death via sequestration of 
hnRNP-H (Lee et al. 2013) Although this provides evidence that RNA foci are toxic and 
possibly mediate their effect through sequestration of RBPs, mouse models have provided 
contradictory results. Two mouse models expressing a patient derived C9orf72 gene 
containing either 500 or 800 G4C2 repeats had abundant sense and antisense RNA foci, 
as well as RAN translated DPR proteins throughout the CNS, but had no 
neurodegeneration or change in survival, motor or cognitive function (O'Rourke et al. 
2015, Peters et al. 2015a). Additionally, a mouse model expressing 66 G4C2 repeats in the 
CNS via AAV delivery had abundant sense RNA foci, sense derived DPR proteins and 
phosphorylated TDP-43 inclusions (Chew et al. 2015). Conversely to the aforementioned 
mouse models, this model also had neuronal loss and behavioural abnormalities 
reminiscent of C9-ALS/FTD patients, including anxiety, antisocial behaviour and motor 
defects (Chew et al. 2015). Contradictory evidence in several in vivo models suggests that 
RNA foci alone may not be sufficient to cause neurodegeneration. However, future work 
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should focus on elucidating the effect of sequestration of identified RBPs in vivo, to 
understand which one, if any, is critical for disease pathogenesis.  
1.2.6.3. Dipeptide repeat (DPR) protein toxicity  
The repeat-associated non-ATG (RAN) translation hypothesis proposes that tracts of 
expanded repeats are translated despite the absence of an initiating AUG codon, resulting 
in the production of polypeptides composed of repeating units of two amino acids, called 
dipeptide repeat (DPR) proteins (Zu et al. 2011). RAN translation was first reported in 
the repeat expansion disorders myotonic dystrophy type 1 and spinocerebellar ataxia type 
8 (Zu et al. 2011). It has been reported that the repeat expansion in C9orf72 is able to 
undergo bidirectional RAN translation of both the (G4C2)n sense and (C4G2)n antisense 
transcripts (Ash et al. 2013, Mori et al. 2013a, Mori et al. 2013c), resulting in the synthesis 
of five DPR proteins: poly-(glycine-alanine, GA), poly-(glycine-proline, GP), poly-
(glycine-arginine, GR), poly-(proline-arginine, PR) and poly-(proline-alanine, PA) (Mori 
et al. 2013a, Zu et al. 2013, Ash et al. 2013, Mori et al. 2013c). All five of these DPR 
proteins co-aggregate in the characteristic p62 positive, TDP-43 negative inclusions seen 
in C9FTD/ALS patients (Mori et al. 2013b, Mori et al. 2013c, Mori et al. 2013a, Ash et 
al. 2013), in locations such as the cerebellum, hippocampus and frontotemporal 
neocortex. Poly-(GA) has been found to be the most prevalent in these inclusions (Mori 
et al. 2013c), with poly-(GP) and poly-(GR) present to a lesser extent. It is suggested that 
DPR protein aggregation may precede TDP-43 pathology, with evidence of poly-(GA) 
aggregate cores inside TDP-43 positive inclusions (Mori et al. 2013c). 
Several groups have now demonstrated in various in vitro and in vivo models that DPRs 
are toxic. Many studies have focussed on poly-GA, as this is the most abundant DPR 
species in patients carrying the repeat expansion  (Mori et al. 2013c). For example, 
expression of poly-GA in primary neurons, in the absence of RNA foci, resulted in 
neurotoxicity due to impaired proteasome activity and induction of endoplasmic 
reticulum (ER) stress (Zhang et al. 2014). Expression of poly-GA in zebrafish was found 
to be highly toxic (Ohki et al. 2017). Additionally, transgenic mice with abundant poly-
GA pathology have neurodegeneration and ALS/FTD-like symptoms (Zhang et al. 2016). 
As well as poly-GA, arginine rich DPR proteins (poly-GR and -PR) have been extensively 
studied. Expression of GR or PR caused toxicity and early lethality in a Drosophila model 
(Wen et al. 2014). Interestingly, a sophisticated study generated two Drosophila models, 
one with a pure (G4C2)n repeat and one with a (G4C2)n repeat engineered to contain regular 
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interruptions with stop codons to prevent translation. Both pure and interrupted repeats 
formed RNA foci. However, unlike the pure repeat, the interrupted repeats could not be 
RAN translated to form DPRs. Expression of the pure repeats caused toxicity and early 
lethality, whereas the interrupted repeats had no effect. This supports the idea that RNA 
foci are not toxic, but the DPRs are (Mizielinska et al. 2014). 
The aforementioned models indicate that DPRs are toxic, but do not confirm that this 
drives pathogenesis in humans. If DPRs are the major pathogenic mechanism underlying 
C9-ALS/FTD, if would be expected that DPRs accumulate in regions commonly affected 
during disease, for example motor neurons. However, in general it is reported that there 
is a low abundance of DPR proteins in these areas in patient post mortem tissue 
(Mackenzie, Frick and Neumann 2014, Mackenzie et al. 2015). This may be explained, 
as if accumulation of DPRs is toxic and results in neuronal death, the surviving neurons 
found in post mortem tissue may never have had abundant DPR pathology to begin with, 
which would explain why they survived. Interestingly, pathological findings from three 
C9orf72-FTD patients who died prematurely after disease onset (two from 
bronchopneumonia and one from myocardial infarction) suggested that DPR pathology 
preceded TDP-43 pathology, and DPRs were abundant throughout cerebral cortical 
regions, hippocampus and cerebellum (Baborie et al. 2015). This highlights that 
developing minimally invasive techniques to detect DPRs in patients during the disease 










1.3. Modelling neurodegenerative disorders in zebrafish   
1.3.1. Advantages of Zebrafish 
The zebrafish (Danio rerio) was established as a vertebrate model to study developmental 
processes in the 1980s. Since then, the experimental value of the zebrafish has been 
demonstrated and it is increasingly being recognised as a model organism of human 
disease, including neurodegeneration. Zebrafish possess several characteristics that make 
them beneficial to scientists. They are vertebrates which develop ex utero in transparent 
eggs, known as chorions, enabling scientists to monitor developing embryos (Kimmel et 
al. 1995). Embryonic development is rapid, with all major organs formed within 1-day 
post fertilisation (dpf) (Kalueff, Stewart and Gerlai 2014), which is an advantage in 
comparison to higher vertebrate models such as rodents, which have longer gestation 
periods. Zebrafish reach sexual maturity at 3-4 months and are excellent breeders, with a 
single female able to produce hundreds of fertile eggs each week (Kalueff et al. 2014). 
Due to their small size they are able to be kept in a relatively small space, which means 
they are ideal for high-throughput genetic and drug screens.  
The zebrafish genome is fully sequenced and is known to have 25 pairs of chromosomes, 
containing >26,000 protein coding genes (Howe et al. 2013). The genetic homology is 
relatively high between zebrafish and mammals, including humans, supporting the 
translational value of the zebrafish. The nucleotide sequences of zebrafish genes show 
approximately 70% homology with human genes and around 84% of human disease 
genes have zebrafish counterparts, including those linked to neurodegenerative disorders 
(Howe et al. 2013). In genetic studies it is important to consider the genome duplication 
which occurred during teleost evolution, resulting in duplicate copies of many genes in 
zebrafish (Kalueff et al. 2014, Howe et al. 2013, Phillips and Westerfield 2014). However, 
despite this, zebrafish have a similar number of chromosomes to humans and the 
duplicated CNS genes seem to mostly encode proteins with similar or substantially 
overlapping function and properties (Kalueff et al. 2014, Howe et al. 2013, Phillips and 
Westerfield 2014). As the zebrafish genome is fully sequenced they are susceptible to 
genetic manipulation (section 1.3.2). Interestingly, the study of embryonic lethal 
mutations is possible in zebrafish, as they do not require a functional circulatory system 
to survive in the first week, relying on their yolk and passive diffusion of oxygen, and 
undeveloped embryos are not resorbed, as mouse embryos are (Kabashi et al. 2010a). 
Thus, analysis of the whole-organism phenotype can be conducted due to their ex utero 
development.  
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The zebrafish has a conserved, yet simplified, nervous system with other higher 
vertebrates (Babin, Goizet and Raldua 2014). In general, although much smaller, the CNS 
and PNS have a similar overall organisation, including cell types and neuron structure 
(Babin et al. 2014).  Key similarities include: fore-, mid- and hind-brain (including 
diencephalon, telencephalon and cerebellum); peripheral nervous system with motor and 
sensory components; a functional blood-brain barrier; main neurotransmitter systems 
such as the cholinergic and dopaminergic pathways are present; higher vertebrate 
behaviours and integrated neural function such as memory and social behaviour 
(Wullimann and Mueller 2004, Panula et al. 2006, Jeong et al. 2008, Lieschke and Currie 
2007, Babin et al. 2014). Conversely, there are some structural differences, including: no 
direct telencephalic projections into the spinal cord, such as the corticospinal tract; 
smaller cerebral hemispheres; zebrafish muscle is polyneuronally innervated throughout 
its lifetime; fish behaviour and cognitive function are simplified in comparison to ‘higher’ 
vertebrates; presence of teleost specific sensory organs such as the lateral line (Wullimann 
and Mueller 2004, Lieschke and Currie 2007, Babin et al. 2014, Westerfield, McMurray 
and Eisen 1986).  
It is important to acknowledge that despite similarities, no model organism can reproduce 
and accurately model all aspects of human neurodegenerative diseases. There are still 
significant differences between zebrafish and humans in terms of genetics, lifespan and 
architecture of the nervous system, for example. It is important to understand both the 
advantages and limitations when interpreting results in all model organisms, including 
zebrafish.   
1.3.2. Genetic tools  
The zebrafish has proven to be an essential model organism for validating pathogenicity 
of novel genes or alleles in human patients. Due to its fully sequenced genome, there are 
multiple known targets for reverse genetic techniques. Genes can be easily manipulated 
by loss- or gain-of-function approaches in simple, transient assays of gene function and 
by creation of stable disease models using targeted genome editing techniques. The 
zebrafish offers an inexpensive and rapid alternative to generating models of 
neurodegenerative disease in comparison to murine models, which are labour-intensive 
and costly.  
In this project, the main focus is generation of LOF mutations. The easiest approach to 
study LOF mutations in zebrafish is the injection of antisense morpholino 
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oligonucleotides (AMOs), and this method has been particularly exploited over the past 
few decades for this reason (Nasevicius and Ekker 2000).  AMOs are a synthetic 
derivative from DNA, with two major changes resulting in a neutral charge: i) a six-
membered morpholine ring replaces the standard deoxyribose ring; ii) a non-ionic 
phosphorodiamidate linkage replaces anionic phosphodiester bond (Summerton and 
Weller 1997). Knockdown (KD) can be easily achieved by the microinjection of AMOs 
at the 1- to 4-cell embryonic stage. The neutral charge and small size (around 25 bases in 
length) allows the AMO to diffuse throughout the embryo following microinjection 
(Nasevicius and Ekker 2000). AMOs bind complementary sequences of RNA or single-
stranded DNA, and can be designed to temporarily downregulate gene expression by 
either blocking translation or splicing (Eisen and Smith 2008).  
The use of AMOs has significantly helped to solidify the relevance of investigating 
zebrafish orthologues of human disease genes. However, the technique is often 
confounded by off-target effects, which are often caused by the induction of p53 that leads 
to apoptosis, but can also be p53-independent (Kok et al. 2015). These inconsistencies 
have resulted in questions about its relevance in the advent of novel genome editing 
techniques in recent years. The potential for off-target effects has been demonstrated in 
zebrafish models of neurodegeneration, such as MND. KD of a Tardbp orthologue in 
zebrafish using translation blocking AMOs has been reported to cause shorter, 
disorganised motor neuron axons (Kabashi et al. 2010b). Subsequently, two independent 
studies demonstrated that stable loss of Tardbp was fully compensated by alternative 
splicing of a second Tardbp orthologue in the zebrafish, Tardbpl (Schmid et al. 2013, 
Hewamadduma et al. 2013). Thus, the Tardbp KD-induced phenotype was not observed 
in these stable Tardbp mutants (Schmid et al. 2013, Hewamadduma et al. 2013). 
Interestingly, one of the groups microinjected the same AMO used in the Kabashi study 
into both wild-type and stable Tardbp knock-out (KO) mutants (Hewamadduma et al. 
2013). They found that this resulted in severe defects in both genotypes, suggesting that 
the AMO used in the Kabashi paper may have had off-target effects which contributed to 
the observed phenotype (Hewamadduma et al. 2013). In addition, AMO-mediated KD of 
C13H9orf72 in zebrafish has been reported to result in locomotor deficits and axonopathy 
of the motor neurons (Ciura et al. 2013). However, we have evidence which suggests that 
stable loss of C13H9orf72 does not recapitulate these same phenotypes, again suggesting 
the phenotypes observed in the KD study were due in part to off-target effects (chapter 
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4). As well as this, a recent study by the same group reported that AMO-mediated KD of 
p62/SQSMT1 in zebrafish again caused locomotor deficits and axonopathy of the motor 
neurons (Lattante et al. 2015b). Currently, this is the only zebrafish model of 
p62/SQSTM1, therefore it will be essential to investigate the effects of p62/SQSTM1 
LOF in a stable KO model to validate the AMO phenotype, given the aforementioned 
discrepancies for Tardbp and C13H9orf72. 
It is important not to disregard off-target effects, as they may result in others 
unintentionally classifying these as genuine effects of the gene under investigation. This 
is a particularly sensitive issue with regards to peer reviewers from disparate fields, who 
may not have the necessary experience to distinguish AMO-induced toxicity from gene-
specific AMO-induced phenotypes. The use of appropriate controls is essential so that 
investigators can ensure that the phenotype they observe is specific to the gene of interest. 
For example, control AMOs should always be used, which could include mismatch or 
scrambled AMOs. However, even if the ‘control’ AMO causes no phenotype, this doesn’t 
rule out that the phenotype observed with the ‘specific’ AMO wasn’t caused by an off-
target effect. Therefore, additional controls to test for specificity should be used. This 
includes using at least two AMOs for any gene targeted, with each AMO tested 
individually to ensure they result in similar phenotypes. Additionally, at least one of these 
should be a splice-inhibiting AMO, therefore even if relevant antibodies are unavailable, 
quantification of the effect of the AMO could be performed using qRT-PCR. Specificity 
could also be determined by mRNA rescue. However, this technique is only effective if 
the genes are ubiquitously expressed or have no overexpression phenotype. If the target 
gene is expressed in a restricted manner or has a strong overexpression phenotype, this 
method would not be suitable. Alternatively, one could compare phenotypes observed to 
existing mutants. However, clearly this method is limited to whether another mutant has 
been generated. This topic has recently been addressed by publication of a set of 
guidelines for the use of morpholinos in zebrafish (Stainier et al. 2017). 
In addition to off-target effects, the transient nature of the technique means it is not 
appropriate for studying the late-onset disease related phenotypes of many 
neurodegenerative diseases, such as adult-onset MND. To circumvent this issue, the 
recent development of genome-editing techniques such as transcription activator-like 
effector nucleases (TALENs) (Joung and Sander 2013) and clustered regularly 
interspaced short palindromic repeats (CRISPR) (Hruscha et al. 2013, Chang et al. 2013, 
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Hwang et al. 2013), have enabled researchers to induce targeted, heritable mutations in 
the zebrafish genome. Both of these techniques consist of a sequence-specific DNA 
targeting subunit and a double stranded DNA cleaving nuclease. TALENs consist of a 
pair of DNA binding proteins fused to a fok1 nuclease. The pair bind opposite sides of 
the target site, separated by a spacer region of 14-20 nucleotides, within which fok1 cuts 
the DNA (Joung and Sander 2013). Additionally, CRISPR consists of a complex between 
a cas9 nuclease and a target specific single guide RNA (gRNA). The gRNA directs the 
cas9 nuclease to a 20 nucleotide target site, immediately followed by a protospacer 
adjacent motif (PAM) site, where it cuts the DNA (Hruscha et al. 2013, Chang et al. 2013, 
Hwang et al. 2013). The induction of double stranded breaks in the genome initiates two 
DNA repair pathways: i) non-homologous end joining (NHEJ), which ligates the DNA 
strands without a template, frequently producing small insertion or deletion (indel) 
mutations; ii) homologous recombination (HR), which repairs the break with a 
homologous DNA template (Schmid and Haass 2013). Despite both techniques being able 
to induce heritable mutations, they both have specific advantages and disadvantages, as 
detailed in table 1.4. 
Overall, the ease at which potentially pathogenic genes can be transiently depleted in 
zebrafish, has been exploited over the past few decades. This technique, alongside rescue 
of LOF mutations with the human wild-type mRNA but not human disease mRNA, 
enables researchers to demonstrate the specificity and pathogenicity of certain human 
disease genes. However, the generation of stable LOF models in recent years has shed 
light on the potential pitfalls of transient techniques such as AMOs. This calls in to 
question past research and highlights the importance of making stable models of these 
genetic variants in the future, to further confirm pathogenicity. As techniques such as 
CRISPR/Cas9 are inexpensive and rapid to perform, the next few years should see a 
wealth of new zebrafish disease models. 
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Table 1.4 Advantages and Disadvantages of TALENs and CRISPR/Cas9.
Genome editing technique  Advantages Disadvantages 
Transcription activator-like 
effector nucleases (TALENs) 
- High target specificity  
- In theory, can be targeted to any position within 
the genome as they are not constrained by a 
PAM site  
- Off-target effects less of an issue, as the DNA 
binding site is very long (approx. 36 base pairs) 
therefore rarely, if ever, found elsewhere in the 
genome (Mussolino et al. 2011, Miller et al. 
2011)  
- Another reason for less off target effect is that 
double stranded breaks (DSB) only occur after 
correct positioning and dimerization of Fok1 
(Christian et al. 2010) 
 
- More expensive  
- More time consuming to generate 
- TALEN specificity/binding is dependent on 
protein-DNA interactions which can be 
affected by epigenetic status, such as 
sensitivity to methylation (Bultmann et al. 
2012) – this is thought to explain the little or 
no mutagenesis activity in some cases 
Clustered regularly interspersed 
short palindromic sequences 
(CRISPR)/Cas9 
- Easy and simple to design  
- Less cost-intensive than TALENs 
- High target specificity  
- Have been reported to have higher mutation 
efficiency - indel formation of up to 70% 
reported (Wang et al. 2014) 
- Not sensitive to methylation like TALENs 
- Multiplexed mutations – mutations can be 
introduced in multiple genes at the same time 
via injection of multiple gRNAs (Wang et al. 
2013) 
- Cas9 nickase mutants used to increase 
specificity and reduce off-target effects (Ran et 
al. 2013). 
 
- Target site selection can be limited, due to 
dependency on PAM site (Sternberg et al. 
2014) 
- Off-target effects reported to occur more 
frequently than TALENs (Boettcher and 
McManus 2015) – one reason is that gRNA 
can tolerate up to 5 mismatches (non-Watson-
Crick base pairing) (Fu et al. 2013) 
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1.3.3. Examining motor function in adult zebrafish models of 
neurodegeneration  
Several neurodegenerative diseases are characterised by motor dysfunction, including 
Parkinson’s disease, Huntington’s disease and motor neuron diseases, such as ALS. The 
zebrafish is increasingly being acknowledged as a model organism to study normal and/or 
pathological motor function throughout its lifetime for several reasons. For example, as a 
vertebrate model, it has conserved organisation of organs and tissues, including the brain 
and spinal cord. Additionally, neurogenesis begins around 10 hours post fertilisation 
(hpf), synaptogenesis around 18 hpf and hatching around 52 hpf in the zebrafish (Kimmel 
et al. 1995). The aforementioned qualities mean that both larval and adult zebrafish are 
ideal to study motor dysfunction associated with many human neurodegenerative 
disorders. 
As gene overexpression or KD can be easily achieved using injections of RNA (or cDNA) 
or AMOs at the embryonic stage, there are a number of transient embryonic models which 
have been used to model the toxic effects of genetic mutations associated with 
neurodegenerative disease, including changes in motor function. Behavioural responses 
to touch and swimming can be monitored shortly after hatching in such models, as they 
already have a repertoire of stereotyped motor behaviours at this stage (Drapeau et al. 
2002, Wolman and Granato 2012). For example, by 24 hpf wild-type zebrafish 
spontaneously contract their tail muscles and by 48 hpf, zebrafish exhibit controlled 
swimming behaviours (Sztal et al. 2016). Reduction or other alterations in these 
movements may indicate a motor dysfunction. There are two main approaches to measure 
swimming behaviour in early development, including; the touch-evoked escape response 
(TEER) and high-throughput locomotion assays. The TEER, involves measuring 
acceleration during a burst of swimming, following an external stimulus to the head or 
tail. Additionally, locomotion assays can be performed using commercially available 
automated tracking systems, such as Zebralab by ViewPoint (France), providing reliable 
and high-throughput measurements of motor function. This test is also suitable for high-
throughput in vivo drug or mutagenesis screens. However, although advantageous to have 
a disease model with phenotypes at these early stages, it is not representative of human 
neurodegeneration. Therefore, in order to fully understand the progressive nature of 
motor dysfunction in these disorders, stable genetic models of neurodegeneration must 
be developed for long-term phenotypic studies in adult zebrafish.  
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There are several ways in which motor function can be investigated in both health and 
disease in adult zebrafish. A study generated a fish that expressed mutant zebrafish sod1 
(Ramesh et al. 2010) and a swim tunnel test was utilised to test the motor abilities in this 
transgenic line, at several different ages. This test measures swimming endurance against 
an increasing flow of water. Critical swimming speed (Ucrit) is calculated for each 
individual, as the maximum swimming velocity a fish can sustain for a set duration (Plaut 
2000, Brett 1964). The transgenic zebrafish generated in this study showed a marked 
decline in Ucrit with increasing age compared to controls, which eventually resulted in  
paralysis at end stage disease (Ramesh et al. 2010). This transgenic model recapitulates 
the progressive trait of ALS. Other models of neuromuscular degeneration, such as the 
Mfn2-linked Charcot Marie Tooth (CMT) disease Type 2 zebrafish model, utilised the 
same technique (Chapman et al. 2013). They also showed progressive swimming defects, 
with adult Mfn2 mutants displaying a decreasing Ucrit with age, in comparison to controls 
(Chapman et al. 2013). In the future, other models of neuromuscular degeneration would 
benefit from using this method of testing motor performance. Another method which has 
been used to observe motor function in adult zebrafish models of neurodegeneration 
involves using various video tracking systems to monitor swimming activity of 
individuals in a tank over a set period (Sakowski et al. 2012, Wang et al. 2017, Da Costa 
et al. 2014). For example, it was reported that swimming velocity of a stable transgenic 
zebrafish, expressing human G93A-SOD1, decreased over time in comparison to controls 
(Sakowski et al. 2012), showing that this method is also sensitive in detecting changes in 
motor function. However, the disadvantage to these studies is that they are time 
consuming to perform on large cohorts. A novel test, called the spinning task, has the 
ability to rapidly measure swimming endurance in adult zebrafish (Blazina, Vianna and 
Lara 2013). However, it is yet to be tested and published on adult zebrafish models of 
neurodegeneration.  
In addition to identifying motor dysfunction, defects at the neuromuscular junction (NMJ) 
and a decrease in the number of motor neurons (MNs) were also observed in the fish 
expressing mutant zebrafish sod1 (Ramesh et al. 2010). The NMJs were analysed in this 
model, as effects at the NMJ are one of the earliest defects in mouse models of ALS (Frey 
et al. 2000, Schaefer, Sanes and Lichtman 2005, Fischer et al. 2004). To do this, whole-
mount staining for synaptic vesicle 2 (SV2 – a presynaptic marker) and α-bungarotoxin 
(α-BTX – a postsynaptic marker) was performed on larvae (11dpf) and adult (12 months) 
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muscle tissue (Ramesh et al. 2010). They found a significant reduction in SV2 and α-
BTX co-localisation in transgenic fish at 12 months in comparison to controls, indicating 
dysfunctional NMJs (Ramesh et al. 2010). In addition, the MNs were analysed as NMJ 
degeneration is followed by MN loss in ALS patients and transgenic ALS rodents (Frey 
et al. 2000, Fischer et al. 2004). To analyse this, spinal cords were taken at end stage 
disease from transgenic sod1 fish and processed for choline acetyl transferase (ChAT) 
immunostaining to examine MNs (Ramesh et al. 2010). End stage, transgenic zebrafish 
had a 38% reduction of MNs in comparison to controls (Ramesh et al. 2010). These results 
suggest the degeneration of NMJs and subsequent loss of MNs in the transgenic zebrafish 
underlie the progressive motor dysfunction observed. Several groups have used the same 
method of examining NMJs for different adult sod1 mutants (Da Costa et al. 2014, 
McGown et al. 2013, Sakowski et al. 2012) and adult Mfn2 mutant zebrafish (Chapman 
et al. 2013). The main difference is the method in which co-localisation was measured. 
For example, one study used the Pearson’s Correlation Coefficients test (Ramesh et al. 
2010), whereas another study used the Intensity Correlation Quotient (ICQ) (Chapman et 
al. 2013, Li et al. 2004). It may be useful in the future to standardise which method is 
used. Additionally, other groups have reported using Cresyl violet Nissl Stain, instead of 
ChAT immunostaining, in order to count MNs in spinal cord cross sections from control 
and transgenic fish expressing human G93A-SOD1 (Sakowski et al. 2012). However, 
both methods of MN counting are sensitive to detecting changes in MN number. 
Despite advantages of using adult zebrafish to study motor function, there are some 
limitations which must be acknowledged when interpreting results. For example, it has 
been shown that zebrafish muscle is polyneuronally innervated throughout its lifetime 
(Westerfield et al. 1986) and that adult zebrafish have the capability to regenerate motor 
neurons (Reimer et al. 2008), unlike mice and humans. It is possible that this capability 
could affect the severity of motor phenotypes observed in zebrafish models of 
neurodegenerative disease. However, it has been reported that zebrafish do develop 
severe motor defects in several models of neurodegenerative disease, highlighting its 
relevance to study such disorders (Ramesh et al. 2010, McGown et al. 2013, Chapman et 
al. 2013, Sakowski et al. 2012). Overall, there are multiple effective methods to study 
both motor function and the underlying pathology in adult zebrafish, showing that they 
are an excellent model to study motor function in long-term phenotypic studies.  
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1.3.4. Examining behaviour in adult zebrafish models of 
neurodegeneration 
In addition to motor dysfunction (section 1.3.3), disruptions in emotional, cognitive and 
social behaviour are common phenotypes observed in several neurodegenerative diseases, 
including Alzheimer’s Disease, FTD, Parkinson’s Disease and ALS. Therefore, it is 
essential when modelling these diseases that changes in behaviour and/or cognition can 
be detected. The zebrafish is rapidly gaining popularity in behavioural research as a useful 
organism to study normal and/or pathological behaviours. Their behavioural responses 
are robust and appear to be conserved, resembling those seen in mammalian species, such 
as humans (Kalueff et al. 2014, Stewart et al. 2014, Norton and Bally-Cuif 2010). As 
discussed previously, the zebrafish has a conserved, yet simplified, nervous system 
compared with other higher vertebrates (Babin et al. 2014). They possess the major 
neuromediator systems, including similar neurotransmitter receptors, transporters, plus 
enzymes of synthesis and metabolism (Kalueff et al. 2014). Zebrafish also have well-
developed, conserved neuroendocrine systems. For example, stress responses are 
mediated by cortisol activated by a cascade of hypothalamo-pituitary hormones and 
acting via glucocorticoid receptors in zebrafish, similar to humans (Ziv et al. 2013). In 
addition, they are sensitive to major neurotropic drugs (such as antipsychotics, anxiolytic, 
antidepressants, ethanol, sedatives and antiepileptics) and respond to these in a similar 
manner to humans (Kalueff et al. 2014, Stewart et al. 2014). These similarities all support 
the translational value of studying behaviour in zebrafish and the potential value of testing 
new drugs for major brain disorders.  
Larvae can be used to measure a number of simple behaviours. For example, with the 
application of automated video tracking tools, robust anxiety-like or anxiolytic-like 
responses can be detected at this early stage in high throughput screens. However, for 
larval stages the most common endpoints for these assays are locomotory, such as 
distance travelled and immobility, which may subsequently increase or decrease with 
anxiety (Kalueff et al. 2013, Ahmad et al. 2012). Although these endpoints may be useful 
when studying the effects of anxiogenic or anxiolytic drugs for example, they may not be 
suitable when studying larval zebrafish models of neurodegenerative diseases, as motor 
function may be affected by alternate factors, such as degeneration of motor neurons. 
Additionally, it is reported that certain complex behaviours are not prominent in larval 
zebrafish, such as social behaviours. A recent study suggests that social behaviours, such 
as social preference, begin to emerge when zebrafish are around 2 weeks old (Dreosti et 
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al. 2015). Analysis of social behaviours are relevant for several neurodegenerative 
disorders, where patients may experience aberrant social behaviours, such as depression, 
disinhibition or apathy, for example. Although the number of stable genetic models of 
neurodegeneration are limited, the increasing use of genome editing techniques, such as 
TALENs and CRISPR/Cas9, will hopefully accelerate their development, allowing for a 
better understanding into the progressive nature of behavioural phenotypes in 
neurodegenerative disease.  
Although more difficult to manipulate than larvae, adult zebrafish display a whole host 
of mature behaviours which make it an enticing model organism to study changes in 
behaviour and/or cognition, complementary to existing rodent models. Adult zebrafish 
are a powerful tool to model behaviours including aggression, anxiety, learning, memory 
and social behaviour, which are relevant to many neurodegenerative diseases (Norton and 
Bally-Cuif 2010). Additionally, the availability of reliable, commercially available video 
tracking systems, such as the Zebralab by ViewPoint (France), markedly strengthens 
neurobehavioral analysis in adult zebrafish. Several groups have developed a wealth of 
behavioural assays which enable the study of aggression, anxiety, learning, memory and 
social behaviours in adult zebrafish, taking advantage of these video tracking systems 
(Stewart et al. 2014, Norton and Bally-Cuif 2010).  
The focus of this study is ALS and as discussed, it has been reported that 50% of ALS 
patients carrying the repeat expansion in C9orf72 have behavioural and/or cognitive 
impairments (Ringholz et al. 2005). Additionally, it has been reported that around 15% 
of these patients meet the clinical criteria for FTD, particularly the behavioural variant of 
FTD (bvFTD) (Ringholz et al. 2005). Patients exhibit symptoms such as anxiety, 
disinhibition, apathy and memory loss (Mahoney et al. 2012). There are several 
established protocols available to investigate these behaviours in adult zebrafish. For 
example, methods available to monitor spatial learning and memory in the zebrafish 
include the T-maze, which is similar to a test used on rodents (Darland and Dowling 2001, 
Norton and Bally-Cuif 2010). There are also several aquatic ‘novelty’ tests, such as the 
novel tank diving test, open field test and light-dark box which have been extensively 
validated to monitor anxiety-like behaviour and are conceptually similar to rodent anxiety 
tests, such as the open field test (Lopez-Patino et al. 2008, Egan et al. 2009, Norton and 
Bally-Cuif 2010, Serra, Medalha and Mattioli 1999). These tests have been used on adult 
zebrafish models of neurodegeneration. For example, a group reported that rotenone 
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treatment of adult zebrafish induced Parkinson’s disease-like motor and non-motor 
symptoms, including anxiety-like behaviour as shown by using the light-dark test (Wang 
et al. 2017). As well as this, zebrafish are naturally social animals and prefer to swim in 
shoals. This behaviour can be disrupted by environmental, pharmacological or genetic 
factors and can be easily assessed in adult zebrafish (Norton and Bally-Cuif 2010).  
1.3.5. C9orf72-ALS/FTD zebrafish models  
As discussed, a noncoding (G4C2)n hexanucleotide repeat expansion in C9orf72 is a major 
cause of both ALS and FTD. In addition, it is not fully understood how the repeat 
expansion causes disease, but three principal mechanisms have gained particular 
attention, including; haploinsufficiency, RNA toxicity and repeat-associated, non-ATG 
(RAN) translation. The pathogenic mechanism underlying C9orf72-linked ALS may be 
attributable to just one of these mechanisms or involve a combination of all three. 
Zebrafish are an excellent organism to utilise as a model of C9-ALS/FTD. As discussed, 
not only do they possess several characteristics which make it an ideal organism to model 
motor neuron diseases in general, but they have a highly conserved C9orf72 orthologue 
(C13H9orf72), sharing 68.55% nucleotide identity with the human gene. Zebrafish have 
only one copy of the C9orf72 orthologue and they are predicted to possess 3 protein-
coding transcripts, encoding two protein isoforms of different lengths, as observed in 
humans (Ciura et al. 2013). It has been reported that C13H9orf72 mRNA is expressed in 
regions of the CNS including forebrain, hindbrain and spinal cord in 24hpf zebrafish 
embryos (Ciura et al. 2013). In adult zebrafish, C13H9orf72 mRNA is present more 
extensively in a number of organs and tissues, with notable expression in regions of the 
CNS such as the forebrain, midbrain, hindbrain and spinal cord (Ciura et al. 2013). Both 
loss-of-function (LOF) and gain-of-function (GOF) models of C9-ALS/FTD have been 
generated in zebrafish, which are discussed in sections 1.3.5.1 and 1.3.5.2.  
1.3.5.1. Loss-of-function models  
To address the LOF hypothesis, a group generated a genetic model of C9orf72 
haploinsufficiency via transient KD of C13H9orf72 transcripts in zebrafish (Ciura et al. 
2013). KD was achieved by designing specific AMOs to target two ATG translation start 
sites for all three predicted transcripts (Ciura et al. 2013). AMO-mediated knockdown of 
C13H9orf72 resulted in disrupted aborization and shortening of the motor neuron axons 
(Ciura et al. 2013), a phenotype which has previously been reported in other KD models 
of ALS in zebrafish, including TDP-43 (Kabashi et al. 2010b). In addition, impaired 
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touch-evoked escape response (TEER) and spontaneous swimming behaviour was also 
observed in this model (Ciura et al. 2013). Despite the fact the level of KD was not 
quantified, due to lack of available anti-C9orf72 antibodies at the time of publication, co-
injection of human C9orf72 mRNA rescued both the axonopathy and locomotor defects, 
supporting the specificity of the observed phenotypes (Ciura et al. 2013). Despite 
promising results, data from AMO KD should be treated with caution, as the technology 
has various limitations, ranging from its transient efficacy to its potential for off-target 
effects, as previously discussed. In addition to this, ALS is principally an adult onset 
disorder in humans, therefore it is desirable to use a complementary approach to the 
AMOs in order to study the adult phenotype in zebrafish. The aforementioned reasons 
highlight the necessity to develop a stable zebrafish C13H9orf72 LOF model. Recently, 
a group utilised the CRISPR/Cas9 system to generate zebrafish C13H9orf72 LOF alleles 
(Hruscha et al. 2013). They reported that the identified LOF mutations successfully 
transmitted through the germline, however, to date there are no publications 
phenotypically characterising this potential model.  
1.3.5.2. Gain-of-function models  
The relative contribution of RNA and DPR toxicity in the context of C9-ALS/FTD is still 
under debate, since many conflicting results have been obtained from a variety of model 
systems. Regarding zebrafish, RNA injections of 8x, 38x and 72x G4C2 repeats has 
previously been reported to result in RNA foci and cell death by apoptosis at 24 hpf, in a 
repeat length-dependent manner, although no C9-ALS/FTD-like motor or behavioural 
phenotypes were reported (Lee et al. 2013). Additionally, this study did not report 
evidence of RAN translation products from the repeat RNA injections in these zebrafish. 
Another recent study generated two independent transgenic zebrafish lines carrying x80 
G4C2 repeats (Ohki et al. 2017). It was observed that this model had key pathological 
features of C9-ALS/FTD at 28 hpf, such as RNA foci present in the spinal cord, however 
RAN translation products were not detected (Ohki et al. 2017). This is possibly because 
no RAN translation occurs in early development or it was below the detection limit of the 
antibodies used. This model showed mild toxicity, with mild pericardial oedema 
commonly observed (Ohki et al. 2017). However, as DPRs were not detected, it cannot 
be determined that this mild toxicity was due to RNA foci or low level DPR protein 
expression. Interestingly, this group also generated two additional transgenic zebrafish 
lines carrying a translation initiation codon (ATG) in front of the x80 G4C2 repeats, 
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driving expression of poly-GA DPR proteins (Ohki et al. 2017). This study focussed on 
poly-GA, as this is most abundant DPR species in patients carrying the repeat expansion  
(Mori et al. 2013c). In addition to the presence of RNA foci in the spinal cord at 28 hpf, 
this model also had abundant poly-GA inclusions and increased toxicity, including severe 
pericardial oedema, circulatory defects and decreased survival (Ohki et al. 2017). 
Blocking production of poly-GA using an antisense approach partially rescued the 
observed phenotype, demonstrating that poly-GA is toxic in vivo and targeting DPR 
proteins might be a useful therapeutic method in the future (Ohki et al. 2017). 
Unfortunately, due to larval lethality of this model, analysis of possible 
neurodegenerative phenotypes in adulthood was not possible. Further development of 
inducible GOF zebrafish models will be necessary to further dissect the relative 
contribution and/or synergistic effect of repeat RNA and DPRs to toxicity in C9-
ALS/FTD zebrafish models.  
1.4. Aims and Objectives 
There are two major gaps in our knowledge regarding this C9orf72. Firstly, it is not fully 
understood how the repeat expansion causes C9-ALS/FTD, however there is evidence 
that C9orf72 mRNA and protein levels are reduced in patients (DeJesus-Hernandez et al. 
2011, Gijselinck et al. 2012, Belzil et al. 2013, Fratta et al. 2013, Almeida et al. 2013, 
Waite et al. 2014, Xiao et al. 2015), suggesting that C9orf72 LOF via haploinsufficiency 
may be causative in C9-ALS/FTD. Secondly, the function of the C9orf72 protein is not 
fully understood, however there is increasing evidence that C9orf72 plays a regulatory 
role in autophagy (Farg et al. 2014, Yang et al. 2016, Sellier et al. 2016, Sullivan et al. 
2016a, Webster et al. 2016a). It is essential that gaps in our knowledge are filled in order 
to identify novel therapeutics for preclinical development, which have the potential to 
help the majority of ALS and FTD patients. Thus, the objective of this project is to test 
the hypothesis that loss of C9orf72 expression causes ALS/FTD by disruption of C9orf72 
function in autophagy. To investigate this, the overall aims of this project are: 
1. To generate a stable zebrafish C13H9orf72 LOF model using targeted genome 
editing techniques 
2. To characterise the model generated to determine whether loss of C13H9orf72 
expression results in any ALS- or FTD-like phenotypes  
3. To investigate the function of C13H9orf72 in vivo  
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As discussed the initial aim of this project is to generate a stable zebrafish C13H9orf72 
LOF model. Developing in vivo models recapitulating C9-ALS/FTD is essential in order 
to further elucidate the pathomechanisms which underlie this disorder and to aid in 
evaluating the potential efficacy of novel therapies. This can be achieved by the 
development of zebrafish models, as they hold several characteristics which make it an 
advantageous model to use in the study of neurodegenerative disorders such as ALS and 
we know there is high homology between human ALS-linked genes and the 
corresponding zebrafish orthologue. Importantly, there is 68.55% nucleotide identity and 
76.14% amino acid identity between human C9orf72 and the zebrafish orthologue, 
C13H9orf72 (zgc: 100846). Therefore, it is expected that functional role of C9orf72 is 
likely to be similar in zebrafish and humans, thus disease mechanisms are expected to be 
conserved. As discussed, AMOs have been utilised to transiently KD both isoforms of 
the zebrafish C13H9orf72, resulting in both locomotor and axonal deficits (Ciura et al. 
2013), which is consistent with the aetiology of ALS. However, as ALS is an adult onset 
disorder it is critical to generate a stable LOF model in order to study the potential adult 
phenotype in the zebrafish. In addition, a recent identification of a novel LOF C9orf72 
splice site mutation in a patient with ALS, supports haploinsufficiency as a disease 
mechanism in C9-ALS/FTD and further highlights the importance of generating this 
model (Liu et al. 2016). In order to produce zebrafish C13H9orf72 LOF alleles, we will 
utilise targeted genome editing techniques to target coding exons 1 and 7 of C13H9orf72, 
to generate LOF mutations in either both isoforms or the long isoform, respectively 
(chapter 3).  
Validated zebrafish C13H9orf72 LOF mutants will be used for characterisation studies to 
address our second aim in determining whether loss of C13H9orf72 results in any 
ALS/FTD-like phenotypes, such as changes in survival, motor dysfunction or changes in 
behaviour (chapter 4). As there are currently no publications characterising a stable 
zebrafish C13H9orf72 LOF model of ALS/FTD, the phenotypic characterisation of the 
generated lines will be highly important during this project. To determine the possibility 
of lethal effects of the C13H9orf72 mutations, survival will be monitored as has been 
done previously in our group (Chapman et al. 2013). During larval stages, they will be 
monitored twice per day, with dead larvae collected for genotyping. Additionally, the 
mutants will also be monitored throughout their lifetime, as it may be expected that 
survival decreases during adulthood, as ALS/FTD is mainly an adult onset disorder in 
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humans. To determine whether the zebrafish C13H9orf72 LOF mutants have a motor 
deficit, two approaches will be used. Firstly, the spinning task will be utilised to monitor 
swimming endurance  (Blazina et al. 2013). Secondly, the swim tunnel will be utilised to 
measure critical swimming velocity (Ucrit) in the zebrafish, which has been used to 
characterise other zebrafish models of ALS previously (Ramesh et al. 2010). 
Furthermore, we will confirm the basis for any altered motor function by quantitative 
assessment of neuromuscular junctions (NMJs). In addition, C9-ALS/FTD patients are 
known to exhibit a number of behavioural changes such as: anxiety, disinhibition, apathy, 
memory loss (Mahoney et al. 2012). There are now several protocols established to 
measure behaviours such as anxiety, aggression, social preference, memory and learning 
in adult zebrafish (Norton and Bally-Cuif 2010). Thus, we aim to examine anxiety-like 
behaviour in our mutants via utilising two tests which robustly measure this behaviour in 
zebrafish; the novel tank diving test and the open field analysis test.  
The final aim of this project is to investigate the C9orf72-linked disease mechanisms by 
investigating and identifying the function of the C9orf72 protein in vivo. A characteristic 
phenotype of C9-ALS/FTD is the presence of p62/SQSTM1 positive, TDP-43 negative 
inclusions found in the cerebellum, hippocampus and the neocortex (Cooper-Knock et al. 
2012, Al-Sarraj et al. 2011). p62/SQSTM1 targets ubiquitinated proteins to the autophagy 
pathway for degradation and accumulation of this protein has been associated to 
inhibition of autophagy, suggesting C9orf72 may function within this protein clearance 
pathway (Hara et al. 2006). The presence of these pathognomonic inclusions, alongside 
the identification of C9orf72 haploinsufficiency in patients, suggests that defective 
autophagy via loss of C9orf72 function may be causative in C9-ALS/FTD. Further 
supporting this hypothesis, recent studies published that disruption of C9orf72 function, 
in both cell lines and primary neurons, results in an inhibition of autophagy initiation and 
accumulation of p62/SQSTM1, similar to the pathology seen in C9-ALS/FTD patients 
(Farg et al. 2014, Yang et al. 2016, Sellier et al. 2016, Sullivan et al. 2016a, Webster et 
al. 2016a). Therefore, the investigation of the role of C9orf72 in vivo, using the stable 
zebrafish C13H9orf72 LOF models, is an important aspect of this project (chapter 5). 
This not only has the potential to allow for further investigation into the possible role of 
autophagy deficits in disease progression, but will provide a useful tool for studying 




2. Materials and Methods  
 
2.1. Materials  
2.1.1. General reagents  
All general chemicals and reagents, unless otherwise stated, were purchased from VWR, 
Lutterworth, UK. For polymerase chain reaction all primers were purchased from Sigma-























Table 2.1 General reagents. 
E3 Embryo Medium  5mM NaCl; 0.17mM KCl; 0.33mM CaCl2; 
0.33mM Mg2SO4; 0.1mg/l Methylene Blue 
in dH2O 
Tricaine 400mg Tricaine powder (Sigma, #A-5040), 
97.9ml dH2O, ~2.1ml 1M Tris (pH 9). 
Adjust if required to ~ pH 7 
50x TAE stock solution 242g Tris Base, 57.1ml acetic acid, 0.5M 
EDTA pH 8.8, up to volume with dH2O 
Embryo Deyolking Buffer 55mM NaCl, 1.8mM NaHCO3, made up to 
volume with dH2O 
Embryo Washing Buffer 110mM NaCl, 3.5mM KCl, 2.7mM CaCl2, 
10mM Tris.HCl pH 8.5 
BRB80 Lysis Buffer  80mM PIPES pH6.8, 1mM EDTA, 1mM 
MgCl, 150mM NaCl, 1% v/v NP40 
RIPA Lysis Buffer 50 mM Tris HCl pH 6.8, 150 mM NaCl, 1 
mM EDTA, 1 mM EGTA, 0.1% SDS, 0.5% 
Deoxycholic acid, 1% Triton X-100 
IP150 Lysis Buffer 150mM NaCl, 1mM EDTA, 1mM DTT, 
0.5% (v/v) Triton-X-100, 50mM HEPES, 
10% (v/v) Glycerol, pH 7.5 
5x Laemmlli Sample Buffer  300mM Tris pH 6.8, 25% v/v glycerol, 10% 
w/v SDS, 0.01% w/v bromophenol blue, 
25% v/v β-mercaptoethanol, made up to 
volume with dH2O 
Resolving Gel Buffer 1.5M Tris.HCl pH 8.8, made up to volume 
with dH2O 
Stacking Gel Buffer 0.5M Tris.HCl pH 6.8, made up to volume 
with dH2O 
For a 1mm thick 15% 
polyacrylamide resolving gel (25ml 
for 4 gels) 
12.50ml of Ultra-Pure ProtoGel® 30% (w/v) 
Acrylamide, 6.25ml resolving gel buffer, 
250l 10% w/v SDS, 5.7ml dH2O, 250l 
10% w/v ammonium persulfate (APS), 25l 
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N, N, N, N’-tetra methylethylethylnediamine 
(TEMED) 
For a 1mm thick 10% 
polyacrylamide resolving gel (25ml 
for 4 gels) 
8.33ml of Ultra-Pure ProtoGel® 30% (w/v) 
Acrylamide, 6.25ml resolving gel buffer, 
250l 10% w/v SDS, 10ml dH2O, 250l 
10% w/v ammonium persulfate (APS), 25l 
TEMED 
For a 1mm thick 6% stacking gel  1ml 30% acrylamide, 1.25ml stacking gel 
buffer, 50l 10% w/v SDS, 3ml dH2O, 30μl 
10% w/v APS, 15l TEMED 
10x Running Buffer Stock (10L) 300g Tris, 1440g Glycine, made to volume 
with dH2O 
Running Buffer (1L)  100ml 10x Running Buffer Stock, 10ml 10% 
w/v SDS, made up to volume with dH2O  
Transfer Buffer (2L) 200ml 10x Running Buffer Stock, 400ml 
Methanol, made to volume with dH2O 
Tris-buffered saline (TBS) (1L) For 20X stock: 48.46g Tris, 160.16g NaCl, 
30ml HCl, up to volume with dH2O 
TBS-T 1X TBS, 0.1% v/v TWEEN-20, made up to 
volume with dH2O 
Blocking Buffer 5% w/v non-fat dry milk (Marvel) in TBS-T 
PBS (1L) For 25X stock: 200g NaCl, 5g KCl, 5g 
KH2PO4, 28.6g Na2HPO4 up to volume with 
dH2O 
PBD-T 50ml 1X PBS, 0.5g BSA, 500l DMSO, 
250l Triton-X-100 
Fish gelatin 27.5ml fish gelatin (Sigma, #G7765), 7.5g 
Sucrose, up to 50ml with dH2O 
Coomassie Stain 50% Methanol, 10% Glacial acetic acid, 






2.2.  General zebrafish methods 
All zebrafish maintenance and experiments were performed at the Bateson Centre or 
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield. All 
procedures were conducted in accordance with the Animal Scientific Procedures Act 
(ASPA) 1986, under the authority of both project and personal licences granted by the 
Home Office, UK.  
2.2.1. Wild-type strains  
All zebrafish stocks were kept in tanks at 28°C on a 14-hour light, 10-hour dark cycle at 
the Bateson Centre, University of Sheffield. The wild-type line AB was used for all 
zebrafish procedures unless otherwise stated in the protocols.  
2.2.2. Zebrafish breeding and embryo collection  
Zebrafish were marbled or paired the previous afternoon in order to stimulate the 
production of embryos at the start of the light-dark cycle. Embryos were collected the 
morning after marbling or pairwise mating. Following this, embryos were reared in E3 
embryo medium and kept at 28°C up to 5 days post fertilisation (dpf), maximum.  
2.2.3. Fin biopsies  
Fin biopsies were taken at >3 months for genotyping. A 96-well plate was prepared with 
approximately 200l of aquaria system water in each well. Fish were put in 200ml of 
Tricaine solution (4.2ml tricaine per 100ml aquaria system water) to anaesthetise them. 
Once anaesthetised, individual fish are removed from the solution and a small section of 
the tail is cut with scissors. Fish are put into a tank to recover from the anaesthetic. The 
fin clip is placed in one well of the PCR plate and the tank is labelled with the 
corresponding number of the well to allow for identification.  
2.2.4. Dechorionating zebrafish embryos  
The removal of the chorion was performed at 24hpf. Using a light microscope for 
guidance, forceps were used to manually pull the chorion apart and release the embryo. 






2.3. General molecular biology techniques  
2.3.1. Making LB broth and LB agar plates 
Sterile LB broth (10g/L Tryptone, 5g/L Yeat extract, 10g/L NaCl) (Fisher Scientific) was 
made by resuspending 25g of LB broth powder in 1L of distilled water (dH2O). 
Additionally, sterile LB agar (10g/L Tryptone, 5g/L Yeat extract, 10g/L NaCl, 
15g/LAgar) (Fisher Scientific) was made by resuspending 40g of LB agar powder in 1L 
of dH2O. The mix was then autoclaved and allowed to cool for around 30 minutes. 
50g/ml of the appropriate antibiotic was added to the LB agar in sterile conditions. The 
LB agar solution was poured into 10cm petri dishes and allowed to set at RT, before being 
stored at 4°C.  
2.3.2. Preparation of glycerol stocks  
Single colonies from LB agar plates were picked and grown in 5ml of LB broth with 
50g/ml of the appropriate antibiotic. These were left overnight on a shaker at 37°C. To 
make the glycerol stock, 500l of the bacterial culture and 500l of sterile 50% glycerol 
was mixed in a microcentrifuge tube. All glycerol stocks were stored at -80°C.  
2.3.3. Preparation and purification of plasmid DNA  
To obtain plasmid DNA, E.coli colonies containing the plasmid of interest were picked 
and grown in 5ml LB broth containing 50g/ml of the appropriate antibiotic.  These were 
then left overnight at 37°C on a shaker. The next day, these were centrifuged at 4000 x g 
for 10 minutes in order to pellet the bacterial cells. Plasmid DNA was then extracted using 
the NucleoSpin® Plasmid DNA, RNA and protein purification kit (Macehery Nagel), 
following manufacturer’s instructions.  
2.3.4. Quantification of plasmid DNA  
Plasmid DNA was quantified using the NanoDrop Spectrophotometer ND-1000 
(NanoDrop Technologies, Wilmington, USA). The NanoDrop was initiated with 1l of 
nuclease free water. Subsequently, it was then blanked with 1l of the elution buffer used 
in the NucleoSpin® Plasmid DNA, RNA and protein purification kit. To assess 







2.4. Cloning of zebrafish C9orf72 (C13H9orf72) 
2.4.1. Zebrafish C13H9orf72 plasmids 
 
Table 2.2 Zebrafish C13H9orf72 plasmids. 




Cloning strategy  










2.4.2. Site-Directed Mutagenesis of C13H9orf72 construct 
2.4.2.1. QuickChange lightning site-directed mutagenesis kit  
The QuickChange lightning site-directed mutagenesis kit (Agient Technologies, 
#210518-5) was used in order to modify the C13H9orf72 construct. Primers used are 
shown in table 2.3. For this, the following reaction was prepared: 5l of 10x reaction 
buffer; 1.9l (25ng) of dsDNA template; 1.25l (125ng) of oligonucleotide primer #1 
and #2 (100ng/l stock); 1l of dNTP mix; 1.5l of QuickSolution reagent; made up to 
50l final volume with dH2O. In addition, 1l of QuickChange Lightning enzyme was 
added. The following cycling parameters were used: 
Temperature 95°C for 2 minutes 
x18 cycles  95°C 20 seconds 
60°C 10 seconds 
68°C 30 seconds/kb of plasmid length 
Temperature 68°C 5 minutes 





Table 2.3 Primers for site-directed mutagenesis of C13H9orf72 construct. 










Following this, 2l of DpnI restriction enzyme was added to each amplification reaction. 
The reaction was thoroughly mixed via pipetting up and down several times and a brief 
spin down. The reaction was then immediately incubated at 37°C for 5 minutes in order 
to digest the parental supercoiled dsDNA. 
2.4.2.2. Molecular cloning of C13H9orf72 
The QuickChange lightning site-directed mutagenesis kit suggests to transform XL-10 
Gold® Ultracompetent cells (Agilent Technologies) with the mutagenesis reaction. 
However, the mutagenized plasmid contained a chloramphenicol resistance marker, and 
these E.coli are resistant to both chloramphenicol and tetracycline, therefore an 
alternative strain of competent cells had to be used. OneShot® TOP10 competent E.coli 
(ThermoFisher Scientific) were instead transformed. OneShot® TOP10 competent E.coli 
were stored long-term at -80°C and for transformations, aliquots were thawed on ice for 
approx. 10 minutes. To 25l of these competent cells, 2l of the mutagenesis reaction 
was added and the mixture left on ice for 30 minutes. After this time, the competent cells 
were heat shocked for 45s at 42°C and subsequently placed on ice for a further 2 minutes. 
Following this, 250l of LB broth was added and the mixture incubated at 37°C for 1 
hour on a shaker. After 1 hour, the sample was centrifuged at 2500 x g for 2 minutes to 
pellet the bacterial cells. In sterile conditions, approx. 200l of the LB broth was pipetted 
off and the pellet was then resuspended in the remaining LB broth. All of the resuspended 
pellet was spread on a LB agar plate containing 50g/ml of the appropriate antibiotic in 
sterile conditions. Once dry, the plates were then incubated upside down at 37°C 
overnight to allow bacterial cultures to grow. Single colonies were picked from the 
bacterial plates and plasmid DNA prepared, purified and quantified as stated in sections 
2.3.3 and 2.3.4. To sequence, 10l of 100ng/l of purified plasmid DNA made up in 
dH2O was sent to the Core Genetics Service at the University of Sheffield, to ensure that 
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the mutagenesis had worked successfully. Once completed, the sequence data was 
analysed using Sequencher Demo Version 5.0.1 (Genecodes, USA). 
2.4.3. Subcloning C13H9orf72 into pCI-neo-myc mammalian expression 
vector 
2.4.3.1. Producing a blunt ended PCR product using the Phusion® 
High Fidelity PCR kit  
In order to subclone the construct into pCI-neo mammalian expression vector, flanking 
XhoI and NotI restriction enzyme sites were required. To do this, the Phusion® high 
fidelity PCR kit (NEB #E0553) was used, according to manufacturer’s instructions, using 
primers containing the XhoI or NotI restriction sites (see table 2.4 below). Following this, 
1l of the reaction was run on a gel to ensure the product was the predicted size.  
Table 2.4 XhoI and NotI primer sequences. 





2.4.3.2. Zero blunt® TOPO® PCR cloning kit 
Following high fidelity PCR, the blunt ended PCR product was subcloned into the 
pCR™-Blunt II-TOPO® Vector, using the Zero blunt® TOPO® PCR cloning kit, 
according to manufacturer’s instructions. The reaction was then transformed in to XL-10 
Gold® Ultracompetent cells as described below.  
2.4.3.3. Molecular cloning of C13H9orf72 
XL-10 Gold® Ultracompetent cells were stored at -80°C and for transformations, aliquots 
were thawed on ice for approx. 10 minutes. To 25l of these competent cells, 1l of β-
mercaptoethanol was added to improve transformation efficiency. To this, 3l of the 
TOPO reaction was added and the mixture was left on ice for 30 minutes. After this time, 
the competent cells were heat shocked for 45s at 42°C and subsequently placed on ice for 
a further 2 minutes. Following this, 250l of LB broth was added and the mixture 
incubated at 37°C for 1 hour on a shaker. After 1 hour, the sample was centrifuged at 
3893 x g for 2 minutes to pellet the bacterial cells. In sterile conditions, approx. 200l of 
the LB broth was pipetted off and the pellet was then resuspended in the remaining LB 
broth. All of the resuspended pellet was spread on a LB agar plate containing 50g/ml of 
53 
 
the appropriate antibiotic in sterile conditions. Once dry, the plates were then incubated 
upside down at 37°C overnight to allow bacterial cultures to grow. Single colonies were 
picked from the bacterial plates and plasmid DNA prepared, purified and quantified as 
stated in sections 2.3.3 and 2.3.4. To sequence, 10l of 100ng/l of purified plasmid DNA 
made up in dH2O was sent to the Core Genetics Service at the University of Sheffield. 
Once completed, the sequence data was analysed using Sequencher Demo Version 5.0.1 
(Genecodes, USA). 
2.4.4.  Restriction digests using XhoI and NotI 
The C13H9orf72 construct was digested using XhoI and NotI. For this, the following 
reaction was set up: 2ug C13H9orf72 construct; 0.5ul XhoI; 0.5ul NotI; 1x fast digest 
buffer (made from 10x stock solution) in dH2O and digested for 10 minutes at 37°C. Pre-
cut pCI-neo vector was used (courtesy of Emma Smith), cut using XhoI and NotI fast 
digest enzymes (Thermo Fisher Scientific, Delaware, USA). 
2.4.5. DNA extraction from agarose gel  
To separate linear DNA fragments following restriction digest, agarose gel 
electrophoresis was used. All of the sample was loaded on to a 1% agarose (Melford, UK) 
gel, containing 2l Ethidium Bromide (EtBr) per 100ml agarose gel. Samples were loaded 
adjacent to 3l of Hyperladder I (Bioline). Gels were run in DNA electrophoresis tanks 
(Geneflow, UK) in 1x TAE buffer. Samples were visualised using a UV transilluminator 
and DNA bands of the desired size were cut manually using a scalpel. The DNA was then 
extracted and purified using the GenElute™ Gel Extraction Kit (Sigma), according to 
manufacturer’s instructions. The amount of purified DNA was quantified using a 
NanoDrop spectrophotometer ND-1000 (Thermo Fisher Scientific, Delaware, USA). 
2.4.6. Ligation of DNA fragments  
To ligate the purified DNA fragment and linearized pCI-neo vector (as described in 
section 2.4.4 and 2.4.5), the Quick Ligation™ kit was used (#M2200, NEB).  For this, 
50ng of vector was combined with a 3-fold molar excess of insert. To this 10l of 2X 
Quick Ligation buffer was added to the mix, followed by 1l of Quick T4 DNA ligase. 
Volume was adjusted to a total of 20l with dH2O. The mixture was centrifuged briefly 
and left at RT for 10 minutes. Following this, 1l of ligation mix was transformed into 
XL-10 Gold® Ultracompetent cells (as described in section 2.4.3.3).   
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2.4.7. Colony screening 
Following transformation, a colony PCR was used to screen for successful ligations in 
the transformed E.coli colonies. Single colonies were picked using a sterile p200 tip, re-
streaked on an LB agar plate containing 50g/ml of the appropriate antibiotic (see section 
2.4.7.1) and then incubated in 10l of PCR reaction mix; 6l of nuclease-free (NF)-water, 
2l of 5x FIREPol® master mix with 7.5mM MgCl2 (Solis BioDyne), 1l of 10M T7 
EEV forward primer (Sigma), 1l of 10M T3 reverse primer (Sigma). The following 
cycling parameters were used:  
Lid temperature  110°C  
Temperature 95°C for 5 minutes 
30x conventional cycles  95°C for 40 seconds 
57°C for 45 seconds 
72°C for 2 minute 30 seconds 
Temperature 72°C for 10 minutes 
Infinite hold 10°C 
 
5l of each sample was loaded on to a 1.5% agarose (Melford, UK) gel, containing 2l 
Ethidium Bromide (EtBr) per 100ml agarose gel. Samples were loaded adjacent to 3l of 
Hyperladder I (Bioline, UK). Gels were run in DNA electrophoresis tanks (Geneflow, 
UK) in 1x TAE buffer. Samples were visualised using the gel imager GENi (Syngene, 
UK). Selected colonies with the correct construct size were picked from the re-streaked 
bacterial plates (see section 2.4.7.1) and plasmid DNA prepared, purified and quantified 
as stated in sections 2.3.3 and 2.3.4. To sequence, 10l of 100ng/l of purified plasmid 
DNA made up in dH2O was sent to the Core Genetics Service at the University of 
Sheffield. Once completed, the sequence data was analysed using Sequencher Demo 
Version 5.0.1. 
2.4.7.1. Re-streaking bacterial plates  
Alongside running the colony PCR as described in section 2.4.7, the single E.coli colonies 
picked for screening were also re-streaked on a new LB agar plate, containing 50g/ml 
of the appropriate antibiotic, for further use. A grid with numbers was taped to the bottom 
of the plate. When a colony was picked, it was streaked across a number and then placed 
into a well containing the PCR mix, with the same number. This meant that colonies 
which produced positive results during screening could be identified in the future. 
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2.4.8. Subcloning C13H9orf72 into a pGEX-6p-1-GST expression vector   
For the TnT® Quick Coupled Transcription Translation Binding assay (see section 2.10), 
the C13H9orf72 construct had to be subcloned into the pGEX-6p-1 GST expression 
vector (GE Healthcare Life Sciences). To do this the C13H9orf72 construct was cut using 
XhoI and NotI as described previously in section 2.4.4. Following this the digested 
product was run on an agarose gel and purified as described previously in section 2.4.5. 
The C13H9orf72 construct was ligated with the pre-cut pGEX-6p-1 GST expression 
vector and transformed into XL-10 Gold® Ultracompetent cells, as described in section 
2.4.6. Following this, single colonies were screened using colony PCR as described in 
section 2.4.7, using the programme below and primers detailed in table 2.5:  
Temperature 94°C for 3 minutes 
Conventional cycle (30 cycles) 95°C for 40 seconds 
57°C for 45 seconds 
72°C for 1 minute 30 seconds 
Temperature 72°C for 10 minutes 
Infinite hold 10°C 
 
Table 2.5 GST forward and reverse primers. 
Name  Forward (5’-3’) Reverse (5’-3’) 
GST GCTGGCAAGCCACGTTTGGTG ATGTGTCAGAGGTTTTCACCG 
 
Selected colonies with the correct insert size (1389bp) were picked from the re-streaked 
bacterial plates (see section 2.4.7.1) and plasmid DNA prepared, purified and quantified 
as stated in sections 2.3.3 and 2.3.4. To sequence, 10l of 100ng/l of purified plasmid 
DNA made up in dH2O was sent to the Core Genetics Service at the University of 
Sheffield. Once completed, the sequence data was analysed using Sequencher Demo 







2.5. Methods for targeted genome-editing in zebrafish 
In order to generate C13H9orf72 LOF zebrafish, two modes of targeted genome editing 
were used: transcription activator-like effector nucleases (TALENs), to target coding 
exon 7, and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and 
CRISPR-associated (Cas) gene 9 (CRISPR/Cas9), to target coding exon 1. Target sites 
were designed in both exon 1 and exon 7, to produce LOF mutations in both isoforms or 
just the long isoform respectively of zebrafish C9orf72.  It would not be possible however 
to generate a zebrafish with LOF mutations affecting only the short isoform, as the entire 
sequence for the short isoform is included in the long isoform.  
2.5.1. TALENs 
TALENs were previously generated and microinjected by Dr Andrew Grierson prior to 
the start of the current project. The TALEN site used was as follows (spacer region 
underlined): 
TATATTTCAGGACGTGATgcacaaagacacgcttgtgAAGTCTTTCATAGATGA 
2.5.2. CRISPR/Cas9 target site design 
The CRISPR/Cas9 genome editing system was used in order to produce targeted insertion 
and/or deletion (INDEL) mutations in exon 1 of zebrafish C9orf72 (C13H9orf72; zgc: 
100846). The guide RNA (gRNA) antisense oligonucleotide sequence (5’-3’) was as 




with the gRNA scaffold shown in italics, the target sequence shown underlined and the 
T7 site shown in bold. The target sequence was adopted from (Hruscha et al.,2013).  
2.5.3. In vitro RNA transcription of the gRNA and nCas9 for 
microinjection 
2.5.3.1. gRNA in vitro RNA transcription  
In order for direct in vitro transcription to occur, the 10M of the custom gRNA antisense 
oligonucleotide was annealed to the 10M T7 primer (TAATACGACTCACTATAG). 
Conditions were as follows: 95°C for 5 minutes, then cooled at room temperature 
overnight. The gRNA was then in vitro transcribed using the MEGAshortscript-T7 kit 
(Ambion), following the manufacturer’s protocol.  The transcribed RNA was then 
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purified using the MEGAclear™ kit (Ambion), again following manufacturer’s 
instructions. The concentration of gRNA produced was 108 ng/l. 
2.5.3.2. nCas9 in vitro RNA transcription  
The nuclear Cas 9 (nCas9) plasmid (pCS2-nCas9n; Addgene #47929) was obtained from 
Addgene (Jao et al., 2013). For this protocol, purified nCas9 plasmid DNA was originally 
obtained from Mr Rich Lucas (SITraN), at a concentration of 3g/l. Firstly, the plasmid 
DNA was linearised using the NotI restriction enzyme (NEB) (30 units per 10g of 
plasmid DNA) and left at 37° overnight. Following this, 1l of linearised plasmid was 
loaded on a 1% agarose gel in comparison to the same volume of an undigested control 
to ensure the digestion had been successful. After linearization, the nCas9 mRNA was in 
vitro transcribed using the mMESSAGE mMACHINE kit (Ambion) following the 
manufacturer’s instructions, using 1g of linearised plasmid DNA as template. The 
transcribed RNA was then purified using the MEGAclear™ kit (Ambion) according the 
manufacturer’s instructions.  
2.5.4. Microinjection of CRISPR/Cas9 into zebrafish embryos   
The injection mix was made with 1l of RNA-grade phenol red dye, added to 5l gRNA 
(540 ng/ul), 2l nCas9 (6g/ul) and up to 10l final volume with NFW. Glass capillaries 
(World Precision Instruments) were pulled on a Model P-97 Flaming/Brown micropipette 
pulling machine (Sutter Instruments Co., USA) to produce capillary needles suitable for 
microinjection. The needle was placed in an Eppendorf containing the injection mix and 
the needle loaded by capillary action. The loaded capillary needle was placed in a 
micromanipulator (Leica Microsysems, Wetzlar, Germany). The needle was calibrated 
using a graticule so that two pulses injected a volume of 1nl. Zebrafish were paired the 
night before injection as described in section 2.2.2. The following morning fertilised, one-
cell staged embryos were collected, as described in section 2.2.2. The embryos were 
placed on a 1% agarose gel mould and excess E3 buffer removed using a Pasteur pipette 
so the mould was dry to prevent the embryos moving during injection. They were then 
injected into the yolk sac with 2nl of the gRNA/Cas9 injection mixture using an air 
pressure injector, with final concentration of gRNA 108pg and Cas9 1.2ng (Narashige 
IM-300 gas line injector). Injected embryos were collected, placed in fresh E3 and 
incubated at 28°C. For each batch of injected embryos, a plate of un-injected embryos 
from the same pair was kept as a control. After 48 hours, a selection of injected embryos 
was collected for genotyping.  
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2.5.4.1. PCR analysis  
DNA was extracted from injected embryos at 48 hpf as described in section 2.6.1. The 
resulting DNA was genotyped as described in section 2.6.4 using Exon 1 primers (see 
table 2.6). 
2.6. Genotyping mutant lines 
2.6.1. DNA extraction  
To extract DNA for genotyping, single embryos or fin clips were placed in 30l of 
QuickExtractTM DNA Extraction solution (Epicentre UK, #QE09050). Samples were then 
incubated at 65°C for 2 hours, 99°C for 2 minutes to terminate the reaction and held at 
10°C.    DNA extract from fin clips was diluted 1:5 with nuclease-free water before use. 
2.6.2. Genotyping primers  
 
Table 2.6 Genotyping primers. 
Name  Forward (5’-3’) Reverse (5’-3’) Product 
size (bp) 




































2.6.3. Detecting TALEN-induced mutations via restriction fragment length 
polymorphism (RFLP)  
TALEN-induced insertion or deletion (INDEL) mutations were detected by RFLP 
analysis of an MslI site overlapping the TALEN target site. Loss of the MslI site indicates 
the presence of an INDEL mutation produced by the TALEN. Each PCR was prepared as 
a 10 l reaction, including; 7.525l of nuclease-free (NF)-water, 1l of 10x Standard Taq 
Reaction Buffer (NEB #B90145), 0.2l of deoxynucleotide (dNTP) solution mix (NEB 
#N64475), 0.1l of 100mM Exon 7 primer 2 (forward), 0.1l of 100M Exon 7 primer 
2 (reverse), 1l of template DNA (diluted 1:5) and 0.075l of Taq DNA polymerase 
(NEB #M0273S). The samples were then run using the following protocol:  
Initial denature 94°C for 3 minutes 
Touchdown (x15 cycles) 94°C for 30 seconds 
65°C - 50°C for 45 seconds* 
72°C for 1 minute 30 seconds 
*decreases by 1°C per cycle 
Conventional cycle (‘n’ cycles) 94°C for 30 seconds 
58°C for 45 seconds 
72°C for 1 minute 30 seconds 
Temperature 72°C for 10 minutes 
Infinite hold 10°C 
 
When using DNA extracted from fin clips 20 conventional cycles were used and when 
from embryos 40 conventional cycles were used. Once completed, 1l of the restriction 
enzyme MslI (NEB #R0571L) was added to PCR product in each well. Samples were 
then incubated at 37°C for 12 hours and held at 10°C. After digestion, 5x DNA loading 
buffer (Bioline, UK, #37045) was added to each sample in order to monitor migration 
rate of the samples during electrophoresis. 5l of each sample was loaded on to a 2.5% 
agarose (Melford, UK) gel, containing 2l Ethidium Bromide (EtBr) per 100ml agarose 
gel. Samples were loaded adjacent to 3l of Hyperladder IV (Bioline, UK) to enable 
estimation of fragment sizes every 100bp. Gels were run in DNA electrophoresis tanks 
(Geneflow, UK) in 1x TAE buffer. Samples were visualised using the gel imager GENi 
(Syngene, UK).   
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2.6.4. Detecting CRISPR/Cas9-induced mutations via restriction fragment 
length polymorphism (RFLP) 
CRISPR/Cas9-induced insertion or deletion (INDEL) mutations were detected by RFLP 
analysis of an DdeI site overlapping the CRISPR/Cas9 target site. Loss of the DdeI site 
indicates the presence of an INDEL mutation produced by the CRISPR/Cas9. Each PCR 
was prepared as a 10 l reaction, including; 6.8l of nuclease-free (NF)-water, 2l of 5x 
FIREPol® master mix with 7.5mM MgCl2 (Solis BioDyne), 0.1l of 100M Exon 1 
primer (forward), 0.1l of 100M Exon 1 primer (reverse) and 1l of template DNA. The 
samples were then run using the following protocol:  
Initial denature 94°C for 3 minutes 
Touchdown (x15 cycles) 94°C for 30 seconds 
65°C - 50°C for 45 seconds* 
72°C for 1 minute 30 seconds 
*decreases 1°C per cycle 
Conventional cycle (‘n’ cycles) 94°C for 30 seconds 
58°C for 45 seconds 
72°C for 1 minute 30 seconds 
Temperature 72°C for 10 minutes 
Infinite hold 10°C 
 
When using DNA extracted from fin clips 20 conventional cycles were used and when 
from embryos 40 conventional cycles were used. Once completed, the following mix was 
added to PCR product in each well:  7.75 l of nuclease-free (NF)- water, 2 l of 
CutSmart Buffer (Biolabs, #B7204S) and 0.25 l Ddel (NEB, #RO175L). Samples were 
then incubated at 37°C for 12 hours and held at 10°C. After digestion, 10l of each sample 
was loaded on to a 2.5% agarose (Melford, UK) gel, containing 2l Ethidium Bromide 
(EtBr) per 100ml agarose gel. Samples were loaded adjacent to 3l of Hyperladder IV 
(Bioline) to enable estimation of fragment sizes every 100bp. Gels were run in DNA 
electrophoresis tanks (Geneflow, UK) in 1x TAE buffer. Samples were visualised using 




2.6.5. Sequencing  
Sequence analysis was used to confirm that loss of the restriction site was due to TALEN- 
or CRISPR/Cas9-induced mutations at the target site. To amplify DNA for sequencing, 
the -6 primer (forward and reverse) and +6 primer (forward and reverse) were used for 
the TALEN lines (see table 2.6). The exon 1 primers (forward and reverse) were used for 
the CRISPR/Cas9 lines (see table 2.6). Each PCR was prepared as a 10l reaction, 
including; 6.8l of nuclease-free (NF)-water, 2l of 5x FIREPol® master mix with 
7.5mM MgCl2 (Solis BioDyne), 0.1l of the appropriate forward primer (100M), 0.1l 
of the appropriate reverse primer (100M) and 1l of template DNA. The PCRs were run 
using the PCR cycle detailed in sections 2.6.3 and 2.6.4. Once completed, 4l of each 
PCR product was loaded on to a 2.5% agarose (Melford, UK) gel, containing 2l EtBr 
per 100ml buffer. PCR products were loaded adjacent to 3l of Hyperladder IV (Bioline 
UK) to enable estimation of fragment sizes every 100bp. Gels were run in DNA 
electrophoresis tanks (Geneflow, UK), in 1x TAE buffer. Products were visualised using 
the gel imager GENi (Syngene). DNA from the amplified PCR products are prepared for 
sequencing by ExoSAP, including: 0.05l Exonuclease 1 (NEB, #M0293S), 1l SAP 
(Affymetrix, #78390) and 3.95l deionised water. The product was then incubated at 
37°C for 45 min, 80°C for 15 min to terminate reaction and held at 10°C. PCR products 
were sequenced by the Core Genetics Service at the University of Sheffield. Once 
completed, the sequence data was analysed using Sequencher Demo Version 5.0.1 
(Genecodes, USA). Subsequent analysis of the sequences was performed using ExPASy 











2.6.6. Real Time Quantitative Polymerase Chain Reaction (RT-qPCR)  
2.6.6.1. RT-qPCR primers 
  
Table 2.7 RT-qPCR primers. 















2.6.6.2. DNA extraction 
From the lines raised, heterozygous carriers for the identified mutations were incrossed 
and offspring raised to 5 dpf. At 5 days, 24 larvae were collected and placed into 
individual 0.5ml tubes. Larvae were suspended in 15l of Trizol reagent (Invitrogen) and 
incubated for 10 minutes at RT. The larvae were then homogenised using a handheld 
homogeniser, ensuring the homogeniser tips were cleaned between each larvae. 
Homogenised larvae were incubated at RT for 5 minutes. 3l of chloroform was added 
to each sample and incubated at RT for 2 minutes. Samples were then centrifuged for 15 
minutes at 12000 x g at 4°C. This leads to the formation of a lower organic phase 
(containing DNA and denatured proteins) and an upper aqueous phase (containing RNA). 
The upper aqueous layer was removed, placed into a sterile 0.5ml tube and snap frozen 
in liquid nitrogen. The upper aqueous layer was stored at -80°C until genotyping had been 
completed. To the lower organic phase 1l of glycoblue (Ambion #AM9515) and 5l of 
100% ethanol was added. Samples were vortexed and centrifuged for 10 minutes at 15500 
x g at 4°C. The resulting supernatant was discarded and the following mix was added to 
each pellet: 1l of glycoblue (Ambion #AM9515), 1l of 7.5M ammonium acetate, 14l 
dH2O and 15l of 100% ethanol. The ammonium acetate and ethanol stabilise the nucleic 
acids via neutralising the backbone of the nucleic acids and by decreasing the dielectric 
constant. This makes the backbone stronger and less hydrophilic respectively. The 
samples were then incubated for 30 minutes at RT and subsequently centrifuged for 10 
minutes at 16000 x g at RT. The supernatant was discarded, the pellet was washed in 15l 
of 75% ethanol and then centrifuged for 10 minutes at 15871 x g at RT. The resulting 
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supernatant was removed and the pellet allowed to dry to complete the removal of ethanol. 
The pellet was then re suspended in 30l dH2O and stored at 4°C for genotyping.  
2.6.6.3. Genotyping  
The extracted DNA was genotyped as described in sections 2.6.3 or 2.6.4 depending on 
the lines being analysed. For the PCR cycle, 40 conventional cycles were used. Individual 
homozygous mutants and wild type siblings were identified for RNA extraction (see 
section 2.6.6.4).  
2.6.6.4. RNA extraction 
The upper aqueous layer collected from all identified homozygous mutants and identified 
wild type siblings were pooled together into two separate 0.5ml tubes. 0.5ml of 
isopropanol per 1ml of trizol was added to precipitate the RNA and incubated at RT for 
10 minutes. The samples were then centrifuged for 10 minutes at 12000 x g at 4°C. The 
RNA precipitate formed a pellet at the side of the tube and the resulting supernatant was 
carefully removed. The pellet was washed with 1ml of 75% ethanol (made to volume with 
NFW) per 1ml of trizol, vortexed and centrifuged for 5 minutes at 12000 x g at 4°C. The 
supernatant was removed and the pellet allowed to air dry. The pellet was then re 
suspended in 10l of NFW before it was quantified using a NanoDrop spectrophotometer 
ND-1000 (Thermo Fisher Scientific, Delaware, USA).  
2.6.6.5. Reverse transcription and complementary DNA (cDNA) 
synthesis  
1-2g of RNA was added to a 0.2ml tube with 1l of DNAse buffer (Invitrogen), 1l of 
DNAse (NEB #M03035) and made up to 10l with NFW. Samples were then incubated 
at 37°C for 10 minutes. The reaction was terminated by adding 1l of 25mM EDTA pH 
8.0 and incubating at 75°C for 10 minutes. Following this, 2l of 25mM dNTP mix (NEB 
#N64475) and 1l of oligo(dT)18 (Thermo Scientific #S0132), which primes the polyA 
tail and ensure amplification of spliced mRNA only, was added and incubated at 65°C 
for 5 minutes. The sample was then chilled on ice for 5 minutes and collected by brief 
centrifugation. To each sample, 4l of 5x first strand buffer (Invitrogen) and 2l of 0.1M 
dithiothreitol (DTT) (Invitrogen) was added.  Samples were incubated at 25°C for 5 
minutes before adding 0.5l of Superscript II (Invitrogen).  Samples were then maintained 
at 25°C for a further 5 minutes, 50°C for 50 minutes and 70°C for 15 minutes to terminate 
the reaction. cDNA samples were stored at -20°C. 
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2.6.6.6. RT-qPCR  
Prior to performing RT-qPCR, primer concentrations were optimised and reaction 
efficiency determined via using a standard curve. All RT-qPCR primers and their 
optimised concentrations are detailed in table 2.7. RT-qPCR was performed using the 
Stratagene Mx3000P™ Real Time Thermal Cycler (Agilent Technologies Ltd) and 
MxPro v4.10 software. The cDNA samples were amplified in triplicate 20l reactions 
using 10l 2x Brilliant-II ultrafast SYBR® green qPCR master mix (Agilent technologies 
#600882), 2l of forward primer and 2l of reverse primer (at their optimised 
concentration – see table 2.7), 1l cDNA and made up to a final volume of 20l with 
dH2O. Cycling conditions were as follows: 95°C for 10 min to denature followed by 35 
cycles of 95°C for 30 s, 60°C for 1 min. Levels of mRNA were quantified relative to 


















2.7. Characterisation of mutant lines  
2.7.1. Survival monitoring  
To monitor survival of the numerous lines, heterozygous mutant carriers were incrossed 
(as described in section 2.2.2), producing offspring with a mixture of genotypes (approx. 
25% wild-type, 25% homozygous and 50% heterozygous for the inherited mutation). The 
larvae were raised in tanks containing up to 60 fish. The tanks were checked twice a day 
up to 21dpf. Dead fish were collected and genotyped (as described in sections 2.6.3 and 
2.6.4). A Kaplan–Meier survival plot was generated using Prism v6 software (Graphpad 
Software, USA). 
2.7.2. Methods to examine motor function  
2.7.2.1. Swimming endurance test 
Critical swimming speed (Ucrit), which is the maximum velocity a zebrafish can maintain 
for a set time, was measured using a custom-built swim tunnel apparatus as described in 
Plaut., 2000 and Ramesh et al., 2010. Adult zebrafish were individually introduced into 
the water flow chamber. The water current flow rate started at 6.58 cm/min. The adult 
zebrafish were then subjected to this flow rate for 5 minutes. The flow rate was then 
increased in 6.58 cm/min increments every 5 minutes. This was done until either 30 
minutes had been reached, at a maximum flow rate of 39.47 cm/sec, or until the zebrafish 
could no longer swim and fell into a mesh net at the end of the water flow chamber. If 
fatigued, the zebrafish were given another opportunity to re-enter the highest achieved 
flow rate by pausing the time, reducing flow and slowly increasing the flow rate back to 
the fatigue velocity. If the zebrafish could still no longer swim in this current, the time 
was recorded when the zebrafish stopped swimming. Ucrit was calculated based on the 
following formula as previously described in Ramesh et al., 2010, Brett., 1964, Plaut., 
2000: Ucrit=Ui + (UiiTi/Tii), where Ui = the highest velocity maintained for a whole 
interval (cm/sec), Uii = the velocity increment (6.58 cm/sec), Ti = the time elapsed at 
fatigue velocity (minutes) and Tii = the time interval (5 minutes). 
2.7.2.2. Spinning task   
An alternative method to observe swimming endurance in our pilot cohort was the 
Spinning Task (Blazina et al. 2013). This test was conducted in a 1L beaker, which 
contained 800 mL of system water and a magnetic stir bar. The beaker was placed on a 
magnetic stirrer and placed within an opaque box to avoid external interference. Adult 
zebrafish were individually placed in the beaker and allowed to habituate for 2 minutes. 
Following this, the stirrer speed was gradually increased until the desired speed was 
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obtained.  The individual zebrafish were subjected to speeds of 400 rotations per minute 
(rpm) and 500 rpm. The water current generated by the magnetic stirrer produces a visible 
whirlpool.  A stopwatch was used to measure the swimming time, defined as the time 
taken for the zebrafish to be swept into the whirlpool at each speed.  
2.7.3. Methods to examine behaviour 
All behavioural analysis was performed between 13.00h-17.00h, using the equipment and 
related software included in the ViewPoint analysis suite (ViewPoint Life Science, Lyon, 
France). All analysis was done within a soundproof box, in the light and when possible 
the experimenter was located outside the area to avoid any interference with the 
behavioural responses.  
2.7.3.1. Novel tank diving test  
In order to measure anxiety levels in adult zebrafish, the novel tank diving test was 
employed as described in (Parker et al. 2014). The test was carried out in trapezoid tanks 
(17cm height × 27.3cm top × 24cm bottom × 10.2cm width) which were filled with 
system water from the main aquarium supply. For consistency, system water was taken 
from the aquarium the zebrafish were originally housed in. Prior to the test, the zebrafish 
were transported into the behavioural test room and allowed to habituate for 1 hour to 
acclimatise to test room conditions. Each adult zebrafish was individually placed into the 
novel tank and immediately filmed over a 5-minute time period. During this time, the 
duration of time spent in the bottom half of the tank and total distance travelled was 
recorded. The filming and analysis was carried out using the ViewPoint system. After the 
test, the zebrafish were placed back into the holding tank. The water in the testing tank 
was changed after each individual fish, to control for possible odour cues left by the 
previous individual. Statistical analysis performed on R3.3.2 for windows, using a one-
way ANOVA with repeated measures. Graphs show mean ± standard deviation, unless 
otherwise stated, and this was performed using GraphPad Prism 7.  
2.7.3.2. Open field analysis  
The open field analysis was designed to be conceptually similar to the rodent open field 
test, in order to measure thigmotaxis. Thigmotaxis was initially measured in a rectangular 
tank (26.3cm length × 16.6cm width × 15.3cm height) filled with system water to a height 
of 10cm. The outer zone was defined as the region 6 cm from the edge of the tank, and 
the time spent in this zone was determined. From 13-months onwards, thigmotaxis was 
measured in a white opaque polypropylene circular tank (27.5cm height × 20.5cm 
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diameter) filled with system water to a height of 10cm. The outer zone was defined as the 
region 5 cm from the edge of the tank, and the time spent in this zone was determined. 
Prior to the test, the zebrafish were transported into the behavioural test room and allowed 
to habituate for 1 hour (as mentioned in section 2.5.3.1). Zebrafish were individually 
placed into the centre of the arena and filmed for a total of 6 minutes using the ViewPoint 
system, with the first 1 minute discounted for acclimatisation. Each behavioural session 
was filmed by a camera placed above the open field apparatus. During recording time, 
the duration of time spent in the periphery of the arena, duration of time spent in the centre 
and total distance travelled was recorded. Following the test, the zebrafish were gently 
netted back to a holding tank. The water in the testing arena was changed after each 
individual fish, for reasons described in section 2.5.3.1. Temporal analysis (per minute) 
of the percentage of time spent in the periphery of the open field apparatus (i.e. 
thigmotaxis) was calculated in the following way: Thigmotaxis (% time spent in the 
periphery) = (Time spent in the periphery (s) / Time spent in the periphery + centre (s)) 
* 100. Graphs show mean ± standard deviation, unless otherwise stated, and this was 
performed using GraphPad Prism 7. 
2.7.4. Staining adult zebrafish muscle 
2.7.4.1. Collection, fixing and sectioning of adult muscle   
11-month adult zebrafish were terminally anaesthetized in tricaine. Muscle was dissected 
using micro dissection tools under the microscope and subsequently fixed overnight in 
4% PFA at 4°C. The tissue was then washed 3-5 times in 1ml of dH2O to wash away any 
remaining PFA. Muscle tissue was embedded in fish gelatine and snap frozen on dry ice, 
before being stored at -80°C. Before snap freezing, the position of the embedded tissue 
was confirmed under the microscope and a line drawn on the mould to aid orientation 
during sectioning. In each block, 1 piece of muscle was embedded. Serial 16m cryostat 
sections of the tissue were performed on the Leica CM3050S cryostat, with both objective 
temperature (where the block is mounted) and chamber temperature set to -30°C. Sections 
were collected on silane-coated microscope slides (CellPath) and stored at -80°C until 
needed. Muscle sections were taken as lateral sections in order to give the best neuro-
muscular junction (NMJ) structures for staining and imaging.  
2.7.4.2. Immunostaining of muscle samples  
Immunostaining of NMJs in adult muscle tissue was performed using synaptic vesicle 2 
(SV2 – a presynaptic marker) and α-bungarotoxin (BTX – a post synaptic NMJ marker). 
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The samples were allowed to air dry at RT for 2 hours, after being removed from -80°C. 
Sections were rehydrated 3x 5mins in PBD-T. The sections were then blocked using 
PBD-T with 5% normal goat serum (NGS) for 30 minutes.  Following this, sections were 
incubated for 30 minutes in PBD-T containing 5% NGS along with alexa 488 conjugated 
α-bungarotoxin (molecular probes, 1:100, #B14322). After incubation, the sections were 
washed 3x 15mins in PBD-T. Sections were then incubated with the anti-SV2 antibody 
(Developmental Studies Hybridoma Bank, 1:50 of supernatant) in PBD-T with 5% NGS 
overnight at 4°C. The following day, the samples were washed 6x 15mins in PBD-T and 
incubated in AlexaFluor-568 donkey anti-mouse secondary antibody (Invitrogen, 1:200) 
in PBD-T with 2% NGS at 4°C overnight. The sections were then washed 6x 15mins in 
PBD-T and the slides then mounted with VectaShield Hardest with DAPI (Vector labs). 
Sections were imaged at 5m intervals using confocal microscopy (TCS Sp5 2, Leica). 
Following this, z-stacks were generated using Image J Software (National Institute of 
Health). Intensity correlation quotient (ICQ) (Li et al. 2004) and pre- and post-synaptic 
area were determined using the intensity correlation analysis and particle analysis plugins 
for ImageJ. 
2.7.5. Collection, fixing and measuring of adult zebrafish spleens  
24-month adult zebrafish were terminally anaesthetized in tricaine. Spleens were 
dissected using micro dissection tools under the microscope and subsequently fixed 
overnight in 4% PFA at 4°C. The tissue was then washed 3-5 times in 1ml of dH2O to 
wash away any remaining PFA. Images of the spleens were taken using a light microscope 




2.8. Autophagic flux assay 
2.8.1. Drug treatments for autophagic flux assay 
Embryos were collected as stated in section 2.2.2. At 2 dpf, 10-30 dechorionated embryos were incubated in 5ml of each of the treatments detailed 
in table 2.8 below for 24 hours at 28°C. Treatments were made in a volume of 10ml and made up to volume using E3 embryo medium, with a 2% 
final DMSO concentration. Following drug treatment, dechorionated embryos were transferred into chilled 1.5ml tubes in order to prepare lysates 
(see section 2.9.1)   






DMSO (Sigma) n/a 2% Control (no effect on the autophagy pathway) 
Torin-1 (Tocris) 1mM 1M Potent and selective MTOR inhibitor resulting in the induction of autophagy  
Trehalose (Sigma) n/a 2% Induces autophagy in a MTOR-independent manger via activation of AMPK  
Rapamycin (Fisher Bioreagents) 1mM 100nM Inhibits MTOR via binding RAPTOR, resulting in the induction of autophagy 
INK128 (Cayman Chemicals) 2mM 250nM-1M This compound is a rapalog (synthetic drugs that are analogues of rapamycin), thus 
induces autophagy in the same way as rapamycin 
Ridafiromilus (APExBIO) 2mM 250nM-1M This compound is a rapalog (synthetic drugs that are analogues of rapamycin), thus 
induces autophagy in the same way as rapamycin 
AZD8055 (LKT Lab) 2mM 250nM-1M This compound is a rapalog (synthetic drugs that are analogues of rapamycin), thus 
induces autophagy in the same way as rapamycin 
Temsirolimus (Cayman 
Chemicals) 
2mM 250nM-1M This compound is a rapalog (synthetic drugs that are analogues of rapamycin), thus 
induces autophagy in the same way as rapamycin 
Bafilomycin (LKT Lab) 100M 100nM A V-ATPase inhibitor, which neutralises lysosomal pH and ultimately prevents 
autophagosome-lyosome fusion, resulting in  autophagy inhibition 
Ammonium Chloride (Acros 
Organics) 
1M 100mM Neutralises lysosomal pH, which results in autophagy inhibition  
Chloroquine (Sigma) 500mM 50M Neutralises lysosomal pH, which results in autophagy inhibition  
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2.9. Preparation of lysates for western blotting   
2.9.1. Collecting tissue from zebrafish embryos < 5dpf  
Prior to protein extraction, zebrafish embryos < 5dpf must be deyolked. It is essential to 
remove the yolk sac before immunoblotting, as it is enriched with the protein 
Vitellogenin, which can cause overloading effects whilst blotting (Mathai, Meijer and 
Simonsen 2017, Link, Shevchenko and Heisenberg 2006). Firstly, dechorionated 
embryos were placed in a 1.5ml tube, to which 1ml of embryo deyolking buffer was 
added. A p1000 was used to pipette the zebrafish embryos up and down in order to disrupt 
the yolk sac. Once all yolk sacs had been disrupted, the deyolking buffer was removed 
and replaced with 1ml of embryo washing buffer. Following this each tube was 
centrifuged at 13000 x g for 2 minutes in embryo washing buffer. Embryo washing buffer 
was removed from the resulting pellet, ready for homogenisation (see section 2.9.3) 
2.9.2. Collecting tissue from zebrafish > 5dpf  
Prior to protein extraction, zebrafish > 5dpf were prepared for lysis. As there is no yolk 
sac at this age, protein was extracted from the heads of fish > 5dpf, which were removed 
using a sterile scalpel before being placed into a 1.5ml tube ready for protein extraction. 
Tissue was kept on ice at all times to prevent degradation.  
2.9.3. Protein extraction method 
For protein extraction, collected tissue (via either method described in 2.9.1 and 2.9.2) 
was homogenised in a lysis buffer. For embryos, the final volume of BRB80 lysis buffer 
added was equal to 2l of lysis buffer per embryo. For the tissue collected from zebrafish 
> 5dpf, a total of 40l of RIPA lysis buffer was added to each head.  Firstly, the lysis 
buffer minus detergent was added and the tissue was homogenised for 30 seconds using 
a handheld homogeniser (Anachem Ltd, UK). Once homogenised, an equal volume of 
lysis buffer containing 2x concentration of detergent (either NP40 or Triton-X-100) was 
added and samples were lysed on ice for 30 minutes. 1x of a 100x stock of protease 
inhibitor cocktail (PIC) (Thermo Scientific) was added to the lysis buffer. Following 
lysing, samples were then centrifuged at 18 000 x g for 20 minutes at 4°C.  
2.9.4. Protein concentration assay 
The total protein concentration of each sample was quantified using the Bio-Rad protein 
assay, following the manufacturer’s protocol. The pheraSTAR FS plate reader (BMG 
Labtech) was used to measure the absorbance of each sample at a wavelength of 595nm, 
and the total protein concentration was calculated by comparing values with the known 
concentrations of bovine serum albumin (BSA) standards. Once the concentrations of the 
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samples were established, appropriate dilution volumes of 5x laemmlli buffer and 
deionised water were added to the samples. 
2.10. Western blotting 
2.10.1. SDS-polyacrylamide gel electrophoresis (PAGE)  
SDS-page was carried out using the Bio-Rad mini-PROTEAN® tetra system. 
Approximately 25g of each sample was loaded onto either a 10% or 15% (w/v) 
polyacrylamide resolving gels with a 6% (w/v) stacking gel. 3l of Precision Plus 
Protein™ all blue standard (Bio-Rad) was run adjacent to the samples as a marker. The 
samples were electrophoresed at 100V in running buffer, until the dye front reached the 
bottom of the gel.  
2.10.2. Immunoblotting 
Once SDS-PAGE was complete, proteins were transferred electrophoretically for 1 hour 
at 100V. For autophagic flux assays, proteins were transferred onto an immun-blot® 
PVDF membrane (Bio-Rad), which needed to be activated by methanol beforehand. 
Everything else was transferred onto nitrocellulose unless otherwise stated. Transfer of 
protein to the membrane was verified via reversible staining with Ponceau S stain (0.1% 
ponceaux, 5% acetic acid, made to volume with deionised water). Membranes were 
washed with deionised water and blocked in blocking buffer for 1 hour at RT. The 
membranes were then incubated with the appropriate primary antibody, diluted in 
blocking buffer for 1 hour at RT (or at 4°C overnight). Membranes were washed three 
times with TBS-T for a total of 30 minutes. The membranes were then incubated in 
secondary antibody, conjugated to horseradish peroxidase (HRP) and diluted in TBS-T 
for 1 hour at RT. This was again followed by washes, as described.  
Antibody binding was detected by using enhanced chemiluminescence (ECL; Thermo 
Scientific, #34080), following the manufacturers protocol. Images were obtained either 
by using the G:box (Syngene) or by exposing films in a dark room. In the dark room, the 
membrane was placed in an autoradiography cassette and exposed on Amersham 
hyperfilm ECL (GE Healthcare) for an appropriate length of time. The film was then 
immersed in 1x Ilford multigrade developer (Harman technology Ltd) for 1 min, rinsed 
in water and then placed in 1x Ilford hypam fixer (Harman technology Ltd) for a further 
2 min. The film was then again rinsed in water and allowed to dry at RT. Films were 
scanned using the CanoScan LiDE 60 scanner (Canon) and semi-quantitative 
densitometry was performed using ImageJ. 
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2.10.3. Antibodies for western blotting 
 
Table 2.9 Primary and Secondary Antibodies for Western Blotting. 
Antibody Host 
species 
Specificity Dilution Company 
Primary Antibody 
 
    
Anti-LC3 
(NB100-2331) 
Rabbit Between residues 25-121 of 






Rabbit Between residues 1-100 of 







Mouse α-tubulin 1:1000 Sigma 
Anti-actin 
(#MAB1501) 












Rabbit Internal region of C9orf72 of 
human origin 




Rabbit Recombinant Protein Epitope  
Signature Tag (PrEST) 
antigen 









Rabbit C9orf72 fusion protein 
ag18326, corresponding to 
residues 1-310 (human) 
1:250 ProteinTech 
















2.11. TnT® Quick Coupled Transcription Translation Kit  
2.11.1. Transforming Rosetta™ Competent Cells  
Rosetta™ pLysS Competent Cells were transformed with the pGEX6p1 vector containing 
either zebrafish C13H9orf72 (see section 2.4.8) or human C9orf72L. The human C9orf72 
construct was obtained from glycerol stocks produced by Dr Chris Webster, SITraN. 
Rosetta pLysS cells were removed from -80°C and thawed on ice for 10 minutes prior to 
transformation. 500 ng of pGEX6p1 control, pGEX6p1-C13H9orf72 or pGEX6p1-
hC9orf72L plasmid DNA was transformed in to 80l of Rosetta™ pLysS Competent 
Cells. The transformation and heat shock protocol was performed as described previously 
(see section 2.4.3.3). After 1 h at 37oC, bacteria were plated onto LB-
ampicillin/chloramphenicol agar plates. Ampicillin resistance is conferred by the 
pGEX6p1 vector, while chloramphenicol resistance is conferred by the T7 lysozyme 
plasmid carried by the Rosetta pLysS cells. 
2.11.2. Inoculation of start-up culture for TnT® Quick Coupled 
Transcription Translation Binding assay  
50ml of terrific broth (TB), supplemented with ampicillin and chloramphenicol, was 
inoculated with multiple colonies from the agar plates. These were incubated overnight 
on a shaker at 37°C.  
2.11.3. Inducing expression of GST protein 
To 750ml of TB, 50g/ml of ampicillin was added. Chloramphenicol was not added as 
this can inhibit protein translation. In a cuvette, 1ml of broth was taken as a blank for the 
OD600 reading, which measures cell density, on the S1200 Diode Array 
Spectrophotometer (WPA). Following this, bacteria from the start-up culture were added 
to the broth, until the OD600 reached an optimal 0.05. At this point, a glycerol stock was 
made (as detailed in section 2.6.2) and stored at -80°C. The inoculated cultures were then 
left on a shaker at 37°C and OD600 measured every 30 minutes. When culture reached 
OD600 0.7 and the bacteria were in the exponential growth phase, 300mM of IPTG was 
added directly to the culture at 37°C to induce expression of the protein of interest from 
the pGEX6p1 vector. This was left on a shaker at 37°C for 3 hours. The post-induction 
broth was poured into 500ml Beckman Tubes and centrifuged at 4000rpm for 15 mins at 
4°C to form bacterial pellets (Avanti J-26 XP centrifuge, Beckman Coulter, JA-10 rotor).  
2.11.4. TnT® Quick Coupled Transcription Translation Binding assay  
The following reaction mix was made in a 1.5ml Eppendorf using the T7 quick system 
(TnT® Quick Coupled Transcription/Translation System, Promega, L1170): 8l of 
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reticulocyte lysate mix, 500ng in 1.5ml of the DNA template (ATG13), 0.5l 35S-
Methionine and nuclease-free water up to a final volume of 10l. This reaction was set 
up for each interaction to be investigated. The mix was then incubated at 30°C for 1.5 
hours. During incubation, 0.1g of the GST bacterial cell pellet or 0.25g of the GST-C9 
bacterial pellets weighed out in an individual Eppendorf. 1ml of RB100 lysis buffer (25 
mM Hepes (pH 7.5), 100 mM KOAc, 10 mM MgCl2, 1 mM DTT, 0.05% Triton X-100, 
10% (vol/vol) glycerol) was added to each bacterial pellet and sonicated at 99% amplitude 
for 5s, followed by 20s on ice. This was repeated 3 times overall and the bacteria were 
incubated at 4°C for 1 hour. During this time, 30l of Glutathione Sepharose High 
performance (GSH) beads (GE healthcare, UK) per reaction tube were washed in RB100 
lysis buffer. Following lysis, the bacteria were centrifuged at 17 000 x g for 5 minutes at 
4°C. 1ml of the cleared bacterial lysate was added to the pre-washed GSH beads and 
incubated at 4°C for 1 hour on a roller. Following this, the beads were washed 3x using 
RB100 buffer to remove any unbound GST proteins and finally re suspended in 400l of 
RB100. Approx. 8-9l of the in vitro translated radiolabelled ATG13 protein was added 
to each reaction and incubated at 4°C for 1 hour on a roller. The beads were then washed 
3x in 1ml RB100 and GST proteins were eluted from the beads in 40l Elution Buffer 
(50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 40 mM reduced glutathione) for 10 minutes 
at RT.  
2.11.5. Preparing samples for SDS-PAGE and detection  
For input controls, 0.5l of pure reticulocyte was added to 15.5l of elution buffer and 
4l 5x laemmli. For the GST control, 1l of the eluted GST was added to 15l of elution 
buffer and 4l of 5x laemmli. For samples of interest, 16l of the eluted protein was 
added to 4l of 5x laemmli. The expression of the GST control is higher than the GST-
tagged proteins of interest, and also binds to the GSH beads with a higher affinity. For 
this reason, less GST control sample was loaded compared to the proteins of interest. 
Samples were given a pulse spin and boiled at 100°C for 5 minutes before loading. All 
samples were run on an appropriate percentage stacking/resolving gel and run at 100V 
until the dye front had run off the gel. The gel was then stained with coomassie and 
subsequently de-stained. The de-stained gel was then dried using a BioRad Gel Dryer 
(Model 583). To detect radioactivity, the dry gel was placed in a cassette with a 
phosphoscreen for 4-7 days, depending on the signal (which was checked using a Geiger 
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Counter). The signal was then detected using a GE healthcare Typhoon FLA7000 

































3. Generation of C13H9orf72 loss-of-function zebrafish models of ALS/FTD 
 
3.1. Introduction  
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease 
characterised by the degeneration of upper- and lower- motor neurons, resulting in 
weakness and eventual paralysis of nearly all of the muscles. It is known that 
approximately 90% of all cases are sporadic and 10% are familial. By studying familial 
ALS cases, over 30 genes have been implicated in the pathogenesis of this disease (Peters, 
Ghasemi and Brown 2015b), highlighting the genetic heterogeneity of this disorder. Of 
particular importance was the identification that a non-coding (G4C2)n hexanucleotide 
repeat expansion, within intron 1 of C9orf72, was the most common cause of ALS 
responsible for approximately 40-50% of all fALS cases and 8-10% of sALS (DeJesus-
Hernandez et al. 2011, Renton et al. 2011, Gijselinck et al. 2012). It is unknown how the 
repeat expansion causes C9-ALS, however there is evidence for three possible, non-
exclusive pathogenic mechanisms. Reduced levels of C9orf72 mRNA in patients has been 
reported, suggesting C9orf72 loss-of-function (LOF) via haploinsuffiency may be 
causative in C9-ALS. Alternatively, pathogenic mechanisms may involve a toxic gain-
of-function (GOF) of the repeat containing transcripts via RNA toxicity and/or repeat-
associated non-ATG (RAN) translation into aggregation-prone, dipeptide repeat (DPR) 
proteins (C9RAN proteins).   
Developing in vivo models recapitulating C9-ALS is essential in order to further elucidate 
the pathomechanisms which underlie this disorder and to aid in evaluating the potential 
efficacy of novel therapies. One way in which this can be achieved is with the 
development of zebrafish models. Zebrafish hold several characteristics which make it an 
advantageous model to use in the study of neurodegenerative disorders such as ALS. It is 
a low-cost vertebrate system, which produces a large number of offspring, with a short 
generation time and a conserved, yet simplified, vertebrate nervous system (Babin et al. 
2014). Importantly, its genome is fully sequenced and we know there is high homology 
between many human ALS-linked genes and the corresponding zebrafish orthologue. 
Importantly, there is 68.55% nucleotide identity and 76.14% amino acid identity between 
human C9orf72 and the zebrafish orthologue (zgc: 100846). Therefore, it is expected that 
the functional role of C9orf72 is likely to be similar in zebrafish and humans, thus disease 
mechanisms are expected to be conserved. In addition, the potential to genetically 
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manipulate genes with a variety of techniques in zebrafish makes it a powerful genetic 
tool for studying disease. 
This study focuses on whether haploinsuffiency of C9orf72 results in the development of 
ALS and in order to investigate this, methods leading to both transient and stable loss of 
C9orf72 can be utilised. Previously, antisense morpholinos oligonucleotides (AMOs) 
have been utilised to transiently knock down (KD) both isoforms of the zebrafish 
C9orf72, resulting in both locomotor and axonal deficits (Ciura et al. 2013), which is 
consistent with the aetiology of ALS. Despite promising results, data from AMO 
knockdown should be treated with caution. The technology has various limitations, 
ranging from its transient efficacy to its potential for off-target effects. Regarding the 
latter point in particular, the same group that published the C9orf72 morpholino 
phenotype previously reported that morpholino-mediated knockdown of tardbp, the gene 
encoding TDP-43, resulted in motor neuron axonopathy in zebrafish embryos (Kabashi 
et al. 2010b). However, subsequent groups have not managed to recapitulate this effect 
(Schmid et al. 2013, Hewamadduma et al. 2013) indicating that in some situations the 
phenotypic changes observed in morpholino studies may be due to off-target effects, as 
previously discussed. 
ALS is principally an adult onset disorder in humans, therefore it is essential to use a 
complementary approach to the AMOs in order to study the adult phenotype in zebrafish. 
As such, this present study aimed to generate stable lines of zebrafish carrying LOF 
mutations in C9orf72, using targeted genome editing techniques. Additionally, as a LOF 
mutation has been reported in one ALS case (Liu et al. 2016), it is especially important 
to use in vivo models to further investigate this. The highly conserved zebrafish 
orthologue is predicted to encode two different protein isoforms, which in humans 
includes; a long protein isoform encoding a 481 amino acid protein, and a short protein 
isoform encoding a 222 amino acid protein which lacks a number of exons encoding the 
c-terminus of the protein. It is unclear whether these isoforms have different functions, 
therefore target sites were designed in both exon 1 and exon 7, to produce LOF mutations 
in both isoforms or just the long isoform respectively of zebrafish C9orf72.  It would not 
be possible however to generate a zebrafish with LOF mutations affecting only the short 
isoform, as the entire sequence for the short isoform is included in the long isoform, 
represented in figure 1.2. 
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Originally, transcription activator-like effector nucleases (TALENs) were used to target 
both exon 1 and 7 of zebrafish C9orf72, in order to produce LOF mutants by either 
nonsense or frameshift mutations. It was also desirable that these mutations would either 
disrupt a restriction enzyme cut site and therefore be detected by restriction fragment 
length polymorphism (RFLP) analysis, or alternatively, be large enough to genotype 
easily throughout the process. However, TALENs initially failed to produce such 
mutations in exon 1. Therefore, exon 1 was targeted again utilising the CRISPR/Cas9 
system, which has been shown to transmit mutations in C9orf72 successfully through the 
germline, with low off-target effects in zebrafish (Hruscha et al. 2013). The effect of the 
identified mutations were characterised at the ribonucleic acid (RNA) level and 
successful LOF mutants taken forward for further characterisation of the ALS phenotype 


















3.2. Generating C13H9orf72 loss of function models using transcription 
activator-like effector nucleases (TALENs)  
3.2.1. Comparisons between human C9orf72 and the zebrafish orthologue  
 
The zebrafish C9orf72 orthologue (C13H9orf72) is highly conserved and shares 68.55% 
nucleotide identity with the human gene. Zebrafish only have one copy of C13H9orf72, 
there is no gene duplication. The zebrafish orthologue (ENSDART00000015127.6) has 
10 exons in total, 9 of which are coding exons, with a total length of 17.24 kb (figure 
3.1a). Transcript length is 2.427 kb and translation length 462 amino acids (aa). The 
human gene (ENST00000619707.4) has 11 exons in total,10 of which are coding exons, 
with a total length of 27.32 kb (figure 3.1b). Transcript length is 3.339 kb and translation 
length 481 aa.  
 
 
Figure 3.1 Diagram of human C9orf72 and the zebrafish orthologue. Schematic 
diagram representing A) zebrafish (Danio rerio) C13H9orf72 and B) human (Homo 






Protein sequences, obtained from ensembl, for both human C9orf72 and the zebrafish 
orthologue indicate that the missing coding exon in zebrafish corresponds to human exon 
3, as indicated by the protein alignment (figure 3.2). This could be because ensembl did 
not predict the existence of exon 3 in zebrafish based on homology for the zebrafish 
orthologue of C9orf72, therefore this region was excluded. However, it may also be that 
fish species do not harbour this exon in C9orf72. 
 
 
Figure 3.2 Protein sequence alignment of human C9orf72 and the zebrafish 
orthologue C13H9orf72. Protein sequences of the wild type human (Homo sapiens) 
C9orf72 and the zebrafish (Danio rerio) orthologue C13H9orf72 are shown. The online 
tool Clustal Omega was used to perform alignments of these protein sequences. The 
position of human exon 3 is shown in red, with the corresponding gap in zebrafish 






Firstly, to ensure that the sequencing data obtained from ensembl was correct and that 
this exon was in fact missing, RNA was extracted from wild-type AB zebrafish embryos. 
cDNA was synthesised via reverse transcription and the area surrounding this region was 
amplified via PCR and subsequently sequenced. It was identified that the ensembl 
sequence was correct and this exon was missing.  
Following this, we investigated whether this region was missing in all fish orthologues of 
human C9orf72. A multiple sequence alignment was generated (figure 3.3). This 
alignment included protein sequences of all fish orthologues of C9orf72, as well as 
lamprey, human, rodent and bird. The region under investigation was highly conserved 
for the human, rodent and bird protein sequences. However, there was virtually no 
conservation between the mammals and other non-mammalian species investigated. 
There do appear to be a number of strongly hydrophobic amino acids encoded by this 
exon in all species, however in the context of the whole protein this region is not 
particularly hydrophobic. In six out of the ten fish orthologues this exon was missing. 
Since the lamprey, which is evolutionary ancestral to all the species investigated, has a 
non-conserved protein sequence in this region we suggest that during evolution the 
common ancestor of all fish species lost this exon, and then subsequently several fish 
species re-gained the exon, while others, including zebrafish, did not.  
We are unclear what the role of exon 3 is in C9orf72 protein. The C9orf72 gene in humans 
encodes two protein isoforms that share structural homology with the Differentially 
Expressed in Normal and Neoplasia (DENN) proteins and the long isoform of C9orf72 
(C9-L, 462aa in length), is predicted to harbour all three domains: u-DENN residues 23-
151; central DENN residues 212-322; d-DENN on c-terminus, exact location unpublished 
(Levine et al. 2013, Zhang et al. 2012). Exon 3 is located between the predicted u-DENN 
and central DENN domains, suggesting that this region may have a spacer role, regulating 




Figure 3.3 Multiple sequence alignment between wild-type zebrafish C13H9orf72 
and orthologues from various species. The online tool Clustal Omega was used to 
perform multiple sequence alignments of these protein sequences. The position of human 





















3.2.2. Investigation of polymorphisms surrounding the target locus in exon 
7 
As discussed in section (2.6.3), to detect TALEN-induced genome modifications within 
exon 7 of C13H9orf72, restriction fragment length polymorphism (RFLP) analysis was 
utilised. Evidence of mutation was confirmed by the loss of MslI restriction enzyme 
cleavage, described in figure 3.4. 
 
Figure 3.4 Detection of mutation at exon 7 TALEN target site using restriction 
fragment length polymorphism (RFLP) analysis. A) Schematic diagram representing 
the size of the amplified PCR product using the exon 7 primers (top) and the size of the 
fragments following restriction enzyme digest with MslI (bottom). B) Schematic 
representation of expected bands for homozygous mutants (432 and 60bp), wild-types 
(344, 88 and 60bp) and heterozygous carriers (432, 344, 88 and 60bp) product are run on 
an agarose gel. C) Image of an actual agarose gel showing product from all three 
genotypes. Bands at approximately 88 and 60bp are usually faint and hard to distinguish. 
However, the larger bands allow for accurate genotyping. Asterisk marks the MslI site 




Once loss of MslI cleavage was determined, sequence analysis was performed on 
undigested PCR product to confirm that this loss was due to a TALEN-induced insertion 
and/or deletion (INDEL) mutation at the target site, resulting in a frameshift. 
Initially, PCR amplification in preparation for sequence analysis was performed using 
‘exon 7 primer 1’ (table 2.6). However, it was found that this resulted in unreadable 
sequencing data, predominantely consisting of uncalled bases. As a result, ‘exon 7 primer 
2’ (table 2.6) were designed. These were situated further from the TALEN spacer region, 
as it was possible the distance between the original primers and spacer region was too 
short, thus reading straight into the heterozygous region. However, the resulting 
sequencing data was still unreadable.  
Further analysis of the sequencing data revealed the presence of two novel 
polymorphisms either side of the target site (figure 3.5). This included a six base pair 
INDEL (TTACTA) upstream of the TALEN spacer region, between coding exons 6 and 
7. It also included a microsatellite situated downstream, a seven dinucleotide (14bp) 
stretch of GT, between coding exons 7 and 8. Both polymorphisms lay between the 
TALEN spacer region and the forward or reverse ‘exon 7 primer 2’, resulting in double 




Figure 3.5 Diagram detailing the position of the novel polymorphisms discovered 
surrounding the TALEN target site in exon 7. The red arrows indicate the position of 
the polymorphisms. The six base pair INDEL lies between coding exons 6 and 7. 
Conversely the microsatellite lies between coding exons 7 and 8. The length of each intron 
and exon is represented (top). The text represents the diagram as the corresponding 
nucleotide sequence. Bold text indicates the ‘exon 7 primer 2’ sequences. Red text 
indicates the polymorphisms. Green text indicates the TALEN spacer region within 











To allow the generation of readable sequence data, allele specific forward primers were 
designed so that the alleles with 6 bp deleted (termed the minus 6 allele; -6 – table 2.6) 
and those including the 6 bp (termed the plus 6 allele; +6 – table 2.6) could be amplified 
in separate PCR reactions. In addition, the reverse primer was designed to lie upstream 
of the microsatellite. Optimal conditions for these primers were determined using 
genomic DNA extracted from fin biopsies, which were confirmed to have the following 
genotypes; homozygous for minus 6 allele (-6/-6), homozygous for plus 6 allele (+6/+6) 
and heterozygous for both alleles (-6/+6). Using the PCR programme noted in section 
2.6.3, optimal cycle numbers were identified as described in figure 3.6.   
 
 
Figure 3.6 Testing the allele specific primers. PCR amplification of the genomic DNA 
extracted from fin biopsies with the following genotypes; -6/-6 (homozygous for minus 
6 allele), +6/+6 (homozygous for plus 6 allele) and -6/+6 (heterozygous for both alleles) 
was performed. A) Shows the result using the ‘exon 7 +6’ primers. A product of 181bp 
is only present in samples with a +6 allele. The corresponding sequence is shown on the 
RHS. Primers are in black, polymorphisms are underlined or red, TALEN spacer region 
is green. B) Shows the result using the ‘exon 7 -6’ primers. A product of 175bp is only 
seen in samples with a -6 allele. The corresponding sequence is shown on the RHS. 
Colours are the same as previous. The cycle numbers optimised for use with the 





Subsequently, all PCR amplification in preparation for sequence analysis was performed 
using the allele specific primers throughout the genotyping process. As well as improving 
the quality of the sequencing data obtained, it revealed that all identified frameshift 
mutations were in linkage disequilibrium with the minus 6 allele.  
3.2.3. Identification and raising mutant lines generated using TALENs 
Initially, before the start of this project, fertilised, one-cell staged zebrafish embryos were 
successfully microinjected with the TALEN targeted against exon 7 of C13H9orf72 and 
raised to adulthood (F0 founders). TALENs consist of a pair of DNA binding proteins 
fused to a fok1 nuclease. The pair bind opposite sides of the target site, separated by a 
spacer region of 14-20 nucleotides, within which fok1 cuts the DNA, resulting in a double 
stranded break (DSB) (Joung and Sander 2013). The cell responds to this with 
endogenous repair mechanisms such as homologous recombination (HR) and non-
homologous end joining (NHEJ) (discussed in chapter 1, section 1.3.2). HR-directed DSB 
repair is mainly error-free, utilising the genetic information contained in the undamaged 
sister chromatid in a template (Li and Heyer 2008). Conversely, NHEJ is error-prone, 
involving direct ligation of the broken ends and can result in insertion and deletion 
(INDEL) mutations (Lieber 2010). In this study, we wanted to detect INDELs within the 
target site which produce frameshift mutations, as these will alter the position of the stop 
codon and most likely result in a non-functional protein. 
For phenotypic characterisation of any TALEN-induced mutations to occur, zebrafish 
with mutations in germline cells needed to be generated. To achieve this, F0 founders 
transmitting frameshift mutations through the germline were identified. Fin biopsies were 
taken from F0 founders for screening, using methods described previously (section 2.6), 
identifying all those with evidence of somatic mutations within the target site. The 
selected zebrafish were subsequently outcrossed with wild-type AB zebrafish. The 
resulting offspring (F1) were screened and sequenced for evidence of TALEN-induced 
mutations within exon 7 of C13H9orf72, in order to determine germline transmission rate 
from the F0 founders. For this locus, out of the 9 F1 clutches screened, four were 
identified to carry mutations (44%).  
F1 offspring produced from transmitting F0 founders were then raised to adulthood. Fin 
biopsies from all F1 offspring raised were screened and sequenced, in order to identify 
those heterozygous for frameshift mutations. Figure 3.7 summarises all the frameshift 




Figure 3.7 Diagram detailing all frameshift mutations identified in F1 offspring.  
A) The wild-type C13H9orf72 sequence (coding exon 7) (Ensembl: 
ENSDARG00000011837). Sequence highlighted in green is the TALEN spacer region. 
B) The sequences derived from the mutant F1 alleles of F0 founders 1, 2, 3 and 4, injected 
with the TALEN targeted against coding exon 7 of C13H9orf72. Sequence highlighted 















In order to produce a large batch with identical mutations, four F1 zebrafish identified as 
heterozygous carriers for frameshift mutations were selected, ensuring that the zebrafish 
chosen were each produced from a different F0 founder. The selected zebrafish were 
outcrossed with wild-type AB zebrafish. Figure 3.8 summarises the four F1 mutants 
outcrossed. The resulting offspring (F2) were raised to adulthood.  
 
 
Figure 3.8 Summary of F1 offspring heterozygous for frameshift mutations in exon 
7 which were selected to outcross. A) PCR amplification of the genomic DNA extracted 
from fin biopsies taken from F1 offspring SH448, SH449, SH50 and SH451 using exon 
7 primers. Following digestion with MslI, the digested PCR product was run on a 2.5% 
agarose gel. Digested bands for each heterozygous carrier are compared to a wild-type 
sibling control.  B) Shows the corresponding mutations identified after sequencing. 








F1 offspring with these particular frameshift mutations were selected to be outcrossed, as 
they were predicted to result in truncated forms of the C13H9orf72 protein and it is 
expected that these are most likely to result in LOF mutations. An online translation tool, 
ExPASy, was used to translate the complementary DNA (cDNA) sequences of wild-type 
C13H9orf72 and of the mutated C13H9orf72 alleles as previously described (figure 3.8) 
in to the corresponding protein sequences. The online tool ClustalW2 was then used to 





Figure 3.9 Multiple sequence alignment of wild-type and mutated C13H9orf72 
protein sequence from TALEN generated lines. Complementary DNA (cDNA) 
sequences of the wild type C13H9orf72 and of the mutated C13H9orf72 alleles, as 
previously described in figure 5, were translated in to the corresponding protein sequences 
using ExPASy. The online tool Clustal Omega was then used to perform multiple 
sequence alignments of these protein sequences. The effects of each insertion or deletion 




Fin biopsies taken from F2 offspring raised to adulthood (SH448, SH449, SH450 and 
SH451) were screened in order to identify those heterozygous carriers for the selected 
frameshift mutations. The expected Mendelian inheritance pattern of 50% wild-type and 
50% heterozygous carriers was observed in all lines.  Once identified, heterozygous 
carriers from all of the lines (SH448, SH449, SH450 and SH451) were incrossed to 
produce offspring (F3), in order to study any effects on early survival (chapter 4). It is 
expected from such an incross to see the following Mendelian inheritance pattern; 25% 
wild-type, 25% homozygous mutant and 50% heterozygous carriers for the previously 
identified mutations 
Following this, F3 offspring were raised to adulthood from lines SH448 and SH451, in 
order to have two TALEN lines for adult phenotypic characterisation. Fin biopsies taken 
from F3 offspring raised to adulthood were screened and subsequently wild-types and 
homozygous mutants were selected for characterisation, following appropriate power 
calculations (chapter 4).  
3.2.4. Identification of null alleles in TALEN-generated lines  
 
As previously discussed, the identified mutations in lines SH448, SH449, SH450 and 
SH451 were predicted to result in a truncated form of C13H9orf72 (see figure 3.9). 
Initially, in order to try and detect endogenous C13H9orf72 protein levels in the wild-
type and homozygous mutant zebrafish, western blotting using three commercially 




Figure 3.10 Observing C13H9orf72 protein levels in zebrafish. A) Untreated wild type 
or C13H9orf72SH451/SH451 lysates were run alongside HEK293 cells treated with C9orf72 
siRNA or non-targeting (NTC). Levels of endogenous C9orf72 were determined on 
immunoblots using three commercially available anti-C9orf72 antibodies (all 1:250). B) 
HEK293 were transfected with Myc-C9L, Myc-C9S or empty vector control. Levels of 
C9orf72 were determined on immunoblots using the same anti-C9orf72 antibodies.   
 
It was expected that the full-length zebrafish C13H9orf72 protein would run at 52 kDa, 
whereas the C13H9orf72SH451/SH451 protein will either not be visible, if the protein is not 
expressed, or if the truncated protein is expressed, produce a band around 40kDa. 
However, no band was visible at these predicted kDa values with any of the commercial 
anti-C9orf72 antibodies used (figure 3.10A), only non-specific bands also seen in the 
siRNA treated cell lysates. The human C9orf72-L was expected to run at 54 kDa and 
human C9orf72-S at 25kDa. Endogenous C9orf72-S was not observed in any of the cell 
lysates. However, endogenous C9orf72-L was observed when HEK-293 were treated 
with non-targeting siRNA with two of the commercial anti-C9orf72 antibodies used 
(Santa Cruz and ATLAS, figure 3.10A). As expected, overexpressed Myc-C9orf72L and 
Myc-C9orf72S was observed with all antibodies tested (figure 3.10B), indicating that 
these antibodies are able to detect both C9orf72 isoforms.  
Due to the lack of reliable antibodies to detect C13H9orf72 protein levels, RT-qPCR was 
performed to investigate C13H9orf72 mRNA levels. This was carried out to determine 
94 
 
whether the predicted truncated C13H9orf72 transcripts are degraded by nonsense-
mediated decay. RT-qPCR analysis revealed a significant decrease in total C13H9orf72 
transcript levels in homozygous mutants in comparison to wild-type siblings in all lines 
(figure 3.11); SH448 (C13H9orf72+/+ mean 1.01±0.01 vs C13H9orf72SH448/SH448 
0.33±0.09, unpaired t-test, p = <0.0001); SH449 (C13H9orf72+/+ 1.01±0.01 vs 
C13H9orf72SH449/SH449 0.34±0.11, unpaired t-test, p = <0.0001); SH450 (C13H9orf72+/+ 
1.05±0.04 vs C13H9orf72SH450/SH450 0.23±0.16, unpaired t-test, p=0.0006); SH451 
(C13H9orf72+/+ 1.00±0.00 vs C13H9orf72SH451/SH451 0.17±0.04, unpaired t-test, p = 
<0.0001).  
 
Figure 3.11 Identified frameshift mutations in coding exon 7 of C13H9orf72 gene 
lead to reduced levels of C13H9orf72 transcripts in zebrafish. Result from RT-qPCR 
to investigate whether truncated C13H9orf72 transcripts are degraded by nonsense-
mediated decay. In comparison to wild type siblings, homozygous mutants show a 
reduction in C13H9orf72 transcript levels of approximately 60-80% (n=3) in lines A) 
SH448 (unpaired t-test, p = <0.0001, n=2); B) SH449 (unpaired t-test, p = <0.0001, n=2); 
C) SH450 (unpaired t-test, p=0.0006, n=2); D) SH451 (unpaired t-test, p = <0.0001, n=3). 
Levels of mRNA were quantified relative to loading control EF1α mRNA levels 
according to the ΔΔCt method. Error bars represent standard deviation of the mean of 
n=2-3 biological repeats. Each biological repeat contains 3-10 zebrafish pooled together 
per genotype.  
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3.3. Generating C13H9orf72 loss of function models using the CRISPR/Cas9 
system 
3.3.1. Investigation of polymorphisms surrounding the target locus in exon 
1 
In addition to the TALEN designed to target exon 7 of C13H9orf72 prior to the start of 
this project, a TALEN was also designed to target exon 1 of C13H9orf72. Embryos 
injected with this TALEN were not taken forward to be raised at this point, as it was 
unsuccessful in producing TALEN-induced genome modifications within this target 
locus. As a result, this region was targeted again utilising an alternative targeted genome 
editing technique, the CRISPR/Cas9 system. We used a previously published 
CRISPR/Cas9 target site within exon 1 of C13H9orf72 (Hruscha et al. 2013) (section 
2.5.2 and figure 3.12-A) 
In preparation for this, genomic DNA from AB zebrafish was amplified using ‘exon 1 
primer’ (table 2.6) and the undigested PCR product, including the potential CRISPR site 
in exon 1, was sequenced. This was done in order to identify possible polymorphisms in 
this region, due to the previous identification of polymorphisms surrounding the target 
locus in exon 7 of C13H9orf72.  
Analysis of the sequencing data revealed a polymorphism located between the forward 
primer and potential CRISPR target site within exon 1 (figure 3.12). This involved a 
single base pair change from thymine to guanine (ZGC_100846:c.66 T>G), resulting in 
a codon change from TGT to TGG. The codon change corresponds to an amino acid 
change from cysteine to tryptophan. These amino acids have different properties; cysteine 
is a polar amino acid with a neutral side chain, whereas tryptophan is an aromatic amino 
acid with a hydrophobic side chain. However, this is a known missense variant 
(rs40965738). The polymorphism occurs in a poorly conserved region of C9orf72 and 





Figure 3.12 Schematic diagram to show position of polymorphism surrounding 
target locus in exon 1. A) The nucleotide sequence represents a portion of C13H9orf72 
including the 5’ UTR and coding exon 1. C9E1 primer sequences are shown in black and 
italicised. The identified polymorphism is shown in red. The CRISPR target sequence is 
shown in green. The PAM site shown in blue. B) Shows part of the chromatogram 









3.3.2. Identification and raising mutant lines generated using 
CRISPR/Cas9 
As described in section 3.3.1, the CRISPR/Cas9 system was utilised to target exon 1 of 
zebrafish C13H9orf72 and we used a previously published CRISPR/Cas9 target site 
within exon 1 of C13H9orf72 (Hruscha et al. 2013) (section 2.5.2 and figure 3.12-A). 
CRISPR/Cas9 is a complex between a target-specific single guide RNA (gRNA) and a 
Cas9 nuclease. The gRNA directs the Cas9 to the target site, which is directly followed 
by a PAM site, resulting in DSBs. As discussed in section 3.2.3, the cell responds to this 
with endogenous repair mechanisms such as HR and NHEJ. In this study, we wanted to 
detect INDELs within the target site which produce frameshift mutations, as these will 
alter the position of the stop codon and most likely result in a non-functional protein 
(figure 3.13). Within the target site there is a restriction enzyme site for DdeI. This 
restriction enzyme has a 5bp recognition sequence, which is optimal for rapidly detecting 
CRISPR/Cas9-induced INDEL mutations for genotyping.  
The published gRNA (Hruscha et al. 2013) was co-injected with Cas9 mRNA into 
fertilised, one-cell stage zebrafish embryos (0-0.75hpf). The embryos used originated 
from the wild-type line AB, consistent with the TALEN lines produced previously. A 
portion of the injected embryos were screened at 48hpf for CRISPR/Cas9-induced 
genome modifications at the target site. PCR products were amplified using ‘exon 1 
primers’ (table 2.6) and analysed via RFLP for evidence of INDEL mutations. Evidence 
of mutation was confirmed by the loss of DdeI restriction enzyme cleavage, described in 
figure 3.14. At this stage, digested and un-digested bands were seen in samples where the 
CRISPR/Cas9 injection was successful, resembling a heterozygous carrier, as the injected 
embryos are genetically mosaic at this point. Following confirmation of genome 
modifications at the target site, the remaining injected zebrafish embryos (F0 founders) 






Figure 3.13 Diagram to show how CRISPR/Cas9 system result in non-homologous 
end-joining (NHEJ). Guide oligonucleotides containing a T7 RNA polymerase binding 
domain were annealed with a T7 primer (green). gRNA containing a target binding site 
(dark green) and the nCas9 plasmid were in vitro transcribed. gRNA and nCas9 mRNA 
were co-injected into one-cell stage zebrafish embryos. The gRNA recruits the Cas9 
protein to the target site to induce double-strand breaks (DSB) close to the protospacer 
adjacent motif or PAM sequence (orange). In the absence of donor DNA template, the 
DSB are repaired by non-homologous end joining (NHEJ). NHEJ results in small 






Figure 3.14 Detection of mutation at exon 1 CRISPR/Cas9 target site using 
restriction fragment length polymorphism (RFLP) analysis. A) Schematic diagram 
representing the size of the amplified PCR product using the exon 1 primers (top) and the 
size of the fragments following restriction enzyme digest with DdeI (bottom). B) 
Schematic representation of expected bands for homozygous mutants (409 and 27bp), 
wild-types (208, 201 and 27bp) and heterozygous carriers (409, 208, 201 and 27bp) 
product are run on an agarose gel. C) Image of an actual agarose gel showing product 
from all three genotypes. Bands at approximately 27bp are usually faint and hard to 
distinguish. However, the larger bands allow for accurate genotyping. Asterisk marks the 




Once F0 founders had reached adulthood, those transmitting frameshift mutations 
through the germline were identified, as previously discussed in section 3.2.3. Fin 
biopsies were taken from F0 founders for screening, using methods described previously 
(section 2.6), identifying all those with evidence of somatic mutations within the exon 1 
target site. The selected zebrafish were subsequently outcrossed with wild-type AB 
zebrafish. The resulting F1 offspring were screened and sequenced for evidence 
CRISPR/Cas9-induced mutations within exon 1 of C13H9orf72, in order to determine 
germline transmission rate from the F0 founders. For this locus, out of the 4 F1 clutches 
screened, three were identified to carry mutations (75%). 
F1 offspring produced from transmitting F0 founders were then raised to adulthood. 
Again, fin biopsies from all F1 offspring raised were screened and sequenced, in order to 
identify those heterozygous for frameshift mutations, as done previously. Figure 3.15 
summarises all the frameshift mutations identified.  
 
 
Figure 3.15 Diagram detailing all frameshift mutations identified in CRISPR/Cas9 
generated F1 offspring. A) The wild-type C13H9orf72 sequence (coding exon 1) 
(Ensembl: ENSDARG00000011837). Sequence highlighted in green is the CRISPR 
target site. B) The sequences derived from the mutant F1 alleles of F0 founders 1, 2 and 
3, injected with the CRISPR/Cas9 targeted against coding exon 1 of C13H9orf72. 
Sequence highlighted in green is the CRISPR target site. Mutations are shown in red. 






In order to produce a large batch with identical mutations, three F1 zebrafish identified 
as heterozygous carriers for frameshift mutations were selected, again ensuring that the 
zebrafish chosen were each produced from a different F0 founder. The selected zebrafish 
were outcrossed with wild-type AB zebrafish. Figure 3.16 summarises the three F1 
mutants outcrossed. The resulting F2 offspring were raised to adulthood.  
 
 
Figure 3.16 Summary of the F1 offspring heterozygous for frameshift mutations in 
exon 1 which were selected to outcross. A) PCR amplification of the genomic DNA 
extracted from fin biopsies taken from F1 offspring SH470, SH471 and SH472 using 
C9E1 primers. Following digestion with DdeI, the digested PCR product was run on a 
2.5% agarose gel. Digested bands for each heterozygous carrier are compared to a wild-
type sibling control.  B) Shows the corresponding mutations identified after sequencing. 
Sequence highlighted in blue is the CRISPR target site. Mutations are shown in red. PAM 








As before, F1 offspring with these particular frameshift mutations were selected to be 
outcrossed, as they were predicted to result in truncated forms of the C13H9orf72 protein 
and it is expected that these are most likely to result in LOF mutations. Figure 3.17 shows 
the multiple sequence alignments of the mutated C13H9orf72 protein sequences 
compared to the wild-type protein sequence. This was carried out in the same way as 
described in section 3.2.3.  
 
 
Figure 3.17 Multiple sequence alignment of wild-type and mutated C13H9orf72 
protein sequence from CRISPR/Cas9 generated lines. Complementary DNA (cDNA) 
sequences of the wild type C13H9orf72 and of the mutated C13H9orf72 alleles, as 
previously described in figure 3.16, were translated in to the corresponding protein 
sequences using ExPASy. The online tool Clustal Omega was then used to perform 
multiple sequence alignments of these protein sequences. The effects of each insertion or 










Fin biopsies taken from F2 offspring raised to adulthood (SH470, SH471 and SH472) 
were screened in order to identify those heterozygous carriers for the selected frameshift 
mutations. As before, the expected Mendelian inheritance pattern of 50% wild-type and 
50% heterozygous carriers was observed in all lines.  Once identified, heterozygous 
carriers from all of the lines (SH470, SH471 and SH471) were incrossed to produce F3 
offspring, in order to study any effects on early survival (chapter 4). It is expected from 
this incross to see the following Mendelian inheritance pattern; 25% wild-type, 25% 
homozygous mutant and 50% heterozygous carriers for the previously identified 
mutations 
Following this, F3 offspring were raised to adulthood from line SH470, in order to have 
a CRISPR/Cas9 line for adult phenotypic characterisation. Fin biopsies taken from F3 
offspring raised to adulthood were screened and subsequently wild-types and 
homozygous mutants were selected for characterisation, following appropriate power 
calculations (chapter 4).  
3.3.3. Identification of null alleles in CRISPR/Cas9-generated lines  
As previously discussed in section 3.2.4, the identified mutations in lines SH470, SH471 
and SH472 were predicted to result in a truncated form of C13H9orf72 (figure 3.16).  Due 
to the lack of reliable antibodies to detect C13H9orf72 protein levels (see figure 3.10), 
RT-qPCR was performed to investigate C13H9orf72 mRNA levels, to determine whether 
the predicted truncated C13H9orf72 transcripts are degraded by nonsense-mediated 
decay. RT-qPCR analysis revealed a significant decrease in total C13H9orf72 transcript 
levels in homozygous mutants compared to wild-type siblings (figure 3.18), in lines 
SH470 and SH471; SH470 (C13H9orf72+/+ 1.01±0.02 vs C13H9orf72SH470/SH470 
0.46±0.07, unpaired t-test, p = <0.0001); SH471 (C13H9orf72+/+ 1.03±0.04 vs 
C13H9orf72SH471/SH471 0.38±0.00, unpaired t-test, p = <0.0001). However, there was not 
a biologically relevant difference in total C9orf72 transcript levels observed between 
homozygous mutants and wild-type siblings in line SH472; SH472 (C13H9orf72+/+ 







Figure 3.18 Identified frameshift mutations in coding exon 1 of C13H9orf72 gene 
lead to reduced levels of C13H9orf72 transcripts in zebrafish. Result from RT-qPCR 
to investigate whether truncated C13H9orf72 transcripts are degraded by nonsense-
mediated decay. In comparison to wild type siblings, homozygous mutants show a 
significant reduction in C13H9orf72 transcript levels in lines A) SH470 (unpaired t-test, 
p = <0.0001, n=2); B) SH471 (unpaired t-test, p = <0.0001, n=2); C) but not SH472 
(unpaired t-test, p = <0.05, n=2). Levels of mRNA were quantified relative to loading 
control EF1α mRNA levels according to the ΔΔCt method. Error bars represent standard 
deviation of the mean of n=2 biological repeats. Each biological repeat contains 3-10 










3.4. Discussion  
The initial aim of this project was to produce a stable zebrafish C9orf72 LOF model of 
C9-ALS/FTD, using targeted genome editing techniques. As discussed, it is not fully 
understood how the repeat expansion in C9orf72 results in ALS/FTD, however there is 
evidence for three possible, non-exclusive pathogenic mechanisms. It is essential to 
model all three potential mechanisms in order to understand their contribution to disease 
and this project focuses particularly on how C9orf72 LOF via haploinsufficiency may 
contribute to C9-ALS/FTD. This project utilised zebrafish for the generation of the 
model, which harbour a highly conserved orthologue of the human C9orf72, called 
C13H9orf72. Currently, only one group has published data investigating C9orf72 LOF in 
zebrafish. As discussed, this group used AMOs to transiently KD C13H9orf72 in their 
zebrafish model, and observed ALS-like phenotypes (Ciura et al. 2013). The stable 
zebrafish C9orf72 LOF models which have been produced in this project are highly 
important, as currently no other stable zebrafish model has been characterised. As ALS 
is mainly an adult-onset disorder in humans, it is essential to study the phenotypes of a 
stable LOF model throughout its lifetime. This will enable further understanding as to 
how this gene contributes to C9-ALS/FTD and to investigate protein function in vivo.  
3.4.1. Comparisons between targeted genome editing techniques: TALENs 
vs CRISPR/Cas9 
Two targeted genome editing techniques were utilised in order to generate the stable 
zebrafish C13H9orf72 LOF model. As discussed, before the start of this project, TALENs 
were used to target exon 1 and exon 7 of C13H9orf72. TALENs are comprised of a pair 
of DNA-binding proteins, which bind to opposite sides of the target site and are separated 
by a spacer region consisting of around 14-20 nucleotides. Within this spacer region, the 
nonspecific fok-1 nuclease fused to the DNA binding proteins makes double-stranded 
breaks. Although successful in targeting exon 7, the TALEN targeting exon 1 initially 
failed. As a result, the CRISPR/Cas9 system was used to target exon 1, utilising a gRNA 
which has been previously published (Hruscha et al. 2013). CRISPRs are a complex 
between a target specific guide RNA (gRNA) and a cas9 nuclease. The gRNA guides the 
cas9 to a 20 nucleotide target site, immediately followed by a PAM site, causing double-
stranded breaks.  This technique was chosen as during the project the CRISPR/Cas9 
system was becoming more widely used, due to the ease of design and high mutation 
efficiency of the technique. However, it is important to note that both techniques 
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successfully exploited DNA repair mechanisms such as NHEJ, resulting in INDEL 
mutations within the chosen target regions of C13H9orf72.  
As previously mentioned, in order for phenotypic characterisation of the CRISPR/Cas9- 
and/or TALEN-induced mutations to occur, zebrafish with mutations in germline cells 
need to be generated. The F0 founders injected with either CRISPR/Cas9 or TALENs 
were raised to adulthood and their offspring (F1) screened for germline transmission 
(section 3.2.3 and 3.3.2). Interestingly, when F1 clutches were screened, it was observed 
that several mutations were passed through the germline from the same founder (figures 
3.7 and 3.15). This variety of inherited mutations is to be expected, as the injected F0 
founder fish are genetically mosaic. Due to the mosaic nature of the founders, it is 
important to select specific F1 offspring heterozygous carriers for frameshift mutations 
to outcross. As a result, all heterozygous carriers identified in F2 offspring will have 
identical mutations.  
Additionally, it was noted in this project that the F0 founders injected with the 
CRISPR/Cas9 system had a high germline transmission rate of 75% compared to those 
injected with TALENs, at only 44%. Interestingly, the germline transmission rate 
produced by the CRISPR/Cas9 injection was higher than that observed with the same 
gRNA in (Hruscha et al. 2013), who observed only 20%. It is possible that whilst 
screening for loss of the DdeI restriction site, that the authors may have missed some 
frame-shift mutations that did not disrupt this site and were therefore not detected. In the 
future, due to ease of design and high germline transmission rate, the CRISPR/Cas9 
system would be the method of choice over TALENs for rapidly generating INDEL 
mutation in desired target sites.   
3.4.2. Genotyping mutations in C13H9orf72 
  
Identification of CRISPR/Cas9- and TALEN-induced mutations was done via RFLP, 
using the restriction enzymes DdeI and MslI, respectively. A limitation of this method is 
that it only allows identification of mutations which have disrupted the restriction enzyme 
cut site. Therefore, it will not detect mutations which are present in the region but have 
not disrupted the restriction cut site. This suggests that there could be more mutations 
present in the founder population which were not discovered. However, the restriction 
enzyme MslI was particularly advantageous to use to avoid this limitation, as it has a long 
cut site of 10bp (CAYNNNNRTG), which means it should detect the majority of 
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insertions and deletions within the target region. A further limitation of RFLP is that it 
only provides information on whether a mutation is present, not if it is an in-frame or 
frameshift mutation. Therefore, it was essential to sequence undigested PCR product in 
order to determine what the mutation was, which elongates the genotyping process. 
However, it is essential to do this step, as frameshift mutations are more likely to result 
in truncated and/or non-functional protein products. In the future, techniques such as High 
Resolution Melt (HRM) analysis and SURVEYOR mutation detection kits could be 
utilised to speed up the genotyping process. These methods are advantageous when 
mutating regions without good restriction sites.  
Novel polymorphisms were identified to surround the target region in exon 7 of 
C13H9orf72, therefore it was impossible to obtain readable sequencing data with the 
original primers (section 3.2.2). As a result, before injection of the CRISPR/Cas9, the 
region surrounding the target site in exon 1 of C13H9orf72 was fully sequenced to ensure 
there were no polymorphisms surrounding it. This led to the identification of a 
nonsynonymous amino acid substitution in a non-conserved region.  Luckily, in both 
cases, the identified polymorphisms were avoidable with the design of new primers. 
However, in the future it should be essential to sequence the region surrounding a 
potential target site before generating a new model. This is important, particularly in 
zebrafish, as their genomes are highly polymorphic (Nasiadka and Clark 2012). This is 
also critical to consider as whole genome sequencing was performed on the Tuebingen 
strain of zebrafish (Howe et al. 2013). Therefore, when using other strains to generate 
models, such as the AB strain in this project, there may be variations in the sequence of 
a particular region due to the polymorphic nature of their genomes. 
Originally, it was hoped that the targeted genome editing techniques used would produce 
large INDEL mutations. This would have been advantageous, as these could be simply 
genotyped by resolving the bands on an agarose gel. This would negate the use of RFLP, 
speeding up the genotyping process.  An allele produced via injection with TALENs, 
SH450, harboured an +80bp insertion in exon 7 of C13H9orf72, which could be easily 
observed on an agarose gel without digestion. However, upon further analysis, when 
cDNA produced from zebrafish carrying this mutation was sequenced, an alternatively 
spliced transcript was identified. The transcript carried an in-frame Δ168bp, 
corresponding to the deletion of exons 7 and 8. As the mutation was in-frame, these 
transcripts could potentially produce functioning protein, therefore this line was not taken 
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forward. In the future, it will be important to sequence cDNA from zebrafish carrying 
large INDELs to ensure that the expected truncated transcript is present before continuing 
with characterisation.  
3.4.3. Identified frameshift mutations in exon 1 and 7 of C13H9orf72 result 
in truncated transcripts 
 
The identified frameshift mutations chosen to be taken forward were selected as they are 
predicted to result in a truncated form of C13H9orf72 (figures 3.9 and 3.17).  The full 
length C13H9orf72 consists of 462 residues. The TALEN-induced frameshift mutations 
located in exon 7 of C13H9orf72 were predicted to result in truncations from the 
following amino acid residues: SH448 residue 356; SH449 residue 362; SH450 residue 
384; SH451 residue 357.  Additionally, the CRISPR/cas9-induced frameshift mutations 
located in exon 1 of C13H9orf72 were predicted to result in truncations from the 
following amino acid residues: SH470 residue 67; SH471 residue 55; SH472 residue 64.  
Our RT-qPCR data demonstrates that the predicted truncated transcripts are degraded by 
nonsense mediated decay before they are able to be translated into protein (discussed 
further below). However, it is possible that a small amount of mutant mRNA may be 
translated into truncated, aberrant proteins. The result this has would be dependent on the 
role of C13H9orf72. As mentioned previously, the C9orf72 gene in humans encodes two 
protein isoforms that share structural homology with the Differentially Expressed in 
Normal and Neoplasia (DENN) proteins (Levine et al. 2013, Zhang et al. 2012). DENN 
proteins are implicated in membrane trafficking events as GDP/GTP exchange factors 
(GEF) of Rab GTPases. The tripartite DENN module consist of the following domains in 
eukaryotes: u-DENN domain on the N-terminus; a central DENN domain; a d-DENN 
domain on the C-terminus (Levivier et al. 2001). The long isoform of C9orf72 (C9-L, 
462aa in length), is predicted to harbour all three domains: u-DENN residues 23-151; 
central DENN residues 212-322; d-DENN on c-terminus, exact location unpublished 
(Levine et al. 2013, Zhang et al. 2012). The short isoform of C9orf72 (C9-S, 212aa in 
length) is predicted to contain only the u-DENN and part of the central DENN domain, 
due to it lacking a portion of the C-terminus of the protein. Due to high conservation 
between human and zebrafish C9orf72 (76.14% amino acid identity), it is expected that 
the functional role of C9orf72 is likely to be similar in both species. Therefore, it could 
be predicted that if a small amount of mutant mRNA is translated, the CRISPR/Cas9-
induced frameshift mutations resulting in truncations at residues 55-67 would result in a 
109 
 
more severe phenotype in the zebrafish, as the truncated protein would only contain part 
of the u-DENN. This would be dependent on whether the location of the three DENN 
domains are similar in zebrafish. It is important to note the distinct roles of each of the 
DENN domains are not fully understood, but it will certainly be interesting to investigate 
whether mutations located in exon 1 are more severe than those in exon 7 during 
characterisation of the models.  
Ideally, western blot analysis would be utilised to examine protein levels of C13H9orf72 
in zebrafish carrying mutant alleles vs wild-type siblings. However, as shown in section 
3.2.4, the commercially available antibodies used were not able to detect endogenous 
protein levels in the zebrafish. A reason for this may be due to the immunogen sequence 
these antibodies were raised against. For example, the polyclonal ATLAS and 
ProteinTech anti-C9orf72 antibodies were raised against immunogen sequences which 
include human exon 3, which as discussed in section 3.2.1, is not present in zebrafish. 
Additionally, an important limitation to consider when using these commercially 
available anti-C9orf72 antibodies is that they do not discriminate between the two protein 
isoforms of C9orf72. However, pioneering work by (Xiao et al. 2015) has led to the 
development of antibodies which are able to detect C9orf72-L and C9orf72-S 
individually. In the future, it would be interesting to test these antibodies on protein 
extracted from the zebrafish lines generated, as the epitopes are well conserved between 
human and the zebrafish orthologue.  
As a result of the lack of reliable, commercially available anti-C9orf72 antibodies during 
this project, RT-qPCR was performed on cDNA produced from identified homozygous 
mutants and their wild-type siblings from all lines (section 3.2.4 and 3.3.3). A reduction 
in C13H9orf72 mRNA levels in homozygous mutants would provide evidence for 
degradation by nonsense mediated decay (NMD). NMD is an important surveillance 
mechanism which exists in eukaryotes. It ensures that mRNA transcripts containing 
premature translation termination codons (PTCs), are degraded and thus cannot be 
translated into potentially aberrant proteins (Kurosaki and Maquat 2016). It is known that 
the zebrafish genome encodes orthologues for most of the genes essential for NMD to 
occur (Wittkopp et al. 2009). If NMD is occurring, a lower steady state of mutant mRNA 
would be expected. This is what was reported in sections 3.2.4 and 3.3.3, for most lines 
tested. However, it is important to acknowledge the limitations in studying NMD by 
examination of mRNA levels via RT-qPCR. For example, it cannot be assumed that the 
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level of mRNA is directly proportional to the level of protein expression. Factors to 
consider which effect this correlation include post-transcriptional processes which are 
essential in determining the final synthesis of the protein (Greenbaum et al. 2003). 
Therefore, in the future it is hoped that there will be anti-C9orf72 antibodies available to 
study the endogenous C13H9orf72 protein levels in these zebrafish in order to compare 
to the RT-qPCR result. 
3.4.4. Determining loss-of-function alleles to take forward for phenotypic 
characterisation 
 
Following generation of frameshift mutations in both exon 1 and exon 7, using 
CRISPR/Cas9 and TALENs respectively, it had to be decided which LOF alleles would 
be taken forward for phenotypic characterisation.  
Following initial injection of the TALEN targeted against exon 7 of C13H9orf72, the 
following four lines were generated: SH448 (Δ4bp exon 7); SH449 (Δ2bp exon 7); SH450 
(+80bp ins exon 7); SH451 (Δ17bp exon 7). As previously discussed in section 3.4.2, the 
allele SH450 was not taken forward for characterisation due to the presence of an 
alternative transcript harbouring an in-frame Δ168bp, corresponding to the deletion of 
exon 7 and 8 of C13H9orf72. It was shown from the RT-qPCR results that zebrafish 
homozygous mutant for the other three mutant alleles had a significant reduction in 
C13H9orf72 mRNA level in comparison to wild-type siblings (section 3.2.4). As a result, 
it was decided to take two alleles forward, SH448 and SH451, for phenotypic 
characterisation. Two lines were chosen to allow confirmation of any phenotypic changes 
observed. This would strengthen confidence that any effects were due to a mutation 
truncating the c-terminus of the protein, and not any side effect in the genetic background 
of that particular line.  
Additionally, following injection of the CRISPR targeted against exon 1 of C13H9orf72, 
the following lines were generated: SH470 (+2bp ins, Δ1bp exon 1); SH471 (Δ2bp exon 
1); SH472 (Δ10bp exon 1). It was noted from the RT-qPCR result in section 3.3.3, that 
zebrafish homozygous mutant for the SH472 allele only had a minimal decrease in 
C13H9orf72 mRNA level (10-14%) in comparison to wild-type siblings. As RT-qPCR 
primers were designed against the 3’-end of the transcript, it was predicted that this 
mutation would not lead to a LOF and that full-length protein would be expressed. 
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Therefore, it was decided not to take forward the SH472 allele for phenotypic 
characterisation.  
RT-qPCR results from zebrafish homozygous mutant for the other two mutant alleles had 
a significant reduction in C13H9orf72 mRNA level in comparison to wild-type siblings 
(section 3.3.3). Initially, it was decided to take forward both alleles for phenotypic 
characterisation, for the same reason noted for the TALEN-generated lines. However, 
allele SH471 was unable to be taken forward due to issues regarding breeding. There was 
a sex skew bias towards males in the F2 generation, with only one female a heterozygous 
carrier for the SH471 mutant allele. As a result, the F2 generation were outcrossed again 
with wild-type AB to produce a better ratio of males:females heterozygous carriers for 
the SH471 allele. However, by the time this generation was raised, it was too late in the 
project to incross these and produce an F3 generation to obtain any meaningful 
characterisation data on. As a result, only one allele, SH470, was taken forward to observe 
the effect of mutations in exon 1 of C13H9orf72.  
3.4.5. Conclusion 
In conclusion, the initial aim of this project was achieved and stable zebrafish 
C13H9orf72 LOF models have been generated to take forward and characterise in the 
future. To summarise, a total of four TALEN-generated lines (SH448, SH449, SH450 
and SH451) and two CRISPR/Cas9-generated lines (SH470 and SH471) showed a 
significant reduction in C13H9orf72 transcript levels (section 3.2.4. and 3.3.3). As a 
result, two TALEN-generated lines (SH448 and SH451) and one CRISPR/Cas9-
generated line (SH470) were taken forward for phenotypic characterisation into 









4. Characterisation of C13H9orf72 loss-of-function zebrafish models of ALS/FTD 
4.1. Introduction  
 
As previously discussed, there is a link between ALS and FTD in patients who carry the 
repeat expansion in C9orf72, therefore observed phenotypes may include both motor 
dysfunction and behavioural and/or cognitive changes in humans. Following the 
generation of stable C13H9orf72 loss-of-function (LOF) zebrafish, as discussed in 
chapter 3, this study focussed on investigating whether loss of C13H9orf72 results in any 
ALS- or FTD-like phenotypes similar to those seen in patients. There is currently no 
characterised stable in vivo model of C9-ALS/FTD in the zebrafish; therefore, an 
important component of this project is the phenotypic characterisation of these zebrafish. 
If loss of C13H9orf72 results in the development of ALS/FTD in the zebrafish, we will 
expect to see changes in phenotypes such as survival, motor function and pathology, as 
has been shown in other models of ALS in zebrafish.  
Regarding survival, previous AMO experiments suggest that knockdown (KD) of 
C13H9orf72 produces viable embryos (Ciura et al. 2013). It is possible that complete loss 
of C13H9orf72 will result in embryonic or larval lethality. However, if this was the case, 
these zebrafish could still be utilised. Due to their external development and availability 
in large numbers, they can be studied easily to the end of life, unlike embryonic lethal 
murine models. Additionally, zebrafish that are heterozygous carriers of the frameshift 
mutations could also be utilised, as C9-ALS/FTD patient mRNA levels are similar to 
what we would expect to see in these fish. To determine whether the frameshift mutations 
in C13H9orf72 result in early loss of viability in these fish, survival monitoring will be 
performed during larval stages by monitoring tanks twice per day and removing dead 
larvae for genotyping as previously described (Chapman et al. 2013). 
In order to observe any changes in motor function of adult C13H9orf72 LOF zebrafish, 
two main approaches will be utilised, including the spinning task (Blazina et al. 2013) 
and the swim tunnel (Ramesh et al. 2010, Plaut 2000). As loss of muscle strength is a 
hallmark phenotype seen in C9-ALS/FTD, these two techniques will aim to examine the 
swimming endurance of the zebrafish. It is expected that if the zebrafish carrying 
frameshift mutations in C13H9orf72 develop ALS/FTD-like phenotypes, a reduction in 
swimming endurance will be observed as noted in previous models of ALS (Ramesh et 
al. 2010). In order to confirm the basis for any alteration in motor function observed, 
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quantitative assessment of neuromuscular junctions (NMJs) will be performed, as carried 
out previously in (Chapman et al. 2013, Ramesh et al. 2010). 
Additionally, due to the link between ALS and FTD in patients harbouring the repeat 
expansion in C9orf72, behavioural changes will be investigated in these zebrafish. As 
previously mentioned, there are a number of established protocols which are able to 
investigate behavioural changes in zebrafish, and for this study a battery of such tests 




















4.2. Characterisation of survival in stable C13H9orf72 loss of function 
zebrafish  
C9-ALS/FTD patients typically survive 30.5 months after diagnosis (Cooper-Knock et 
al. 2012). To address whether C13H9orf72 LOF zebrafish had a shorter lifespan, we 
analysed survival over time, as reported in section 4.2.1 and 4.2.2. 
4.2.1. Investigating whether frameshift mutations in exon 1 of C13H9orf72 
lead to loss of viability  
4.2.1.1. Viability up to 21dpf 
To address whether frameshift mutations in exon 1 of C13H9orf72 resulted in early loss 
of viability in the zebrafish, survival monitoring was performed during larval stages for 
all lines generated. Heterozygous carriers from each line were in-crossed and the resulting 
offspring were monitored twice a day, with dead larvae removed for genotyping as 
previously described in section 2.7.1.  
There was no significant difference in survival at larval stages for lines SH471 and 
SH472, with all three genotypes showing 96-100% survival up to 21dpf (figure 4.1, B 
and C). However, there was a significant decline in survival at larval stages in line SH470 
(p = 0.0006, Mantel-Cox log-rank test; figure 4.1 A), with knockout of C13H9orf72 in 
the C13H9orf72SH470/SH470 embryos resulting in only 41% survival by 21dpf in the 





Figure 4.1 Survival characterisation in zebrafish carrying frameshift mutations in exon 1 of C13H9orf72. Figure shows Kaplan-Meier plots 
for lines A) SH470 (n = 3 clutches, p=0.0006, Mantel-Cox log-rank test) B) SH471 (n=1 clutch, ns, Mantel-Cox log-rank test) and C) SH472 (n=4 
clutches, ns, Mantel-Cox log-rank test), up to 21 dpf. Survival of wild-types are shown in green, heterozygous carriers in blue and homozygous 
mutants in red. Plots generated using GraphPad Prism 6. 
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4.2.1.2. Viability up to 90dpf 
Heterozygous carriers from line SH470 were in-crossed and raised to adulthood for 
phenotypic characterisation. Fin biopsies were taken for genotyping at 90dpf. A chi-
squared (χ2) test was calculated, comparing the observed and expected Mendelian 
inheritance patterns for line SH470 at 90dpf (table 4.1). A non-significant interaction was 
found (χ2 (2) = 4.380, p = 0.1119), which indicates that the observed pattern was not 
significantly different from the expected Mendelian ratio. 
Table 4.1 Expected and observed Mendelian inheritance patterns at 90dpf for line 
SH470 
Line Genotype Expected Mendelian 
inheritance at 90dpf (%) 
Observed Mendelian 
inheritance at 90dpf  (%) 
SH470 C13H9orf72+/+ 25 27 
 C13H9orf72SH470/+ 50 57 
 C13H9orf72SH470/SH470 25 16 
 
In addition, the survival for this batch was better than observed previously (section 
4.2.1.1), as knockout of C13H9orf72 in the C13H9orf72SH470/SH470 embryos resulted in an 
average survival of 68% by 90dpf, with an average of 96% survival for C13H9orf72+/+ 
and 100% for C13H9orf72SH470/+. This indicates that the result seen previously (figure 
4.1) may have been due to variability in husbandry.  
4.2.1.3. Survival at end stage 
Following the genotyping at 90dpf, groups of 11 wild-type and 11 homozygous mutants 
from line SH470 were selected, based on power calculations from swim tunnel data 
obtained from a transgenic SOD-1 zebrafish model of ALS (Ramesh et al. 2010). Table 
4.2 below summarises the original and end-stage group sizes in this cohort, indicating 
there was no further decrease in survival by 12 months. A chi-squared (χ2) test was 
calculated, comparing the original and end-stage group sizes for each clutch. A non-
significant interaction was found for line SH470 (χ2 (1) = 0, p = 1). 
Table 4.2 Group sizes at end stage for line SH470 






SH470 C13H9orf72+/+ 30.3.16 12 months 11 11 





4.2.1. Investigating whether frameshift mutations in exon 7 of C13H9orf72 
lead to loss of viability  
4.2.1.1. Viability up to 21dpf 
To address whether frameshift mutations in exon 7 of C13H9orf72 resulted in early loss 
of viability in the zebrafish, survival monitoring was performed during larval stages for 
all lines generated, as described in section 2.7.1.  
There was no significant difference in the survival of lines SH449, SH450 and SH451 up 
to 21dpf, with all three genotypes surviving at a similar rate (figure 4.2, B-D). However, 
there was a significant decline in survival at larval stages in line SH448 (p = 0.03, Mantel-
Cox log-rank test; see figure 4.2 A), with average survival up to 21dpf for 
C13H9orf72SH448/SH448 and C13H9orf72SH448/+ embryos were 37% and 48%, respectively, 
compared to 55% for C13H9orf72+/+. It is important to note that survival overall, 
especially for lines SH448, SH449 and SH450 (figure 4.2, A-C) appears lower for all 
















Figure 4.2 Survival characterisation in zebrafish carrying frameshift mutations in exon 7 of C13H9orf72. Figure shows Kaplan-Meier plots for 
lines A) SH448 (n = 3 clutches, p = 0.03, Mantel-Cox log-rank test) B) SH449 (n = 3 clutches, ns, Mantel-Cox log-rank test) C) SH450 (n = 2 clutches, 
ns, Mantel-Cox log-rank test) and D) SH451 (n = 1 clutch, ns, Mantel-Cox log-rank test), up to 21 dpf. Survival was performed during larval stages. 
Survival of wild-types are shown in green, heterozygous carriers in blue and homozygous mutants in red. Plots generated using GraphPad Prism 6. 
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4.2.1.2. Viability up to 90dpf 
Heterozygous carriers from lines SH448 and SH451 were in-crossed and raised to 
adulthood for phenotypic characterisation. Fin biopsies were taken for genotyping at 
90dpf. A chi-squared (χ2) test was calculated, comparing the observed and expected 
Mendelian inheritance patterns for both lines at 90dpf (table 4.3). For each line, 2 clutches 
were raised for phenotypic characterisation.  A non-significant interaction was found for 
line SH448 clutch 1 (χ2 (2) = 0.09, p = 0.9560) and clutch 2 (χ2 (2) = 5.94, p = 0.0513). 
Additionally, a non-significant interaction was found for line SH451 clutch 1 (χ2 (2) = 
0.04, p = 0.9802) and clutch 2 (χ2 (2) = 2.46, p = 0.2923). Therefore, this shows that the 
observed patterns were not significantly different from the expected Mendelian ratios 
resulting from a heterozygous in-cross, in any of the lines raised. 
Table 4.3 Expected and observed Mendelian inheritance patterns at 90dpf for lines 
SH448 and SH451 
Line Genotype Expected Mendelian 
inheritance at 90dpf 
(%) 
Observed Mendelian 
inheritance at 90dpf  
(%) 
SH448 clutch 1 C13H9orf72+/+ 25 24.25 
 C13H9orf72SH448/+ 50 51.5 
 C13H9orf72SH448/SH448 25 24.25 
SH448 clutch 2 C13H9orf72+/+ 25 22.5 
 C13H9orf72SH448/+ 50 42 
 C13H9orf72SH448/SH448 25 35.5 
SH451 clutch 1 C13H9orf72+/+ 25 24.5 
 C13H9orf72SH451/+ 50 51 
 C13H9orf72SH451/SH451 25 24.5 
SH451 clutch 2 C13H9orf72+/+ 25 19 
 C13H9orf72SH451/+ 50 51 
 C13H9orf72SH451/SH451 25 30 
 
In addition, the survival for line SH448 was better than observed previously (section 
4.2.2.1), as knockout of C13H9orf72 in the C13H9orf72SH448/SH448 embryos resulted in an 
average survival of 75% by 90dpf, with an average of 84% survival for C13H9orf72+/+ 
and 81% for C13H9orf72SH448/+. This indicates that the result seen previously (figure 4.2) 







4.2.1.3. Survival at end stage 
Following the genotyping at 90dpf, groups of 11 wild-type and 11 homozygous mutants 
from lines SH448 and SH451 were selected, based on power calculations from swim 
tunnel data obtained from a transgenic SOD-1 zebrafish model of ALS (Ramesh et al. 
2010). However, group sizes of 10 wild-type and 10 homozygous mutants were selected 
for SH451 clutch 2, as we were limited by the number of available wild-types. A chi-
squared (χ2) test was calculated, comparing the original and end-stage group sizes for 
each clutch. The use of a chi-square test is usually inappropriate if the expected frequency 
is below 5 in more than 20% of your cells. However, in the 2x2 case of the chi-square test 
of independence, expected frequencies less than 5 are usually considered acceptable if 
Yates’ correction is employed, which was done here (table 4.4). In addition, a continuity 
correction of 0.5 was added to each cell. A non-significant interaction was found for line 
SH448 clutch 1 (χ2 (1) = 0.178, p = 0.6731) and clutch 2 (χ2 (1) = 0, p = 1). Additionally, 
a non-significant interaction was found for line SH451 clutch 1 (χ2 (1) = 0, p = 1) and 
clutch 2 (χ2 (1) = 0, p = 1). Therefore, this shows that end-stage group sizes were not 
significantly different from the original group sizes, in any of the lines.   
Table 4.4 Group sizes at end stage for line SH448 and SH451 






SH448 clutch 1 C13H9orf72+/+ 28.1.15 24 11 8 
 C13H9orf72SH448/SH448 28.1.15 24 11 6 
SH448 clutch 2 C13H9orf72+/+ 13.1.16 12 11 8 
 C13H9orf72SH448/SH448 13.1.16 12 11 9 
SH451 clutch 1 C13H9orf72+/+ 18.3.15 24 11 11 
 C13H9orf72SH451/SH451 18.3.15 24 11 10 
SH451 clutch 2 C13H9orf72+/+ 25.2.16 12 10 9 










4.3. Characterisation of motor function in a stable C13H9orf72 loss of function 
zebrafish  
As discussed previously, loss of muscle strength is a hallmark phenotype seen in C9-
ALS/FTD. Thus, the next aim of this project was to examine swimming endurance of the 
adult zebrafish carrying frameshift mutations in C13H9orf72. It was expected that if the 
zebrafish develop ALS/FTD-like phenotypes, a reduction in swimming endurance would 
be observed. In order to investigate this, two methods were used. Firstly, the swim tunnel 
was used to measure critical swimming speed (Ucrit) of individual zebrafish (Plaut 2000). 
This method had previously been used to examine motor function in zebrafish models of 
motor neuron dysfunction, including in our lab (Chapman et al. 2013, Ramesh et al. 
2010). Secondly, a novel method called the Spinning Task was used to examine 
swimming endurance (Blazina et al. 2013). This method had an advantage over the swim 
tunnel in that it was quicker to test motor function of large clutches of zebrafish, taking 
only a few minutes per individual, compared to up to 30 minutes using the swim tunnel 















4.3.1. Pilot study examining swimming endurance using the Spinning Task 
in adult zebrafish  
The Spinning Task is represented in figure 4.3, consists of individually placing a zebrafish 
in to a beaker of system water containing a magnetic stirrer. The latency of the individual 
to be swept into the whirlpool was recorded, at both 400rpm (figure 4.4) and 500rpm 
(figure 4.5). The line SH448 (DOB 24.09.14) were the first line carrying LOF mutations 
raised to adulthood. Therefore, this line was used as the pilot cohort for this experiment. 
Group sizes consisted of n=6 wild-type (5 males and 1 female) and n=6 homozygous 
mutants (4 males and 2 females). At first, each individual was recorded for 60 seconds. 
However, this was increased up to 300s at 7 months onwards. This was done to ensure 
the latency of being swept into the whirlpool was recorded accurately. 
 
 
Figure 4.3 Schematic of Spinning Task apparatus. Design of the apparatus used for 
the spinning task. A 1-L beaker is placed on top of a stirrer with 800mL of aquarium 





Figure 4.4 Spinning task at 400rpm. Time taken to be swept into the whirlpool at 
400rpm is represented for both genotypes (C13Horf72+/+ n=6 and C13H9orf72SH448/SH448 
n=6) at months 5-10. Mean average time for the group and standard deviation is shown. 





Figure 4.5 Spinning task at 500rpm. Time taken to be swept into the whirlpool at 
500rpm is represented for both genotypes (C13H9orf72+/+ n=6 and C13H9orf72SH448/SH448 
n=6) at months 5-10. Mean average time for the group and standard deviation is shown. 
An unpaired t-test revealed that there is no significant difference at time points 6-10 




There was no significant difference observed between C13H9orf72SH448/SH448 mutants and 
their wild-type siblings at any time point tested (5-10 months) at 400rpm (figure 4.4). 
Additionally, there was no significant difference observed between 
C13H9orf72SH448/SH448 mutants and their wild-type siblings at time points 6-10 months at 
500rpm (figure 4.5). However, a significant difference was seen at 5 months (unpaired t-
test, p=0.0173), with homozygous mutants swimming longer against the current than their 
wild-type siblings.  
Additionally, the coefficient of variation was high at both speeds tested (table 4.5). The 
coefficient of variation is the standard deviation as a percentage of the mean. The higher 
this percentage is, the greater the level of dispersion around the mean. For example, the 
average coefficient of variation of wild-types in the spinning task was 95.68% at 400rpm 
and 80.34% at 500rpm. In comparison, the average coefficient of variation of wild-types 
in the swim tunnel was 11.67% (table 4.7, SH448 clutch 1), indicating the swim tunnel 
method is less variable than the spinning task. As a result, the spinning task was no longer 





























C13H9orf72+/+ 5 400 6 17.33±18.66 107.66% 
C13H9orf72SH448/SH448 5 400 6 14.83±7.36 49.62% 
C13H9orf72+/+ 5 500 6 4.50±2.26 50.18% 
C13H9orf72SH448/SH448 5 500 6 11.17±5.27 47.19% 
C13H9orf72+/+ 6 400 6 13.33±15.85 118.84% 
C13H9orf72SH448/SH448 6 400 6 13.83±5.27 38.09% 
C13H9orf72+/+ 6 500 6 17.50±22.40 128.02% 
C13H9orf72SH448/SH448 6 500 6 10.67±10.54 98.80% 
C13H9orf72+/+ 7 400 6 19.17±14.22 74.18% 
C13H9orf72SH448/SH448 7 400 6 44.50±33.99 76.39% 
C13H9orf72+/+ 7 500 6 10.83±8.33 76.88% 
C13H9orf72SH448/SH448 7 500 6 16.17±8.45 52.25% 
C13H9orf72+/+ 8 400 6 55.83±33.44 59.89% 
C13H9orf72SH448/SH448 8 400 6 71.83±72.99 101.60% 
C13H9orf72+/+ 8 500 6 44.83±33.11 73.85% 
C13H9orf72SH448/SH448 8 500 6 23.00±9.98 43.39% 
C13H9orf72+/+ 9 400 6 70.17±98.27 140.06% 
C13H9orf72SH448/SH448 9 400 6 58.50±34.92 59.69% 
C13H9orf72+/+ 9 500 6 36.17±32.39 89.55% 
C13H9orf72SH448/SH448 9 500 6 28.83±22.63 78.49% 
C13H9orf72+/+ 10 400 6 182.83±134.29 73.45% 
C13H9orf72SH448/SH448 10 400 6 162.17±118.69 73.19% 
C13H9orf72+/+ 10 500 6 47.50±30.18 63.53% 











4.3.2. Examination of critical swimming speed (Ucrit) using the Swim 
Tunnel in adult zebrafish  
As discussed in section 4.3.1, the primary method chosen for examining motor output 
was the swim tunnel. As noted in tables 4.7 – 4.11, coefficient of variation is relatively 
low for both genotypes tested at all the time points, providing confidence that this protocol 
has low variability and is sensitive to detect significant changes in motor function. This 
method involved placing the individual zebrafish into the swim tunnel (figure 4.6) and 
enabling them to swim against a current of water, starting at approximately 6.58cm/s. 
Every five minutes, this current increased by approximately 6.58cm/s, until the zebrafish 
could no longer swim or until a maximum of 39.47cm/s was established.  To quantify 
endurance, critical swimming speed (Ucrit) was determined by monitoring the ability of 
the zebrafish to swim against the increasing current over time (Plaut 2000), on the cohorts 
summarised in table 4.6.   
 
 
Figure 4.6 Image of swim tunnel apparatus used to measure swimming endurance. 
The custom-built swim tunnel was used to measure swimming endurance. Zebrafish were 
placed in the tunnel and a current of water applied. Which they naturally swim against. 
Every 5 minutes this current was increased until they could no longer swim against it or 








Table 4.6 Genotype and group sizes of clutches tested through swim tunnel 
apparatus. Key words: WT = wild type; HOM = homozygous mutant.  
Line DOB Genotype Number 
of males 
Number 
of females  
Overall 
sample size 
SH448 clutch 1 28.1.15 WT 5 6 11 
-- -- HOM 5 6 11 
SH448 clutch 2 13.1.16 WT 6 5 11 
-- -- HOM 6 5 11 
SH451 clutch 1 18.3.15 WT 5 6 11 
-- -- HOM 5 6 11 
SH451 clutch 2 25.2.16 WT 6 4 10 
-- -- HOM 6 4 10 
SH470 30.3.16 WT 5 6 11 




















4.3.2.1. SH448 swimming endurance clutch 1 (DOB 28.1.15) 
Critical swimming velocity (Ucrit) of C13H9orf72
SH448/SH448 zebrafish and their wild-type 
siblings was initially determined at 12, 15, 18, 21 and 24 months (± 7 days). The results 
demonstrate that Ucrit is significantly reduced in C13H9orf72
SH448/SH448 zebrafish at 15 
months (p=0.0042, 2-way ANOVA with fisher’s LSD test) and 21 months (p=0.0195, 2-
way ANOVA with fisher’s LSD test), relative to wild-types (figure 4.7). Additionally, a 
non-significant reduction in Ucrit is seen at 12, 18 and 24 months in C13H9orf72
SH448/SH448 
zebrafish (figure 4.7). The mean Ucrit ± SD, plus coefficient of variation is summarised in 
table 4.7. 
 
Figure 4.7 Ucrit values for line SH448 clutch 1 (DOB 28.1.15) Graph shows mean 
Ucrit values ± s.d. for C9orf72
SH448/SH448 vs wild-type siblings at all the time points tested 
in the swim tunnel. Significance tested using 2-way ANOVA with Fisher’s LSD test, * 
p<0.05 and ** p<0.01, n = 6-11. 
 
Table 4.7 Summary of line SH448 clutch 1 (DOB 28.1.15)  




C13H9orf72+/+ 28.1.15 12 30.76 ± 2.24 7.28% 
C13H9orf72SH448/SH448 28.1.15 12 28.79 ± 6.25 21.70% 
C13H9orf72+/+ 28.1.15 15 35.57 ± 3.64 10.24% 
C13H9orf72SH448/SH448 28.1.15 15 29.21 ± 3.57 12.22% 
C13H9orf72+/+ 28.1.15 18 31.43 ± 5.19 16.52% 
C13H9orf72SH448/SH448 28.1.15 18 29.25 ± 5.66 19.34% 
C13H9orf72+/+ 28.1.15 21 32.27 ± 6.06  18.78% 
C13H9orf72SH448/SH448 28.1.15 21 26.69 ± 6.96  26.06% 
C13H9orf72+/+ 28.1.15 24 27.44 ± 1.52 5.54% 
C13H9orf72SH448/SH448 28.1.15 24 27.34 ± 5.46 19.97% 
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4.3.2.2. SH448 swimming endurance clutch 2 (DOB 13.1.16) 
Next, the Ucrit of C13H9orf72
SH448/SH448 zebrafish and their wild-type siblings was 
determined in a second clutch at 4, 6, 9 and 12 months (± 7 days), to see if the reduction 
in Ucrit reported in section 4.3.2.1 was observed earlier than 12 months. The results 
demonstrate that Ucrit is reduced in C13H9orf72
SH448/SH448 zebrafish relative to wild-types 
at all the time points (figure 4.8). However, this was not statistically significant at any 
time point tested. The mean Ucrit ± SD, plus coefficient of variation is summarised in table 
4.8. 
 
Figure 4.8 Ucrit values for line SH448 experiment 2 (DOB 13.1.16). Graph shows 
mean Ucrit values ± s.d. for C9orf72
SH448/SH448 vs wild-type siblings at all the time points 
tested in the swim tunnel. Significance tested using 2-way ANOVA with Fisher’s LSD 
test, ns, n=8-11. 
 
Table 4.8  Summary of line SH448 experiment 2 (DOB 13.1.16) 




C13H9orf72+/+ 13.1.16 4 29.92 ± 4.14 13.84% 
C13H9orf72SH448/SH448 13.1.16 4 27.38 ± 2.52 9.21% 
C13H9orf72+/+ 13.1.16 6 31.95 ± 5.68 17.78% 
C13H9orf72SH448/SH448 13.1.16 6 29.28 ± 4.23 14.45% 
C13H9orf72+/+ 13.1.16 9 32.32 ± 4.96  15.36% 
C13H9orf72SH448/SH448 13.1.16 9 30.14 ± 4.51 14.95% 
C13H9orf72+/+ 13.1.16 12 29.34 ± 3.70 12.62% 





4.3.2.3. SH451 swimming endurance experiment 1 (DOB 18.3.15) 
The Ucrit of C13H9orf72
SH451/SH451 zebrafish and their wild-type siblings was initially 
determined at 9, 12, 15, 18, 21 and 24 months (± 7 days). The results demonstrate that 
Ucrit is significantly reduced in C13H9orf72
SH451/SH451 zebrafish at 12 months (p=0.0114, 
2-way ANOVA with fisher’s LSD test), relative to wild-types (figure 4.9). Additionally, 
a non-significant reduction in Ucrit is seen at 9, 15, 18, 21 and 24 months in 
C13H9orf72SH451/SH451 zebrafish (figure 4.9). The mean Ucrit ± SD, plus coefficient of 
variation is summarised in table 4.9. 
 
Figure 4.9 Ucrit values for line SH451 experiment 1 (DOB 18.3.15). Graph shows 
mean Ucrit values ± s.d. for C9orf72
SH451/SH451 vs wild-type siblings at all the time points 
tested in the swim tunnel. Significance tested using 2-way ANOVA with Fisher’s LSD 
test, * p<0.05, n = 9-11. 
 
Table 4.9 Summary of line SH451 experiment 1 (DOB 18.3.15) 




C13H9orf72+/+ 18.3.15 9 34.00 ± 5.41 15.94% 
C13H9orf72SH451/SH451 18.3.15 9 32.68 ± 6.65 20.36% 
C13H9orf72+/+ 18.3.15 12 33.97 ± 5.42 15.35% 
C13H9orf72SH451/SH451 18.3.15 12 28.22 ± 3.68 13.04% 
C13H9orf72+/+ 18.3.15 15 34.38 ± 5.43 15.78% 
C13H9orf72SH451/SH451 18.3.15 15 30.13 ± 4.38 14.54% 
C13H9orf72+/+ 18.3.15 18 29.98 ± 4.63 15.44% 
C13H9orf72SH451/SH451 18.3.15 18 28.87 ± 4.24  14.68% 
C13H9orf72+/+ 18.3.15 21 28.99 ± 3.89 13.40% 
C13H9orf72SH451/SH451 18.3.15 21 26.77 ± 4.07 15.94% 
C13H9orf72+/+ 18.3.15 24 27.60 ± 4.08 14.80% 
C13H9orf72SH451/SH451 18.3.15 24 23.61 ± 9.07 38.39% 
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4.3.2.4. SH451 swimming endurance experiment 2 (DOB 25.2.16) 
Next, the Ucrit of C13H9orf72
SH451/SH451 zebrafish and their wild-type siblings was 
determined in a second clutch at 4, 6, 9 and 12 months (± 7 days), to see if the reduction 
in Ucrit reported in section 4.3.2.3 was observed earlier than 9 months. The results 
demonstrate that Ucrit is reduced in C13H9orf72
SH451SH451 zebrafish relative to wild-types 
at all the time points (figure 4.10). However, this was not statistically significant at any 
time point tested. The mean Ucrit ± SD, plus coefficient of variation is summarised in table 
4.10. 
 
Figure 4.10 Ucrit values for line SH451 experiment 2 (DOB 25.2.16). Graph shows 
mean Ucrit values ± s.d. for C9orf72
SH451/SH451 vs wild-type siblings at all the time points 
tested in the swim tunnel. Significance tested using 2-way ANOVA with Fisher’s LSD 
test, ns, n = 9-10. 
 
Table 4.10 Summary of line SH451 experiment 2 (DOB 25.2.16) 




C13H9orf72+/+ 25.2.16 4 34.16 ± 6.03 17.64% 
C13H9orf72SH451/SH451 25.2.16 4 33.42 ± 4.40 13.17% 
C13H9orf72+/+ 25.2.16 6 34.98 ± 5.18 14.80% 
C13H9orf72SH451/SH451 25.2.16 6 30.37 ± 4.01 13.21% 
C13H9orf72+/+ 25.2.16 9 35.03 ± 6.50 18.57% 
C13H9orf72SH451/SH451 25.2.16 9 33.42 ± 5.52 16.51% 
C13H9orf72+/+ 25.2.16 12 34.14 ± 5.45  15.96% 





4.3.2.5. Swimming endurance line SH470 (DOB 30.3.16) 
The Ucrit of C13H9orf72
SH470/SH470 zebrafish and their wild-type siblings was determined 
at 4, 6, 9 and 12 months (± 7 days). The results demonstrate that Ucrit is significantly 
reduced in C13H9orf72SH470/SH470 zebrafish at 9 months (p=0.0276, 2-way ANOVA with 
fisher’s LSD test), relative to wild-types (figure 4.11). Additionally, a non-significant 
reduction in Ucrit is seen at 4, 6 and 12 months in C13H9orf72
SH470/SH470 zebrafish (figure 
4.11). The mean Ucrit ± SD, plus coefficient of variation is summarised in table 4.11. 
 
Figure 4.11 Ucrit values for line SH470. Graph shows mean Ucrit values ± s.d. for 
C9orf72SH470/SH470 vs wild-type siblings at all the time points tested in the swim tunnel. 
Significance tested using 2-way ANOVA with Fisher’s LSD test, * p<0.05, n = 11. 
 
Table 4.11 Summary of line SH470 experiment (DOB 30.3.16) 
Genotype DOB Age 
(months) 
Mean Ucrit 
(cm/s) ± SD 
Coefficient 
of variation 
C13H9orf72+/+ 30.3.16 4 29.85 ± 3.12 10.45% 
C13H9orf72SH470/SH470 30.3.16 4 30.23 ± 2.83 9.36% 
C13H9orf72+/+ 30.3.16 6 33.67 ± 4.83 14.33% 
C13H9orf72SH470/SH470 30.3.16 6 31.94 ± 3.30 10.33% 
C13H9orf72+/+ 30.3.16 9 34.24 ± 3.78 11.04% 
C13H9orf72SH470/SH470 30.3.16 9 30.88 ± 2.39  7.74% 
C13H9orf72+/+ 30.3.16 12 32.06 ± 2.80 8.72% 





4.3.2.6. Investigating the correlation between weight and/or length vs 
Ucrit value 
If possible, zebrafish of a similar weight and length were selected when determining 
experimental groups for the swim tunnel. To investigate whether the weight and lengths 
of individuals were influencing swimming performance, the correlation coefficient for 
weight vs Ucrit and length vs Ucrit (n=8-11) was calculated. The correlation coefficient can 
take a range of values from -1 to +1. A value of 0 indicates that there is no association, a 
positive value indicates a positive association and a negative value indicates a negative 
association between the two variables investigated. The magnitude of the correlation 
coefficient determines the strength of the correlation, summarised in the table below 
(table 4.12) (Mukaka 2012).  
Table 4.12 Guidelines to determine the strength of the correlation coefficient 
Adapted from (Mukaka 2012). 
Strength of association Size of Correlation  
Very high positive (negative) correlation 0.90 to 1.00 (-0.9 to – 1.00) 
High positive (negative) correlation  0.70 to 0.90 (-0.70 to -0.90) 
Moderate positive (negative) correlation  0.50 to 0.70 (-0.50 to -0.70) 
Low positive (negative) correlation  0.30 to 0.50 (-0.30 to -0.50) 
Negligible correlation  0.00 to 0.30 (0.00 to -0.30)  
 
Figures 4.12 and 4.13 show data collated from each line at the 12-month time point for 
comparison. In most lines tested, there was a negligible correlation between weight and 
Ucrit at this time point (values <0.3, figure 4.12, A-C). However, the wild-type siblings 
for line SH470 showed a low positive correlation between weight and Ucrit (value >0.3) 
(figure 4.12 C). Regarding length, line SH448 showed a low positive correlation between 
length and Ucrit (value >0.3, figure 4.13 A). However, both lines SH451 and SH470 
showed a negligible correlation between length and Ucrit (values >0.3, figure 4.13 B-C). 
As no high correlations were observed for this time point, it provides confidence that the 
weight and lengths of the individuals selected for the experimental groups are not 




Figure 4.12 Investigating the correlation between weight vs Ucrit values at 12 
months. Graphs represent correlation coefficients for weight (g) vs Ucrit (cm/s) for line 
A) SH448, B) SH451 and C) SH470. R2 values shown on the graphs, with wild-type 




Figure 4.13 Investigating the correlation between length vs Ucrit values at 12 
months. Graphs represent correlation coefficients for length (mm) vs Ucrit (cm/s) for line 
A) SH448, B) SH451 and C) SH470. R2 values shown on the graphs, with wild-type 





4.3.2.7. Investigating the effect of gender on swimming endurance   
To determine whether gender had an effect on the Ucrit of the zebrafish, the Ucrit ± SD for 
both wild-type and mutant males and females were compared. Figure 4.14 shows data 
collected from each line at a 9-month time point for all lines tested. In 4.14 A, there is a 
significant difference between female C13H9orf72SH448/SH448 vs male 
C13H9orf72SH448/SH448 (p=0.0070). In 4.14 B, there is a significant difference between 
male C13H9orf72+/+ vs female C13H9orf72+/+ (p=0.0030). There is also a significant 
difference between male C13H9orf72SH451/SH451 vs female C13H9orf72SH451/SH451 
(p=0.0303). Additionally, in 4.14 C, there is a significant difference between male 
C13H9orf72+/+ vs female C13H9orf72+/+ (p=0.0144). This data demonstrates that female 
Ucrit is lower than male Ucrit in over half of the 9-month data sets. This is possibly linked 
to body shape, as observed in figure 4.15, the female zebrafish have a distended belly, as 
they contain eggs, whereas male zebrafish are generally slimmer.  The females may 
therefore experience increased hydrodynamic drag when swimming in the tunnel, causing 




Figure 4.14 Observing the effect of gender on Ucrit (cm/s) at 9 months. Graphs show 
the range of Ucrit (cm/s) values for males and females, of both genotypes, for lines A) 
SH448 (n=9-10), B) SH451 (n=9-10) and C) SH470 (n=11). Significance tested using a 
one-way ANOVA with Tukey’s post-test A) p < 0.01 B) p < 0.001 and C) p < 0.01. 





Figure 4.15 Comparisons between male and female zebrafish body shape. 
Photograph depicts an adult wild-type male (WT, M) and a wild-type female (WT, F) 

















4.3.2.8. Examination of neuromuscular junctions (NMJ) in adult 
zebrafish  
Defects at the neuromuscular junction (NMJ) are apparent in both ALS rodent models 
and patients well before symptom onset (Fischer et al. 2004, Fischer and Glass 2007). 
Therefore, it was important to perform pathological characterisation of NMJs in control 
and homozygous mutant zebrafish. We stained trunk musculature with α-bungarotoxin (a 
post-synaptic marker of the NMJ) and SV2 (a presynaptic marker that labels motor 
neurons), and used confocal microscopy to quantify the intensity correlation quotient 
(ICQ) (Li et al. 2004), size and number of both the pre- and post-synaptic compartments, 
as has been done in previous studies (Ramesh et al. 2010, Chapman et al. 2013). The ICQ 
is a statistically testable single-value assessment of the relationship between two staining 
patterns: colocalising signals have 0<ICQ≤+0.5, for random staining ICQ = 0, and for 
non-colocalising (segregated) staining 0>ICQ≥–0.5 (Li et al. 2004). This was investigated 
in 11-month old zebrafish from the lines SH448 and SH451, because it was observed that 
the zebrafish had a moderate reduction in Ucrit around this time point. If defects at the 
NMJ are associated with this altered swimming, we would expect to see a reduction in 
ICQ, as well as the size and number of pre- and post- synaptic compartments, indicative 













4.3.2.8.1. NMJ analysis in C13H9orf72+/+ vs 
C13H9orf72SH448/SH448 
In 11-month old C13H9orf72SH448/SH448 zebrafish, the SV2 and α-bungarotoxin staining 
(figure 4.16) showed ICQ values of 0.20 ± 0.02, which was not statistically significant 
from wild-type siblings ICQ value of 0.24 ± 0.06 (unpaired t-test, ns, n=4 per genotype, 
figure 4.17 A). There was no significant difference in the number of pre- or post-synaptic 
compartments analysed for each section between genotypes (unpaired t-test, ns, n=4 per 
genotype, figure 4.17 B-C). The sizes of the pre- and post- synaptic compartments were 
not evenly distributed, thus taking a mean average value for size was not appropriate in 
this study. Therefore, the relative frequency of pre- and post-synaptic area was elucidated 
for both wild-type and C13H9orf72SH448/SH448 zebrafish (figure 4.17 D-E). There was a 
significantly lower frequency of pre-synaptic compartments with an area of up to 10m2 
in the C13H9orf72SH448/SH448 zebrafish in comparison to wild-type siblings (two-way 
ANOVA with Fisher’s LSD test, p=<0.0001, n=4 per genotype, see figure 4.17 D). 
However, there was no significant difference in the frequency of pre-synaptic 
compartments at any other size (figure 4.17 D). There was a significantly higher 
frequency of post-synaptic compartments with an area of up to 10m2 in the 
C13H9orf72SH448/SH448 zebrafish in comparison to wild-type siblings (two-way ANOVA 
with Fisher’s LSD test, p=<0.01, n=4 per genotype, figure 4.17 E). However, there was 
no significant difference in the frequency of pre-synaptic compartments at any other size 




Figure 4.16 NMJ analysis for SH448 cohort at 11 months. Representative images of dual immunofluorescence staining of 11-month old adult 





Figure 4.17 NMJ analysis for SH448 cohort at 11 months. A) ICQ analysis reveals no 
alteration of SV2/α-Bungarotoxin co-localisation in C13H9orf72+/+ or 
C13H9orf72SH448/SH448 zebrafish (unpaired t-test, ns). B-C) There is no difference in pre- 
and post-synaptic compartment analysed per section (unpaired t-test, ns). D-E) Graphs 
show frequency distribution of pre- and post-synaptic area (two-way ANOVA, ** p = 




4.3.2.8.2. NMJ analysis in C13H9orf72+/+ vs 
C13H9orf72SH451/SH451 
In 11-month old C13H9orf72SH451/SH451 zebrafish, the SV2 and α-bungarotoxin staining 
(figure 4.18) showed ICQ values of 0.22 ± 0.05, which was not statistically significant 
from wild-type siblings ICQ values of 0.23 ± 0.04 (unpaired t-test, ns, n=4 per genotype, 
figure 4.19 A). There was no significant difference in the number of pre-synaptic 
compartments analysed for each section between genotypes (unpaired t-test, ns, n=4 per 
genotype, figure 4.19 B). However, there was significant difference in the number of post-
synaptic compartments (unpaired t-test, p=<0.05, n=4 per genotype, figure 4.19 C). As 
seen in line SH448, the sizes of the pre- and post- synaptic compartments were not evenly 
distributed, thus taking a mean average value for size was not appropriate in this study.  
Therefore, the relative frequency of pre- and post-synaptic area was elucidated for both 
wild-type and C13H9orf72SH451/SH451 zebrafish (figure 4.19 D-E). There was a 
significantly lower frequency of pre-synaptic compartments with an area of up to 10m2 
in the C13H9orf72SH451/SH451 zebrafish in comparison to wild-type siblings (two-way 
ANOVA with Fisher’s LSD test, p=<0.0001, n=4 per genotype, figure 4.19 D). However, 
there was no significant difference in the frequency of pre-synaptic compartments at any 
other size (figure 4.19 D). There was a significantly lower frequency of post-synaptic 
compartments with an area of up to 10m2 in the C13H9orf72SH451/SH451 zebrafish in 
comparison to wild-type siblings (two-way ANOVA with Fisher’s LSD test, p=<0.0001, 
n=4 per genotype, figure 4.19 E). However, there was no significant difference in the 




Figure 4.18 NMJ analysis for SH451 cohort at 11 months. Representative images of dual immunofluorescence staining of 11-month old adult 





Figure 4.19 NMJ analysis for SH451 cohort at 11 months. A) ICQ analysis reveals no 
alteration of SV2/α-Bungarotoxin co-localisation (unpaired t-test, ns). B-C) There is no 
difference in pre-synaptic compartments analysed per section, but a significant difference 
in post-synaptic (unpaired t-test, p = <0.05). D-E) Graphs show frequency distribution of 
pre- and post-synaptic area (two-way ANOVA, **** p = <0.0001).  Graphs show 
standard deviation. Sample size n=4 per genotype.  
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4.4. Characterisation of behavioural changes in stable C13H9orf72 loss of 
function adult zebrafish  
It is reported that 50% of ALS patients carrying the repeat expansion in C9orf72 also 
show behavioural and/or cognitive impairments (Ringholz et al. 2005). Additionally, a 
study on a large ALS patient cohort revealed around 15% of these patients met the clinical 
criteria for FTD, particularly the behavioural variant of FTD (bvFTD) (Ringholz et al. 
2005). Patients show symptoms such as: anxiety, disinhibition, apathy, memory loss 
(Mahoney et al. 2012). As well as this, there is high evidence of psychosis, most 
commonly featuring hallucinations and delusions (Sha et al. 2012, Snowden et al. 2012, 
Cooper-Knock et al. 2014a). Adult zebrafish are a powerful tool to model such 
behaviours. There are now several protocols established to measure behaviours such as 
anxiety, aggression, social preference, memory and learning in adult zebrafish, which are 
relevant to the behavioural and/or cognitive changes seen in C9-ALS/FTD (Norton and 
Bally-Cuif 2010). In order to characterise behaviour in our C13H9orf72 LOF mutants, 
we examined anxiety-like behaviour via utilising two tests which robustly measure this 
behaviour in adult zebrafish; the novel tank diving test and the open field test (Norton and 
Bally-Cuif 2010).  
4.4.1. Investigating the impact of frameshift mutations in C13H9orf72 on 
anxiety in adult zebrafish using the Novel Tank Diving Test  
The novel tank diving test measures anxiety evoked by novelty stress. Zebrafish are 
known to exhibit a robust behavioural response to this type of stress (Cachat et al. 2010, 
Parker et al. 2012). When the individual is first placed in the novel environment, their 
natural instinct is to stay in the bottom of the tank. As the course of exposure to the novel 
environment continues, they become more exploratory. This behaviour can be 
investigated by using the novel tank diving test to examine the amount of time a zebrafish 
spends at the lower half of the tank in comparison to the top, with more time spent in the 
lower half indicative of anxious behaviour (figure 4.20). The same cohorts used for the 
swim tunnel were also used for the novel tank diving test (table 4.6), and tested in the 
same week. Additionally, we show the pilot data (line SH448, DOB 24.09.14). During 
testing, each individual zebrafish was filmed from the side, with position and locomotion 
tracked using the equipment and related software included in the ViewPoint analysis 
suite, as described in section 2.7.3.1 (ViewPoint Life Science, Lyon, France). To analyse 
any effect a two-way ANOVA with repeated measures was performed, using genotype 
(wild-type or homozygous mutant) and time (five time intervals: mins 1-5) as independent 
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variables, with time spent in the lower half of the tank entered as the response. This 
analysis provided 3 main results, which are summarised in tables 4.13 – 4.18. The 
measurements ‘genotype’ and ‘time interval’ analyse the effect that each independent 
variable has on time spent in the lower half of the tank, separately. The measurement 
‘genotype: time interval’ analyses the interaction of both variables on the time spent at 
the lower half. If a significant interaction between ‘genotype: time interval’ is observed 
(highlighted in yellow in tables 4.13-4.18), this means that the effect of genotype on time 
spent in the lower half of the tank is significantly different at different time intervals. If 
this is the case, results from the analysis of the two independent variables separately can 
be disregarded, since these variables are interacting, and post-hoc analysis can be 
performed at different time intervals.  
 
Figure 4.20 Schematic of Novel Tank Diving Test. A) Diagram of the novel tank diving 





4.4.1.1. Line SH448 (pilot study) 
Figures 4.21 and 4.22 display the time spent in the lower half (s) during the 5-minute 
exposure to the novel tank, for months 8-23 (pilot study, line SH448, DOB 24.09.14, n=5-
6 per genotype). During the pilot study, the groups were tested once a month. There is a 
significant main effect of time interval at all of the time points tested (table 4.13), 
indicating that time spent at the lower half of the tank decreases as a function of time as 
we expect (figure 4.21 and 4.22). It is also observed that C13H9orf72SH448/SH448 zebrafish 
spend longer in the lower half of the tank over the course of exposure in comparison to 
wild-type siblings, at all of the time points tested (figure 4.21 and 4.22). This effect was 
confirmed at months 9-14, 16 and 20, as there was a significant main effect of genotype 
(table 4.13). There was no significant genotype: time interval interaction at any time point 
except for at 16 months (table 4.13, highlighted yellow). Post-hoc analysis revealed 
C13H9orf72SH448/SH448 spent significantly longer in the lower half of the tank compared 
to wild-type siblings at minute 1 and 2 only (figure 4.22, unpaired t-test, minute 1 
p=0.0005, minute 2 p=0.0422). Figure 4.23 shows that there were no differences between 
the two groups in the distances travelled at any time point tested, confirming that any 
differences seen were due to behaviour and not motor function (2-way ANOVA with 




Figure 4.21 Mean time (s) spent in the lower half of the novel tank during the tank 
diving test for pilot cohort (8-15m). Graphs display time spent in lower half of tank 
during the 5-minute exposure to the novel tank at 8 – 15 months. There was no significant 
genotype: time interval interaction at any time point (two-way ANOVA with repeated 





Figure 4.22 Mean time (s) spent in the lower half of the novel tank during the tank diving 
test for pilot cohort (16-23m). Graphs display time spent in lower half of tank during the 5-
minute exposure to the novel tank at 16 – 23 months. There was a significant genotype: time 
interval interaction at 16 months (two-way ANOVA with repeated measures). Post-hoc 
analysis at 16 months revealed C13H9orf72SH448/SH448 spent longer in the lower half of the 
tank compared to wild-type siblings at minute 1 and 2 only (unpaired t-test, minute 1 
p=0.0005, minute 2 p=0.0422). Error bars show standard deviation. Group sizes n=5-6. 
152 
 
Table 4.13 Result from two-way ANOVA with repeated measures for pilot study line 
SH448 DOB 24.09.14. Significance codes: 0 ‘***’; 0.001 ‘**’;0.01 ‘*’; 0.05 ‘.’. Analysis 
performed on R3.3.2 for Windows. 
Line Age Measurement Df F Value Pr (>F)  Sig 
SH448 8 Genotype 1;9 0.029 0.869 ns 
  Time Int 1;42 3.442 0.0706 . 
  Genotype: Time Int 1;42 0.073 0.7876 ns 
SH448 9 Genotype 1;9 11.8 0.00744 ** 
  Time Int 1;42 23.703 1.63e-05 *** 
  Genotype: Time Int 1;42 1.554 0.22 ns 
SH448 10 Genotype 1;10 6.46 0.0293 * 
  Time Int 1;46 8.894 0.00457 ** 
  Genotype: Time Int 1;46 0.329 0.56910 ns 
SH448  11 Genotype 1;10 7.526 0.0207 * 
  Time Int 1;46 15.830 0.000244 *** 
  Genotype: Time Int 1;46 0.006 0.940377 ns 
SH448 12 Genotype 1;10 5.673 0.0385 * 
  Time Int 1;46 14.990 0.00034 *** 
  Genotype: Time Int 1;46 1.461 0.23288 ns 
SH448  13 Genotype 1;10 27.38 0.000383 *** 
  Time Int 1;46 11.933 0.0012 ** 
  Genotype: Time Int 1;46 0.581 0.4499 ns 
SH448  14 Genotype 1;10 9.882 0.0104 * 
  Time Int 1;46 25.77 6.9e-06 *** 
  Genotype: Time Int 1;46 0.00 0.993 ns 
SH448  15 Genotype 1;10 3.123 0.108 ns 
  Time Int 1;46 9.533 0.00342 ** 
  Genotype: Time Int 1;46 0.339 0.56331 ns 
SH448 16 Genotype 1;10 6.673 0.0273 * 
  Time Int 1;46 9.022 0.0043 ** 
  Genotype: Time Int 1;46 5.729 0.0208 * 
SH448  17 Genotype 1;10 3.019 0.113 ns 
  Time Int 1;46 15.485 0.000279 *** 
  Genotype: Time Int 1;46 0.114 0.737675 ns 
SH448 18 Genotype 1;9 2.366 0.158 ns 
  Time Int 1;42 4.303 0.0442 * 
  Genotype: Time Int 1;42 0.353 0.5553 ns 
SH448  19 Genotype 1;8 2.39 0.161 ns 
  Time Int 1;38 7.634 0.00878 ** 
  Genotype: Time Int 1;38 3.031 0.08980 . 
SH448 20 Genotype 1;8 12.04 0.00844 ** 
  Time Int 1;38 20.852 5.09e-05 *** 
  Genotype: Time Int 1;38 0.401 0.53 ns 
SH448  21 Genotype 1;8 2.164 0.18 ns 
  Time Int 1;38 17.019 0.000194 *** 
  Genotype: Time Int 1;38 0.019 0.890392 ns 
SH448 22 Genotype 1;8 3.487 0.0988 . 
  Time Int 1;38 19.566 7.89e-05 *** 
  Genotype: Time Int 1;38 2.102 0.155 ns 
SH448  23 Genotype 1;8 4.534 0.0659 . 
  Time Int 1;38 19.338 8.54e-05 *** 




Figure 4.23 Total distance travelled during pilot novel tank diving. Displays the total 
distance travelled in the whole tank during the 5-minute exposure to the novel tank. There 
is no significant difference in total distance travelled between C13H9orf72+/+ zebrafish 
and C13H9orf72SH448/SH448 zebrafish at 8-23 months of age (2-way ANOVA with Fisher’s 






4.4.1.2. SH448 clutch 1 (DOB 28.1.15) 
Figure 4.24 displays the time spent in the lower half (s) during the 5-minute exposure to 
the novel tank, for months 9-24 (SH448 clutch 1, DOB 28.1.15, n=6-11 per genotype - 
table 4.6).  During the study, the cohort was tested once every 3 months. There is a 
significant main effect of time interval at months 9 and 15-24, indicating that time spent 
at the lower half of the tank decreases as a function of time, as we expect (figure 4.24, 
table 4.14). However, this effect is not observed at month 12 (figure 4.24, table 4.14), 
which indicates that the zebrafish are not displaying the typical response to a novel 
environment at this time point. It is also observed that C13H9orf72SH448/SH448 zebrafish 
spend longer in the lower half of the tank over the course of exposure in comparison to 
wild-type siblings, at 9 months (figure 4.24). This effect was confirmed, as there was a 
significant main effect of genotype at this time point (table 4.14). However, there was no 
significant effect of genotype at any other time points tested (table 4.14). Additionally, 
there was no significant genotype: time interval interaction at any time point except for 
at 15 and 18 months (table 4.14, highlighted yellow). Post-hoc analysis at 15 months 
revealed C13H9orf72SH448/SH448 spent longer in the lower half of the tank compared to 
wild-type siblings at minute 1 only (unpaired t-test, minute 1 p=0.0331). Conversely, 
post-hoc analysis at 18 months revealed C13H9orf72SH448/SH448 spent less time in the 
lower half of the tank compared to wild-type siblings at minute 3 (unpaired t-test, minute 
3 p=0.0333), suggesting that at 18 months, C13H9orf72SH448/SH448 were less anxious. 
Figure 4.25 shows that there were no differences between the two groups in the distances 
travelled at any time point tested, confirming that any differences seen were due to 





Figure 4.24 Mean time (s) spent in the lower half of the novel tank during the tank 
diving test for line SH448 DOB 28.1.15. Graphs display time spent in lower half of tank 
during the 5-minute exposure to the novel tank at 9-24 months. There was a significant 
genotype: time interval interaction at 15 and 18 months (two-way ANOVA with repeated 
measures). Post-hoc analysis at 15 months revealed C13H9orf72SH448/SH448 spent longer 
in the lower half of the tank compared to wild-type siblings at minute 1 only (unpaired t-
test, minute 1 p=0.0331). Post-hoc analysis at 18 months revealed C13H9orf72SH448/SH448 
spent less time in the lower half of the tank compared to wild-type siblings at minute 3 







Table 4.14 Result from two-way ANOVA with repeated measures for line SH448 
DOB 28.01.15. Significance codes: 0 ‘***’; 0.001 ‘**’;0.01 ‘*’; 0.05 ‘.’. Analysis 
performed on R3.3.2 for Windows.  
Line Age Measurement Df F Value Pr (>F)  Sig 
SH448 9 Genotype 1;20 6.433 0.0197 * 
  Time Int 1;86 10.202 0.00196 ** 
  Genotype: Time Int 1;86 0.539 0.46477 ns 
SH448  12 Genotype 1;20 0.997 0.33 ns 
  Time Int 1;86 0.934 0.3366 ns 
  Genotype: Time Int 1;86 2.911 0.0916 . 
SH448 15 Genotype 1;19 2.36 0.141 ns 
  Time Int 1;82 5.033 0.0276 * 
  Genotype: Time Int 1;82 6.759 0.0111 * 
SH448  18 Genotype 1;18 0.869 0.363 ns 
  Time Int 1;78 12.318 0.000749 *** 
  Genotype: Time Int 1;78 4.073 0.047006 * 
SH448  21 Genotype 1;16 0.14 0.713 ns 
  Time Int 1;70 66.136 1.04e-11 *** 
  Genotype: Time Int 1;70 1.579 0.213 ns 
SH448  24 Genotype 1;12 2.904 0.114 ns 
  Time Int 1;54 15.443 0.000244 *** 












Figure 4.25 Total distance travelled during novel tank diving test SH448 DOB 
28.1.15. Displays the total distance travelled in the whole tank during the 5-minute 
exposure to the novel tank. There is no significant difference in total distance travelled 
between C13H9orf72+/+ zebrafish and C13H9orf72SH448/SH448 zebrafish at 9-24 months of 


















4.4.1.3. SH448 clutch 2 (DOB 13.1.16) 
To determine whether anxiety-like behaviour was altered in C13H9orf72SH448/SH448 prior 
to 9 months, a second clutch (SH448 clutch 2, DOB 13.1.16, n=9-11 per genotype –  table 
4.6) was run through the novel tank diving test. Figure 4.26 displays the time spent within 
the lower half (s) during the 5-minute exposure to the novel tank, at months 4-12. During 
the study, the cohort was tested once every 3 months. There is a significant main effect 
of time interval at all of the time points tested (table 4.15), indicating that time spent at 
the lower half of the tank decreases as a function of time as we expect (figure 4.26). It is 
also observed that wild-types spend longer in the lower half of the tank over the course 
of exposure in comparison to C13H9orf72SH448/SH448 zebrafish, at 4 and 6 months (figure 
4.26). This effect was confirmed, as there was a significant main effect of genotype at 
this time point (table 4.15), indicating higher anxiety levels in the wild-types. However, 
there was no significant effect of genotype at any other time points tested (table 4.15), 
complimentary to SH448 clutch 1 at months 12-24. Additionally, there was no significant 
genotype: time interval interaction at any time point tested (table 4.14). Figure 4.27 shows 
that at 4 months C13H9orf72SH448/SH448 zebrafish swim significantly less over the course 
of exposure in comparison to wild-type siblings (2-way ANOVA with Fisher’s LSD test, 
n=9-11, p = <0.001), however, there were no significant differences at any other time 
point tested, confirming that any differences seen were due to behaviour and not motor 






Figure 4.26 Mean time (s) spent in the lower half of the novel tank during the tank 
diving test for line SH448 DOB 13.1.16. Graphs display time spent in lower half of tank 
during the 5-minute exposure to the novel tank at 4-12 months. There was no significant 
genotype: time interval interaction at any time point (two-way ANOVA with repeated 














Table 4.15 Result from two-way ANOVA with repeated measures for line SH448 
DOB 13.01.16. Significance codes: 0 ‘***’; 0.001 ‘**’;0.01 ‘*’; 0.05 ‘.’. Analysis 


















Line Age Measurement Df F Value Pr (>F)  Sig 
SH448 4 Genotype 1;20 9.567 0.00573 ** 
  Time Int 1;86 49.890 3.97e-10 *** 
  Genotype: Time Int 1;86 1.575 0.213 ns 
SH448  6 Genotype 1;17 7.318 0.015 * 
  Time Int 1;74 18.735 4.64e-05 *** 
  Genotype: Time Int 1;74 0.029 0.864 ns 
SH448 9 Genotype 1;17 1.554 0.229 ns 
  Time Int 1;74 23.793 5.98e-06 *** 
  Genotype: Time Int 1;74 0.132 0.178 ns 
SH448  12 Genotype 1;17 0.219 0.646 ns 
  Time Int 1;74 31.164 3.71e-07 *** 




Figure 4.27 Total distance travelled during novel tank diving test SH448 DOB 
13.1.16. Displays the total distance travelled in the whole tank during the 5-minute 
exposure to the novel tank. There is no significant difference in total distance travelled 
between C13H9orf72+/+ zebrafish and C13H9orf72SH448/SH448 zebrafish at 6-12 months of 
age (2-way ANOVA with Fisher’s LSD test, n=9-11), however there is at 4 months 


















4.4.1.4. SH451 clutch 1 (DOB 18.3.15) 
Figure 4.28 displays the time spent within the lower half (s) during the 5-minute exposure 
to the novel tank, at months 9-24 (SH451 clutch 1, DOB 18.3.15, n=10-11 per genotype 
– table 4.6). During the study, the cohort was tested once every 3 months. There is a 
significant main effect of time interval at months 9-15, indicating that time spent at the 
lower half of the tank decreases as a function of time, as we expect (figure 4.28, table 
4.16). However, this effect is not observed at months 18-24 (figure 4.28, table 4.16), 
which indicates that the zebrafish are not displaying the typical response to a novel 
environment at these time points. It is also observed that wild-types spend longer in the 
lower half of the tank over the course of exposure in comparison to C13H9orf72SH448/SH448 
zebrafish, at 21 months (figure 4.28). This effect was confirmed, as there was a significant 
main effect of genotype at this time point (see table 4.16), indicating higher anxiety levels 
in the wild-types. However, there was no significant effect of genotype at any other time 
points tested (see table 4.16). Additionally, there was no significant genotype: time 
interval interaction at any time point tested (see table 4.16). Figure 4.29 shows that at 9 
months C13H9orf72SH451/SH451 zebrafish swim significantly more over the course of 
exposure in comparison to wild-type siblings (2-way ANOVA with Fisher’s LSD test, 
n=10-11, p = <0.05), however, there were no significant differences at any other time 
point tested, confirming that any differences seen were due to behaviour and not motor 





Figure 4.28 Mean time (s) spent in the lower half of the novel tank during the tank 
diving test for SH451 DOB 18.3.15. Graphs display time spent in lower half of tank 
during the 5-minute exposure to the novel tank at 9-24 months. There was no significant 
genotype: time interval interaction at any time point (two-way ANOVA with repeated 






Table 4.16 Result from two-way ANOVA with repeated measures for line SH451 
DOB 18.03.15. Significance codes: 0 ‘***’; 0.001 ‘**’;0.01 ‘*’; 0.05 ‘.’. Analysis 
performed on R3.3.2 for Windows.  
Line Age Measurement Df F Value Pr (>F)  Sig 
SH451 9 Genotype 1;20 0.491 0.492 ns 
  Time Int 1;86 70.79 7.68e-13 *** 
  Genotype: Time Int 1;86 0.00 0.996 ns 
SH451  12 Genotype 1;20 0.126 0.727 ns 
  Time Int 1;86 16.782 9.45e-05 *** 
  Genotype: Time Int 1;86 0.673 0.414 ns 
SH451 15 Genotype 1;20 0.115 0.738 ns 
  Time Int 1;86 23.21 6.17e-06 *** 
  Genotype: Time Int 1;86 0.00 0.985 ns 
SH451  18 Genotype 1;20 0.019 0.893 ns 
  Time Int 1;86 2.318 0.132 ns 
  Genotype: Time Int 1;86 0.341 0.561 ns 
SH451  21 Genotype 1;19 5.452 0.0307 * 
  Time Int 1;82 0.203 0.653 ns 
  Genotype: Time Int 1;82 0.467 0.496 ns 
SH451  24 Genotype 1;19 0.778 0.389 ns 
  Time Int 1;82 0.830 0.3651 ns 










Figure 4.29 Total distance travelled during novel tank diving test SH451 DOB 
18.3.15. Displays the total distance travelled in the whole tank during the 5-minute 
exposure to the novel tank. There is no significant difference in total distance travelled 
between C13H9orf72+/+ zebrafish and C13H9orf72SH451/SH451 zebrafish at 12-24 months 
of age (2-way ANOVA with Fisher’s LSD test, n=10-11), however there is at 9 months 

















4.4.1.5. SH451 experiment 2 (DOB 25.2.16) 
To determine whether anxiety-like behaviour was altered in C13H9orf72SH451/SH451 prior 
to 9 months, a second clutch (SH451 clutch 2, DOB 25.2.16, n=9-10 per genotype –  table 
4.6) was run through the novel tank diving test. Figure 4.30 displays the time spent within 
the lower half (s) during the 5-minute exposure to the novel tank, at months 4-12. During 
the study, the cohort was tested once every 3 months. There is a significant main effect 
of time interval at all of the time points tested (table 4.17), indicating that time spent at 
the lower half of the tank decreases as a function of time as we expect (see figure 4.30). 
It is also observed that wild-types spend longer in the lower half of the tank over the 
course of exposure in comparison to C13H9orf72SH448/SH448 zebrafish, at 6 months (figure 
4.30). This effect was confirmed, as there was a significant main effect of genotype at 
this time point (table 4.17), indicating higher anxiety levels in the wild-types. However, 
there was no significant effect of genotype at any other time points tested (table 4.17), 
complimentary to SH451 clutch 1 at months 9-18 and 24. Additionally, there was no 
significant genotype: time interval interaction at any time point tested (table 4.17). Figure  
4.31 shows that at 6 months C13H9orf72SH451/SH451 zebrafish swim significantly more 
over the course of exposure in comparison to wild-type siblings (2-way ANOVA with 
Fisher’s LSD test, n=9-10, p = <0.05), however, there were no significant differences at 
any other time point tested, confirming that any differences seen were due to behaviour 





Figure 4.30 Mean time (s) spent in the lower half of the novel tank during the tank 
diving test for line SH451 DOB 25.2.16. Graphs display time spent in lower half of tank 
during the 5-minute exposure to the novel tank at 4-12 months. There was no significant 
genotype: time interval interaction at any time point (two-way ANOVA with repeated 














Table 4.17 Result from two-way ANOVA with repeated measures for line SH451 
DOB 25.02.16. Significance codes: 0 ‘***’; 0.001 ‘**’;0.01 ‘*’; 0.05 ‘.’. Analysis 

















Line Age Measurement Df F Value Pr (>F)  Sig 
SH451 4 Genotype 1;18 0.757 0.396 ns 
  Time Int 1;78 32.085 2.37e-07 *** 
  Genotype: Time Int 1;78 1.174 0.282 ns 
SH451  6 Genotype 1;18 21.14 0.000223 *** 
  Time Int 1;78 11.438 0.00113 ** 
  Genotype: Time Int 1;78 2.322 0.13161 ns 
SH451 9 Genotype 1;17 3.13 00948 . 
  Time Int 1;74 9.690 0.00263 ** 
  Genotype: Time Int 1;74 1.578 0.21304 ns 
SH451  12 Genotype 1;17 0.306 0.588 ns 
  Time Int 1;74 11.132 0.00133 ** 




Figure 4.31 Total distance travelled during novel tank diving test SH451 DOB 
25.2.16. Displays the total distance travelled in the whole tank during the 5-minute 
exposure to the novel tank. There is no significant difference in total distance travelled 
between C13H9orf72+/+ zebrafish and C13H9orf72SH451/SH451 zebrafish at 4, 9 and 12 
months of age (2-way ANOVA with Fisher’s LSD test, n=9-10), however there is at 6 


















4.4.1.6. SH470 (DOB 30.3.16) 
Figure 4.32 displays the time spent within the lower half (s) during the 5-minute exposure 
to the novel tank, at months 4-12 (SH470, DOB 30.3.16, n=11 per genotype – table 4.6). 
During the study, the cohort was tested once every 3 months. There is not a significant 
effect of time interval at any time point tested (figure 4.32, table 4.18), which indicates 
that the zebrafish are not displaying the typical response to a novel environment as we 
would expect. There was also no significant effect of genotype at any of the time points 
tested (table 4.18). Additionally, there was no significant genotype: time interval 
interaction at any time point except for at 12 months (table 4.18, highlighted yellow). 
Post-hoc analysis at 12 months revealed C13H9orf72SH470/SH470 spent longer in the lower 
half of the tank compared to wild-type siblings at minute 1 only (unpaired t-test, minute 
1 p=0.0221). Figure 4.33 shows that there were no differences between the two groups in 
the distances travelled at any time point tested, confirming that any differences seen were 









Figure 4.32 Mean time (s) spent in the lower half of the novel tank during the tank 
diving test for line SH470 DOB 30.3.16. Graphs display time spent in lower half of tank 
during the 5-minute exposure to the novel tank at 9-24 months. There was a significant 
genotype: time interval interaction at 12 months revealed C13H9orf72SH470/SH470 spent 
longer in the lower half of the tank compared to wild-type siblings at minute 1 only 
(unpaired t-test, minute 1 p=0.0221). (two-way ANOVA with repeated measures). Post-

















Table 4.18 Result from two-way ANOVA with repeated measures for line SH470 
DOB 30.3.16. Significance codes: 0 ‘***’; 0.001 ‘**’;0.01 ‘*’; 0.05 ‘.’. Analysis 


















Line Age Measurement Df F Value Pr (>F)  Sig 
SH470 4 Genotype 1;20 3.285 0.0849 . 
  Time Int 1;86 0.808 0.371 ns 
  Genotype: Time Int 1;86 2.563 0.113 ns 
SH470 6 Genotype 1;20 0.171 0.684 ns 
  Time Int 1;86 1.237 0.269 ns 
  Genotype: Time Int 1;86 2.188 0.143 ns 
SH470 9 Genotype 1;20 0.613 0.443 ns 
  Time Int 1;86 0.056 0.813 ns 
  Genotype: Time Int 1;86 0.144 0.705 ns 
SH470 12 Genotype 1;20 1.668 0.211 ns 
  Time Int 1;86 1.43 0.2350 ns 




Figure 4.33 Total distance travelled during novel tank diving test SH470 DOB 
30.3.16. Displays the total distance travelled in the whole tank during the 5-minute 
exposure to the novel tank. There is no significant difference in total distance travelled 
between C13H9orf72+/+ zebrafish and C13H9orf72SH470/SH470 zebrafish at 4-9 months of 
















4.4.2. Pilot study investigating the impact of frameshift mutations in 
C13H9orf72 on thigmotaxis using the Open Field test  
In addition to the novel tank diving, the open field test was also used to examine anxiety-
like behaviour in the C13H9orf72 LOF mutants.  This is a commonly used method to 
measure anxiety in rodents, via observation of thigmotaxic behaviour (increased amount 
of time exploring the periphery of an arena compared to the centre). It has been reported 
that adult zebrafish exhibit thigmotaxic behaviour in an aquatic open field test, thus this 
test was set up to examine the effect that frameshift mutations in C13H9orf72 has on 
thigmotaxic behaviour in adult zebrafish (Schnorr et al. 2012). This was done on the pilot 
cohort only (line SH448, DOB 24.09.14). Additionally, after placing the zebrafish in the 
middle of the test arena, each individual was left 60s to acclimatise. This was done to 
reduce the effects of any differences between zebrafish in the time to be netted, and is a 
technique that has been reported with zebrafish and other fish species (Burns 2008, 
Ariyomo and Watt 2012, Ariyomo and Watt 2015). Therefore, this means that unlike the 
novel tank test, anxiety behaviour is observed under a lower stress environment.  
Initially, this test was performed in a rectangular tank and the bottom of the tank was 
divided into two virtual zones – the centre and the periphery (the area within 6 cm of the 
walls). Each individual was filmed from above for 6 minutes in total (including 
acclimatisation) (figure 4.34, A-B), with time spent in each zone (s) and overall distance 
travelled (cm) recorded using the equipment and related software included in the 
ViewPoint analysis suite (ViewPoint Life Science, Lyon, France). Thigmotaxis was 
defined as the percentage of time spent in the periphery, as described in section 2.7.3.2. 
Figure 4.34 C shows that there was no significant difference between the groups in 
percentage time spent in the periphery of the tank during the time points 8-12 months (2-
way ANOVA with Fisher’s LSD test, ns, n = 5-6). Additionally, figure 4.34 D shows that 
there was no significant difference between the groups in total distance travelled during 




Figure 4.34 Frameshift mutations in C13H9orf72 do not lead to changes in 
thigmotaxis age 8-12 months. A) Original rectangular, transparent arena used for the 
Open Field test. B) Shows example traces produced from the ViewPoint system during 
the test from a C13H9orf72+/+ and C13H9orf72SH448/SH448 fish. C) Bar graph representing 
the mean percentage time spent in the periphery (thigmotaxis) of each group (2-way 
ANOVA with Fisher’s LSD test, ns, n = 5-6 fish per group). D) Bar graph representing 
total distance travelled of each group (2-way ANOVA with Fisher’s LSD test, ns, n = 5-




During months 8-12, we had consistent problems with the ViewPoint analysis suite being 
sensitive to reflections on the side of the tank during the experiment. Despite the addition 
of several non-reflective materials surrounding the tank, it was difficult to prevent this in 
the initial arena used. Following personal communication with Dr Caroline Brennan, the 
arena was changed to an opaque, white cylinder from 13 months onwards as described in 
section 2.7.3.2 (figure 4.35, A). The change of arena prevented issues with reflection in 
future tests.  As before, the bottom of the tank was divided into two virtual zones – the 
centre and the periphery (the area within 5 cm of the walls). Each individual was filmed 
from above for 6 minutes in total (including acclimatisation) (figure 4.35, A-B), with time 
spent in each zone (s) and overall distance travelled (cm) recorded using the equipment 
and related software included in the ViewPoint analysis suite (ViewPoint Life Science, 
Lyon, France). Thigmotaxis was defined as the percentage of time spent in the periphery, 
as described in section 2.7.3.2. Figure 4.35 C shows that there was no significant 
difference between the groups in percentage time spent in the periphery of the tank during 
the time points 13-23 months (2-way ANOVA with Fisher’s LSD test, ns, n = 5-6). 
Additionally, figure 4.35 D shows that there was no significant difference between the 
groups in total distance travelled during the test at 13-23 months (2-way ANOVA with 
Fisher’s LSD test, ns, n = 5-6). Overall, the observed results indicate that there was no 
change in anxiety-like behaviour in either group in the open field test, thus other 




Figure 4.35 Frameshift mutations in C13H9orf72 do not lead to changes in 
thigmotaxis age 13-23 months. A) Schematic representation of the white, circular arena 
used for the Open Field test. B) Shows example traces produced from the ViewPoint 
system during the test from a C13H9orf72+/+ and C13H9orf72SH448/SH448 fish. C) Bar graph 
representing the mean percentage time spent in the periphery (thigmotaxis) of each group 
(2-way ANOVA with Fisher’s LSD test, ns, n = 5-6 fish per group). D) Bar graph 
representing total distance travelled for each group (2-way ANOVA with Fisher’s LSD 




Following the generation of several C13H9orf72 LOF zebrafish lines, as discussed in 
chapter 3, this study focussed on investigating whether loss of C13H9orf72 results in 
ALS- and/or FTD-like phenotypes. Previously, no stable in vivo model of C9-ALS/FTD 
in zebrafish has been characterised, highlighting the importance of phenotypic 
characterisation during this project. As mentioned, phenotypes such as survival, motor 
function and NMJ pathology were investigated, as has been done in other models of ALS 
in zebrafish (Ramesh et al. 2010, Hewamadduma et al. 2013). In addition, due to the link 
between ALS and FTD in C9orf72-related disease, zebrafish were investigated for any 
behavioural changes. Characterisation of these zebrafish has allowed further 
understanding in to the role that haploinsufficiency of C9orf72 may play in C9-ALS/FTD.  
4.5.1. Characterisation of survival in C13H9orf72 loss-of-function 
zebrafish  
As mentioned previously, AMO experiments suggest that transient KD of C13H9orf72 
in zebrafish produce viable embryos (Ciura et al. 2013). However, a previous AMO 
experiment which transiently KD tardbp in zebrafish reported viable embryos (Kabashi 
et al. 2010b), but when both orthologues were knocked out, homozygous mutants only 
survived up to 10dpf (Hewamadduma et al. 2013, Schmid et al. 2013). Therefore, early 
viability of C13H9orf72 LOF zebrafish was characterised during this project, as it was 
unknown whether complete loss of the gene would result in embryonic or larval lethality.  
To determine this, zebrafish heterozygous carriers for all identified frameshift mutations 
were in-crossed and the resulting progeny monitored twice per day, removing dead larvae 
for genotyping, as previously done (Chapman et al. 2013). As discussed in sections 
4.2.1.1 and 4.2.2.1, the majority of the lines investigated showed no significant difference 
in early survival of all three genotypes. This supports the previous study which showed 
transient knockdown of C13H9orf72 did not result in embryonic lethality (Ciura et al. 
2013).  However, it was observed that two lines investigated showed a significant 
difference in early survival of the three genotypes.  
Initial survival characterisation of line SH470 showed that only 41% of 
C13H9orf72SH470/SH470 embryos survived up to day 21, in comparison to 68% 
C13H9orf72+/+ and 74% C13H9orf72SH470/+ embryos (figure 4.2). Additionally, in a 
separate batch raised to adulthood, although survival rates were improved for all three 
genotypes, there was still a decrease in survival of homozygous mutants. The decreased 
viability of the homozygous mutants in this line could be due to a genetically linked 
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mutation, causing a proportion of the embryos to be non-viable. This could be examined 
further via exome sequencing. However, when the aforementioned clutch was genotyped 
at 90dpf, there was no significant difference between the observed and expected 
Mendelian ratios (section 4.2.1.2, table 4.1), suggesting further analysis into this line may 
not be necessary. The line SH470 was the only one raised to adulthood for phenotypic 
characterisation, because the heterozygous carriers obtained for line SH471 showed a sex 
skew bias towards males, therefore it was not possible to raise F3 offspring to characterise 
before the end of this project. Additionally, as described previously, line SH472 did not 
show a significant reduction in C13H9orf72 mRNA levels and was therefore not taken 
forward for further studies.  
In addition, a significant difference in survival was observed for line SH448, with 37% 
survival for C13H9orf72SH448/SH448, 48% for C13H9orf72SH448/+ and 55% for 
C13H9orf72+/+ embryos reported. However, although viability of C13H9orf72SH448/SH448 
embryos was low, survival overall was low for all genotypes (see figure 4.2). This was 
also seen for lines SH449 and SH450 (see figure 4.2). This was due to a high rate of failed 
PCRs when genotyping, as some of the larvae collected were degrading thus the extracted 
DNA failed to amplify. Despite this, when the line SH448 was genotyped at 90dpf, there 
was no significant difference between the observed and expected Mendelian ratios (see 
section 4.2.2.2, table 4.3), suggesting there is no difference between genotypes and 
viability is normal.  
To determine if C13H9orf72 is important for viability in adult life we also monitored 
survival until end stage. This would better reflect human disease, as disease onset and 
death occurs in adulthood. This would also compare well with other zebrafish models of 
ALS, such as the transgenic zebrafish overexpressing sod1, where survival has been 
reported to decrease in adulthood but not during larval stages (Ramesh et al. 2010). As 
discussed, there was no significant difference between original and end-stage group sizes 
in any line (tables 4.2 and 4.4). This data suggests that the frameshift mutations identified 
in C13H9orf72 do not impact survival at any stage throughout the lifetime of the 
zebrafish. These findings do not recapitulate what has been shown in some C9orf72 LOF 
mouse models, who report a decrease in survival of homozygous mutants during 
adulthood in comparison to wild-type controls (Burberry et al. 2016, Sudria-Lopez et al. 
2016). However, the reduction in survival observed in the C9orf72 LOF mice may be 
linked to an immune defect and not neurodegeneration, and we go on to investigate 
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whether our model recapitulates any of the immune defect symptoms found in the next 
chapter (O'Rourke et al. 2016, Sudria-Lopez et al. 2016, Koppers et al. 2015).   
4.5.2. Characterisation of motor function in C13H9orf72 loss-of-function 
zebrafish  
As loss of muscle strength is a characteristic phenotype of C9-ALS/FTD, the next aim of 
the project was to examine motor function of the zebrafish carrying frameshift mutations 
in C13H9orf72. The Spinning Task and the Swim tunnel were utilised in order to do this. 
It was expected that if loss of C13H9orf72 results ALS/FTD-like phenotypes in these 
zebrafish, a reduction in swimming endurance would be observed during the 
aforementioned tests.  
4.5.2.1. The spinning task as a measure of swimming endurance 
As discussed, one of the main disadvantages of using the swim tunnel was that it took a 
long time to test motor function in large clutches of zebrafish, taking up to 30 minutes per 
individual. Therefore, we initially used a novel method called the Spinning Task, due to 
the protocols ability to test the swimming endurance of an individual zebrafish in only a 
few minutes (Blazina et al. 2013). However, we demonstrated that the coefficient of 
variation (which is the standard deviation as a percentage of the mean) was high for this 
test, reflecting the variability of this method in measuring motor function. For example, 
an average coefficient of variation of wild-types in the swim tunnel was 11.67%, whereas 
the average for wild-types in the Spinning Task was 95.68% at 400rpm and 80.34% at 
500rpm (section 4.3.1). A reason for this variability may be due to the subjective nature 
of determining the latency of individuals to be ‘swept in’ to the whirlpool. This 
observation meant that the suggested recording time of 180s was not suitable, thus we 
increased recording time up to 300 seconds from 7 months onwards, in order to fully 
determine when the individual was ‘swept in’ (Blazina et al. 2013). There were no other 
major differences in the overall protocol used minus recording time, with similar speeds 
and age of zebrafish used.  
It was reported in the original publication that the time spent swimming during the test 
increases with the size of the individual, with fish of 3-4cm in length able to swim longer 
than smaller fish (Blazina et al. 2013). There is a trend that individuals are able to swim 
longer as time goes on (see table 4.5), which may be due to increasing size over time. 
However, as there is no data on length of this cohort it cannot be determined size of the 
individuals cause this. It may be that as the recording time was increased at 7 months, 
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they were recorded to swim for longer due to the subjective nature of the test as discussed. 
Alternatively, they may get used to the test over time.   Additionally, there is a trend (table 
4.5) that the fish swim for less time at 500rpm. This also agrees which the original 
publication, which showed that at lower speeds the fish could swim for longer (Blazina 
et al. 2013). Therefore, if this test would be utilised in the future, higher speeds should be 
used. However, overall due to the high level of variation observed during this test, it 
suggests that this protocol is not a reliable method to measure swimming endurance. As 
a result, it was decided to primarily use the swim tunnel in order to investigate motor 
function for this project going forward. 
4.5.2.2. The swim tunnel as a measure of swimming endurance  
The swim tunnel is an established method used to determine the critical swimming 
velocity (Ucrit) of individual zebrafish, which is the maximum flow rate a fish can swim 
against for a sustained period (Plaut 2000, Brett 1964). This method has previously been 
used to characterise motor function in several zebrafish models of neuromuscular 
degeneration (Ramesh et al. 2010, Chapman et al. 2013), and is similar in nature to the 
rotarod test used to measure motor function in mouse models. As described in section 
4.3.2, for each line tested there was a mild reduction in Ucrit observed for homozygous 
mutant zebrafish in relation to wild-type siblings, which was statistically significant at 
some time points. The mild motor deficit observed in this current study is in keeping with 
a C9orf72 LOF mouse model, which demonstrated mild motor deficits in open field 
observations and CatWalk gait analysis (Atanasio et al. 2016). Interestingly, they did not 
report a difference in time spent on the rotarod (Atanasio et al. 2016). Conversely, neither 
the stable zebrafish or the mouse model of C9orf72 LOF  agree with the more severe 
locomotor deficits reported at larval stages following transient KD of C13H9orf72 in 
zebrafish (Ciura et al. 2013), suggesting that this phenotype may have been an off-target 
mediated effect. To investigate this in the future, we would microinject the same AMOs 
used in the KD study into both wild-types and our stable C13H9orf72 KO mutants. We 
would expect to see the same effect in wild-types as reported in the paper, but not in the 
stable knockout zebrafish, as these should not have endogenous C13H9orf72. However, 
if we did see the same effects in our mutants, it would suggest the AMOs used in the 
aforementioned study had off-target effects. A similar method has been used to show that 
an AMO used to KD Tardbp in zebrafish also had off-target effects (Kabashi et al. 2010b, 
Hewamadduma et al. 2013).  
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Initial characterisation suggests a mild swimming defect in the C13H9orf72 LOF 
zebrafish, however the model needs further development to see if it will be useful as a 
model of motor dysfunction in the future. Firstly, the coefficient of variation was 
relatively high at some time points, ranging from 5.54% to 18.78% in controls and 7.74% 
to 38.39% in mutants. Although overall this is lower in comparison to the Spinning Task, 
it indicates that there is still variation within the groups. High variation may be 
attributable to the fact that unlike rodents, zebrafish are not maintained as inbred strains 
in the laboratory. This is because it can lead to a phenomena called inbreeding depression, 
resulting in loss of fitness due to increased homozygosity (Monson and Sadler 2010). 
Inbreeding depression has been reported to result in fewer successful matings and smaller 
clutch sizes in common wild-type zebrafish strains, including AB which is the strain used 
in this project (Monson and Sadler 2010).  As a result, the zebrafish used in this project 
are genetically diverse due to outcrossing, therefore resulting in possible heterogeneity 
within the different lines.  
Secondly, the original swim tunnel utilised for characterisation was used to detect the 
motor dysfunction of the Mitofusin 2 (Mfn2) zebrafish model (Chapman et al. 2013), and 
could reach a maximum flow rate of 18.04 cm/s. However, as the phenotype displayed 
by the C13H9orf72 LOF zebrafish was less severe than that of the Mfn2 zebrafish, this 
original tunnel was unable to exhaust both the wild-type and mutant zebrafish in the 
current study. Therefore, this tunnel was modified in order to reach a maximum flow rate 
of 39.47cm/s, whilst the studies were ongoing. This meant that data was only obtained 
from 9 or 12 months onwards for line SH451 clutch 1 and SH448 clutch 1, respectively 
(section 4.3.2.1 and 4.3.2.3). As a result, a second clutch was raised for these lines, in 
order to obtain data at earlier time points (section 4.3.2.2 and 4.3.2.4). The modified swim 
tunnel had already been established by the time the clutch for line SH470 had been raised 
to adulthood (section 4.3.2.5).   
Thirdly, it is important to consider when analysing these data that we may only see a mild 
motor dysfunction in our C13H9orf72 LOF zebrafish, as individual muscle fibres are 
polyneuronally innervated throughout the zebrafish lifetime, unlike in rodents and 
humans (Westerfield et al. 1986). Additionally, it has been reported that adult zebrafish 
have the capability to regenerate motor neurons (Reimer et al. 2008), which rodents and 
humans cannot do. Therefore, it is possible that compensatory mechanisms such as 
polyneuronal innervation and motor neuron regeneration that occur in zebrafish may 
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affect the observed phenotype. Thus, possible degeneration or death of a few motor 
neurons may not have much of an effect on movement overall. However, NMJs were 
investigated via immunohistochemical analysis to look into this further, which will be 
discussed in section 4.5.2.3.  
Finally, power analysis using G*Power Version 3.0.3, based on Ucrit values obtained from 
a transgenic SOD-1 zebrafish model of ALS (Ramesh et al. 2010), indicated a sample of 
11 zebrafish per group would provide 80% power to detect a 20% reduction in Ucrit 
(student’s t-test, two-tailed, α = 0.05, β = 0.8). This was then applied to the other 
characterisation tests. However, due to variability and the mild phenotype observed in the 
C13H9orf72 LOF zebrafish, the study was underpowered. Retrospective power 
calculations using G*Power Version 3.0.10, based on Ucrit values obtained in this study, 
revealed a sample of 25 zebrafish per group would provide 80% power to detect a 20% 
reduction in Ucrit (student’s t-test, two-tailed, α = 0.05, β = 0.8). Based on these 
calculations, a cohort of this size has been raised, with motor function analysis ongoing. 
As we know that there is most likely genetic heterogeneity within these lines due to 
outcrossing, resulting in an increase in the coefficient of variation. Therefore, larger group 
sizes will increase sensitivity of the swim tunnel test and allow us to address these issues.   
However, such large group sizes are not ideal for this type of analysis, due to the length 
of time it takes to obtain data.  
4.5.2.2.1. Impact of body size on swimming endurance  
It is important to account for body size when using the swim tunnel apparatus, as previous 
research has linked body shape and size to swimming ability in a variety of fish species 
(Domenici 2003, Langerhans 2009, Gordon et al. 2015). As discussed in section 4.3.2.6, 
when experimental groups for the swim tunnel were determined, zebrafish of a similar 
weight and length were selected when available numbers permitted. At each time point, 
the weight and length of each individual zebrafish was recorded, alongside its Ucrit value. 
The data revealed that there were no strong correlations between recorded weights and/or 
lengths vs Ucrit values in all lines tested. Therefore, it can be concluded that the weights 
and lengths of the chosen individuals did not have a significant influence on the 
swimming performance of the fish. 
In order to maintain consistency in the future, it would be advisable to ensure that 
experimental groups are of a similar weight and length, in order to limit variation. This 
can be difficult if there is only a limited number of zebrafish of the correct genotype. 
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Additionally, it is known that the rate of zebrafish growth is influenced by many factors, 
including water quality, temperature, food quality and availability, and population density 
of the tank (Singleman and Holtzman 2014). Thus, it is suggested that husbandry is 
standardised and zebrafish are not raised in high density tanks before genotyping to 
prevent variation in growth. This would ensure that individuals in the tank have an 
increased access to food and develop at a similar rate. However, even when grown in 
standardized conditions, zebrafish can still develop into a range of sizes (Singleman and 
Holtzman 2014). Thus, as well as standardising conditions, raising large clutches to 
ensure you can obtain an experimental group of similarly sized zebrafish would be 
essential. This is also something to consider with regards to gender, discussed in section 
4.5.2.2.2. 
4.5.2.2.2. Impact of gender on swimming endurance  
Interestingly, it was observed that gender had a significant impact on the swimming 
endurance of zebrafish in the swim tunnel. In all lines tested, there was evidence that 
female Ucrit was significantly lower than male Ucrit, but there were some notable 
exceptions. Firstly, in line SH448, there was no significant decrease in Ucrit between male 
C13H9orf72+/+ and female C13H9orf72+/+. However, this could be explained by an outlier 
in the female group, who had a much higher Ucrit value compared to the rest of the group 
(figure 4.14A). Additionally, in line SH470, there was no significant decrease in Ucrit 
between male C13H9orf72SH470/SH470 and female C13H9orf72SH470/SH470 (figure 4.14C). In 
this case, there was a significant difference between male C13H9orf72+/+ and male 
C13H9orf72SH470/SH470 (p=0.0092), but no difference between the female genotypes. This 
suggests that the mutation, which is located in exon 1 in comparison to lines SH448 and 
SH451 which are located in exon 7, may have a greater effect on male Ucrit.    
As discussed, the evidence that female Ucrit was significantly lower than male Ucrit may 
be linked to body shape. Female zebrafish typically have a distended belly which contains 
eggs, which means that they will have an increased maximum cross-section area in 
comparison to males. This increase in cross-section area may lead to increased 
hydrodynamic drag when swimming in the tunnel, which in turn may result in the 
decrease in maximum Ucrit observed in females. Interestingly, other groups have 
previously published that there is not a difference in Ucrit between the sexes in zebrafish, 
at a range of ages (8-30 months) (Marit and Weber 2011, Gilbert, Zerulla and Tierney 
2014). However, the effect of gender on swimming ability has been extensively observed 
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in other fish species, and has revealed some differences. Converse to the present study, 
investigation into the effect of gender on Ucrit in Trinidadian guppies revealed that on 
average males had much lower Ucrit values than females (Gordon et al. 2015). However, 
this same study did report that pregnant females had lower Ucrit in comparison to non-
pregnant females. This in part was attributed to a large distension of the body due to 
pregnancy. This caused females to have rounder bodies, resulting in increased 
hydrodynamic drag. Previous studies have also shown that in various fish systems, 
rounder bodies result in a decrease in Ucrit due to increased drag (Webb 1994, Plaut 2002). 
This complements our explanation as to why female zebrafish have decreased swimming 
endurance on average in comparison to males in the present study.  
Overall, gender should be matched between experimental groups for swim tunnel studies, 
as it is clear that bias towards one gender in either group could skew data. However, sex 
ratios in groups of zebrafish can be problematic. In many species, gender is determined 
by a chromosomal background, but no distinct genetic mechanism has been identified in 
zebrafish thus far. Several candidate genes have now been implicated in the process, 
which suggests that sex determination it is likely to be a complex interaction between 
several loci interacting with environmental factors (Wilson 2012). All zebrafish initially 
have undifferentiated, ovary-like gonads but by 30dpf all oocytes disappear from male 
gonads, and males undergo testicular differentiation (Watts, Powell and D'Abramo 2012, 
Takahashi 1977). However, the point at which spermatogenesis is determined in zebrafish 
that go on to develop into males is not known (Wilson 2012, Orban, Sreenivasan and 
Olsson 2009). Interestingly, one study found that somatic genes were expressed 
indifferently at 10 to 17dpf, but became sexually dimorphic after 3 weeks (Wilson 2012, 
Tong, Hsu and Chung 2010). This suggests that if there is an environmental effect on sex 
determination, husbandry during larval rearing is likely to affect it (Wilson 2012). 
Anecdotally, it has been observed that high stocking densities and limited food resources 
may produce more males, and vice versa (Wilson 2012). Additionally, other 
environmental factors such as hypoxia, temperature, nutrition, exposure to hormones 
have been shown to have an effect on sex determination (Nagabhushana and Mishra 
2016). Due to the unpredictable nature of sex determination, raising larger clutches could 
help to ensure experimental groups can be sex matched in the future. 
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4.5.2.3. Immunohistochemical analysis of neuromuscular junctions  
In order to further investigate the basis for the subtle alteration in motor function that was 
observed, quantitative assessment of NMJs was performed (see section 4.3.2.8). As 
described, we stained trunk musculature with α-bungarotoxin (a post-synaptic marker of 
the NMJ) and SV2 (a presynaptic marker that labels motor neurons), and used confocal 
microscopy to quantify the intensity correlation quotient (ICQ) (Li et al. 2004), size and 
number of both the pre- and post-synaptic compartments. This was investigated in 11-
month old zebrafish from the lines SH448 and SH451, because it was observed that the 
zebrafish had a moderate reduction in Ucrit around this time point. If defects at the NMJ 
are associated with this altered swimming, we would have expected to have seen a 
reduction in ICQ, as well as the size and number, of pre- and post- synaptic compartments, 
indicative of NMJ degeneration.   
Firstly, the number of pre- and post-synaptic compartments per section was analysed, to 
determine if there was a loss of NMJs. There is a trend that the number of pre- and post-
synaptic compartments is decreased in homozygous mutants in comparison to wild-type 
siblings, in both lines tested. However, this is only significantly reduced for post-synaptic 
compartments in C13H9orf72SH451/SH451 trunk musculature in comparison to wild-type 
siblings. These observations may indicate that there is a loss of NMJs, but further work 
would need to be done to explore this. Secondly, to look at co-localisation between SV2 
and α-bungarotoxin the ICQ value was quantified, as this method has been published in 
relation to examining the integrity of NMJs in zebrafish previously (Chapman et al. 2013).  
We found that there was no difference in ICQ values between homozygous mutants 
(C13H9orf72SH448/SH448 and C13H9orf72SH451/SH451) and wild-type siblings in both lines 
tested, indicative of intact NMJs in both genotypes. Finally, the frequency distribution of 
pre- and post-synaptic area was observed and compared between genotypes. This was 
done, as the sizes of the pre- and post-synaptic compartments were not normally 
distributed, therefore taking a mean value for comparison would not have been an 
appropriate method. It was observed in both lines that there was a high frequency of small 
(up to 10m2) pre- and post-synaptic compartments. There may be several reasons for 
this. For example, zebrafish have striated skeletal muscle, therefore it could be that when 
processing the sections, they were not cut longitudinally along the muscle, resulting in 
some NMJs being cut at an angle, affecting the size of pre- or post-synaptic compartment 
observed. Alternatively, this could be an artefact of the microscope settings used. 
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Interestingly, a significant difference was only observed between pre- and post-synaptic 
compartments up to 10m2 in both lines. However, the differences between the mean 
frequencies are actually very small therefore calling in to question the biological 
relevance of this observation.  
Overall, despite the observation that homozygous mutants have a moderate decrease in 
swimming endurance in comparison to wild-type siblings, quantitative assessment did not 
reveal any significant abnormalities relating to NMJs. It is possible that compensatory 
mechanisms such as polyneuronal innervation of zebrafish muscle (Westerfield et al. 
1986) and the capacity for motor neurons to regenerate (Reimer et al. 2008), affects the 
phenotype observed. Additionally, we are limited in this study as only a single time point 
was tested. Based on these results, it is unlikely there would be any difference at earlier 
time points but examination of NMJs at later time points would be interesting.  
4.5.3. Characterisation of behaviour in C13H9orf72 loss-of-function 
zebrafish  
It is reported that 50% of ALS patients carrying the repeat expansion in C9orf72 also 
show behavioural and/or cognitive impairments (Ringholz et al. 2005). Additionally, a 
study on a large ALS patient cohort revealed around 15% of these patients met the clinical 
criteria for FTD, particularly the behavioural variant of FTD (bvFTD) (Ringholz et al. 
2005). Patients show symptoms such as: anxiety, disinhibition, apathy, memory loss 
(Mahoney et al. 2012). As well as this, there is high evidence of psychosis, most 
commonly featuring hallucinations and delusions (Sha et al. 2012, Snowden et al. 2012, 
Cooper-Knock et al. 2014a). As gene function is widely conserved between zebrafish and 
humans, there is homology between their nervous systems and behaviours (Lieschke and 
Currie 2007). As a result, zebrafish are now widely used in behavioural neuroscience 
(Champagne et al. 2010, Norton and Bally-Cuif 2010). There are now several protocols 
established to measure behaviours such as anxiety, aggression, social preference, memory 
and learning in adult zebrafish (Norton and Bally-Cuif 2010). As discussed in section 4.4, 
the following tests were performed in order to establish whether C13H9orf72 LOF in the 
zebrafish resulted any behavioural changes: novel tank diving and open field analysis, 
both of which are tests to examine anxiety.  
4.5.3.1. Novel tank diving test  
Increased anxiety has been observed in patients carrying the repeat expansion in C9orf72 
(Mahoney et al. 2012). This may be directly linked to C9orf72-linked disease, but it is 
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important to consider that this may be a consequence of the patient understanding they 
have a terminal illness. However, it has been reported that these symptoms are present in 
FTD patients carrying the repeat expansion in C9orf72, before being in contact with 
psychiatric services, suggesting this is an important behavioural change in patients 
(Mahoney et al. 2012). To examine this behavioural trait in C13H9orf72 LOF adult 
zebrafish, the novel tank diving test was performed (section 4.4.1). The test measures 
anxiety evoked by novelty stress. Adult zebrafish have been reported to exhibit a robust 
behavioural response to this stress (Cachat et al. 2010, Parker et al. 2012). When the 
individual is first placed in the novel environment, their natural instinct is to stay in the 
bottom of the tank. As the course of exposure to the novel environment continues, they 
become more exploratory. As a result, the amount of time spent in the lower half of the 
tank should decrease over the time course of the experiment, which is response we expect 
to see in controls. The novel tank diving test can quantify this behaviour by examining 
the amount of time a zebrafish spends at the lower half of the tank in comparison to the 
top, with more time spent in the lower half indicative of anxious behaviour (Cachat et al. 
2010). It has been reported that use of anxiolytic treatments significantly decrease the 
amount of time spent in the lower half of the tank (Cachat et al. 2010, Parker et al. 2014, 
Bencan, Sledge and Levin 2009, Levin, Bencan and Cerutti 2007), further supporting this 
protocols ability to measure anxiety.  
The pilot cohort displayed the typical diving response at each time point, meaning that 
they gradually spent less time in the lower half over the course of exposure to the novel 
tank. This observation is supported as there was a significant main effect of time interval 
at all of the time points tested (table 4.13). C13H9orf72SH448/SH448 zebrafish spent more 
time in the lower half of the tank over the course of exposure in comparison to their wild-
type siblings, indicative of increased anxiety (section 4.4.1.1). Again, this effect was 
confirmed at months 9-14, 16 and 20, as there was a significant main effect of genotype 
(table 4.13). Additionally, no significant difference in distance travelled during the course 
of exposure was noted between the two genotypes, allowing further confidence that the 
result seen was due to behaviour and not because the motor function of the C13H9orf72 
LOF zebrafish was impaired. Due to the consistency of the pilot study, characterisation 
of behaviour was carried out in three separate lines using the novel tank diving test. The 
lines tested included SH448, which carried the same mutation in exon 7 as the pilot 
cohort, SH451 (another exon 7 mutant) and SH470 (an exon 1 mutant) (details for all 
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mutants generated in chapter 3). As discussed earlier, a second clutch was raised for line 
SH448 and SH451, in order to obtain data for earlier time points (which was also 
necessary for the swim tunnel, as discussed previously). Overall, it was observed that 
C13H9orf72 LOF adult zebrafish showed no evidence for increased anxiety under 
stressed conditions in lines SH448, SH451 and SH470, converse to the pilot data. 
However, these findings are consistent with recently published C9orf72 LOF mouse 
models, which do not report on any observed behavioural phenotype, such as anxiety 
(Atanasio et al. 2016, Burberry et al. 2016, Koppers et al. 2015, O'Rourke et al. 2016, 
Sudria-Lopez et al. 2016). 
The typical diving response in the novel tank diving test, for both homozygous mutants 
and wild-types, can be represented by line SH448 clutch 2 (figure 4.26), which show a 
clear decrease in the amount of time spent in the lower half over time. However, it was 
found that the typical diving response we expect to see was not observed in homozygous 
mutants nor wild-types in some of the lines. For example, line SH470 did not show the 
typical diving response at any time point tested, supported as there was not a significant 
effect of time interval (see figure 4.32 and table 4.17). Interestingly for SH451 clutch 1 
there was not a significant effect of time interval at months 18-24, but there was at the 
earlier time points of 9-15 (see figure 4.28 and table 4.15). This suggests that the zebrafish 
may acclimatise to the test over time, thus are no longer susceptible to novelty stress. If 
this is the case, it would suggest that it is not advisable to perform this test over an 
extended period of time. However, most of the lines tested did show the expected diving 
response at all of the time points, including SH448 clutch 2 and SH451 clutch 2 (see 
section 4.4.1.3 and 4.4.1.5). Additionally, the pilot cohort, which was tested once a month 
compared to once every three months, also showed the expected diving response at all of 
the time points. Therefore, this does not support the fact that the zebrafish acclimatise to 
the test over time. Anecdotally, it was noted that when zebrafish showed signs of aging 
(at later time points) they spent most their time at the top of the tank. Thus, as the analysis 
is done on the group as a whole, this may have affected the diving response seen overall. 
In the future, it may be suggested to exclude zebrafish which have aged and are therefore 
not behaving as expected. However, this observation does not explain why the typical 
diving response wasn’t see at earlier time points for line SH470, as mentioned previously. 
There was no difference in housing conditions of any of the lines, which is known to 
effect the diving response seen in the novel tank diving test (Parker et al. 2012). In 
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summary, we found that some clutches did not show the typical diving response. As wild-
type controls were among this group, it is difficult to draw conclusions on the behaviour 
of mutants.   
4.5.3.2. Open field test  
In addition to the novel tank diving test, the open field test was performed to observe 
anxiety. The open field test is a commonly used method to measure anxiety in rodents, 
via observing thigmotaxic behaviour and it is now understood that zebrafish exhibit this 
same behaviour (Schnorr et al. 2012). Increase in thigmotaxic behaviour is known to be 
indicative of anxious behaviour (Schnorr et al. 2012). Additionally, it  has been reported 
that use of anxiolytic treatments such as diazepam and ethanol decreases thigmotaxic 
behaviour, further supporting this tests ability to measure anxiety (Baiamonte et al. 2016). 
During this project, after placing the individual zebrafish in the middle of the test arena, 
they were left 60s to acclimatise. This was done to reduce the effects of any differences 
between zebrafish in the time to be netted, and is a technique that has been reported with 
zebrafish and other fish species (Burns 2008, Ariyomo and Watt 2012, Ariyomo and Watt 
2015). Therefore, this means that unlike the novel tank test, anxiety behaviour is observed 
under a standard, low stress environment. 
The open field analysis was performed on the pilot cohort only. As the results observed 
for the novel tank diving test were indicative of anxiety, it was expected that increased 
thigmotaxic behaviour would be observed in the C13H9orf72 LOF zebrafish during the 
open field analysis. As discussed in section 4.4.2, no significant difference in thigmotaxic 
behaviour was observed between the two genotypes at any time point, suggesting the pilot 
cohort was not anxious under these conditions. One reason for this may be that this cohort 
only exhibits a difference in anxious behaviour under a more stressful stimulus. Overall, 
this result again complements observations made in C9orf72 LOF mouse models, where 
behavioural changes were not reported (Atanasio et al. 2016, Burberry et al. 2016, 
Koppers et al. 2015, O'Rourke et al. 2016, Sudria-Lopez et al. 2016).  
4.5.4. Conclusion  
Overall, it can be concluded from this study that C13H9orf72 LOF does not have an effect 
on early or late viability of the zebrafish. There is evidence of a subtle motor defect with 
no corresponding NMJ abnormalities at 11 months. However, a more highly statistically 
powered study is being undertaken in order to understand if it will be useful as a model 
of motor dysfunction. Additionally, there is not a significant difference in anxiety 
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behaviour between the C13H9orf72 LOF mutants and wild-types, which has been 
observed in two separate tests of anxiety. These findings conclude that haploinsufficiency 
of C13H9orf72 may not be enough to cause C9-ALS/FTD alone, which complements 
what has been reported in C9orf72 LOF mouse models (Atanasio et al. 2016, Burberry et 
al. 2016, Koppers et al. 2015, O'Rourke et al. 2016, Sudria-Lopez et al. 2016). However, 
these findings do not rule out that C13H9orf72 LOF may modulate disease onset and 
progression in C9-ALS/FTD patients, alongside other proposed gain-of-function 
mechanisms. Further characterisation will be necessary to determine the full potential of 


















5. Investigating the function of C9orf72 in vivo  
 
5.1. Introduction  
C9orf72 is alternatively spliced into three transcript variants, which are predicted to 
encode two protein isoforms, namely a 481aa isoform of approximately 50 kDa, referred 
to as C9orf72 long or C9orf72-L, and a 222aa isoform of approximately 25 kDa, referred 
to as C9orf72 short or C9orf72-S (Xiao et al. 2015, DeJesus-Hernandez et al. 
2011)(Figure 1.2). Due to the lack of reliable, commercially available anti-C9orf72 
antibodies, it is difficult to detect endogenous protein expression. However, one group 
has reported the development of antibodies which are able to detect C9orf72-L and 
C9orf72-S individually (Xiao et al. 2015). Using these antibodies, they showed that 
C9orf72-L exhibited diffuse cytoplasmic staining in neurons and labelled large speckles 
in cerebellar Purkinje cells (Xiao et al. 2015). Additionally, they showed that C9orf72-S 
exhibited specific staining of the nuclear membrane in healthy neurons, with 
relocalisation to the plasma membrane in diseased motor neurons in ALS (Xiao et al. 
2015). Overall, the protein itself does not show any obvious homology to other proteins, 
however bioinformatic analysis by two groups have identified that C9orf72 is structurally 
related to Differentially Expressed in Normal and Neoplasia (DENN) domain-containing 
proteins (Zhang et al. 2012, Levine et al. 2013). DENN domain-containing proteins 
function as GDP/GTP exchange factors (GEFs) for Rab GTPases, which are involved in 
regulating a number of cellular trafficking events, including autophagy (Ao, Zou and Wu 
2014).  
Autophagy is a conserved lysosomal degradation pathway, involving the degradation of 
cytoplasmic components within an autophagolysosome. Defects in the autophagy 
pathway have previously been linked to several neurodegenerative diseases, including 
ALS (Harris and Rubinsztein 2012). C9-ALS/FTD patients characteristically have  
p62/SQSTM1 positive, TDP-43 negative inclusions in the cerebellum, hippocampus and 
neocortex (Cooper-Knock et al. 2012, Al-Sarraj et al. 2011). p62/SQSTM1 binds 
ubiquitinated cargoes and delivers them to the phagosome (Pankiv et al. 2007)(figure 
5.4). As p62/SQSTM1 is degraded by autophagy in the process of delivering 
ubiquitinated cargo, accumulations of this protein indicate defective autophagy (Pankiv 
et al. 2007). Thus, the presence of these inclusions, together with evidence of C9orf72 
haploinsufficiency, first suggested the possibility that defective autophagy via loss of 
C9orf72 function contributed to C9-ALS/FTD. Recent studies revealed that disruption of 
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C9orf72 function, in both cell lines and primary neurons, results in an inhibition of 
autophagy initiation and accumulation of p62/SQSTM1, similar to the pathology seen in 
C9-ALS/FTD patients (Farg et al. 2014, Yang et al. 2016, Sellier et al. 2016, Sullivan et 
al. 2016a, Webster et al. 2016a). These findings further suggest that defects in autophagy 
via C9orf72 haploinsufficiency may be involved in C9-ALS/FTD pathogenesis. 
Therefore, it is important as part of this project to investigate the role of C9orf72 further 
in vivo, using the C9orf72 LOF zebrafish. This not only will allow further investigation 
into the function of C9orf72 in vivo, but will also allow investigation into the possible 
role of autophagy deficits in disease progression.  
Loss of the mouse orthologue of C9orf72 (3110043021Rik), in either a tissue-specific or 
ubiquitous manner, has also been linked to defects in the immune system in vivo 
(O'Rourke et al. 2016, Sudria-Lopez et al. 2016, Koppers et al. 2015). For example, these 
models have consistently reported symptoms such as enlarged spleens and lymph nodes, 
microglia activation with abnormal lysosomal activity, altered cytokine production and 
impaired autophagy function (Atanasio et al. 2016, O'Rourke et al. 2016, Sudria-Lopez 
et al. 2016). Interestingly, these studies do not report any neurodegeneration in response 
to partial or complete loss of C9orf72. Therefore, it will be interesting to use the generated 
C9orf72 LOF zebrafish to study whether defects to the immune system are evident, in 












5.2. Generating the pCI-neo-Myc-C13H9orf72 construct 
To be able to explore the function of C13H9orf72 in vitro as well as in vivo, we first 
aimed to generate a C13H9orf72 expression construct. In order to achieve this, the 
C13H9orf72 cDNA reference sequence (ensembl: ENSDART00000015127.6) was 
BLAST searched against the NCBI expressed sequence tag (EST) database to identify a 
full length cDNA clone. As a result, complementary sequencing data for both the 5’ and 
3’ ends were identified for cDNA clone ID FDR306-p00004_BR_K14 (accession number 
EH579768.1 and EH597144.1, respectively), suggesting this would be a full-length 
cDNA clone. The identified cDNA clone was purchased from GE Healthcare Life 
Sciences (corresponding ID: MDR-1734-202835311). Primers were designed to fully 
sequence the purchased cDNA clone, to ensure it was full length and had no sequence 
variations from the reference. Sequencing data revealed the cDNA clone was full length, 
but had a number of sequence variants throughout the cDNA clone when aligned to the 

















Table 5.1 Sequence variants identified in the C13H9orf72 sequence. 
Sequence variants locus  Effect of sequence variants 
ZGC_100846:c.66 T>G Codon change TGT>TGG, resulting in an amino 
acid change of cysteine to tryptophan. Known 
missense variant, rs40965738. Position 66, within 
coding exon 1. Found previously, see section 3.3.1 
ZGC_100846:c.634 T>C Codon change TGC>CGC, resulting in an amino 
acid change of cysteine to arginine. Novel variant. 
Position 634, within coding exon 4. In a conserved 
region.  
ZGC_100846:c.687 T>G Codon change GTT>GTG, synonymous mutation 
encoding the amino acid valine. Known variant, 
rs179848938. Position 687, within coding exon 5.  
ZGC_100846:c.813 T>C Codon change AGT>AGC, synonymous mutation 
encoding the amino acid serine. Novel variant. 
Position 813, within coding exon 6.  
ZGC_100846:c.916_917del Deletion of two base pairs (AC) at position 916-17, 
within coding exon 6. This polymorphism causes a 
frameshift, resulting in a premature stop codon 






















A novel sequence variant ZGC_100846:c.634 T>C was identified (figure 5.1), resulting 
in a codon change of TGC>CGC. This resulted in non-synonymous change in the 
corresponding amino acid sequence, which was located in a conserved region (table 5.1). 
In order to correct this sequence, we used site directed mutagenesis to change the C>T, 
see section 2.4.2 for details (figure 5.1).  
 
 
Figure 5.1 Chromatographs following site-directed mutagenesis on 
ZGC_100846:c.634 T>C. Chromatographs, produced by Sequencher v5.4.5, highlight 
the site variant ZGC_100846:c.634 T>C before site-directed mutagenesis (Tgc/Cgc 
position 634) and after site-directed mutagenesis (TGT position 634). Both sequences are 















Another novel sequence variant ZGC_100846:c.916_917del was identified (figure 5.2), 
resulting in the deletion of two base pairs (AC) and causing a frameshift. This variant was 
predicted to result in a premature stop codon in the translated protein sequence (table 5.1 
for details). In order to correct this sequence, we used site directed mutagenesis to insert 
the two base pairs (AC), see section 2.4.2 for details (figure 5.2). 
 
 
Figure 5.2 Chromatographs following site-directed mutagenesis on 
ZGC_100846:c.916_917del. Chromatographs, produced by Sequencher v5.4.5, 
highlight the ZGC_100846:c.916_917del before site-directed mutagenesis (2bp deletion) 
and after site-directed mutagenesis (AC insert position 916-917). Both sequences are 














The sequence variant ZGC_100846:c.66 T>G corresponded to a known missense variant, 
rs40965738 (table 5.1). This variant had previously been identified when sequencing the 
region surrounding the CRISPR gRNA target site (section 3.1.1) and was revealed to be 
in a non-conserved area. Additionally, a known sequence variant ZGC_100846:c.687 
T>G and a novel sequence variant ZGC_100846:c.813 T>C, were identified. These both 
resulted in synonymous changes in the corresponding amino acid sequence (table 5.1). 
The aforementioned sequence variants were therefore not corrected by site-directed 
mutagenesis, as did not affect the protein sequence. 
Following correction by site-directed mutagenesis, the C13H9orf72 cDNA construct was 
subcloned from pDNR-LIB into the mammalian expression vector pCI-neo-Myc 
(detailed in section 2.4.3). C13H9orf72 was amplified using PCR, introducing 5’ NotI 
and 3’ XhoI restriction sites, and the PCR DNA fragment was sent for sequencing, 
confirming restriction sites were in-frame. The PCR DNA fragment was subsequently 
inserted in pCI-neo-Myc vector via complementary restriction digest using NotI/XhoI, 
followed by ligation and transformation into competent cells. Following screening of 















5.3. Investigating whether the function of C9orf72 is conserved in zebrafish  
5.3.1. C13H9orf72 interacts with human ATG13  
There is 68.55% nucleotide identity and 76.14% amino acid identity between human 
C9orf72 (hC9orf72) and the zebrafish orthologue (C13H9orf72; zgc: 100846). This high 
sequence similarity suggests a conservation of C9orf72 protein function between species. 
hC9orf72 has been reported to play a role in the autophagy pathway (Amick et al. 2016, 
Sellier et al. 2016, Sullivan et al. 2016a, Webster et al. 2016b, Webster et al. 2016a, Yang 
et al. 2016). Autophagy is initiated by the ULK-1 complex, consisting of Unc-51-like 
kinase 1 (ULK-1), FAK family kinase-interacting protein of 200 kDa (FIP200), 
autophagy-related 13 (ATG13) and ATG101 (Klionsky et al. 2012). Published data from 
our lab reported that C9orf72 interacts with components of the ULK-1 complex, including 
ULK-1, ATG13 and FIP200 (Webster et al. 2016a). Overall amino acid identity between 
human and zebrafish core autophagy proteins range from 40-96%, with zebrafish 
orthologues of the ULK-1 initiation complex sharing 50-87% amino acid identity with 
their human counterpart (Mathai et al. 2017). Assuming functional conservation, 
zebrafish C9orf72 would be expected to also bind and interact with members of the ULK-
1 initiation complex. To determine whether C13H9orf72 interacts with the ULK-1 
initiation complex, the interaction between C13H9orf72 and human ATG13 (hATG13) 
was investigated. hATG13 showed a strong interaction with hC9orf72 in vitro (Webster 
et al. 2016a). Furthermore, the high conservation with the zebrafish atg13 orthologue 
(>70% identity) made hATG13 a promising candidate to study the interaction 
C13H9orf72 with the autophagy initiation complex. 
To investigate whether C13H9orf72 was directly interacting with hATG13, we performed 
an in vitro binding assay (section 2.9.5). Firstly, C13H9orf72 was cloned into the 
pGEX6p1 vector to allow bacterial expression and recombinant protein production 
(section 2.4.8). Recombinant GST-tagged C13H9orf72 and hC9orf72 protein, produced 
in bacteria, was incubated with in vitro translated 35S-labelled hATG13. Following this, 
GST-tagged C13H9orf72 and hC9orf72, plus a GST control, were pulled down using 
Glutathione Sepharose High performance (GSH) beads and proteins eluted using excess 
glutathione. Samples were analysed by SDS-PAGE and 35S-labelled protein detected 
using a phosphoimager (figure 5.3 B). It was shown that hATG13 directly interacts with 
both C13H9orf72 and hC9orf72, but not with the GST control (figure 5.3 B). This data 
reproduces the interaction between hC9orf72 and hATG13 as previously reported 
(Webster et al. 2016a). It also shows that C13H9orf72 is capable of interacting with 
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hATG13, therefore supporting the idea that there is conservation of protein function and 




Figure 5.3 C13H9orf72 directly interacts with hATG13.35S-labelled recombinant 
ATG13 was added to GST, GST-C13H9orf72 and GST-hC9orf72 immobilized on 
glutathione-coated beads. Samples were analysed by SDS-PAGE and 35S-labelled 
detected using a phosphoimager. Coomassie-stained GST, GST-C13H9orf72 and GST-
hC9orf72 from the pull-down samples are shown (A). 35-S labelled ATG13 was visualised 
using a phosphoimager, showing hATG13 directly interacts with GST-C13H9orf72 and 












5.3.2. Further investigating the role of C13H9orf72 in the autophagy 
pathway in vivo  
Publications from our lab and others have shown that hC9orf72 plays a role upstream in 
autophagy, regulating initiation of the pathway (Webster et al. 2016a, Sellier et al. 2016).  
As C13H9orf72 binds hATG13, supporting the idea that there is conservation of protein 
function between C13H9orf72 and hC9orf72, we reasoned that it would also regulate the 
initiation of autophagy in zebrafish. To investigate this, we utilised two different 
strategies. Firstly, we aimed to examine autophagic flux in the C9orf72 LOF zebrafish, 
as recent studies have shown that depletion of C9orf72 expression, in both cell lines and 
primary neurons, results in defective autophagy initiation (section 5.3.2.1-
5.3.2.2)(Webster et al. 2016a, Sellier et al. 2016). Secondly, we aimed to examine the 
levels of p62/SQSTM1 in the C9orf72 LOF zebrafish, as depletion of C9orf72 expression, 
in cell lines and primary neurons, has also resulted in accumulation of p62/SQSTM1 
levels, reflective of the p62/SQSTM1 positive, TDP-43 negative inclusions observed in 
C9-ALS/FTD patients (section 5.3.2.3)(Webster et al. 2016a, Sellier et al. 2016, Cooper-
Knock et al. 2012, Al-Sarraj et al. 2011).  
5.3.2.1. Examining autophagic flux in vivo  
The most widely used marker to measure autophagic flux is microtubule-associated 
protein 1A/1B light chain 3 (LC3). During autophagy, cytosolic LC3-I is lipidated to form 
LC3-II, which is then recruited to the autophagosome membrane (Klionsky et al. 2012). 
LC3-II remains associated with the autophagosome until it is eventually degraded 
downstream within the autophagolysosome. Thus, turnover of LC3-II reflects the 
progression of autophagy (Klionsky et al. 2016) . LC3-II can be visualised as cytoplasmic 
puncta by immunofluorescence microscopy or by an apparent shift in molecular weight 
when analysed via SDS-PAGE. The latter method was used in this study and this method 
has been used to measure levels of autophagy in several zebrafish autophagy studies (He 
et al. 2009, Benato et al. 2013, Underwood et al. 2010, Renna et al. 2013).  
To achieve this, zebrafish embryos were treated with autophagy initiating drugs (such as 
mTOR inhibitors), autophagy inhibiting drugs (such as lysosomotrophic reagents), or 
both (table 2.8 and figure 5.4). In the presence of mTOR inhibitors only, biogenesis of 
autophagosomes is increased which in turn will increase LC3-II levels (Klionsky et al. 
2012). However, this increase may not be detectable on immunoblot due to rapid 
degradation in lysosomes under these conditions. In the presence of lysosomotrophic 
reagents only, autophagosomes-lyososome fusion is prevented, resulting in an 
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accumulation of autophagosomes and subsequent stabilisation of LC3-II, as lysosomal 
degradation is blocked (Klionsky et al. 2012). This results in an increase of LC3-II levels 
on immunoblot. When embryos are treated with both drug types in combination, specific 
quantification of autophagy induction can be determined. In wild-type embryos, we 
would expect a further increase in LC3-II levels on immunoblot, as biogenesis of 
autophagosomes is increased, but lysosomal degradation is simultaneously blocked. 
However, if initiation is impaired, for example due to loss of C9orf72 as has been shown 
previously, we would not expect to see an increase in LC3-II levels under these conditions 




Figure 5.4 Autophagy initiating and inhibiting drugs. Schematic overview of the autophagy, as described in figure 1.3, and a non-exhaustive 
list of reagents that can initiate or inhibit autophagy. mTOR inhibitors, such as torin-1 and rapamycin (shown in green), activate the autophagy 
pathway. Conversely, lysosomotrophic reagents, such as ammonium chloride (NH4Cl), Bafilomycin-A1 and Chloroquine (shown in red), prevent 
autophagosome-lysosome fusion. A detailed description of treatments used can be found in table 2.8.  
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5.3.2.1.1. Optimisation of the autophagic flux assay   
We first optimised the assay using wild-type AB zebrafish, which is the same wild-type 
strain used to generate the C13H9orf72 LOF zebrafish. Initially, to determine whether 
zebrafish LC3-I and LC3-II could be visualised by immunoblotting, wild-type embryos 
were incubated for 6-hours at 24 hpf with the following treatments; 2% DMSO (as a 
control), 1 M torin-1 (an mTOR inhibitor, figure 5.4), 100 nM bafilomycin-A1 (a 
lysosomotrophic reagent, figure 5.4) or both 1 M torin-1 and 100 nM bafilomycin-A1. 
These treatments have been used previously to show C9orf72 KD results in a disruption 
of autophagy induction in cells and primary neurons (Webster et al. 2016a). Following 
incubation, embryos were homogenised and lysed in BRB80 lysis buffer (Webster et al. 
2016a) and the total protein concentration of each sample was quantified. Samples were 
subjected to SDS-PAGE and immunoblot analysis alongside a lysate of HEK-293 cells 
treated with torin-1 + bafilomycin-A1 (baf-A1), which was used as a control for the LC3 
antibody.  
For the HEK-293 torin-1 + baf-A1 treated cells, two strong bands were evident around 
17 kDa and 14 kDa, which correspond to the expected molecular weight (MW) for LC3-
I and LC3-II respectively (figure 5.5). This indicates the antibody can detect endogenous 
human LC3. The treated embryo samples gave a single band was visible around 14kDa, 
which is the expected MW for zebrafish LC3-II, but we did not observe a 16kDa band, 
which is the expected MW of LC3-I (He et al. 2009). Additionally, inhibition of mTOR 
using torin-1 in the presence of baf-A1 did not result in a marked increase in LC3-II levels 
compared to baf-A1 alone (figure 5.5). This indicates torin-1 did not efficiently induce 
autophagy in the zebrafish in this experiment. Overall, these results indicated that using 







Figure 5.5 LC3-II is observed in zebrafish lysates. 24hpf embryos were treated with 
the indicated chemicals for 6 hours. Protein extracts were analysed by SDS-PAGE and 
detected using anti-LC3 or anti-α-tubulin as a loading control.  Samples were run 
alongside lysates of HEK-293 cells treated with bafilomycin-A1+ torin-1, acting as a 






















In an attempt to detect endogenous LC3-I on immunoblot, we optimised several steps in 
the protocol. Firstly, as homogenisation and lysis of embryos in BRB80 involves 
sequential steps (section 2.9.3), we reasoned that LC3-I might not be detectable via 
immunoblot due to loss of protein during this sample preparation process. Therefore, we 
optimised the protein extraction method. To do this, we compared the original method 
(method 1) with an alternate lysis protocol which contained less steps and involved the 
transfer of treated, deyolked embryos straight into laemmli loading buffer (method 2) 
(figure 5.6). Secondly, although nitrocellulose membrane was used previously (figure 
5.5), it is known that Polyvinylidene Difluoride (PVDF) membranes have a higher protein 
binding capacity than nitrocellulose (Klionsky et al. 2016). Therefore, we reasoned that 
use of PVDF membrane, may result in a higher retention of LC3-I and allow us to 
visualise this protein on immunoblot. To investigate this in the same experiment, we also 
compared the transfer of both LC3-I and –II on nitrocellulose membrane to PVDF.  
As before, wild-type zebrafish were incubated for 6-hours at 24 hpf with the following 
treatments; 2% DMSO, 1 M torin-1, 100 nM baf-A1 or both 1 M torin-1 and 100nM 
baf-A1. Following incubation, protein was extracted as described. Samples were 
subjected to SDS-PAGE and immunoblot analysis. For all samples, a band was visible 
around 14kDa, the expected MW for zebrafish LC3-II, but we did not observe a 16kDa 
band, the expected MW of LC3-I (figure 5.6). This indicated that the method of protein 
extraction did not impact the ability to visualise endogenous LC3-I on immunoblot, thus 
the original method of protein extraction was used in future experiments. In comparison 
to PVDF, transfer of LC3-II appeared weaker on nitrocellulose. Therefore, PVDF 
membrane was used for transfer in all future experiments. Additionally, treatment with 
baf-A1 did not markedly increase LC3-II levels compared to torin-1 treatment alone, 
indicating that baf-A1 did not efficiently block autophagy in the zebrafish in this 
experiment (figure 5.6). Overall, these results indicate that we can visualise endogenous 
zebrafish LC3-II on immunoblot, but not LC3-I, consistent with a previous publication 





Figure 5.6 Optimisation of protein extraction and transfer method. 24hpf embryos 
were treated with the indicated chemicals for 6 hours. Protein lysates were prepared in 
two ways. Method 1: embryos from each treatment were homogenised then lysed in 
BRB80 lysis buffer and the total protein concentration of each sample was quantified. 
Method 2: Embryos were transferred straight into laemmli buffer. Protein extracts were 
analysed by SDS-PAGE and transferred onto either A) Nitrocellulose or B) PVDF 














We found that baf-A1 does not efficiently block autophagy in zebrafish (figure 5.6). Other 
groups have shown that lysosomotrophic reagents such as ammonium chloride (NH4Cl) 
and chloroquine, which increase lysosomal pH preventing autophagosome-lysosome 
fusion like baf-A1, were effective in blocking autophagy in zebrafish at 48hpf (He et al. 
2009, Underwood et al. 2010, Renna et al. 2013, Benato et al. 2013). Therefore, in order 
to confirm optimal lysosomotrophic reagents, wild-type AB zebrafish embryos were 
treated at 48hpf with either baf-A1, chloroquine or NH4Cl. These treatments were tested 
with or without the addition of torin-1 and incubated for a total of 24 hours.  
Treatment with 100 nM baf-A1 and 50 M chloroquine for 24 hours resulted in high level 
of toxicity (data not shown). Treatment with 100 mM NH4Cl markedly increased LC3-II 
levels compared to 1M torin-1 treatment alone, indicating NH4Cl efficiently blocked 
autophagy in the zebrafish under these conditions (figure 5.7). However, treatment with 
torin-1 and NH4Cl did not markedly increase LC3-II levels compared to NH4Cl treatment 
alone, indicating that torin-1 did not efficiently induce autophagy in the zebrafish in this 
experiment, as shown previously (figure 5.5 and 5.7). Overall, it was concluded that 





Figure 5.7 Ammonium chloride treatment results in LC3-II accumulation after a 
24-hour incubation. 2dpf embryos were treated with the indicated chemicals for 24 
hours. Embryos were homogenised and lysed in BRB80. Samples were analysed by SDS-
PAGE and detected using anti-LC3 or anti-α-tubulin as a loading control. Samples were 




Previously, torin-1 was used as it has been shown to be effective in inducing autophagy 
in mammalian cells (Klionsky et al. 2016). However, we found that its effect was 
marginal in zebrafish (figures 5.5 and 5.7). Therefore, as well as optimising the 
lysosomotrophic reagent used, it was essential to optimise the mTOR inhibitor used. 
Another mTOR inhibitor, rapamycin, is commonly used to initiate autophagy in 
zebrafish, therefore this was tested (He et al. 2009). Additionally, a number of rapalogs, 
which have the same molecular scaffold but different physiochemical properties (Meng 
and Zheng 2015), were tested alongside. We reasoned that if C13H9orf72 LOF does result 
in a defect in autophagy initiation, the improved pharmacokinetics of rapalogs would be 
beneficial to test as a future treatment, if they are shown to initiate autophagy in zebrafish 
effectively. As well as this, we tested an mTOR-independent autophagy initiating drug, 
trehalose, as another potential drug treatment.  
To confirm the optimal mTOR inhibitor to use, wild-type AB zebrafish embryos were 
treated at 48hpf with varying concentrations of the treatments detailed in figure 5.8 A-C. 
These treatments were tested with or without the addition of 100 mM NH4Cl and 
incubated for a total of 24 hours. Overall, it was observed that incubation with rapamycin 
at 250 nM in the presence of NH4Cl caused a marked increase in LC3-II levels, indicating 
induction of autophagy (see figure 5.8 A).  This effect was also observed for all of the 
rapalogs (see figure 5.8 A-B), except AZD8055 (see figure 5.8 C). Additionally, 
incubation with torin-1 or trehalose, in the presence of NH4Cl, did not consistently 
increase LC3-II levels in comparison to NH4Cl treatment alone (see figure 5.8 A-C), 
indicating these treatments do not efficiently induce autophagy in zebrafish. It was 
decided to further optimise rapamycin concentration for future experiments, as this had 





Figure 5.8 Optimisation of autophagy initiating drug treatments. LC3-II levels were 
observed in response to various autophagy initiating compounds, as well as the lysosomal 
inhibitor treatment NH4Cl. In A, B and C 2dpf embryos were treated with the indicated 
chemicals in 2% DMSO for 24 hours. Protein extracts were analysed by SDS-PAGE and 
detected using anti-LC3 or anti-α-tubulin as a loading control. NH4Cl: Ammonium 
Chloride; Rap: Rapamycin; Tem: Temsirolimus; INK: INK128; AZD: AZD8055. (n=1). 
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As rapamycin was shown to efficiently induce autophagy, we further optimised the 
concentration of rapamycin to use in future experiments. To achieve this, wild-type AB 
zebrafish were incubated for 24-hours at 48 hpf with the following treatments; 2% 
DMSO, 100 nM or 500 nM rapamycin, 100mM NH4Cl or both. Overall it was observed 
that incubation with rapamycin at 100 nM, but not 500 nM, in the presence of NH4Cl 
caused a marked increase in LC3-II levels, indicating induction of autophagy (see figure 
5.9 A-B). As efficient autophagy induction was observed following incubation with 100 




Figure 5.9 Optimisation of rapamycin treatment. 2dpf embryos were treated with A) 
DMSO, 100nM Rapamycin, 100mM NH4Cl or both and B) DMSO, 500nM Rapamycin, 
100mM NH4Cl or both, for 24 hours. Embryos were homogenised and lysed in BRB80. 
Samples were analysed by SDS-PAGE and detected using anti-LC3 or anti-α-tubulin as 
a loading control. (n=1). 
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5.3.2.1.2. Examining autophagic flux in C13H9orf72 loss-of-
function mutants  
To investigate the effect of loss of C13H9orf72 expression on autophagy, optimised 
autophagic flux assays were performed on C13H9orf72 LOF mutants and wild-type 
controls. Autophagic flux experiments were only performed on lines SH448 and SH451, 
which carry frameshift mutations in exon 7, as these were generated first and embryos 
were available. If zebrafish C9orf72 encodes both protein isoforms as predicted, this 
means that we can only observe the effect of loss of C9orf72-L on autophagy function in 
these lines.  
5.3.2.1.2.1. Examining autophagic flux in 
C13H9orf72SH451/SH451 mutants 
To investigate the effect of loss of C13H9orf72 expression on autophagy initiation in 
zebrafish, we performed the autophagic flux assay on C13H9orf72SH451/SH451 embryos and 
wild-type controls.  In 48 hpf wild-type embryos, inhibition of mTOR with 100 nM 
rapamycin in the presence of 100 mM NH4Cl resulted in a non-significant increase in 
LC3-II levels, compared to 100 mM NH4Cl treatment alone, indicating induction of 
autophagy (Figure 5.10 A-B). The same effect was also seen in 48hpf 
C13H9orf72SH451/SH451 embryos, indicating that mTOR-dependent autophagy induction is 
not impaired in C13H9orf72SH451/SH451 embryos under these conditions (Figure 5.10 A-
B).  
Interestingly, others have reported that C9orf72 depletion results in an increase, not 
decrease, of basal LC3-II levels, which could be a result of increased autophagic flux or 
accumulation of autophagosomes due to a defect in lysosome function (Farg et al. 2014, 
O'Rourke et al. 2016). Therefore, we quantified basal levels of LC3-II in 2% DMSO 
treated C13H9orf72+/+ and C13H9orf72SH451/SH451 embryos from previous autophagic 
flux assays. As seen in figure 5.10 C, there was a non-significant increase in basal LC3-





Figure 5.10 Examining autophagy in C13H9orf72SH451/SH451 zebrafish. A) 2dpf 
embryos were treated with the indicated chemicals for 24 hours. Protein extracts were 
analysed by SDS-PAGE and detected using anti-LC3 and anti-α-tubulin as a loading 
control. B) Relative levels of LC3-II quantified using ImageJ software. Levels of LC3-II 
were normalised against α-tubulin and are shown relative to the NH4Cl treated control 
sample, which is set to 1.0 (mean ± SEM; one-way ANOVA with fisher’s LSD test; ns, 
not significant, n=3). C) Indicates levels of LC3-II in zebrafish treated with DMSO (2%) 
only. LC3-II levels were normalised against α-tubulin loading control and are shown 
relative to the DMSO treated control sample, which is set to 1.0 (mean ± SEM, unpaired 




5.3.2.1.2.2. Examining autophagic flux in 
C13H9orf72SH448/SH448 mutants 
We investigated the effect of loss of C13H9orf72 expression on autophagy initiation in 
C13H9orf72SH448/SH448 embryos and wild-type controls, to understand whether the results 
reported for line SH451 were line specific or observed in other C13H9orf72 LOF mutants. 
In 48 hpf C13H9orf72+/+ zebrafish embryos, inhibition of mTOR with 100 nM rapamycin 
in the presence of 100 mM NH4Cl resulted in a non-significant increase in LC3-II levels, 
compared to 100 mM NH4Cl treatment alone (figure 5.11 A-B), consistent with induction 
of autophagy. The same effect was also seen in 48 hpf C13H9orf72SH448/SH4448 embryos 
(figure 5.11 A-B). Again, this indicates that autophagy induction is not impaired in 
C13H9orf72SH448/SH448 embryos under these conditions, as seen in the 
C13H9orf72SH451/SH451 embryos (section 5.3.2.1.2.1).  
Due to reports that C9orf72 depletion results in an increase, not decrease, of basal LC3-
II levels (Farg et al. 2014, O'Rourke et al. 2016), we quantified basal levels of LC3-II in 
DMSO treated C13H9orf72+/+ and C13H9orf72SH448/SH448 embryos from previous 
autophagic flux assays. As seen in figure 5.11 C, there was no significant difference 





Figure 5.11 Examining autophagy in C13H9orf72SH448/SH448 zebrafish. A) 2dpf 
embryos were treated with the indicated chemicals for 24 hours. Protein extracts were 
analysed by SDS-PAGE and detected using anti-LC3 and anti-α-tubulin as a loading 
control. B) Relative levels of LC3-II quantified using ImageJ software. Levels of LC3-II 
were normalised against α-tubulin and are shown relative to the NH4Cl treated control 
sample, which is set to 1 (n=3). C) Indicates levels of LC3-II in zebrafish treated with 
DMSO (2%) only. LC3-II levels were normalised against α-tubulin loading control and 
are shown relative to the DMSO treated control sample, which is set to 1.0 (mean ± SEM, 
unpaired t-test, ns = non-significant, n=3). 
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5.3.2.2. Investigating p62/SQSTM1 protein levels in vivo  
A characteristic phenotype of C9-ALS/FTD patients is the presence of p62/SQSTM1 
positive, TDP-43 negative inclusions (Cooper-Knock et al. 2012, Al-Sarraj et al. 2011). 
p62/SQSTM1 is important for targeting ubiquitinated proteins to the autophagy pathway 
for degradation and accumulation of this protein has been associated with inhibition of 
autophagy (Hara et al. 2006). There is evidence from our lab that disruption of C9orf72 
function in cell lines and primary neurons, results in accumulation of 
p62/SQSTM1(Webster et al. 2016a). Therefore, we reasoned that if C13H9orf72 is 
involved in the regulation of autophagy in zebrafish, loss of C13H9orf72 expression 
would also result in defective autophagy and accumulation of autophagy substrates such 
as p62/SQSTM1. However, based on the LC3 results discussed in the previous section, 
we expected that we would not see a difference in p62/SQSTM1 levels between wild-
type and C9orf72 LOF zebrafish.   
In order to see whether we could detect endogenous p62/SQSTM1 protein levels by 
western blot, a commercially available antibody was optimised (see table 2.9). A previous 
report performing western blots on zebrafish embryo lysates has demonstrated a clear 
band at 50kDa for the endogenous wild-type p62/SQSTM1 protein using this antibody 
(Mostowy et al. 2013). Initially, we homogenised and lysed wild-type AB zebrafish 
embryos at 2dpf in BRB80 lysis buffer and the total protein concentration of each sample 
was quantified. Samples were subject to SDS-PAGE and western blot analysis. Although 
a band was observed at 50kDa (see figure 5.12) as previously reported, there were many 
non-specific bands which were not present in the previous publication, therefore it was 








Figure 5.12 Examining p62/SQSTM1 protein levels in wild-type zebrafish. Protein 
was extracted from 2dpf wild-type AB. Protein extracts were analysed by SDS-PAGE 



















To establish which of these bands was specific to p62/SQSTM1, we utilised three 
p62/SQSTM1 deletion zebrafish lines that were generated in our laboratory. These lines 
carry nonsense mutations in the final exon of p62/SQSTM1 and are predicted to truncate 
the C-terminus of the p62/SQSTM1 protein, resulting in the deletion of the UBA domain, 
which binds to ubiquitinated proteins (Seibenhener et al. 2004). The heads of three 21 dpf 
wild-type, heterozygous carriers and homozygous mutants from each of these lines were 
homogenised and lysed in RIPA buffer and the total protein concentration of each sample 
was quantified (see section 2.9.2 and 2.9.3). Samples were subject to SDS-PAGE and 
western blot analysis. It was expected that the mutant protein would either not be visible 
on immunoblot if the truncated protein is not expressed, or, if the truncated protein is 
expressed, produce bands at a lower MW, as detailed in table 5.2. 
Table 5.2 Summary of wild-type and mutant p62/SQSTM1 protein length.  





Wild-type N/A 452aa 49.21 
A ZGC_85784:c.1211_1221del 420aa 45.63 
C ZGC_85784:c.1211_1216del 417aa 45.19 
D ZGC_85784:c.1212_1216del 422aa 45.98 
 
As before, immunoblotting revealed a band at approximately 50kDa for all samples, 
which is the same MW that has been published for wild-type endogenous p62/SQSTM1 
(Figure 5.13 A-C). However, again there were several non-specific bands (Figure 5.13). 
None of the bands showed altered size or intensity in p62/SQSTM1 C-terminal deletion 
zebrafish, suggesting that the antibody did not detect endogenous zebrafish 
p62/SQSTM1. Therefore, we were unable to determine which bands represented wild-




Figure 5.13 Examining p62/SQSTM1 protein levels in p62/SQSTM1 loss-of-function 
zebrafish. Protein was extracted from heads of 21dpf zebrafish from the following lines 
A) Line A, B) Line C, C) Line D. Protein extracts were analysed by SDS-PAGE and 







5.4. Investigating the link between C9orf72 LOF and splenomegaly  
Complete or partial loss of the mouse orthologue of C9orf72 (3110043021Rik) has not 
been reported to result in neurodegeneration in mice, but has been linked to defects in the 
immune system (O'Rourke et al. 2016, Sudria-Lopez et al. 2016, Koppers et al. 2015, 
Atanasio et al. 2016). In C9orf72 knockout (KO) mice, splenomegaly, enlargement of the 
spleen, was evident as early as at 1 month of age (Atanasio et al. 2016, O'Rourke et al. 
2016, Sudria-Lopez et al. 2016). Additionally, disrupted tissue structure and infiltration 
of immune cells such as macrophages in splenic tissue were reported (Sudria-Lopez et al. 
2016, O'Rourke et al. 2016, Atanasio et al. 2016). Therefore, we reasoned that similar 
changes might be detected in the C13H9orf72 LOF zebrafish.  
5.4.1. Investigating splenomegaly in C13H9orf72SH448/SH448 adult zebrafish  
Spleens were dissected from C13H9orf72SH448/SH448 adult zebrafish and their wild-type 
siblings at 24 months (Figure 5.14 A). To estimate the size of the spleens, we imaged 
dissected spleens by light microscopy and the area of the spleen was subsequently 
calculated. C13H9orf72 LOF spleens were larger than wild-type siblings by 35%, but this 
was not significant, given the small sample size (figure 5.14 B).  
 
 
Figure 5.14 C13H9orf72SH448/SH448 zebrafish show no signs of splenomegaly. Images 
of spleens from 24-month old C13H9orf72SH448/SH448 zebrafish and their wild-type 
siblings. Scale bar = 1.0 mm B) Quantification of spleen surface area (mm2), was carried 
out using ImageJ following dissection of the spleens (n=4 C13H9orf72+/+ and n=3 




5.5. Discussion  
There is evidence that C9orf72 LOF via haploinsufficiency may be a pathogenic 
mechanism in C9-ALS/FTD. In order to fully understand how haploinsufficiency of 
C9orf72 may result in disease, it is essential to unravel the protein functions of C9orf72. 
There is high conservation between human C9orf72 and the zebrafish orthologue, 
C13H9orf72, which indicates there may be functional conservation. This project focuses 
mainly on exploring the role of C13H9orf72 in autophagy, as reports from our laboratory 
and from others have shown that C9orf72 is involved in this process (Sellier et al. 2016, 
Sullivan et al. 2016a, Webster et al. 2016a, Farg et al. 2014, Yang et al. 2016, Ugolino et 
al. 2016). Additionally, due to reports that loss of the mouse orthologue of C9orf72 
(3110043021Rik) results in defects in the immune system in vivo, resulting in symptoms 
such as splenomegaly, we examined whether this was present in the C13H9orf72 LOF 
zebrafish (O'Rourke et al. 2016, Sudria-Lopez et al. 2016, Atanasio et al. 2016, Koppers 
et al. 2015).  
5.5.1. Generation of the pCI-neo-Myc-C13H9orf72 construct 
We successfully generated a pCI-neo-Myc-C13H9orf72 construct, to allow for 
examination of C13H9orf72 function in vitro (section 5.2). To achieve this, the 
C13H9orf72 cDNA reference sequence (ensembl: ENSDART00000015127.6) was 
BLAST searched against the NCBI EST database, identifying a full length cDNA clone 
FDR306-p00004_BR_K14 which was subsequently purchased from GE Healthcare Life 
Sciences. ESTs are short sub-sequences of transcripts, important for evaluating gene 
expression, annotating genes and identifying potential variation (Lindlof 2003). A 
limitation to using the NCBI EST database to identify a full length cDNA clone, is that 
the way that ESTs are produced means that they are often of low quality and have a high 
error rate (Lindlof 2003). For example, ESTs are sequenced only once, and are not 
verified. This means that they can contain a number of unidentified errors, which can 
result in site variations. These errors may come from the original mRNA sequence or 
from the experimental procedure itself (Lindlof 2003). Therefore, it was essential to 
sequence the clone we identified to ensure that any site variation would not affect the 
overall protein sequence, as this may result in aberrant functions and we wanted to 
identify a wild-type C13H9orf72 construct to examine normal function. It was identified 
that the cDNA clone FDR306-p00004_BR_K14 contained a number of variants that 
would potentially affect protein function (table 5.1). These were successfully reverted 
back to the reference sequence using site-directed mutagenesis (figure 5.1 and 5.2).   
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5.5.2. Investigating the role of C13H9orf72 in autophagy in vivo 
Autophagy is a conserved lysosomal degradation pathway which involves the degradation 
of cytoplasmic components, such as misfolded proteins and damaged organelles, within 
an autophagolysosome, for bulk degradation or recycling (Klionsky et al. 2012). The 
process consists of several sequential steps, including: the sequestration of cytoplasmic 
components, transport of these to lysosomes, degradation via lysosomal hydrolases and 
utilization of the degradation products. A characteristic phenotype of C9-ALS/FTD is the 
presence of p62/SQSTM1 positive, TDP-43 negative inclusions found in the cerebellum, 
hippocampus and the neocortex (Cooper-Knock et al. 2012, Al-Sarraj et al. 2011). 
Accumulation of p62/SQSTM1 has been shown to occur when autophagy is blocked, 
therefore suggesting that C9orf72 may function in autophagy (Hara et al. 2006). In this 
project we further investigated the role of C9orf72 in vivo, using the C13H9orf72 LOF 
zebrafish generated. Proteins involved in autophagy in zebrafish are highly conserved 
with their human counterparts, with amino acid identity ranging from 40-96% (Mathai et 
al. 2017). The similarity between autophagy components alongside the advantages of this 
vertebrate model system, as previously discussed, has led to several assays being 
established in order to examine this pathway in zebrafish, some of which have been used 
in this project as described below.  
5.5.2.1. C13H9orf72 interacts with human ATG13 
Autophagy is activated by the ULK-1 complex, which consists of ULK-1, FIP200, 
ATG13 and ATG101. This complex is kept inactive via the phosphorylation of ULK-1 
by mTOR. Inactivation of mTOR, for example in nutrient poor conditions, results in the 
release of the ULK-1 initiation complex. ULK-1 is then able to phosphorylate FIP200 
and ATG13, activating the complex and initiating autophagy (Jung et al. 2009, Ganley et 
al. 2009). Various reports have suggested C9orf72 interacts with the ULK-1 initiation 
complex. Overexpression of C9orf72 has been reported to activate autophagy (Webster 
et al. 2016a). However, when the ULK-1 complex was disrupted, via depletion of the 
component FIP200, overexpression of C9orf72 no longer activated the pathway, 
indicating that C9orf72 functions at the level of the ULK-1 complex (Webster et al. 
2016a). Strengthening this association, it was reported that C9orf72 directly interacts with 
ULK-1, FIP200 and ATG13 via co-immunoprecipitation, proximity ligation assay (PLA) 
and in vitro binding assays (Webster et al. 2016a). This data agrees with a previous report 
that C9orf72 interacts with FIP200 (Behrends et al. 2010). Additionally, it has also been 
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reported that C9orf72, in complex with SMCR8 and WDR41, interacts with the ULK-1 
initiation complex (Sullivan et al. 2016b).  
If C9orf72 is functionally conserved in zebrafish and humans, then we predict that 
zebrafish C9orf72 will interact with the ULK-1 initiation complex. To test this, we chose 
human ATG13. This member of the ULK-1 initiation complex was chosen first, due to 
its strong interaction with human C9orf72 in vitro (Webster et al. 2016a). Additionally, 
human ATG13 shares >70% identity with the zebrafish orthologue (ensembl: 
ENSDARG00000036040). As shown via an in vitro binding assay in section 5.3.1, 
zebrafish C9orf72 interacts with human ATG13. As there is an interaction between these 
two proteins, it supports the idea that there is functional conservation between zebrafish 
and human C9orf72. It would be of interest in the future to investigate whether zebrafish 
C9orf72 interacts with the other members of the ULK-1 initiation complex in vitro, such 
as ULK-1 and FIP200, as it has been shown in humans (Webster et al. 2016a). Human 
ULK1 and FIP200 both share >60% identity with the corresponding zebrafish 
orthologues. Thus, as with ATG13, it is predicted that these proteins should interact due 
to high conservation. In addition to the initiation complex, there are reports that C9orf72 
forms a complex alongside SMCR8 and WDR41 (Sullivan et al. 2016a, Sellier et al. 2016, 
Amick et al. 2016, Yang et al. 2016). Therefore, it would also be interesting to see whether 
zebrafish C9orf72 interacts with these proteins as well.  
Due to time constraints, we were unable to investigate whether there is a direct interaction 
between zebrafish C9orf72 and zebrafish ATG13, which is a limitation to this study. We 
have previously identified a potential full length cDNA clone of zebrafish ATG13 via a 
BLAST search of the zebrafish ATG13 reference sequence against the NCBI expressed 
sequence tag (EST), as we have done previously for C13H9orf72 (section 5.2). By 
obtaining a full length zebrafish ATG13 cDNA clone, we would have the potential to 
look at its interaction with zebrafish C9orf72 using several assays including co-
immunoprecipitation, proximal ligation assay and an in vitro binding assay.  
5.5.2.2. Understanding the role of C13H9orf72 in autophagy in vivo  
As well as interacting with components of the ULK-1 initiation complex, as stated above, 
it has been reported that there is a dysfunction in autophagy induction when C9orf72 
expression is depleted in cell lines, primary neurons and in vivo (Webster et al. 2016a, 
Sellier et al. 2016, Sullivan et al. 2016a). This indicates that the protein may regulate the 
function of the ULK-1 initiation complex. Further analysis from our lab has shown that 
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depletion of C9orf72 in cell lines prevented the translocation of the ULK-1 initiation 
complex to the phagophore, which is essential for the formation of the autophagosome 
(Webster et al. 2016a). As we showed that C13H9orf72 binds hATG13, further 
supporting the idea that there is conservation of protein function between C13H9orf72 
and hC9orf72, we investigated whether C13H9orf72  regulated the initiation of 
autophagy, as has been reported with hC9orf72 previously (Webster et al. 2016a). This 
was initially examined via an autophagic flux assay, using LC3-II levels as a readout. 
Several studies have used zebrafish embryos to monitor LC3-II levels in this way via 
immunoblotting using commercially available anti-LC3 antibodies (He et al. 2009, He 
and Klionsky 2010, Underwood et al. 2010, Renna et al. 2013, Benato et al. 2013). 
However, there is still not a standardised procedure for this experiment in zebrafish. 
Therefore, it was essential to optimise several conditions in wild-type zebrafish before 
performing it in the C13H9orf72 LOF mutants.  
Several conditions were optimised for the autophagic flux assay during the project. 
Firstly, it was established that incubation of embryos in multiple autophagy inducers and 
blockers was optimal at 48 hpf (see section 5.3.2). We initially found that LC3-II protein 
levels were very low when treated at 24 hpf and were difficult to observe via immunoblot 
(Figure 5.5). This agrees with a previous report which stated that although transcripts of 
autophagy genes such as LC3 are present at 0 hpf, others such as ULK1 are not expressed 
until around 23 hpf (He et al. 2009). Thus, they report that LC3-II is only detectable via 
western blot analysis at around 32 hpf onwards (He et al. 2009). However, in contrast to 
this report we show evidence of LC3-II at around 30 hpf (Figure 5.5), as these 24 hpf 
embryos were treated for 6 hours although it is clear that expression of LC3-II was higher 
at the later time points (Figure 5.7). Other groups have also reported treating embryos at 
48 hpf when performing autophagic flux assays, which suggests this is a suitable 
minimum age to study autophagic flux in zebrafish (He et al. 2009, Benato et al. 2013, 
Underwood et al. 2010, Renna et al. 2013). Secondly, we optimised treatments over a 24-
hour incubation time. It was identified that rapamycin and NH4Cl were most effective in 
inducing or blocking autophagy, respectively. These treatments have also been used by 
other groups (He et al. 2009, Underwood et al. 2010). As shown in Figure 5.8, we 
incubated 48 hpf zebrafish embryos in a variety of autophagy inducing drugs. If there is 
a link between defective autophagy and the causation of C9-ALS/FTD, this class of drug 
could be a potential therapy to investigate in the future using zebrafish. It has been 
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previously reported that daily intake of 2% (w/v) trehalose significantly reduced levels of 
mutant SOD1 and p62, as well as increased LC3-II levels in the spinal cords of SOD1-
G93A mice in early-stage ALS (Li et al. 2015). Additionally, trehalose treatment 
postponed disease onset and preserved motor function at this stage (Li et al. 2015). 
Although trehalose did not efficiently induce autophagy in zebrafish (Figure 5.8) many 
of the different rapalogs tested did. For example, Temsirolimus treatment showed a 
marked increase in LC3-II levels in combination with NH4Cl, in comparison to NH4Cl 
treatment alone (figure 5.8). As this drug is water soluble, its therapeutic potential in C9-
ALS/FTD could easily be tested in larval and/or adult zebrafish. Additionally, use of 
rapalogs such as Temsirolimus could also be translatable to C9-ALS/FTD patients as it is 
FDA-approved.  Finally, transfer of LC3-II protein onto PVDF membrane was optimal 
over nitrocellulose (see figure 5.6). Although it has been reported that nitrocellulose has 
a higher affinity for LC3-I, we were unable to visualise LC3-I when transferred onto 
either membrane (Mathai et al. 2017). However, it has been suggested that using PVDF 
may result in higher retention of LC3-II, because it has a higher affinity for hydrophobic 
proteins (Klionsky et al. 2012). 
It was consistently reported during this project that LC3-I, the cytosolic form of LC3, was 
not observed via immunoblot. This phenomenon is something that has been reported by 
another group (Benato et al. 2013). LC3-I may be less sensitive to detection by some anti-
LC3 antibodies in comparison to LC3-II (Klionsky et al. 2012). We did test a different 
anti-LC3 antibody, which had been published to show immunoreactivity for both LC3-I 
and LC3-II in zebrafish (He et al. 2009). However, no LC3 was observed for any sample 
when this was used (data not shown).  Despite this, we are confident that the band we are 
observing is LC3-II, as the protein responds in the way that we would expect to the 
autophagy inducing and blocking treatments, as shown in section 5.3.2. The fact that LC3-
II responds in the expected way to multiple mTOR inhibitors, further supports 
conservation of mTOR-dependent autophagy induction in zebrafish, which has been 
previously reported (Makky, Tekiela and Mayer 2007).  
The optimised autophagic flux assay was performed on C13H9orf72 LOF zebrafish and 
wild-type controls from lines SH448 and SH451, which carry frameshift mutations in 
exon 7, as these were generated first and embryos were available. If zebrafish C9orf72 
encodes both protein isoforms as predicted, this means that we can only observe the effect 
of loss of C9orf72-L on autophagy function in these lines. These lines were used to 
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investigate the effect of loss of C13H9orf72 expression on autophagy, and primarily to 
observe whether the dysfunction in autophagy induction previously reported (Webster et 
al. 2016a, Sellier et al. 2016, Sullivan et al. 2016a) recapitulated in our model. We 
performed the autophagic flux assay in two lines to establish that any effect seen was not 
line specific. We did not observe that loss of C13H9orf72 expression resulted in a defect 
in autophagy. This is surprising, as it is clear from results in this project that C13H9orf72 
does interact with members of the ULK-1 initiation complex, suggesting conservation of 
protein function between C13H9orf72 and hC9orf72. Interestingly, there are an 
increasing number of studies reporting an increase, not a decrease, in LC3-II levels in 
response to reduced C9orf72 expression (Farg et al. 2014, O'Rourke et al. 2016). This 
increase in basal LC3-II levels could be a result of increased autophagic flux or defective 
clearance of autophagosomes via the lysosome. Therefore, we investigated basal LC3-II 
levels in our zebrafish, but no statistically significant difference was observed between 
genotypes in two mutant lines. However, a major limitation to this analysis was that in 
most of the immunoblots analysed, LC3-II was below the level of detection in DMSO 
treated wild-types embryos, which therefore limited the analysis of control samples 
(Figure 5.10).  
Overall, disparity in results between our C13H9orf72 LOF zebrafish and functional 
analysis completed in cell culture could be because C13H9orf72 is not ubiquitously 
expressed in zebrafish, with expression of C13H9orf72 mRNA reported in a subset of 
tissues, including regions of the CNS, such as the forebrain, midbrain, hindbrain and 
spinal cord (Ciura et al. 2013). Therefore, the effect of loss of C13H9orf72 expression on 
autophagy may be harder to observe via immunoblotting, as we are using the whole fish 
embryo in comparison to a homogenous population of cells, as used previously (Webster 
et al. 2016a). In the future, we could extend our in vivo study of autophagy into live 
embryos via injecting mCherry-LC3-EGFP into wild-type and C13H9orf72 mutant 
zebrafish embryos to avoid the limitations experienced via immunoblot (Pankiv et al. 
2007). The fusion of acid-sensitive GFP and acid-insensitive mCherry to LC3 results in 
a pH-sensitive sensor to measure autophagy in live cells. This will allow us to probe 
delivery of autophagy substrates to the lysosome, as we will be able to distinguish 
autophagosomes (red and green fluorescence) from the acidic autolysosomes (red 
fluorescence only) in individual cells (Pankiv et al. 2007). Utilising this technique would 
allow us to detect cell-specific defects, which is not possible using the western blot-based 
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approach taken in this project. Additionally, there could be a compensatory mechanism 
in vivo which activates autophagy in an mTOR-independent manner, protecting the 
zebrafish from a defect in the autophagy pathway caused by loss of C13H9orf72 
expression. As well as this, the difference in conservation between zebrafish C13H9orf72 
and human C9orf72 may explain why we do not see a defect in autophagy. However, we 
reported C13H9orf72 binds hATG13, supporting the idea that there is conservation of 
protein function between C13H9orf72 and hC9orf72, which does not support this theory.   
5.5.2.3. Examining p62/SQSTM1 protein levels in zebrafish  
C9-ALS/FTD patients harbour pathognomonic p62/SQSTM1 positive, TDP-43 negative 
inclusions in several brain regions (Cooper-Knock et al. 2012, Al-Sarraj et al. 2011). 
p62/SQSTM1 targets ubiquitinated proteins to the autophagy pathway for degradation 
within the  autophagolysosome (Pankiv et al. 2007). The p62/SQSTM1 protein remains 
bound to its cargo and is eventually degraded within the autophagolysosome. Thus, an 
impairment either upstream at the initiation complex, or downstream at the lysosome, 
would prevent its degradation resulting in accumulation of p62/SQSTM1. In support of 
this theory, it has been shown that blocking autophagy, for example in FIP200-/- MEFs, 
lead to p62 accumulation (Hara et al. 2008). Additionally, there is published evidence 
from our laboratory and others that depletion of C9orf72 expression in cell lines and/or 
primary neurons, results in accumulation of p62/SQSTM1 (Webster et al. 2016a, Sellier 
et al. 2016).  
We reasoned that if C13H9orf72 was involved in the regulation of autophagy in zebrafish, 
loss of C13H9orf72 expression would also result in defective autophagy and 
accumulation of p62/SQSTM1, as has been shown in mammalian cells (Webster et al. 
2016a, Sellier et al. 2016). In order to see whether we could detect endogenous 
p62/SQSTM1 protein levels by western blot, a commercially available antibody was used 
(see table 2.9), which was previously reported to show a specific band at 50kDa for the 
endogenous wild-type p62/SQSTM1 protein in zebrafish embryo lysates (Mostowy et al. 
2013). However, we found that although a band was observed at 50 kDa, there were many 
non-specific bands that were not present in the previous publication. Therefore, we cannot 
be certain that the band at 50 kDa is specific for endogenous p62/SQSTM1. 
In the future, alternative antibodies need to be tested. Several publications have shown 
alternative antibodies that are immunoreactive for p62/SQSTM1, but due to time 
constraints we were unable to test these during this project (Zhang et al. 2017, Zhu et al. 
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2017, Buhler et al. 2016). Additionally, as the p62/SQSTM1 antibody used was 
polyclonal, it may be better to use a monoclonal antibody specific for this protein to 
decrease background and cross-reactivity in the future, which may have confounded 
results in this study. As well as testing alternative anti-p62/SQSTM1 antibodies to detect 
protein levels on immunoblot, it would be interesting to use these to examine 
p62/SQSTM1 positive, TDP-43 negative pathology in the brains of zebrafish. This would 
be useful as it may be that accumulation of p62/SQSTM1 protein is not detectable on 
immunoblot, as levels overall do not increase, but rather mislocalise. However, it may be 
that we do not see such pathology, as we do not report a defect in autophagy in the 
C13H9orf72 LOF zebrafish and none of the C9orf72 LOF mice have reported evidence 
of these characteristic inclusions.  
5.5.3. Investigating whether C13H9orf72 loss-of-function results in 
splenomegaly   
It has been reported that when the mouse orthologue of C9orf72 (3110043021Rik) is 
either completely or partially lost, there is no evidence of neurodegeneration in the mice, 
but there is evidence of defects in the immune system (O'Rourke et al. 2016, Sudria-
Lopez et al. 2016, Koppers et al. 2015, Atanasio et al. 2016, Burberry et al. 2016). In 
particular, a major phenotype reported in these mice is splenomegaly, which may be 
caused by neoplastic events or immune dysregulation (O'Rourke et al. 2016, Atanasio et 
al. 2016, Sudria-Lopez et al. 2016, Burberry et al. 2016). Several groups have reported 
large infiltrations of immune cells, such as macrophages, in multiple organs including the 
spleen (O'Rourke et al. 2016, Atanasio et al. 2016, Sudria-Lopez et al. 2016). This 
suggests defects in the immune system cause this phenotype. Interestingly, autophagy 
plays a role in both innate and adaptive immunity (Deretic, Saitoh and Akira 2013). 
Several studies have now revealed the importance of C9orf72 function in autophagy, thus 
suggesting the immune phenotypes observed in these mice may be a result of 
compromised autophagy due to loss of C9orf72 expression. Supporting this, ULK-1 
knockout mice also exhibit splenomegaly as seen in the C9orf72 KO mice (Honda et al. 
2014).  
We decided to investigate whether the C13H9orf72 LOF zebrafish harboured defects in 
the immune system, in particular splenomegaly. As discussed in section 5.4, there was a 
trend that C13H9orf72 LOF zebrafish spleens were larger compared to wild-types, but 
this was not significant. A limiting factor to this analysis is that we could only analyse 
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four wild type and three mutant spleens. In the future, we would need to analyse more 
spleens to see if there is a true difference in size. Retrospective power calculation were 
performed using G*Power Version 3.0.10, based on the spleen areas obtained from 
SH448 mutants and wild-type siblings analysed during this project. This indicated a 
sample of 11 spleens per group would provide 80% power to detect a 20% increase in 
spleen size (student’s t-test, two-tailed, α = 0.05, β = 0.8). Another issue with this 
quantification is that size was measured from a 2-D image. Although measuring area in 
this way is often used for organelles such as mitochondria, which are also 3-D, it would 
be beneficial to measure the 3-D area of the spleens in the future, so that sizes can be 
more accurately compared. Additionally, due to the small size of the spleens in general, 
it was impossible to weigh them accurately as has been done in the mouse papers 
(O'Rourke et al. 2016, Burberry et al. 2016). Despite the limitations discussed, in contrast 
to the mouse models, there was no significant difference in spleen size in the C13H9orf72 
LOF zebrafish. In some cases, homozygote spleens were reported to be two-times bigger 
than the wild-type controls (O'Rourke et al. 2016, Atanasio et al. 2016). As well as this, 
others have reported an increase in spleen size from as early as one month (O'Rourke et 
al. 2016). The fact that even at the late time points examined in the present study revealed 
no significant difference in size or tissue structure, may indicate splenomegaly is not 
present.  
Additionally, although the immune system in zebrafish and other teleosts is 
physiologically similar to higher vertebrates like mice, there are some differences. For 
example, teleosts do not have lymph nodes and C9orf72 LOF mice reportedly exhibit 
lymphadenopathy, enlarged lymph nodes, as well as splenomegaly (Uribe et al. 2011, 
O'Rourke et al. 2016, Atanasio et al. 2016, Sudria-Lopez et al. 2016). It  has also been 
reported in the C9orf72 LOF mouse model that Trem2 expression is significantly 
upregulated in spleen tissue, but zebrafish do not harbour an orthologue for this gene 
(O'Rourke et al. 2016). Thus, despite the similarities, these differences may be why we 
do not see symptoms such as splenomegaly in the C13H9orf72 LOF zebrafish. Further 
work will need to be done to understand whether these zebrafish have a defective immune 
response. For example, we could section the spleen tissue and perform Haemotoxylin and 
Eosin (H&E) staining. This has been done for the C9orf72 LOF mice and has shown 
disrupted tissue structure (Atanasio et al. 2016, O'Rourke et al. 2016). Additionally, we 
could look at the levels of macrophages in the zebrafish spleen, as two groups found 
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evidence of an increase in macrophage number in the spleens of C9orf72 LOF  mice 
(Atanasio et al. 2016, O'Rourke et al. 2016). Also, we could examine the expression levels 
of inflammatory cytokines found in zebrafish, such as IL-1β, IL-6 and IL-10, which have 
been reported to be upregulated in C9orf72 LOF mouse models splenic tissue (O'Rourke 
et al. 2016).  
5.5.4. Conclusion  
We have shown that C13H9orf72 interacts with hATG13, as has been demonstrated 
previously with the human orthologue. In spite of this, using western blot analysis no 
defect in autophagy induction was observed in the C13H9orf72 LOF zebrafish. In 
addition, no significant difference in the basal levels of autophagy substrates such as LC3-
II were observed between C13H9orf72 LOF zebrafish and wild-type controls. There is 
also no clear evidence of splenomegaly in these zebrafish, contradictory to recent reports 
in C9orf72 LOF rodent models. Overall, we have generated an important tool to be able 
to further study the function of C9orf72 in vivo, which is essential to both further 
















6. Discussion and future work  
This project aimed to test the hypothesis that loss-of-function (LOF) mutations in C9orf72 
contribute to ALS/FTD by disruption of the autophagy pathway. In order to achieve this, 
we generated stable zebrafish C13H9orf72 LOF models using targeted genome editing 
techniques (chapter 3) and subsequently characterised them in adulthood to determine 
whether loss of C13H9orf72 resulted in any ALS/FTD-like phenotypes, such as changes 
in survival, motor function or behaviour (chapter 4). Additionally, we investigated the 
function of the C13H9orf72 protein in vivo, with a focus on autophagy (chapter 5).  
6.1. Animal Models of ALS 
6.1.1. Mouse  
Developing in vivo models of ALS is essential in order to further elucidate the 
pathomechanisms underlying this disorder and aid in evaluating the potential efficacy of 
novel therapies. Mutations in SOD1 were discovered to cause ALS twenty years ago 
(Rosen et al. 1993) and this subsequently led to the development of the first transgenic 
animal model of ALS, the SOD1-G93A mouse (Gurney et al. 1994). In particular, mutant 
SOD1 transgenic mouse models have been successful in recapitulating characteristic 
phenotypes of ALS and thus have been used extensively to study the disorder. 
Unfortunately, translation of findings from these models into the clinic has largely been 
unsuccessful, with repeated failure of phase 2 and 3 clinical trials based on such studies 
(Turner et al. 2013). Possible explanations for this failure may be that some mouse lines 
express high levels of mutant protein, which are not reflective of the human disease state, 
and that mice are highly inbred, which may in turn affect the disease phenotype. Another 
major limitation is poor study design, including determining dosing, timing of treatments, 
number of patients included and the overall selection of patients. For example, the success 
rate of these clinical trials may significantly increase if they were restricted to patients 
with SOD1 mutations only. However, this in itself is challenging, as only 2% of ALS 
patients harbour mutations in SOD1. In addition, the genetic and clinical heterogeneity 
of ALS may be a key factor.  For example, it has been reported TDP-43 positive 
inclusions are characteristic of around 80-90% of ALS cases (Neumann et al. 2006) but 
these are not found in SOD1- and FUS-linked ALS, indicating the possibility of distinct 
pathomechanisms. This shared pathology between the majority of ALS patients resulted 
in a surge of TDP-43 transgenic rodent models in recent years, as creating a model which 
had TDP-43 pathology had a high translational potential in comparison to previous SOD1 
models. Despite variation in the design of these models, they share common phenotypes 
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including ubiquitin accumulation, TDP-43 fragmentation, astrogliosis, neuronal loss, 
defects in motor function and shortened lifespans (Gendron and Petrucelli 2011, Philips 
and Rothstein 2015).  However, none of the TDP-43 models so far develop full blown 
ALS-disease symptoms as seen in humans. In addition to TDP-43, several mouse models 
have been developed to understand how a noncoding (G4C2)n hexanucleotide repeat 
expansion in C9orf72 results in ALS. As the most prevalent ALS-causing gene identified 
to date, such models also have a high translational potential. To date, it has been reported 
that C9orf72 LOF mouse models do not show signs of neurodegeneration, but show 
evidence of immune dysregulation (table 6.1). Additionally, C9orf72 gain-of-function 
(GOF) mouse models have reported contradictory results, with some models showing no 
signs of neurodegeneration (O'Rourke et al. 2015, Peters et al. 2015a) and others which 
do (Chew et al. 2015). As well as SOD1, TARDBP and C9orf72, multiple other genes 
have also been identified in rare fALS cases, but mouse models have only been generated 
for some of these, including FUS (Hicks et al. 2000, Mitchell et al. 2013, Sephton et al. 
2014), Ubiquillin-2 (Gorrie et al. 2014, Ceballos-Diaz et al. 2015) and Optineurin 
(Gleason et al. 2011). Generating multiple genetic models is important, as amalgamation 
of data from several genetically heterogeneous models could produce more powerful 
results than those obtained from a single model alone. Overall, despite their positives 
attributes, many of the mouse models that exist so far have a number of pitfalls, including 
only modelling certain aspects of disease, developing non-ALS/FTD phenotypes and/or 
lack of translation from lab to clinic. For now, the SOD1 mutant mice are still the only 
models that develop a phenotype reminiscent of human ALS. 
6.1.2. Zebrafish  
Although rodents remain to be the gold standard for ALS model organisms, they are 
expensive to maintain and it is time consuming to generate the multiple genetic models 
that are necessary to study this heterogeneous disease.  However, this could be achieved 
effectively in zebrafish, as they hold several characteristics which make it an 
advantageous model to use in the study of neurodegenerative disorders such as ALS, due 
to their reduced cost and ability to produce hundreds of eggs at weekly intervals. In 
addition, all of the ALS-causing genes are conserved in the zebrafish genome and these 
genes can be easily manipulated by LOF or GOF approaches in simple, transient assays 
of gene function and by creation of stable disease models using targeted genome editing 
techniques. Regarding stable genetic models, several previous reports have exhibited the 
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effectiveness of using zebrafish models of ALS to investigate the pathogenesis underlying 
the disorder. Transgenic zebrafish overexpressing mutant sod1 have been reported to 
display several hallmarks of ALS pathology, including: loss of motor neurons, muscle 
atrophy, defective motor performance, loss of neuromuscular connectivity and premature 
death (Ramesh et al. 2010, Sakowski et al. 2012, McGown et al. 2013). Two other studies 
have demonstrated that stable loss of tardbp is fully compensated by alternative splicing 
of a second tardbp orthologue, tardbpl, contradictory to previous knockdown studies of 
this gene in zebrafish (Hewamadduma et al. 2013, Schmid et al. 2013).  Additionally, 
they report that double-homozygous null mutants of tardbp and tardbpl resulted in muscle 
degeneration, impaired spinal motor neuron outgrowth and decreased survival 
(Hewamadduma et al. 2013, Schmid et al. 2013).   
As well as their ability to recapitulate phenotypes reminiscent of ALS in humans, due to 
their small size, the zebrafish is recognised as a powerful model organism amenable to 
high-throughput drug screening in vivo at embryonic and larval stages. The potential of 
zebrafish as a model system for drug screening for neurodegeneration has been reported, 
using a SOD1 transgenic zebrafish line (McGown et al. 2013). A neuronal-stress reporter 
line has previously been utilised to validate the effectiveness of riluzole (McGown et al. 
2013). Additionally, this line has been used to develop a high-throughput screening assay, 
ZNStress, screening over 2000 compounds to identify modulators of neuronal stress 
(McGown, Shaw and Ramesh 2016). Interestingly, many of the compounds that emerged 
from murine preclinical studies and failed to show efficacy in human ALS clinical trials 
also showed no efficacy in the ZNStress assay (McGown et al. 2016). In general, it is 
important to acknowledge that despite similarities, no model organism can reproduce and 
accurately model all aspects of human neurodegenerative diseases, including zebrafish. 
However, the aforementioned studies indicate that zebrafish models of ALS can be used 
to complement existing rodent models, particularly by revealing novel therapies targets 
ready for validation in more complex, but low-throughput, mouse models.  
6.2. Zebrafish models of C9-ALS/FTD 
A noncoding (G4C2)n hexanucleotide repeat expansion in C9orf72 is the most common 
cause of ALS/FTD, however it is not fully understood how this causes disease. Three 
pathomechanisms have gained particular attention, including; haploinsufficiency, RNA 
toxicity and repeat-associated, non-ATG (RAN) translation. It is likely that these 
pathomechanisms are not mutually exclusive and act in combination. A zebrafish model 
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recapitulating C9-ALS/FTD would aid in elucidating the unknown function of this novel 
gene and evidence gathered from such models have the potential to influence future 
treatments for the largest proportion of ALS patients. Both LOF and GOF models of C9-
ALS/FTD have previously been generated in zebrafish. Regarding LOF mechanisms, a 
group generated a genetic model of C9orf72 haploinsufficiency via transient knockdown 
(KD) of C13H9orf72 transcripts in zebrafish using antisense morpholino oligonucleotides 
(AMOs), which resulted in disrupted aborisation and shortening of the motor neuron 
axons, as well as an impaired touch-evoked escape response (Ciura et al. 2013). 
Regarding GOF mechanisms, RNA injections of 8x, 38x and 72x G4C2 repeats has 
previously been reported to result in RNA foci and cell death by apoptosis in zebrafish at 
24 hpf, in a repeat length-dependent manner, although no C9-ALS/FTD-like motor or 
behavioural phenotypes were reported (Lee et al. 2013). Additionally, another group 
reported generation of two transgenic lines expressing (G4C2)80 repeats and two lines with 
the translation initiation codon ATG in front of the (G4C2)80 repeat sequence, driving 
expression of poly-GA (Ohki et al. 2017). The transgenic zebrafish with (G4C2)80 repeats 
were reported to have key pathological features of ALS/FTD, such as RNA foci, but no 
RAN translation was detectable and they only showed minor toxicity (mild pericardial 
oedema) (Ohki et al. 2017).  However, toxicity was greatly increased following 
expression of poly-GA, resulting in severe pericardial oedema, circulatory defects and 
decreased survival (Ohki et al. 2017). 
The focus of this thesis was to study whether LOF mutations in C9orf72 contribute to 
ALS/FTD. In order to investigate this, methods leading to both transient and stable loss 
of C9orf72 can be utilised. A transient KD of both isoforms of C13H9orf72 using AMOs 
in zebrafish embryos has already been published (Ciura et al. 2013). However, we 
successfully generated stable C13H9orf72 LOF zebrafish using two different targeted 
genome editing techniques; TALENs to target exon 7 and CRISPR/Cas9 to target exon 
1. Generation of these stable models was essential for several reasons. Firstly, there is 
currently no publication characterising a stable C13H9orf72 LOF zebrafish, thus the 
generation and subsequent characterisation of our zebrafish is novel and essential for the 
C9-ALS/FTD field. Secondly, AMOs are only transient and as ALS is mainly an adult 
onset disorder, the generation of a stable model allowed us to study the long term 
phenotypic effects of loss of C13H9orf72 expression. Finally, off-target effects can 
confound AMO-mediated knockdown studies. For example, KD of Tardbp orthologue in 
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zebrafish using AMOs was reported to cause shorter, disorganised motor neuron axons 
(Kabashi et al. 2010b). However, two independent studies demonstrated that stable loss 
of Tardbp was fully compensated by alternative splicing of a second Tardbp orthologue 
in the zebrafish, Tardbpl, thus the Tardbp KD-induced phenotype was not observed in 
these stable Tardbp mutants, suggesting the AMO produced off-target effects (Schmid et 
al. 2013, Hewamadduma et al. 2013). As the same group published the KD of 
C13H9orf72 in zebrafish using AMOs, it was essential to generate a stable C13H9orf72 
LOF zebrafish to determine whether these phenotypes were real. It is important not to 
disregard these off-target issues, as it may result in others unintentionally classifying 
these side effects as genuine phenotypes, which will not aid advancement of the field. In 
the future, methods such as CRISPRi, which involve co-expressing a catalytically 
inactive Cas9 protein (dCas9) along with a customizable gRNA, may be used as an 
alternative to AMOs (Larson et al. 2013). This method has demonstrated specific 
silencing of genes by blocking transcription (via interfering with transcriptional 
elongation, RNA polymerase binding or transcription factor binding), without off-target 
effects (Larson et al. 2013). In addition, multiple gRNAs can be used, silencing multiple 
genes simultaneously (Larson et al. 2013). This technique is reversible, has high 
specificity and has been used successfully in model organisms such as the zebrafish (Long 
et al. 2015).  
As well as the limitations surrounding the use of AMOs, it is important to consider 
limitations, for example the potential for off-target effects, associated with the targeted 
genome editing techniques used in this study. In comparison to CRISPR/Cas9, off-target 
effects using TALENs are rare, as the DNA binding site is very long (approx. 36 base 
pairs) therefore rarely, if ever, is this found elsewhere in the genome (Mussolino et al. 
2011, Miller et al. 2011). Additionally, several publications, using genome-wide studies 
for example, have reported that TALEN-mediated genome modifications are rarely 
accompanied by off-target effects (Pattanayak, Guilinger and Liu 2014). Thus, we could 
assume that our TALEN lines are unlikely to be confounded by such effects. Conversely, 
the CRISPR/Cas9 technique has the potential to deliver unwanted, off-target effects due 
to the ability of the gRNA to tolerate up to five mismatches (non-Watson-Crick base 
pairing) (Fu et al. 2013). A simple way of detecting off-target effects is amplification of 
pre-selected potential off-target sites, followed by sequencing of PCR products using 
sanger or next generation sequencing methods (Hruscha et al. 2013). This was performed 
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in the original paper which published the CRISPR/Cas9 target site that we used in the 
current study, reporting mutation rates at potential off-target sites are only 1.1-2.5% 
(Hruscha et al. 2013). As we used the same target site and same wild-type strain (AB) as 
the original paper, it is likely we would have similar low rates of off-target effects in those 
regions. However, a drawback of this method of screening pre-selected sites is the biased 
nature of the technique and the risk of overlooking mutations at alternative loci. Recently, 
several methods have been developed to help reduce the off-target activity of 
CRISPR/Cas9 system in the future. For example, in one approach two closely-spaced 
gRNAs are combined with a Cas9 nickase mutant, introducing staggered DSBs by 
nicking the DNA in two positions, inspired by the dimeric nature of TALENs which are 
not plagued by off-target effects (Ran et al. 2013). Reduction of off-target effects is not 
only important with regards to making models of human disease. As the topic of utilising 
CRISPR/Cas9 to treat and even cure certain human diseases is at the forefront of the 
media, it is essential that we develop methods to reduce the potential for off-target effects 
before using them in patients. One consideration is that no two people’s genomes are 
identical, thus identifying off-target sites from a ‘reference’ human genome would not be 
suitable. Therefore, reducing or even abolishing the off-target capability the gRNA or 
nuclease seems the most logical approach to focus on in the future.  
6.3. Characterisation of the C13H9orf72 loss-of-function zebrafish generated in 
this project  
We reported that a total of four TALEN-generated lines (SH448, SH449, SH450 and 
SH451) and two CRISPR/Cas9-generated lines (SH470 and SH471) had a significant 
reduction in C13H9orf72 transcript levels, indicating that the predicted truncated 
transcripts are degraded by nonsense mediated decay before they are able to be translated 
into protein. We were not able to further confirm this by examining endogenous 
C13H9orf72 protein levels due to the lack of reliable antibodies available. Further 
investment in developing reliable anti-C9orf72 antibodies is necessary for investigating 
C9orf72 haploinsufficiency and the function of the corresponding protein.  Currently, 
several commercially available antibodies are able to robustly detect overexpression of 
C9orf72, but are not sufficient to detect endogenous protein or distinguish between the 
two protein isoforms. As discussed, there has been development of antibodies which are 
able to detect C9orf72-S and C9orf72-L, individually (Xiao et al. 2015). However, it is 
uncertain whether these will work in zebrafish models, thus future work would have to 
involve testing these in the future. It is essential to produce anti-C9orf72 antibodies which 
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can detect endogenous levels of the two protein isoforms in a variety of species. This will 
allow us to be certain that C9orf72 is definitely reduced or abolished in previous models 
of haploinsufficiency and help to advance the field in understanding C9orf72 function. 
Characterisation studies were performed on two TALEN-generated lines (SH448 and 
SH451), as well as one CRISPR/Cas9-generated line (SH470). We were able to 
characterise the lines SH448 and SH451 up to 24 months, but due to time constraints we 
were only able to characterise line SH470 up to 12 months. Initially, we expected to see 
changes in phenotypes such as survival, motor function and pathology, as has been shown 
in other models of ALS in zebrafish (Ramesh et al. 2010). Additionally, due to the link 
between ALS and FTD in patients harbouring the repeat expansion in C9orf72, we 
observed for behavioural changes. Unfortunately, due to time constraints we were unable 
to study pathology in these zebrafish. In the future, it would be beneficial to conduct a 
thorough pathological investigation on these lines, including staining brain and spinal 
cord tissue for p62/SQSTM1, ubiquitin and phospho TDP-43, which are hallmarks of C9-
ALS. However, as no pathological hallmarks of ALS were reported in C9orf72 LOF 
mouse models, it is possible that we will not see any in the C13H9orf72 LOF zebrafish 
either (Atanasio et al. 2016, Sudria-Lopez et al. 2016, Burberry et al. 2016, O'Rourke et 
al. 2016, Koppers et al. 2015). 
6.3.1. Survival  
We reported that loss of C13H9orf72 expression did not impact survival at any age in the 
zebrafish. These findings do not recapitulate the phenotype observe in human C9-ALS 
patients, whose mean disease duration has been reported to be 30.5 months (Cooper-
Knock et al. 2012). These findings do agree with the C13H9orf72 KD zebrafish which 
showed no difference in early viability (Ciura et al. 2013). Additionally, they agree with 
two C9orf72 LOF mouse models, which did not show a decrease in survival (O'Rourke 
et al. 2016, Koppers et al. 2015). However, some studies have reported that C9orf72 LOF 
mouse models have a reduced survival (Atanasio et al. 2016, Sudria-Lopez et al. 2016, 
Burberry et al. 2016). It is important to note that the reduction in survival observed in 
these mouse models may be linked to an immune defect and not neurodegeneration. The 
discrepancy reported in survival between these mouse models may suggest that 
environmental factors or differences in the genetic strain may influence survival in mice 
lacking C9orf72 expression. 
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6.3.2. Motor function  
We demonstrated that the swim tunnel is a robust test to measure swimming ability in 
comparison to the spinning task. We suggest that the spinning task is not suitable for long-
term phenotypic studies monitoring motor function, due to its high variability in 
comparison to the swim tunnel. Additionally, we highlighted the importance of 
controlling for both gender and size in experimental groups using the swim tunnel, which 
has important implications for future experimental design. Overall, our results showed 
that the C13H9orf72 LOF adult zebrafish had a mild motor defect, but no corresponding 
defect in NMJs. These findings agree with one study which reports the C9orf72 LOF 
mouse has mild motor impairments, but no corresponding neurodegeneration (Atanasio 
et al. 2016). The authors suggest that motor defects could be secondary to the already 
established lymphoid organ hyperplasia and glomerulonephropathy in these mice 
(Atanasio et al. 2016). However, we are yet to determine whether immune defects were 
the cause of the mild motor defect seen in the zebrafish (discussed below). However, 
these findings do not recapitulate what is observed in human C9-ALS/FTD patients, who 
experience neurodegeneration and severe motor defects as a result. Therefore, our data 
suggests LOF is not sufficient to cause C9-ALS. Additionally, this model does not 
support the C.elegan ALFA-1 deletion model, which showed age-dependent progressive 
motor defects with an increased sensitivity to stress induced paralysis (Therrien et al. 
2013). As well as this, our model does not support the C13H9orf72 KD zebrafish which 
showed locomotor deficits at the embryonic stage (Ciura et al. 2013), suggesting that this 
phenotype may be a result of off-target mediated effects. In the future we could 
microinject the same AMOs used in the KD study into both wild-type and stable 
C13H9orf72 KO mutants. We would expect to see the same effect in wild-types as 
reported in the paper, but not in the stable KO zebrafish. However, if we did see the same 
effects in our mutants, it would suggest the AMOs used in the aforementioned study had 
off-target effects.  
Overall, a major limitation of this study was that it was underpowered. Power analysis 
was originally performed using G*Power Version 3.0.3, based on Ucrit values obtained 
from a transgenic SOD-1 zebrafish model of ALS (Ramesh et al. 2010), indicating a 
sample of 11 zebrafish per group would provide 80% power to detect a 20% reduction in 
Ucrit (student’s t-test, two-tailed, α = 0.05, β = 0.8). This was then applied to the other 
characterisation tests. However, due to variability and the mild phenotype observed in the 
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C13H9orf72 LOF zebrafish, this meant that the study was underpowered. As discussed, 
retrospective power calculations using G*Power Version 3.0.10, based on Ucrit values 
obtained in this study, revealed a sample of 25 zebrafish per group would provide 80% 
power to detect a 20% decrease in Ucrit (student’s t-test, two-tailed, α = 0.05, β = 0.8). A 
cohort of this size has been raised, for which we are currently measuring Ucrit in the swim 
tunnel test. 
6.3.3. Behaviour  
Finally, we characterised behaviour in the aforementioned lines. As FTD and ALS/FTD 
patients have been reported to display symptoms such as anxiety, we examined anxiety-
like behaviour in adult zebrafish using two different tests: the novel tank diving test and 
the open field test (Mahoney et al. 2012). We did not report any difference in anxiety-like 
behaviour between C13H9orf72 LOF mutants and their wild-type siblings. However, we 
cannot conclude from this that these fish do not have any FTD-like symptoms. There is 
robust evidence that these tests measure anxiety. For example, it has been reported that 
use of anxiolytic treatments significantly decrease the amount of time spent in the lower 
half of the tank during the novel tank diving test (Cachat et al. 2010, Parker et al. 2014, 
Bencan et al. 2009, Levin et al. 2007), which supports this protocols ability to measure 
anxiety. Additionally, the use of anxiolytic treatments such as diazepam and ethanol 
decreases thigmotaxic behaviour in the open field test, again supporting this tests ability 
to measure anxiety (Baiamonte et al. 2016). However, there is a lack of adult zebrafish 
models with stable mutations in dementia genes that report on behavioural phenotypes, 
such as anxiety. Therefore, it is possible this kind of phenotype doesn’t manifest in such 
models without the use of anxiogenic drugs, for example. 
In the future additional behavioural tests could be conducted. Patients carrying the repeat 
expansion in C9orf72 often present with psychosis, as well as other aberrant social 
behaviours such as disinhibition and apathy (Mahoney et al. 2012, Cooper-Knock et al. 
2014a). It is possible to study social interactions in adult zebrafish because they are a 
social species that have a tendency to form shoals, a type of group-forming behaviour 
which can be easily assessed in adult zebrafish (Miller and Gerlai 2007). It would also be 
interesting to examine their social approach behaviour in the future, to examine whether 
a focal zebrafish prefers to associate with conspecifics or be on its own (McRobert and 
Bradner 1998). This would be relatable to patients as a measure of disinhibition. As well 
as social interactions, memory and cognition can also be observed in adult zebrafish for 
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example by using a T-Maze, which is similar to a test used on rodents (Darland and 
Dowling 2001, Norton and Bally-Cuif 2010). This is relevant to patients because they are 
reported to have memory loss (Mahoney et al. 2012). It is essential that behaviour is 
monitored in animal models of C9orf72-related disease, due to the close link between 
ALS and FTD in patients carrying the repeat expansion in C9orf72. Studies of the 
C9orf72 LOF mouse model do not report any attempt to observe behaviour and cognition 
in the mice, thus studies to evaluate this should be considered in the future. However, in 
order to do this effectively, behavioural tests need to be standardised to allow for 
consistency and cross-laboratory comparability. Lack of standardisation is a particular 
issue surrounding zebrafish behavioural tests. In the future, further scrutiny is needed to 
understand the effect that previous testing experience (test battery effect) and gender have 
on the outcome of behavioural tests, for example.   
6.4. The function of C13H9orf72 in vivo  
6.4.1. Role in autophagy  
Thus far, C13H9orf72 LOF zebrafish and C9orf72 LOF mouse models have not been 
reported to display ALS/FTD-like symptoms (O'Rourke et al. 2016, Sudria-Lopez et al. 
2016, Koppers et al. 2015, Atanasio et al. 2016, Burberry et al. 2016). However, recent 
studies using C9orf72 LOF mice have consistently implicated C9orf72 protein function 
in autophagy and immune regulation (Atanasio et al. 2016, Amick et al. 2016, O'Rourke 
et al. 2016, Yang et al. 2016, Ugolino et al. 2016). Regarding autophagy, the pathway is 
known to be important for neuronal health; for example, neuronal-specific knockout (KO) 
of essential autophagy genes - such as ATG7, ATG5 and FIP200 - results in the inhibition 
of autophagy in neurons and subsequently neurodegeneration in mouse models (Hara et 
al. 2006, Komatsu et al. 2006, Liang et al. 2010). Furthermore, defective autophagy has 
been implicated in the causation of several neurodegenerative disorders such as 
Alzheimer’s disease and Parkinson’s disease. There are also multiple reports that 
defective autophagy plays a role in the pathogenesis of ALS (Menzies et al. 2017). As 
mentioned, UBIs are a neuropathological hallmark of C9-linked ALS, as well as non-C9 
linked ALS (Menzies et al. 2017). Additionally, several ALS-linked genes are known to 
encode proteins which function within the pathway, including: p62/SQSTM1, UBQLN2, 
OPTN, TBK-1 and VCP. Regarding C9orf72, it has been reported in our lab and others 
that C9orf72 plays a role in the regulation of the autophagy pathway, therefore we 
examined this in our C13H9orf72 LOF model (Farg et al. 2014, Yang et al. 2016, Sellier 
et al. 2016, Sullivan et al. 2016a, Webster et al. 2016a). 
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We reported that C13H9orf72 directly interacted with a component of the initiation 
complex, ATG13, in an in vitro binding assay, as has been shown in our lab with human 
C9orf72 previously (Webster et al. 2016a). Interestingly, we also report that loss of 
C13H9orf72 expression does not result in defective autophagy initiation, converse to 
previous reports in vitro (Webster et al. 2016a, Sellier et al. 2016, Sullivan et al. 2016a). 
We reasoned this may be because C13H9orf72 exerts its effect downstream from the 
initiation complex, which evidence has suggested from previous studies (Farg et al. 2014, 
Amick et al. 2016, O'Rourke et al. 2015). For example, there are an increasing number of 
studies reporting an increase, not a decrease, in LC3-II levels in response to reduced 
C9orf72 expression (Farg et al. 2014, O'Rourke et al. 2016). This increase in basal LC3-
II levels could be a result of increased autophagic flux or defective clearance of 
autophagosomes via the lysosome. As a result, we investigated basal LC3-II levels in our 
zebrafish, but no statistically significant difference was observed between genotypes in 
two lines (SH451 and SH448). The disparity in results between our C13H9orf72 LOF 
zebrafish and functional analysis completed in cell culture could be for several reasons. 
Firstly, we know that C13H9orf72 is not ubiquitously expressed in zebrafish, with 
expression of C13H9orf72 mRNA reported in a subset of tissues, including regions of the 
CNS, such as the forebrain, midbrain, hindbrain and spinal cord (Ciura et al. 2013). 
Therefore, the effect of loss of C13H9orf72 expression on autophagy may be harder to 
observe via immunoblotting, as we are using the whole fish embryo in comparison to a 
homogenous population of cells, as used previously (Webster et al. 2016a). In the future, 
we could extract protein from relevant tissues taken from adult zebrafish, such as the 
brain, to examine LC3-II levels after treatment with the same drugs used in this study or 
to examine basal levels of LC3-II under normal conditions. Additionally, we could extend 
our in vivo study of autophagy into live embryos via injecting mCherry-LC3-EGFP into 
wild-type and C13H9orf72 mutant zebrafish embryos (Pankiv et al. 2007). The fusion of 
acid-sensitive GFP and acid-insensitive mCherry to LC3 results in a pH-sensitive sensor 
to measure autophagy in live cells. This will allow us to probe delivery of autophagy 
substrates to the lysosome, as we will be able to distinguish autophagosomes (red and 
green fluorescence) from the acidic autolysosomes (red fluorescence only) in individual 
cells (Pankiv et al. 2007). Thus, utilising this technique would allow us to detect cell-
specific defects, which is not possible using the western blot-based approach taken in this 
project. Secondly, there could be a compensatory mechanism in vivo which can activate 
autophagy in an mTOR-independent manner, protecting the zebrafish from a defect in the 
242 
 
autophagy pathway caused by loss of C13H9orf72 expression. Anecdotally, in support of 
this we have observed in our lab that ATG5 LOF zebrafish could survive up to 30dpf, 
which is surprising as when ATG5 is ablated in mice they are reported to die within 1 day 
of delivery (He et al. 2009) and suggests that alternative mechanisms may compensate 
for defects in the autophagy pathway. Finally, C9orf72 may have different functions in 
different systems. For example, there are multiple reports that C9orf72 LOF mice have 
defects in autophagy (Atanasio et al. 2016, Amick et al. 2016, O'Rourke et al. 2016, Yang 
et al. 2016, Ugolino et al. 2016). Mouse C9orf72 (3110043021Rik) shares >90% 
nucleotide identity with human C9orf72, whereas zebrafish C9orf72 shares 76% 
nucleotide identity. Additionally, we have reported in this study that C13H9orf72 is 
missing an exon in comparison to higher vertebrates, such as mice and humans, which 
corresponds to coding exon 3. Thus, this difference in conservation may also explain why 
we do not see a defect in autophagy when C13H9orf72 expression is lost in the zebrafish. 
Although, we reported C13H9orf72 binds hATG13, supporting the idea that there is 
conservation of protein function between C13H9orf72 and hC9orf72, which does not 
support the latter theory.   
6.4.2. Role in the immune system 
Immune defects are also reported in C9orf72 LOF mice (O'Rourke et al. 2016, Sudria-
Lopez et al. 2016, Koppers et al. 2015, Atanasio et al. 2016, Burberry et al. 2016). As 
discussed in chapter 5, we decided to investigate whether the C13H9orf72 LOF zebrafish 
we generated had defects in the immune system, in particular focussing on whether they 
showed signs of splenomegaly. We reported that C13H9orf72 LOF zebrafish spleens 
were 35% larger than wild-type, but this was not significant due to a small sample size. 
However, we cannot confirm from these findings that loss of C13H9orf72 expression in 
these zebrafish has not affected the immune system, and further work will need to be done 
in the future to confirm this. For example, two groups found evidence of an increase in 
macrophage number in mutant animals suggesting that the inflammatory phenotypes 
observed may be due to dysfunction in this or other phagocytic cells (Atanasio et al. 2016, 
O'Rourke et al. 2016). Therefore, we could look at the levels of macrophages in 
haematopoietic tissues, such as the spleen, in the zebrafish. Multiple genes have been 
suggested as markers for macrophage lineage in zebrafish, such as L-plastin (Herbomel, 
Thisse and Thisse 1999). Use of L-plastin antibodies has been reported in zebrafish, thus 
could be used in the future (Mathias et al. 2009). Overall, it is important to note that 
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although the immune system in zebrafish and other teleosts is physiologically similar to 
higher vertebrates, like mice, there are some differences. For example, teleosts do not 
have lymph nodes and C9orf72 LOF mice reportedly exhibit lymphadenopathy, enlarged 
lymph nodes, as well as splenomegaly (Uribe et al. 2011, O'Rourke et al. 2016, Atanasio 
et al. 2016, Sudria-Lopez et al. 2016). Additionally, it has been reported in the C9orf72 
LOF mouse model that Trem2 expression is significantly upregulated in splenic tissue, 
but zebrafish do not harbour an orthologue for this gene (O'Rourke et al. 2016). Thus, 
despite the similarities, these differences may be why we do not see symptoms such as 
splenomegaly in the C13H9orf72 LOF zebrafish.  
6.5. A noncoding (G4C2)n hexanucleotide repeat expansion in C9orf72: one 
mutation, many mechanisms  
Overall, the relative contribution of C9orf72 haploinsufficiency, RNA toxicity and DPR 
toxicity in the pathogenesis of ALS/FTD is still unclear. Although there are contradictory 
results for all disease mechanisms, most in vivo models suggest that GOF mechanisms 
such as RNA toxicity and DPR proteins are neurotoxic, whereas LOF mechanisms are 
not. However, it is possible that a combination of multiple mechanisms results in the 
development of C9orf72-linked ALS/FTD in humans and not just one mechanism in 
isolation. Therefore, although C9orf72 LOF may not be neurotoxic alone, it may 
modulate disease onset and/or progression in C9-ALS/FTD alongside proposed GOF 
mechanisms. For example, as C9orf72 is reported to function in autophagy, partial or 
complete loss of its function may disrupt the pathway and exacerbate RNA toxicity or 
dipeptide repeat (DPR) protein toxicity in disease. In the future, we need to develop 
models to further understand how these proposed disease mechanisms interact in vivo, as 
this may have more relevance to humans with C9-ALS/FTD.  
We have the potential to use our C9orf72 LOF zebrafish to generate models that harbour 
both LOF and GOF disease mechanisms to further investigate this in the future. Many 
cellular and animal models seem to suggest that the arginine rich DPR species (poly-GR 
and –PR) are highly toxic (Xu et al. 2013, Lee et al. 2013, Chew et al. 2015, Zhang et al. 
2014, Ohki et al. 2017, Zhang et al. 2016, Wen et al. 2014, Mizielinska et al. 2014). 
Additionally, it is reported that poly-GA is the most abundant DPR species in patients 
carrying the repeat expansion (Mori et al. 2013c). Therefore, observing the interaction 
between these particular DPRs and C9orf72 haploinsufficiency may be an interesting 
place to start. As we know that the C13H9orf72 LOF mutants generated in this study are 
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able to breed and produce viable offspring, we could cross our mutants with transgenic 
zebrafish expressing these DPRs for further study. Interestingly, a recent study generated 
transgenic zebrafish expressing poly-GA (Ohki et al. 2017). However, as this zebrafish 
showed high levels of larval lethality, it would not be possible to cross this with our 
C13H9orf72 LOF zebrafish (Ohki et al. 2017). In the future, it could be of interest to 
optimise microinjection the poly-GA, -GR and -PR constructs (available in our lab) into 
our C13H9orf72 LOF zebrafish at larval stages. If C13H9orf72 does play an essential 
role in the autophagy pathway in zebrafish, a worsened phenotype may be observed in 
our mutants at this stage if the defective autophagy pathway is unable to clear the toxic, 
aggregated protein.  
6.6. Oligogenic disease and a multi-hit model 
Another point for consideration is the potential oligogenic nature of ALS. The 
C13H9orf72 LOF zebrafish generated in this study could also be used to further 
investigate this in the future, especially as oligogenic inheritance of mutant C9orf72 with 
other ALS-linked genes is the most commonly reported combination (Lattante et al. 
2015a). For example, OPTN mutations have been reported in combination with C9orf72 
(Bury et al. 2016, Lattante et al. 2015a, Millecamps et al. 2011, Millecamps et al. 2012). 
However, mutations in OPTN are not the only ones that have been reported to be in 
combination with C9orf72 and in total over 10 ALS-causing genetic variants have been 
described (Lattante et al. 2015a).  As we know that the C13H9orf72 LOF mutants 
generated in this study are able to breed and produce viable offspring, we have the 
potential to rapidly generate several novel oligogenic models in the future. This would 
enable us to identify whether both genes are needed to cause disease in a synergistic or 
additive way. Alternatively, it could reveal if one of the mutations, or whole gene itself, 
has been falsely related to ALS. Re-evaluation of ALS cases where a casual mutation was 
identified before the discovery of C9orf72 may reveal further combinations which could 
also be studied. Additionally, it would be interesting to investigate the combinations 
which have been reported to be in pure FTD cases only (C9orf72 with tau or 
p62/SQSTM1) and pure ALS cases only (C9orf72 with TDP-43, FUS or SOD1), to see 
whether this recapitulates distinct phenotypes in zebrafish (Lattante et al. 2015a). This 
would provide insight into how C9orf72 repeat expansions can be responsible for the 
ALS-FTD spectrum of disease. Overall, zebrafish are more efficient to use than 
mammalian models to define the degree of interaction among causative genes due to their 
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reduced cost, their ability to produce hundreds of eggs at weekly intervals and ease of 
genetic manipulation.  
6.7. Conclusions  
We have successfully generated and characterised a C13H9orf72 LOF zebrafish. For a 
comparison between the C9orf72 LOF models, including the model generated in this 
study, see table 6.1. Results from the characterisation completed so far do not support the 
hypothesis that C9orf72 LOF is sufficient to cause C9-ALS/FTD alone, which 
complements published findings in C9orf72 LOF mouse models (see table 6.1). However, 
our findings do not rule out that C9orf72 LOF may modulate disease onset and/or 
progression in C9-ALS/FTD patients alongside proposed GOF mechanisms. 
Additionally, we examined C9orf72 protein function in these zebrafish and confirmed it 
interacts with a member of the autophagy initiation complex, but further work is needed 
to determine whether it plays a regulatory role in autophagy in zebrafish. Overall, we 
have generated a powerful tool to use in the future to test the potential interaction of LOF 
and GOF disease mechanisms, oligogenic nature of C9-ALS/FTD and the function of the 
C9orf72 protein. Understanding of these important areas is paramount in identifying 




Table 6.1 Summary of C9orf72 loss-of-function models. Details of organism, orthologue name, method(s) used, phenotype(s) of null mutants 
and reference to the original study is given.  
Organism Orthologue Method(s) Phenotype(s) Original study 
C.elegan ALFA-1 Knockout line alfa-1(ok3062) or RNA 
interference (RNAi) 
Age-dependant motor phenotype  
Neurodegeneration of GABAergic motor neurons  
Hypersensitivity to osmotic stress  
(Therrien et al. 
2013) 
D.rerio C13H9orf72 Knockdown using antisense 
morpholinos (AMOs) injected into 
fertilised embryos    
Disrupted arborization and shortening of motor neuron 
axons  
Impaired touch-evoked escape response (TEER)  
(Ciura et al. 2013) 
  CRISPR/Cas9- mediated frameshift 
mutation in exon 1, causing 
premature stop codon; TALEN-
mediated frameshift mutation in exon 
7, causing premature stop codon  
No alteration in survival  
Mild defect in motor function, but no 
corresponding defect in the NMJs 
No change in anxiety-like behaviour  
No evidence of dysfunctional autophagy pathway 
No evidence of splenomegaly  
Current study  
M.musculus 3110043O21Rik Intracerebroventricular (ICV) 
stereotactic injection of C9orf72-specific 
antisense oligonucleotides (ASO)   
No evidence of C9-ALS/FTD associated pathology 
No change in anxiety-like behaviour  
No defect in motor function   
Minimal genome-wide mRNA alterations  
(Lagier-Tourenne et 
al. 2013) 
  Cre-lox mediated excision of exons 4-5 
in neurons and glial cells only  
No alteration in survival  
No defect in motor function  
No evidence of C9-ALS/FTD associated pathology 
(including motor neuron number, gliosis, TDP-43 
mislocalisation or increased ubiquitination)  




 Transgenic mice with exons 2-6 
replaced with LacZ construct; CRISPR-
Cas9 mediated disruption of exon 4 
Evidence of decreased survival 
No evidence of neurodegeneration 
Evidence of immune dysregulation  
(Burberry et al. 
2016) 
  Transgenic mice with exons 2-6 
replaced with LacZ construct; Zinc 
Finger Nuclease (ZFN)-mediated 
deletion of exon 2 
No defect in motor function  
No evidence of C9-ALS/FTD associated pathology  
Evidence of immune dysregulation  




  Transgenic mice with exons 2-11 
replaced with LacZ construct  
Evidence of decreased survival  
Mild defect in motor function  
Evidence of immune dysregulation  
(Atanasio et al. 
2016) 
  Cre-lox mediated excision of exons 4-5 
in whole genome 
Evidence of decreased survival 
No defect in motor function  
No evidence of C9-ALS/FTD associated pathology 
(including motor neuron number, gliosis, TDP-43 
mislocalisation or increased ubiquitination) 
Evidence of immune dysregulation  
(Sudria-Lopez et al. 
2016) 
  CRISPR/Cas9-mediated frameshift 
mutation in exon 2, causing a premature 
stop codon, effecting transcripts 1 and 3 
Evidence of dysfunctional autophagy pathway 
Evidence of immune dysregulation  
(Sullivan et al. 
2016b) 
  Transgenic mice with exons 2-6 
replaced with LacZ construct 
Evidence of decreased survival  
Mild defect in motor function, but no corresponding 
decrease in motor neuron number 
No change in anxiety-like behaviour, but mild 
abnormalities in social interaction and recognition  
No overt C9-ALS/FTD associated pathology 
Evidence of immune dysregulation  
(Jiang et al. 2016) 
  Transgenic mice with exons 2-6 
replaced with LacZ construct  
Evidence of decreased survival  
No evidence of neurodegeneration  
Evidence of immune dysregulation  
Evidence of dysfunctional autophagy pathway  
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